ERYTHEMA A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Erythema: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-497-00418-6 1. Erythema-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on erythema. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON ERYTHEMA ................................................................................................ 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Erythema....................................................................................... 4 E-Journals: PubMed Central ....................................................................................................... 20 The National Library of Medicine: PubMed ................................................................................ 23 CHAPTER 2. NUTRITION AND ERYTHEMA ...................................................................................... 65 Overview...................................................................................................................................... 65 Finding Nutrition Studies on Erythema...................................................................................... 65 Federal Resources on Nutrition ................................................................................................... 67 Additional Web Resources ........................................................................................................... 68 CHAPTER 3. ALTERNATIVE MEDICINE AND ERYTHEMA ................................................................ 69 Overview...................................................................................................................................... 69 National Center for Complementary and Alternative Medicine.................................................. 69 Additional Web Resources ........................................................................................................... 76 General References ....................................................................................................................... 79 CHAPTER 4. PATENTS ON ERYTHEMA ............................................................................................ 81 Overview...................................................................................................................................... 81 Patents on Erythema.................................................................................................................... 81 Patent Applications on Erythema ................................................................................................ 93 Keeping Current ........................................................................................................................ 104 CHAPTER 5. BOOKS ON ERYTHEMA .............................................................................................. 105 Overview.................................................................................................................................... 105 Book Summaries: Federal Agencies............................................................................................ 105 Book Summaries: Online Booksellers......................................................................................... 109 The National Library of Medicine Book Index ........................................................................... 109 Chapters on Erythema................................................................................................................ 110 CHAPTER 6. PERIODICALS AND NEWS ON ERYTHEMA ................................................................ 111 Overview.................................................................................................................................... 111 News Services and Press Releases.............................................................................................. 111 Newsletter Articles .................................................................................................................... 113 Academic Periodicals covering Erythema .................................................................................. 113 CHAPTER 7. RESEARCHING MEDICATIONS .................................................................................. 115 Overview.................................................................................................................................... 115 U.S. Pharmacopeia..................................................................................................................... 115 Commercial Databases ............................................................................................................... 116 Researching Orphan Drugs ....................................................................................................... 117 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 121 Overview.................................................................................................................................... 121 NIH Guidelines.......................................................................................................................... 121 NIH Databases........................................................................................................................... 123 Other Commercial Databases..................................................................................................... 125 APPENDIX B. PATIENT RESOURCES ............................................................................................... 127 Overview.................................................................................................................................... 127 Patient Guideline Sources.......................................................................................................... 127 Finding Associations.................................................................................................................. 130 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 133 Overview.................................................................................................................................... 133 Preparation................................................................................................................................. 133 Finding a Local Medical Library................................................................................................ 133
viii Contents
Medical Libraries in the U.S. and Canada ................................................................................. 133 ONLINE GLOSSARIES................................................................................................................ 139 Online Dictionary Directories ................................................................................................... 142 ERYTHEMA DICTIONARY ........................................................................................................ 143 INDEX .............................................................................................................................................. 209
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with erythema is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about erythema, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to erythema, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on erythema. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to erythema, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on erythema. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON ERYTHEMA Overview In this chapter, we will show you how to locate peer-reviewed references and studies on erythema.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and erythema, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “erythema” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Erythematous Oral Lesions: Which are Benign, Which are More Worrisome? Source: Consultant. 34(10): 1446-1451. October 1994. Summary: This article discusses erythematous oral lesions, with a goal of providing guidelines for determining which of these lesions are benign and which may be more serious. The author's discussion deals with true mucosal lesions, rather than focal areas of hemorrhage from trauma, hematologic disorders, or vascular abnormalities. Lesions discussed include erythroplasia and erythroplakia, stomatitis migrans, candidiasis, allergy, denuded bullous lesions, and psoriasis. Allergic reactions to several types of drugs (e.g., methyldopa, antibiotics, NSAIDs, and beta-blockers) and various dental products can induce a mucosal reaction resembling erythema multiforme or lichen planus. 4 figures. 1 table. 9 references. (AA-M).
4
•
Erythema
Ectopic Erythema Migrans in an Adolescent with a Skin Disorder Source: Pediatric Dentistry. 22(1): 63-64. January-February 2000. Contact: Available from American Academy of Pediatric Dentistry. Publications Department, 211 East Chicago Avenue, Suite 700, Chicago, IL 60611-2616. Summary: This article reports on a case in which red and white circular lesions of the buccal and labial mucosa were observed in a healthy 16 year old African American female. Periodically, these nontender patches would resolve and move to other oral sites. Except for localized gingivitis and a coated tongue, no other intraoral soft tissue abnormalities were observed. Mildly pruritic (itchy), hyperpigmented papules and plaques with scaly surfaces were noted around the hairline, hands, and elbows. In this case, detection of ectopic erythema migrans (also known as geographic stomatitis, ectopic geographic tongue, and migratory stomatitis) aided in the diagnosis of a bothersome skin condition. Ectopic erythema migrans, a benign inflammatory condition, primarily affects the tongue, with infrequent involvement of other mucosal sites. The author describes the diagnosis, differential diagnosis, treatment, and pediatric significance of ectopic erythema migrans. In the case described, the detection of the oral lesions prompted a referral for the young woman's symptomatic skin condition, which was diagnosed as psoriasis and appropriate treatment was initiated. 3 figures. 4 references.
Federally Funded Research on Erythema The U.S. Government supports a variety of research studies relating to erythema. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to erythema. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore erythema. The following is typical of the type of information found when searching the CRISP database for erythema: •
Project Title: ASSAY TO DETECT EARLY NEUROLOGIC LYME DISEASE Principal Investigator & Institution: Schutzer, Steven E.; Professor; Bioscience Development, Inc. 1467 3Rd Ave, Ste 1R New York, Ny 10028 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 29-SEP-2004 Summary: (provided by applicant): Neurologic involvment is one of the most serious and common complications of Lyme disease (LD). Yet there is no reliable test available to detect this at an early stage. LD cases due to Borrelia burgdorferi (Bb) are increasing.
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
5
Serious consequences can occur when Bb invades the central nervous system(CNS). Early detection of invasion would permit CNS-penetrating antibiotics to reduce sequelae. Our objective is to develop an assay to detect active CNS infection. Preliminary data suggests that Bb immune complexes (IC) analysis in cerebrospinal fluid (CSF) is a potential test. Specific Aim : To determine whether early neurologic LD patients have CSF IC which contain anti-Bb antibodies (Abs) and Bb antigens (Ags). Hypothesis: Early neurologic LD patients form IC in CSF. Rationale: In many infections IC Ab is found bound to its Ag target earlier than free Ab. In contrast to free Ab, specific IC Ab or Ag reflects active infection. Samples are already banked from neurologic LD patients with both erythema migrans AND microbiological confirmation. We will study blinded CSF specimens and compare CSF BbIC to free Bb Ab assays, PCR, and cultures (data already available). BbIC will be isolated by a proven simple technique, polyethylene glycol. BbIC Ab and Ag will be identified. Focus will be towards on specific and in vivo expressed Bb Ags. Results will be statistically analyzed. Phase 2 will be designed for broadscale usage and refinement. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHLAMYDIA SIGNIFICANCE
PNEUMONIAE
ANTIGENS
OF
BIOLOGICAL
Principal Investigator & Institution: Campbell, Lee Ann.; Professor; Pathobiology; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 01-APR-1998; Project End 31-MAR-2007 Summary: (provided by the applicant): Chlamydia pneumoniae is a human respiratory pathogen that causes 5 percent to 10 percent of pneumonia, bronchitis, and sinusitis. Virtually everyone is infected in his or her lifetime and reinfection is common. Infection is difficult to treat even with sensitive antibiotics. Chronic infection is common and has been associated with asthma, reactive airway disease, Reiter's syndrome, erythema nodosum, and sarcoidosis. The potential public health impact of infection with this pathogen is underscored by the association of C. pneumoniae with atherosclerosis and related clinical manifestations such as coronary heart disease, carotid artery stenosis, aortic aneurysm, claudication, and stroke. If C. pneumoniae infection plays a role in atherogenesis, there will be an urgent need to facilitate diagnosis and develop strategies for intervention and prevention. The overall goal of this proposal is two fold. First, C. pneumoniae specific antigens that are recognized during human infection will be exploited to facilitate serodiagnosis and identify putative vaccine candidates. The second goal is to define chlamydial/host cell interactions that lead to entry and survival of C. pneumoniae in host cells relevant to atherosclerosis. The specific focus will be on the interaction of the chlamydial glycan moiety with carbohydrate binding receptors on the host cell. Importantly, infection of epithelial cells can be inhibited with N-linked high mannose type oligosaccharide, the major component of the glycan. The novel hypothesis to be tested is that C. pneumoniae enters through the mannose-6 phosphate receptor by binding to the site involved in transport of phosphomannosylated residues to the lysosome and this differs from C. trachomatis, which utilizes the mannose receptor. The ultimate goals of these studies are to identify C. pneumoniae specific antigens to facilitate laboratory diagnosis and virulence factors playing a role in pathogenesis to guide vaccine development or develop anti-adhesive strategies for prevention of infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
6
•
Erythema
Project Title: COMBINED PREVENTION
NATURAL
INHIBITORS
IN
SKIN
CANCER
Principal Investigator & Institution: Slaga, Thomas J.; Scientific Director; Amc Cancer Research Center 1600 Pierce St Denver, Co 80214 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2008 Summary: (provided by applicant): The overall goal of this proposal is to determine the mechanism(s) of synergistic action of the natural source compounds, known to inhibit one or more stages of skin carcinogenesis, i.e., initiation and promotion/progression. Our hypothesis is that concurrent topical and systemic (i.e., dietary) treatment with selected natural source inhibitors of different stages of skin carcinogenesis result in synergistic effects leading to more efficient prevention of skin cancer. The inhibitors to be tested include ellagic acid, proanthocyanidin B-2-gallate, N-acetylcysteine, calcium D-glucarate, lycopene, ursolic acid from rosemary extract, and resveratrol. We propose to initially utilize a number of very predictive short-term in vitro and in vivo tests in order to identify the mechanism(s) and to differentiate the potencies of selected inhibitors at various concentrations under standard conditions. The most effective compounds will then be studied in long-term tumor experiments utilizing a 7,12dimethylbenz[a]anthracene (DMBA)-initiated, 12-O-tetradecanoylphorbol-13-acetate (TPA)- promoted multistage carcinogenesis model in SENCAR mice and an ultraviolet light (UV)-initiated, TPA-promoted multistage carcinogenesis model in SKH-1 mice. Finally, combinations of the best anti-initiating and anti-tumor promoting agents will be tested in the DMBA-initiated, TPA-promoted skin carcinogenesis model in SENCAR mice as well as in the UV-initiated, TPA-promoted skin carcinogenesis model in SKH-1 mice. The following Specific Aims will be studied: (i) identification, using various very predictive short-term in vitro and in vivo tests, including the DMBA-induced inflammatory-hyperplasia assay in SENCAR mice and the UV-induced erythemahyperplasia assay in SKH-1 mice, the most promising mechanisms of anti-initiation and anti-tumor promotion as well as the most effective natural source inhibitors and their delivery means, i.e., topical vs. systemic (dietary); (ii) analysis of the long-term antiinitiation and antitumor promoting effects of the selected, promising natural source inhibitors using the DMBA-initiated, TPA-promoted multistage skin carcinogenesis model in SENCAR mice to better understand their mechanism(s) of action and predict their performance in the following combination studies; (iii) studying the long-term inhibitory effects of the best anti-initiators and anti-tumor promoters identified in Aims 1 and 2, on UV-initiated, TPA-promoted multistage skin carcinogenesis in SKH-1 mice, in order to establish a bridge between the chemically induced and UV-induced mouse skin carcinogenesis data bases; (iv) examining how various combinations of mechanistically different anti-initiators and antitumor promoting agents and also how various combinations of their delivery means, i.e., topical vs. systemic (dietary), inhibit DMBA-initiated, TPA-promoted skin carcinogenesis in SENCAR mice as well as UVinitiated, TPA-promoted skin carcinogenesis in SKH-1 mice, with the view of discovering the most pronounced synergistic effects of the selected natural source inhibitors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DBPA/B PROTEINS OF BORRELIA BURGDORFERI & LYME ARTHRITIS Principal Investigator & Institution: Parveen, Nikhat; Molecular Genetics & Microbiol; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, Ma 01655
Studies
7
Timing: Fiscal Year 2003; Project Start 01-MAR-2003; Project End 28-FEB-2006 Summary: (provided by applicant): Lyme disease presents a unique clinical system to study cellular and molecular mecahnisms responsible for chronic inflammatory diseases. The disease, caused by the spirochete Borrelia burgdorfen, is the most prevalent arthropod borne disease in the United States. It is a multisystemic illness that affects skin, muscles, joints, heart and nervous system. If left untreated, chronic manifestations are frequenctly observed and Lyme arthritis is the most common symptom in North America. My Iong term qoal is to identify the virulence factors of B. burgdorferi involved in attachment to host cells and in colonization of various tissues, and characterize their role in the pathogenesis, diagnosis and prevention of chronic Lyme disease. Glycosaminoglycans (GAGs), ubiquitously expressed on the surface of all nucleated cells, are recognized by various Lyme spirochetes and several bacterial molecules are involved in this adherence. Decorin binding lipoproteins DbpA and DbpB of B. burgdorferi show affinity for heparin and dermatan sulfate GAGs in addition to the proteoglycan decorin. My hypothesis is that DbpA and DbpB contribute to the colonization of various tissues by B. burgdorferi binding to GAGs and decorin present on the host cells and trigger an inflammatory response in skin and joints causing erythema migrans and Lyme arthritis. The major question to be addressed in this study are: (1) Do DbpA and DbpB contribute to the GAGsmediated attachment of B. burgdorferi to host cells and to the inflammatory response in the joints of susceptible mice? (2) Does deletion of dbpA and dbpB genes affect attachment of B. burgdorferi to the host cells? (3) Are DbpA and DbpB lipoproteins essential virulence factors of B. burgdorferi that trigger Lyme arthritis? Si,qniflcance: Lyme arthritis exhibits several symptoms similar to those of rheumatoid arthritis. However, unlike rheumatoid arthritis, the causative agent is known in Lyme disease and hence, it is feasible to analyze the molecular mechanisms involved in this form of destructive arthritis. In addition, B. burgdorfer/ infected mouse exhibits symptoms similar to those of human Lyme disease, and hence, murine model provides an ideal system to analyze the mechanisms of Lyme borreliosis. This study will characterize the role of two spirochete lipoprotein adhesins in Lyme arthritis in the murine model. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIAGNOSIS AND PATHOGENESIS OF EARLY LYME DISEASE Principal Investigator & Institution: Steere, Allen C.; Chief; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2008 Summary: (provided by applicant): The goal of this grant proposal is to improve diagnostic testing for Lyme disease and to identify spirochetal and host factors that lead to more severe disease. This goal will be carried out by the analysis of samples from large retrospective and prospective series of well-characterized patients with Lyme disease. For this project, a leading candidate second-generation serologic test, an IgM OspC (C10)-peptide ELISA and an IgG VIsE (IR6)-peptide ELISA, will be assessed prospectively' and compared with the results obtained by whole-cell sonicate ELIoA and Western blot in patients with early or late Lyme disease and in control subjects. Antibody responses to novel glycolipid antigens of B. burgdorferi will be explored to learn whether serial determinations of these responses after antibiotic treatment may serve as a potential surrogate marker for spirochetal killing. The value of quantitative PCR as a diagnostic test will be determined for patients with Lyme disease as compared with standard PCR and culture. The spirochetal burden in skin biopsy samples of erythema migrans (EM) skin lesions and spirochetal virulence factors in isolates from
8
Erythema
these lesions will be delineated, and the results will be correlated with clinical markers of spirochetal dissemination and severity of infection. Finally, cytokine and chemokine profiles in EM lesions from these patients will be determined and correlated with clinical markers of spirochetal dissemination and severity of infection and with blood test results of cellular and humoral immune function. These studies are likely to lead to more accurate tests for the serodiagnosis of Lyme disease, for direct detection of the spirochete, and for the assessment of spirochetal killing. In addition, greater knowledge of spirochetal virulence and host factors associated with severe disease may allow the development of laboratory markers for patients who would benefit from more intensive treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIV AND NEUTROPHIL FUNCTION IN ORAL DISEASE Principal Investigator & Institution: Thomas, Larry L.; Professor; Rush University Medical Center Chicago, Il 60612 Timing: Fiscal Year 2002; Project Start 03-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant): Neutrophils play a key and essential role in the innate immune response against candida infection, which is the most frequent oral manifestation of HIV infection. Results obtained with neutrophils isolated from blood of HIV-infected individuals have variously demonstrated that neutrophils of HIV-infected individuals display increased apoptosis, constitutive activation, and diminished responsiveness to inflammatory stimuli. It is not known, however, how HIV infection influences the functional status of neutrophils within the oral cavity. It is postulated that an alteration in neutrophil function contributes to the increased incidence of candidiasis and periodontal disease in HIV-infected individuals. Moreover, a second role for neutrophils in HIV infection is suggested by the findings that neutrophils bind HIV-1 and increase infection of T lymphocytes as well as increase viral replication in HIVinfected PBMC. Consistent with this postulated role, increased shedding of HIV-1 is observed with gingival linear erythema, which is frequently associated with candida infection and, thus, also an influx of neutrophils into the oral cavity. The relationship between the neutrophil functional status and the capacity of neutrophils to enhance HIV infection and replication, however, is not known. This relationship may be directly relevant to the vertical transmission of HIV infection to infants via breast-feeding by HIV+ mothers, which remains an important route of infant HIV infection in underdeveloped countries. Indeed, oral candidiasis in infants is a risk factor for the vertical transmission of HIV infection via breast milk by HIV+ mothers. Accordingly, this proposal has two specific aims. (1) Does dysregulation of neutrophil function contribute to the increased incidence of oral candidiasis and periodontal disease in HIVinfected patients? (2) Does activation or apoptosis alter the capacity of neutrophils to bind HIV and/or to enhance HIV infection and replication of macrophages or lymphocytes? It is proposed that the results of this study will provide important insight into the essential role of neutrophils in innate immunity within the oral cavity of HIVinfected patients and also into a possible role of neutrophils in the vertical transmission of HIV infection. As such, the results may provide an additional target to enhance innate immunity within the oral cavity and also to decrease the vertical transmission of HIV in breast milk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
9
Project Title: IRRITANTS EFFECTS ON EPIDERMAL ANTIGEN PRESENTATION Principal Investigator & Institution: Gaspari, Anthony A.; Professor; Dermatology; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2002; Project Start 30-SEP-1998; Project End 31-AUG-2004 Summary: (Adapted from the Investigator's Abstract) Irritant contact dermatitis (ICD) is a common and clinically important type of inflammatory skin disorder, and is thought to be the result of non-immunologic inflammation resulting from chemical injury to the skin. This is in contrast to allergic contact dermatitis (ACD), in which hapten specific CD4+ T-lymphocytes are thought to be critical in the immunopathogenesis of this type of dermatitis. However, previous clinical, histologic and immunologic research studies comparing irritant to allergic contact dermatitis indicated that in most assays, these two types of dermatitis are similar, if not identical. We hypothesize that irritant and allergic contact dermatitis share common pathways of immune-mediated skin damage, resulting in the common phenotype of the two kinds of contact dermatitis. Irritants and allergens damage the epidermis, resulting in the release of self-antigens. We hypothesize that these self-antigens are presented to auto-reactive T-lymphocytes by epidermal antigen presenting cells (APC), which are central to the pathogenesis of both irritant and allergic contact dermatitis. To test our hypothesis, we will study the direct effects of irritants on human keratinocytes (KC) and Langerhans cell (LC)-like dendritic cells (DC) in their expression of adhesion molecules and cytokines that are known to be critical for regulating APC-functions or T-lymphocyte growth. Antigen presentation by normal or irritant-treated epidermal KC or LC-like DC cells to skin homing T-lymphocyte populations will be studied. The autologous mixed lymphocyte reaction will be used a model for presentation of self-antigens to autoreactive T-lymphocytes by irritantstressed epidermal APC. The following T-lymphocyte populations will be studied for autoreactivity against irritant-treated APC: Skin homing T-cell populations (Cutaneous leukocyte antigen+) (CLA) derived from the peripheral blood; T-lymphocytes that infiltrate into irritant skin challenge sites; or non-classical T-lymphocytes (CD4-CD8-, Tcell receptor y/8 bearing) derived from normal human epidermis. These studies will define novel immunologic mechanisms of ICD, and will lead to a better understanding of the effects of irritants on the regulation of APC function and the subsequent interactions with skin homing T-lymphocytes. Some of these assays may be useful as an in vitro to identify individuals at risk for irritancy. Since ICD can be a debilitating skin problem that potentially affects millions of Americans, the identification of individuals at risk for irritancy using in vitro tests would be of utility in preventing this common and potentially disabling condition. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: LYME DISEASE MODEL--PATHOGENESIS AND IMMUNITY Principal Investigator & Institution: Miller, James N.; Professor; Microbiol, Imm & Molec Genetics; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 30-SEP-1994; Project End 30-JUN-2004 Summary: We have developed a rabbit Lyme Disease model in which early erythema migrans (EM) lesions and disseminated infection occur and in which complete infectionderived immunity results. The long term - objectives of this study are to determine protective and pathological immune mechanisms operative during the course of rabbit infection with Borrelia burgdorferi (Bb). The rabbit model of Lyme disease provides a unique opportunity to address local and disseminated disease manifestations similar to
10
Erythema
those in human infection, and to address the cellular and humoral immune mechanisms in infection-derived immunity. Specific and cross-reactive immunity to challenge will be determined utilizing several well-defined strains. The in situ localization and fate of Bb in skin following intradermal challenge will be correlated with the presence and distribution of PMN's, B cells, and T cell subsets both in situ and in peripheral blood. correlations with acquired resistance will also be made with in vitro lymphocytic cell proliferative responses and humoral immune responses including quantitative ELISA and Western blot analysis, passive protection, opsonophagocytosis, complemetdependent borreliacidal activity, adherence inhibition, and freeze-fracture electron microscopy for the detection of antibody against Bb outer membrane proteins. The rabbit model will also be employed to address the efficacy of Bb challenge following vaccination with OspA, OspB, an avirulent Bb OspA- and OspB-less mutant, and with a recombinant gene product encoding an exported plasmid protein antigen (EppA). The cellular and humoral arms of the immune response as it relates to the development and healing of the EM lesion will also be addressed utilizing the above described procedures. Further, continued persistence, location, and subsequent elimination of the spirochete after EM healing will be determined by specific in situ analysis. Passive protection studies will be conducted with serum obtained at the time of Bb clearance from the skin in order to determine the immune status of these animals. The possibility of exotoxin in EM formation will be determined by injecting rabbits intradermally with concentrated supernatants from in vitro Bb cultures and by the use of filtrates prepared and concentrated from surgically implanted subcutaneous chambers containing Bb. The rabbit model permits the elucidation of those mechanisms that control persistence versus elimination in tissues to which the organism has disseminated. Studies directed toward the elucidation of dermatotropic, arthritogenic, and/or neurotropic strains utilizing several isolates of Bb are proposed and should contribute toward our understanding of chronicity in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: 'LYME DISEASE: A POSSIBLE TEST FOR CURE Principal Investigator & Institution: Philipp, Mario T.; Chairman; None; Tulane University of Louisiana New Orleans, La New Orleans, La 70112 Timing: Fiscal Year 2002; Project Start 01-JUL-2001; Project End 30-MAY-2004 Summary: (provided by applicant): It would be immensely useful for the management of Lyme disease (LD) treatment to have available a test for cure. Such a test could be employed not only to ascertain if treatment of acute LD was successful, thereby preventing the transition to the chronic, more intractable form of the disease, but also to distinguish among the possible etiologies of the so-called post-treatment LD syndrome. The PI and coworkers recently developed a sensitive and specific enzyme-linked immunosorbent assay (ELISA) for the serological diagnosis of LD. The test is based on the detection of antibody (Ab) to an immunodominant, invariable region (lR) of the lipoprotein VIsE. VIsE is the molecule that undergoes antigenic variation in Borrelia hurgdorfen (the etiologic agent of LD). A peptide (C6) representing the invariable region 6 (IR6) of VIsE serves as antigen. It is hypothesized that, because the spirochete should not simultaneously express on its surface more than one (or a few) VIsE variant(s) at any time, the VIsE lipoprotein must be rapidly turned over and degraded by the spirochete as new variants are progressively expressed. As a consequence of this postulated intrinsic instability, VIsE should be scarce on dead or dying spirochetes, and secondary Ab responses to the C6 peptide should decline in unison with the infection's demise, following antibiotic treatment. It is further hypothesized that the decline in titer of the
Studies
11
C6 Ab as a function of time after treatment may serve as a test for Lyme disease cure. Preliminary results indicate that the C6 ELISA titer in cured patients falls by a factor greater or equal than 4 whereas for treatment-resistant patients the fall is by a factor <4. This is similar to the VDRL test used to diagnose syphilis cure.The broad, long-term objective of this project is to assess both retrospectively and prospectively the ability of the C6 ELISA to serve as a test for LD cure. In this proposal the C6 test will be assessed retrospectively by achieving three specific aims: Specific Aim 1: To assess retrospectively the C6 ELISA as a test for cure in patients with acute LD. Serial serum samples from patients with either erythema migrans ( n = 90) and/or culture-confirmed infection ( n = 156) will have been collected at presentation and at 6 and 12 months thereafter. The samples will be titrated for anti-C6 Ab. Specific Aim 2: To assess retrospectively the C6 ELISA as a test for cure in patients with chronic LD and posttreatment LD syndrome. Same as for SAl, but with patients with chronic LD (n = 150) and post-treatment LD syndrome (n = 60). Specific Aim 3: To assess the C6 ELISA as a test for cure in animal models of LD. Cure of LD will be assessed objectively (by culture and PCR) both in rhesus monkeys (chronic LD) and in mice (acute LD). Correlation between LD cure and anti-C6 Ab titers will be evaluated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR ETIOLOGY OF FAMILIAL MEDITERRANEAN FEVER Principal Investigator & Institution: Gumucio, Deborah L.; Associate Professor; Cell and Developmental Biology; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 31-DEC-2007 Summary: (provided by applicant): Patients with the autosomal recessive disease, Familial Mediterranean fever (FMF), suffer periodic, unpredictable attacks of fever associated with severe pain; the pain is localized most commonly in joints (arthritis), abdomen (peritonitis) or chest (pleuritis). Occasionally, this disease presents with skin manifestations (erysipeloid erythema), pericarditis, vasculitis, or myalgia. In many patients, amyloidosis is a complication, and if untreated, this can be life-threatening. FMF is caused by missense mutations in pyrin, a protein of unknown function expressed in neutrophils, monocytes, eosinophils, dendritic cells, synovial cells and skin and peritoneal fibroblasts. Pyrin expression in these cells is induced by proinflammatory cytokines and by LPS. Thus, it has been speculated that pyrin modulates the inflammatory response. Evolutionary studies of the pyrin molecule indicate that it has been under positive Darwinian selection during evolution of the primates. Moreover, the high frequency of mutant pyrin alleles in several human ethnic groups supports a heterozygote (selective) advantage for the mutant allele. Mutant forms of pyrin may enhance the body's ability to clear important pathogen(s). Indeed, acute phase reactants, important agents of innate immunity, are up-regulated not only in patients but in carriers of mutant alleles. Structural analysis of the pyrin molecule revealed that exon 1 encodes a death-domain related structural motif (known as the pyrin domain or PyD) that is found in a growing family of proteins involved in inflammation and innate immunity. Identification of pyrin-interacting proteins as well as additional functional studies reveal that pyrin is linked directly to apoptotic and cytoskeletal signaling cascades, and that it modulates cytokine secretion. Experiments described in this proposal are designed to further explore these functions of pyrin and determine the effects of pyrin mutations on apoptosis (Aim 1); cytoskeletal signaling (Aim 2); and cytokine production (Aim 3). Recently identified pyrin isoforms will also be examined in these functional assays, since preliminary studies indicate that the
12
Erythema
various isoforms may function differently. Such studies could provide clues to understanding of the molecular pathogenesis of FMF, and may reveal new information about inflammatory pathways in general. In fact, pyrin-interacting proteins and pyrin domain-containing family members have already been connected to several human diseases, including inflammatory bowel disease, PAPA syndrome, Muckle-Wells syndrome, familial cold urticaria, Blau syndrome and Bechet's disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR STUDIES OF ERYTHEMA MULTIFORME Principal Investigator & Institution: Aurelian, Laure; Professor; Pharmacol & Exper Therapeutics; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2002; Project Start 10-MAR-1994; Project End 28-FEB-2005 Summary: (Adapted from the applicant's abstract) - Erythema multiforme (EM) is a hypersensitivity reaction caused by many provoking agents including herpes simplex virus (HSV) infection (HAEM). HSV DNA sequences were identified in HAEM lesions, but infectious virus was not isolated. T cell responses were also implicated in HAEM pathogenesis, but their HSV specificity and function are still unclear. The applicants showed that viral DNA clearance is impaired in HAEM relative to HSV lesions, but clinical HAEM symptoms correlate with HSV gene expression. The HSV DNA polymerase gene (Pol) is expressed in HAEM lesions, and they are positive for CD4+ Vbeta-2 T cells and IFN-gamma. Healed lesional skin were all negative. The investigator hypothesizes that HAEM is an immunopathological disease resulting from the combination of T cell responses to HSV antigens (likely Pol) and virus-mediated pathological effects. The specific aims are: (I) To examine the role of virus (Pol)-specific T cell responses in HAEM pathogenesis by establishing T cell lines/clones from HAEM lesional and healed skin and determining their HSV protein specificity and properties (viz. IFN-gamma production). ELISA spot assay will be used to estimate the clonal size of responding T cells in the skin. Both T cell clones and PBMC from HAEM and HSV patients will be examined for the presence of the skin homing receptor CLA. The second aim (II) is to examine the role of Pol in epidermal damage by determining(a) expression of the Pol accessory protein UL42 and Pol catalytic activity in HAEM lesions, and (b) the induction/activation of TGF-beta and p21waf in keratinocytes transfected with Pol or Pol/UL42 as it relates to growth arrest/apoptosis. Aim (III) is to define the route of HSV DNA transport to the skin. This will be done by determining the presence of HSV DNA fragments in CLA+ (and CD34+/CLA+) Langerhans cells (LC) precursors from HAEM and HSV patients and examining the ability of these cells to fragment HSV DNA/retain Pol DNA as they mature into LC in vitro. These studies will provide a better understanding of HAEM pathogenesis and its relationship to HSV, thereby allowing the development of novel therapies based on the targeting of disease-related HSV gene(s). They will also generate clinically relevant information for the diagnosis and management of HAEM patients as differentiated from those with EM caused by other pathogens or by drug sensitivity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NIACIN SENSITIVITY AND FATTY ACIDS IN SCHIZOPHRENIA Principal Investigator & Institution: Messamore, Erik; Psychiatry; Oregon Health & Science University Portland, or 972393098 Timing: Fiscal Year 2004; Project Start 01-JUL-2004; Project End 30-JUN-2006
Studies
13
Summary: (provided by applicant): Subsensitivity to the skin flush effect of niacin is among the most reliable and widely-replicated peripheral physiological abnormalities in schizophrenia. However, the mechanism and significance of this abnormality has not been described. Since the flush response to niacin is mediated by vasodilatory prostaglandins that are derived from arachidonic acid, one possible mechanism for niacin subsensitivity in schizophrenia relates to reduced arachidonic acid levels. Low levels of arachidonic acid in cell membranes from the brain as well as from the red blood cells have been consistently observed in schizophrenia. This study will test the hypothesis that niacin subsensitivity in patients with schizophrenia is a functional marker of low membrane arachidonic acid levels. A secondary goal of the study is to determine if low arachidonic acid levels and/or low niacin sensitivity are related to the expression of symptoms or the severity of illness in patients with schizophrenia. We will quantify cutaneous niacin sensitivity by measuring the skin blood flow response to graded doses of topical alpha-methylnicotinate (AMN). Laser Doppler flowmetry will be used to quantify blood flow response and niacin sensitivity will be defined by the EC50 value for AMN. Symptom expression and illness severity will be assessed by the Positive and Negative Synfrome Scale, Global Assessment of Function, and StraussCarpenter scales. The data will help to determine whether niacin subsensitivity in schizophrenia is a marker of arachidonic acid deficiency, and will help to determine whether arachidonic acid deficiency and/or niacin subsensitivity are related to aspects of symptom expression or illness severity in schizophrenia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OPTICAL DETECTION OF INTRAVENOUS INFILTRATION Principal Investigator & Institution: Winchester, Leonard W.; Chief Scientist; Cw Optics, Inc. 905 Seaford Rd Yorktown, Va 23666 Timing: Fiscal Year 2002; Project Start 01-JAN-1999; Project End 31-AUG-2004 Summary: (provided by applicant): About 80% of hospital patients in the United States require IV therapy and 50% of IV lines fail due to infiltration, a clot in the cannula, an inflammatory response of the vein, or separation of the cannula from the vein. IV infiltration is usually accompanied by pain, erythema, and swelling at the cannula tip or the insertion site. Severe infiltration may lead to necrosis requiring skin debridement, skin grafting, or amputation. Early detection of infiltration prevents the occurrence of serious incidents that may require surgical correction. The long-term objective of this project is to develop an infiltration sensor for monitoring IV failures. The Phase II research design includes the development of an advanced prototype, improvement of algorithms, evaluation of the prototype on animal models and human measurements, investigation of its accuracy and utility, and the examination of the commercial potential. The innovation of this project lies in the use of an optical method coupled with the advanced development in fiber optics and algorithms for tissue optics to provide a means for noninvasive monitoring of the IV sites. It will provide routine, automated, continuous, and real-time monitoring capabilities for patients undergoing IV therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ORAL MICROBIAL ASSOCIATIONS IN HIV+SUBJECTS Principal Investigator & Institution: Paster, Bruce J.; Senior Member of Staff; Forsyth Institute Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2004
14
Erythema
Summary: (provided by applicant): The broad objectives of this proposal are to examine the hypothesis that the more common periodontal infections in HIV+ subjects are caused by specific bacterial or fungal species, which are not necessarily the typical putative periodontal pathogens usually found in comparable periodontal infections in HIV negative subjects. Our preliminary data indicated that HIV+ subjects with necrotizing ulcerative periodontitis (NUP), a more severe periodontal disease unique to these individuals, indeed lacked many of the classical periodontal pathogens, but instead possessed "unusual" taxa, such as Bulleidia extructa and Dialister pneumosintes, and novel "uncultivable" phylotypes of the genera Dialister, Peptostreptococcus, Selenomonas, and members of the "uncultivable" phylum TM7. Our objectives are addressed in two Specific Aims. Aim 1 will identify the predominant cultivable and notyet-cultivated bacteria and fungi that are associated with periodontal infections in HIV+ subjects, such as gingivitis, low/moderate and severe adult periodontitis, and Linear Gingival Erythema (LGE), another periodontal infection unique to HIV+ subjects. These studies will be performed by analyzing bacterial 16S rRNA and fungal 18S rRNA gene sequences of inserts in clones from plaque libraries. The libraries will be generated by PCR amplification of rRNA genes present in subgingival plaque followed by ligation of the amplicons into appropriate vectors and by transformation of E. coli. The sequence of each clone will be used to determine species identity, or if unknown, its phylogenetic position. It is anticipated that 25 to 50 additional new taxa will be identified. Aim 2 will test the hypothesis that specific bacterial and fungal species are associated with periodontal infections with the deterioration of immune status in HIV+ patients. In each periodontal disease category, 25 subjects with high viral loads and low CD4 levels and 25 subjects with low viral load and high CD4 levels will be analyzed. Comparisons of subgingival microbial and fungal populations will be made between these HIV+ groups vs. control groups of HIV negative subjects. Up to 200 predominant bacterial species will be assayed for each sample using Checkerboard hybridization, which allows for the simultaneous analysis of multiple samples with multiple probes. Up to 30 fungal species will be assayed for each sample in a second, separate checkerboard hybridization. It is likely that specific bacterial complexes (e.g., specific combinations of bacteria/fungi) are associated with these periodontal diseases and may change with the severity of HIV infection. The proposed studies may provide insight for the identity of putative pathogens in comparable periodontal infections in HIV negative individuals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOBIOLOGY OF HUMAN LEPROSY Principal Investigator & Institution: Kaplan, Gilla; Full Member; Public Health Research Institute 225 Warren St Newark, Nj 071033535 Timing: Fiscal Year 2002; Project Start 01-APR-1986; Project End 31-JUL-2003 Summary: (Adapted from the Applicant's Abstract): This is a revised competitive renewal application to conduct a clinical and laboratory investigation aimed at understanding the regulation of cell-mediated immunity (CMI) and how it is subverted in leprosy. The focus of the proposal is on the immunologic mechanisms underlying the long term sequelae and complications of leprosy. The studies will (1) analyze the nature and etiology of the reactional states of leprosy to determine whether genetic polymorphisms and/or bacillary load in the nerves contribute to the development of reversal reactions (RR) and erythema nodosum leprosum (ENL) and whether T cell activation plays a role in the pathogenesis and/or cure of ENL. (2) The proposed studies will examine the process of nerve damage and establish whether it affects cell recruitment and activation and/or poor wound healing in the skin of leprosy patients. A
Studies
15
variety of approaches will be used, including genetic analyses involving specific oligonucleotide probing, immunological assays involving cell activation and cytotoxicity as well as cytokine evaluation by ELISA and semiquantitative PCR, and morphologic analyses employing histology, immunocytochemistry, and electron microscopy, to evaluate the nature, interactions and secretory repertoire of the cells involved in the pathobiology of the disease. The studies will be carried out on patient samples and selected patient populations through collaborative efforts in Addis Ababa, Ethiopia and Kathmandu, Nepal. The proposed studies are an extension of the achievements reported in the prior grant period. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHOTODYNAMIC AND PHOTOTHERMAL PORT WINE STAIN TREATMENT Principal Investigator & Institution: Kelly, Kristen M.; Dermatology; University of California Irvine Irvine, Ca 926977600 Timing: Fiscal Year 2004; Project Start 01-JUL-2004; Project End 31-MAR-2007 Summary: (provided by applicant): Port wine stains (PWS) are congenital, progressive vascular malformations of the skin that occur in approximately 0.7% of neonates and have potentially devastating psychological complications and, in some cases, serious physical effects as well. Current therapies achieve complete blanching of less than 10% of these lesions and multiple treatments (5 -30 or more) are generally required. We intend to combine photodynamic (PDT) and pulsed dye laser (PDL) therapies (PDT + PDL) to achieve permanent destruction of the most clinically relevant PWS blood vessels without injury to the surrounding skin. We will use a vascular specific photosensitizer, benzoporphyrin derivitive monoacid ring A (BPD), and continuous wave (CW) yellow light to confine PDT effects to the most superficial 1.0 mm below the skin surface. Vascular flow will be monitored during PDT using optical Doppler tomography (ODT). CW irradiation will be stopped when a reduction in blood flow is noted or after a light dose of 100 J/cm2 has been delivered. This approach will limit the depth and extent of vascular injury to the targeted vessels and prevent skin necrosis, which would result from total vascular destruction. PDT will be followed immediately, or after a brief time interval, by PDL irradiation to complete superficial vessel destruction without injury to the surrounding skin. Initial experiments using a chick chorioallantoic membrane confirmed the superior efficacy of PDT + PDL PWS vessel destruction as compared to either modality alone. This proposal includes a protocol to confirm the superior efficacy of PDT + PDL using a rat dorsal skin flap window model. The threshold of vascular lesion damage for PDT using BPD and yellow light and optimal treatment parameters for PDT + PDL vascular therapy will also be evaluated using the same animal model. Finally, we will determine the efficacy and safety of PDT + PDL PWS therapy in comprehensive clinical trials. The results of the studies in this proposal are expected to lead to the development of novel and innovative technology which will provide a more effective and, most importantly, safer method for removal of PWS birthmarks. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PHOTOPROTECTION OF SKIN BY NOVEL POLYPHENOL ANTIOXIDANTS Principal Investigator & Institution: Pinnell, Sheldon R.; Professor; Skinresearch, Inc. Box 13169 Research Triangle Park, Nc 277093169 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 28-FEB-2004
16
Erythema
Summary: (provided by applicant): Novel derivatives of common plant polyphenol antioxidants have been synthesized. The compounds improve water and lipid solubility of the parent compounds, making them more suitable for topical application. The derivatives will be tested for their ability to photoprotect pig skin in vivo. Photoprotection will be measured as reduction in erythema, thymine dimer formation, apoptosis and signal transduction. After maximizing formulations for photoprotection, observations will be extended to human skin. The goal of this work will be to develop topical antioxidant formulations to protect human skin from skin cancer and photoaging changes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PILOT INVESTIGATION OF SAFETY AND EFFICACY OF THALIDOMIDE IN SARCOIDOSIS Principal Investigator & Institution: Oliver, Stephen J.; Rockefeller University New York, Ny 100216399 Timing: Fiscal Year 2002 Summary: Sarcoidosis is a multisystem disease of unknown etiology characterized by the formation of noncaseating granulomas. Disease involvement can be self limited or chronic, ranging from asymptomatic to end organ failure. The disease may affect lungs, thoracic lymph nodes, skin, eyes, and other organs. Corticosteroids remain the primary sarcoidosis therapy. However, steroid treatment has multiple side effects and may fail to alter the disease course. The proinflammatory cytokine TNF-alpha may play an important role in mediating sarcoid disease activity. TNF-alpha production by activated macrophages is an important element in the cell mediated immune response leading to granuloma formation. Serum levels of TNF-alpha and soluble TNF-alpha receptors are elevated in sarcoidosis patients and correlate with disease activity. Thalidomide, an inhibitor of TNF-alpha production, has been shown to have both anti-inflammatory and immune modulating effects in a number of autoimmune diseases, including discoid lupus, aphthous ulcer formation, erythema nodosum leprosum, and others. The addition of thalidomide to antibiotic regimens has also improved morbidity and mortality in animal models of M. tuberculosis infection of the pulmonary and central nervous systems. This study will evaluate the effect of daily thalidomide administration in sarcoidosis patients over a 4 month period, using clinical and laboratory based disease activity measures. Serially recorded clinical disease activity measures include spirometry, skin photographs, erythrocyte sedimentation rates, Health Assessment Questionnaires, and joint counts. Chest x-rays and several skin biopsies will be performed at several defined time points. Laboratory based disease activity measures include plasma TNF-alpha and soluble TNF-alpha receptor, soluble interleukin 2 receptor, and intercellular cell adhesion molecule-1. Interferon gamma plasma levels will also be determined. T-lymphocytes subsets and antigen-stimulated lymphocyte proliferation will be measured. Drug safety in this patient group will be monitored by blood chemistries and cell counts, history and physical exams, and renal function assessments performed during monthly patient visits. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PREVENTION OF SKIN CANCER BY SCUTELLARIA BAICALENSIS Principal Investigator & Institution: Wei, Huachen; Associate Professor/Director; Dermatology; Mount Sinai School of Medicine of Nyu of New York University New York, Ny 10029
Studies
17
Timing: Fiscal Year 2002; Project Start 18-SEP-2000; Project End 30-JUN-2005 Summary: Chinese herbal medicine Huang Qin (Scutellaria baicalensis) has a variety of anti-inflammatory and anti-cancer activities. The central hypothesis of this proposal is that Scutellaria baicalensis extracts (SBE) inhibit ultraviolet (UV) B-induced pyrimidine dimers and oxidative DNA damage, and modulate UVB-activated signal transduction cascades and inflammatory responses, thereby suppressing the initiation and promotion of photocarcinogenesis. The initial aim of the project is to determine if pre- or postapplication of SBE prevents UVB-induced skin carcinogenesis. The initial aim of the project is to determine if pre- or post-application of SBE prevents UVB-induced skin carcinogenesis. SBE will be topically applied to hairless mice during exposure to UVB. The protective effect will be evaluated by analyzing the latency period, tumor incidence and multiplicity. The second aim is to evaluated the effects of SBE on the initiation, promotion, and progression of photocarcinogenesis. A combined UVB-carcinogen model will be used to dissect the anti-initiational or anti-promotional effects of SBE on UBV- induced skin carcinogenesis. SBE will be topically applied to mouse skin before an initiating dose of UVB, followed by TPA promotion, or applied before UCB radiation in DMBA-initiated mice. The therapeutic effect of SBE will be tested on the existing cutaneous tumors by recording the tumor regression rate and malignant conversion rate. The third aim is to determine if SBE modifies UVB-induced intermediate endpoints relevant to initiation and promotion, e.g. DNA photoproducts, oxidative DNA damage, inflammatory responses, protooncogene expression and activation of AP-1 factor in vivo and in vitro. Lastly, we will further evaluate the efficacy of SBE in protection of UVBinduced erythema and discomfort in human skin. The molecular markers of DNA damage (pyrimidine dimers and 8-OHdG), apoptosis (p53 protein expression), and cell proliferation (PCNA) will be determined in the human skin biopsies as well as in 3dimensional reconstituted human skin chronically exposed to UVB. Successful completion of the proposed studies will not only contribute to innovative use of herbal extracts as preventive and/or therapeutic agents against human skin cancer, but also promote the research on the anti-cancer action of BE in other human malignancies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RHESUS MONKEY MODEL FOR HUMAN B19 PARVOVIRUS INFECT: HEMOLYTIC ANEMIA Principal Investigator & Institution: Traina-Dorge, Vicki L.; Tulane University of Louisiana New Orleans, La New Orleans, La 70112 Timing: Fiscal Year 2002 Summary: Parvovirus infection is responsible for erythema infectiosum (Fifth?s disease) in children and aplastic crisis, hemolytic anemias, and fetal death, as well as a rheumatic syndrome in adults. It is also reported to be responsible for anemias, fevers, pneumonitis, and aplastic crisis in AIDS patients. The human B19 parvovirus is most commonly implicated. Little is known about B19 due to its difficult in vitro propagation. Histologic evidence was shown in the bone marrow of a severely anemic rhesus monkey with advanced SIV immunodeficiency disease and suggested parvovirus infection in the rhesus as well. Bone marrow and other tissues from this animal were collected and cryopreserved. A pilot study was conducted to determine whether we could reisolate virus as well as reproduce the disease, and whether immunodeficient animal would more readily progress to disease, and if SIV is a cofactor of disease. We developed a molecular PCR assay for diagnosis of infection. Six animals were inoculated intravenously with the bone marrow preparation. 2of 3 naive animals not only developed progressive SIV immunodeficiency disease, but also severe anemia
18
Erythema
coincident with high reticulocytes and Parvovirus viremia the time of necropsy. The 3 previously SIV-infected animals, however, had only one animal progress to SIV disease, but none became anemic. A second study was then conducted with six additional SIV infected animals. Only two of six became infected and viremic. One animal progressed to disease, and Parvovirus was documented at necropsy, however, again no anemia was apparent. We are following the other animal for signs of SIV disease and/or anemia. This resistance to disease progression in the previously infected SIV animals was observed in both studies. It may be due to a lack of severe immunodeficiency from the original SIV. These animals were relatively stable, having all been infected with SIV for 1.5years or greater. In addition, they appear resistance to superinfection with the second SIV strain in the bone marrow inoculum, which had a more rapid disease course in the naive animals. FUNDING Base Grant, Venture Research. PUBLICATIONS None Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF LIBC IN INFLAMMATORY BREAST CANCER PHENOTYPE Principal Investigator & Institution: Kleer, Celina G.; Pathology; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): Inflammatory breast cancer (IBC) is the most lethal form of locally advanced breast cancer with unique clinical and pathologic features. Clinically, patients present with skin erythema and nodularity; pathologically, IBC is highly angiogenic and angioinvasive with multiple tumor emboli that plug the dermal lymphatics and are responsible for the striking clinical picture. Recently, a novel gene, WISP3 (LIBC) whose expression is lost in 80% of IBC and in 20% of non-IBC tumors has been identified in our laboratory. WISP3 gene belongs to the CCN family of proteins together with connective tissue growth factor, Cyr61 and NOV. Based on amino acid sequence analysis, WISP3 encodes for a putative IGF-binding protein related protein. We demonstrated that WISP3 has growth, invasion and angiogenesis inhibitory functions in breast cancer, both in vivo and in vitro. We hypothesize that loss of WISP3 expression results in unregulated breast cancer growth and angiogenesis by two possible mechanisms: 1. increasing the availability of IGF to the IGF receptor on epithelial and mesenchymal cells, and 2. directly through IGF-independent effects. The broad, long-term objectives of this proposal are to elucidate the role of WISP3 in breast cancer development and progression. In order to test this hypothesis and address the broad objective, we propose the following aims: 1) To elucidate the structure-function relationship of the WISP3 protein, and its relationship to the IGF family, 2) To investigate the role of WISP3 in breast cancer growth and in the in vivo angiogenic switch, and 3) To investigate the usefulness of detecting WISP3 protein as a potential prognostic marker in patients with breast cancer. The research design to study the structure/function relationship of the WISP3 protein involves immunoprecipitation and binding assays utilizing WISP3 protein and recombinant IGF-I and IGF-II. The relevance of the IGFBP domain in WISP3 function will be studied using mutagenesis assays of the IGFBP domain of the WISP3 protein, followed by transfection experiments and functional biological assays, including growth in soft agar, invasion, and angiogenesis assays. The in vivo role of WISP3 in the angiogenic switch involves the development of mammary tumors in athymic nude mice derived from transfected cells with different WISP3 protein expression and detection of angiogenic factors in the mice serum using ELISA assays. Immunohistochemistry of the resected mice tumors will be performed using antibodies for VEGF, bFGF and CD31. The translational study of patients' breast cancers and normal breast tissues will complete these experiments and involves
Studies
19
immunohistochemistry for WISP3, CD31 and apoptosis, as well as development of a high-density tissue microarray. The experiments proposed may provide the foundation for the design of new therapeutic interventions that target WISP3. Also, understanding the role of WISP3 will shed light on the mechanisms of cancer development in general and serve as a model for other related CCN genes involved in carcinogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SKIN CANCER CHEMOPREVENTION Principal Investigator & Institution: Bickers, David R.; Carl Truman Nelson Professor/Chair; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2002; Project Start 19-JUL-2002; Project End 30-JUN-2003 Summary: (Applicant's Description) Non-melanoma skin cancer (NMSC) is the most common type of human cancer and epidemiological evidence strongly implicates ultraviolet radiation in sunlight as the major cause of this form of malignancy. The most common type of NMSC is basal cell carcinoma (BCC) and there are two major types of BCC, those occurring sporadically and those that develop in patients with the genetic disorder known as the basal cell nevus syndrome (BCNS). Sun exposure is a crucial factor in the development of BCC in both populations and recent studies have shown that mutations in the human homologue of the Drosophila segment polarity gene PATCHED (PTC) occur in patients with BCNS and in patients with sporadic BCCs. In this project we plan to conduct a series of studies in SKH-l hairless mice, in patched gene knockout mice (ptc +/-) and in human volunteers to test the hypothesis that systemic administration of the chemopreventive agents, Polyphenone E, a mixture of constituents of green tea, Sulindac, an inhibitor of cyclooxygenase (COX) I and 2 and Celecoxib, an inhibitor of COX 2 can diminish the phototoxic response to ultraviolet B (UVB) and psoralen-ultraviolet A (PUVA) in the skin. Minimal erythema dose (MED) to UVB and minimum phototoxic dose (MPD) to PUVA will be employed to induce a localized phototoxic response in the skin of the animals and the human subjects and the ability of the systemically administered chemopreventive agents to protect against these responses determined. Surrogate biological markers of cancer risk including erythema and edema, apoptosis, c-jun, c-fos and ras p21 induction, BrUdr incorporation, proliferating cell nuclear antigen (PCNA) expression and epidermal growth factor (FGFR) phosphorylation will be assessed. Tumor studies in the animals will permit direct comparison of the susceptibility of the mouse strains to UVB induced tumors and the ability of the chemopreventive agents to reduce the risk of cancer. These studies are closely integrated with those in Projects 1 and 2 and will generate strong supportive data that can be correlated with the findings from those studies. This combined approach has the unique potential to more frilly define the anticarcinogenic effects of selected chemopreventive agents in human populations and to further characterize their mechanism of action. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TISSUE SPECIFIC BORRELIA GENE EXPESSION Principal Investigator & Institution: Fikrig, Erol; Professor; Internal Medicine; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 01-MAY-2001; Project End 31-MAR-2006 Summary: (provided by the applicant): This project seeks to understand how microbial antigens that are selectively expressed in vivo, and in specific tissues, contribute to the
20
Erythema
genesis of protective host immune responses and can serve as rational targets for vaccines. Borrelia burgdorferi has been shown to preferentially express different genes during infection of the mammalian host and within distinct host tissues. Moreover, B. burgdorferi has a tropism for the skin, joints, heart and nervous system, and these organs/tissues are associated with particular clinical manifestations of Lyme disease, such as erythema migrans or Lyme arthritis. B. burgdorferi genes that are selectively expressed in vivo and in precise host tissues will be identified using 2 strategies. First, differential immunoscreening, a technique developed in our laboratory, will be used. In this approach, a B. burgdorferi expression library is probed with 2 sets of sera (for example, [a] sera from an infected host, and [b] sera from a host hyperimmunized with killed B. burgdorferi) to identify antigens that only react with [a], and may therefore be selectively expressed in vivo. Secondly, DECAL (Differential Expression analysis using a Custom Amplified Library), will be adapted to identify B. burgdorferi genes expressed in the host. In this strategy, prokaryotic ribosomal RNA is removed for a bacterial expression library, which can then be used for subtractive analysis of gene expression in host tissues. Then the immune responses to the host-specific B. burgdorferi antigens will be characterized. We will directly assess tissue-specific gene expression, by RT-PCR using patient specimens and also in an experimental murine model of Lyme borreliosis. Then we will correlate antigen-specific immune responses with the course of Lyme disease in patients and determine whether immune responses to tissue-specific antigens influence the course of infection and/or prevent specific clinical manifestations of disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “erythema” (or synonyms) into the search box. This search gives you access to fulltext articles. The following is a sample of items found for erythema in the PubMed Central database: •
Characterization of Borrelia burgdorferi Isolated from Erythema Migrans Lesions: Interrelationship of Three Molecular Typing Methods. by Iyer R, Liveris D, Adams A, Nowakowski J, McKenna D, Bittker S, Cooper D, Wormser GP, Schwartz I.; 2001 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88267
•
Characterization of Lyme Borreliosis Isolates from Patients with Erythema Migrans and Neuroborreliosis in Southern Sweden. by Ornstein K, Berglund J, Nilsson I, Norrby R, Bergstrom S.; 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87927
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
21
•
Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. by Luger SW, Paparone P, Wormser GP, Nadelman RB, Grunwaldt E, Gomez G, Wisniewski M, Collins JJ.; 1995 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=162601
•
Comparison of four immunoserologic assays for detection of antibodies to Borrelia burgdorferi in patients with culture-positive erythema migrans. by Mitchell PD, Reed KD, Aspeslet TL, Vandermause MF, Melski JW.; 1994 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=263910
•
Critical residues of the Mycobacterium leprae LSR recombinant protein discriminate clinical activity in erythema nodosum leprosum reactions. by Singh S, Jenner PJ, Narayan NP, Ramu G, Colston MJ, Prasad HK, Nath I.; 1994 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=303325
•
Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin. by Berger BW, Johnson RC, Kodner C, Coleman L.; 1992 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=265060
•
Detection of Borrelia burgdorferi sensu lato in lesional skin of patients with erythema migrans and acrodermatitis chronica atrophicans by ospA-specific PCR. by Moter SE, Hofmann H, Wallich R, Simon MM, Kramer MD.; 1994 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=264211
•
Detection of Borrelia burgdorferi-specific DNA in urine specimens from patients with erythema migrans before and after antibiotic therapy. by Schmidt B, Muellegger RR, Stockenhuber C, Soyer HP, Hoedl S, Luger A, Kerl H.; 1996 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229025
•
Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions. by Schwartz I, Wormser GP, Schwartz JJ, Cooper D, Weissensee P, Gazumyan A, Zimmermann E, Goldberg NS, Bittker S, Campbell GL, et al.; 1992 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=270592
•
Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. by Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP.; 1996 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228718
•
Experimental Lyme disease in rabbits: spirochetes found in erythema migrans and blood. by Kornblatt AN, Steere AC, Brownstein DG.; 1984 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=261456
•
Inflammatory Cytokine Production Predominates in Early Lyme Disease in Patients with Erythema Migrans. by Glickstein L, Moore B, Bledsoe T, Damle N, Sikand V, Steere AC.; 2003 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=201073
22
Erythema
•
Lyme Disease in Taiwan: First Human Patient with Characteristic Erythema Chronicum Migrans Skin Lesion. by Shih CM, Wang JC, Chao LL, Wu TN.; 1998 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104630
•
Mutational Analysis of Superantigen Activity Responsible for the Induction of Skin Erythema by Streptococcal Pyrogenic Exotoxin C. by Yamaoka J, Nakamura E, Takeda Y, Imamura S, Minato N.; 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=108623
•
Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum. by Laal S, Bhutani LK, Nath I.; 1985 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=261163
•
Ovalbumin blocking improves sensitivity and specificity of immunoglobulin M immunoblotting for serodiagnosis of patients with erythema migrans. by Lange R, Bocklage H, Schneider T, Kolmel HW, Heesemann J, Karch H.; 1992 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=265029
•
Photoreactivation of UV-induced pyrimidine dimers and erythema in the marsupial Monodelphis domestica. by Ley RD.; 1985 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=397567
•
Polymorphonuclear cell function in the various polar types of leprosy and erythema nodosum leprosum. by Sher R, Anderson R, Glover A, Wadee AA.; 1978 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=422090
•
Quantitative Detection of Borrelia burgdorferi in 2-Millimeter Skin Samples of Erythema Migrans Lesions: Correlation of Results with Clinical and Laboratory Findings. by Liveris D, Wang G, Girao G, Byrne DW, Nowakowski J, McKenna D, Nadelman R, Wormser GP, Schwartz I.; 2002 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=140402
•
Rabbit model of Lyme borreliosis: erythema migrans, infection-derived immunity, and identification of Borrelia burgdorferi proteins associated with virulence and protective immunity. by Foley DM, Gayek RJ, Skare JT, Wagar EA, Champion CI, Blanco DR, Lovett MA, Miller JN.; 1995 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=185284
•
Serodiagnosis of erythema migrans and acrodermatitis chronica atrophicans by the Borrelia burgdorferi flagellum enzyme-linked immunosorbent assay. by Hansen K, Asbrink E.; 1989 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267355
•
Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis. by Hammers-Berggren S, Lebech AM, Karlsson M, Svenungsson B, Hansen K, Stiernstedt G.; 1994 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=264030
Studies
•
23
United States Standard Diphtheria Toxin for the Schick Text and the Erythema Potency Assay for the Schick Text Dose. by Barile MF, Kolb RW, Pittman M.; 1971 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=416303
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with erythema, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “erythema” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for erythema (hyperlinks lead to article summaries): •
A case of erythema elevatum diutinum associated with B-cell lymphoma: a rare distribution involving palms, soles and nails. Author(s): Futei Y, Konohana I. Source: The British Journal of Dermatology. 2000 January; 142(1): 116-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10651705
•
A case of hereditary angioedema with recurrent arthritis, erythema marginatum-like rash and chest pain. Author(s): Ergin H, Baskan M, Akalin N, Gurses D. Source: Turk J Pediatr. 2003 July-September; 45(3): 261-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14696809
•
A case of intravascular large B-cell lymphoma mimicking erythema nodosum: the importance of multiple skin biopsies. Author(s): Kiyohara T, Kumakiri M, Kobayashi H, Shimizu T, Ohkawara A, Ohnuki M. Source: Journal of Cutaneous Pathology. 2000 September; 27(8): 413-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10955689
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
24
Erythema
•
A case report of erythema induratum of Bazin's disease. Author(s): Lim LC, Chua SH, Tan SH. Source: Ann Acad Med Singapore. 2000 September; 29(5): 688-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11126711
•
A clinico-pathologic correlation. Erythema multiforme. Author(s): Eng R, Gagari E, Papageorge MB. Source: J Mass Dent Soc. 2001 Spring; 50(1): 55-7. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11326711
•
A febrile infant who has hand edema and erythema. Author(s): Zenel JA. Source: Pediatrics in Review / American Academy of Pediatrics. 2000 September; 21(9): 321-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10970456
•
A linear erythema on the nose of a Korean girl. Author(s): Choi JC, Chang SE, Choi JH, Sung KJ, Moon KC, Koh JK. Source: The Journal of Dermatology. 2001 February; 28(2): 106-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11320704
•
A patient with dermatomyositis and linear streaks on the back. Centripetal flagellate erythema (CFE) associated with dermatomyositis. Author(s): Kimyai-Asadi A, Tausk FA, Nousari HC. Source: Archives of Dermatology. 2000 May; 136(5): 667, 670. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10815865
•
A prediction model to identify risk of developing Stevens-Johnson syndrome or toxic epidermal necrolysis in patients with erythema multiforme. Author(s): Tham LS, Tambyah PA. Source: Ann Acad Med Singapore. 2003 September; 32(5 Suppl): S46-8. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14968733
•
A rare variant of erythema nodosum leprosum: a case report. Author(s): Dave S, Thappa DM, Nori AV, Jayanthi S. Source: Dermatology Online Journal [electronic Resource]. 2003 December; 9(5): 11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14996384
Studies
25
•
Acral erythema in children receiving high-dose methotrexate. Author(s): Millot F, Auriol F, Brecheteau P, Guilhot F. Source: Pediatric Dermatology. 1999 September-October; 16(5): 398-400. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10571844
•
All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia. Author(s): Kuo MC, Dunn P, Wu JH, Shih LY. Source: Annals of Hematology. 2004 June; 83(6): 376-80. Epub 2003 November 26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14648024
•
An adult male with facial swelling, erythema, and sensation of arm tightness. Author(s): Popek C, Schaeffer R. Source: Journal of Emergency Nursing: Jen : Official Publication of the Emergency Department Nurses Association. 2000 December; 26(6): 633-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11106472
•
An annular erythema secondary to primary genital herpes. Author(s): Mahto M, Mandal D, Beck MH, Wells S. Source: International Journal of Std & Aids. 2000 February; 11(2): 123-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10678482
•
Annular erythema of Sjogren's syndrome in a white woman. Author(s): Haimowitz JE, McCauliffe DP, Seykora J, Werth VP. Source: Journal of the American Academy of Dermatology. 2000 June; 42(6): 1069-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10827414
•
Association of Sweet syndrome and erythema nodosum. Author(s): Ginarte M, Toribio J. Source: Archives of Dermatology. 2000 May; 136(5): 673-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10815868
•
Atypical erythema multiforme occurring at the early phase of Lyme disease? Author(s): Lesire V, Machet L, Toledano C, de Muret A, Maillard H, Lorette G, Vaillant L. Source: Acta Dermato-Venereologica. 2000 May; 80(3): 222. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10954224
26
Erythema
•
Autoimmune keratolysis in a patient with leukocytoclastic vasculitis: unusual erythema elevatum diutinum with granulomatous pattern. Author(s): Casanova FH, Meirelles RL, Tojar M, Martins MC, Rigueiro MP, de Freitas D. Source: Cornea. 2001 April; 20(3): 329-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11322426
•
Autoimmune thyroid disease in anti-Ro/SS-A-positive children with annular erythema: report of two cases. Author(s): Miyagawa S, Tanaka M, Okamoto S, Ishihara T, Nakajima M, Taira K, Yoshioka A, Asada H. Source: The British Journal of Dermatology. 2004 May; 150(5): 1005-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15149517
•
Bacterial interdigital scaly erythema (Kitamura): a possible new clinical entity. Author(s): Mochizuki T, Kinebuchi T, Fujii T, Ishizaki H, Kitamura K. Source: Dermatology (Basel, Switzerland). 1999; 199(4): 341-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10640846
•
Basal cell carcinoma after frequent episodes of cutaneous erythema and peeling induced by welding. Author(s): Donoghue AM, Sinclair MJ. Source: Occupational and Environmental Medicine. 1999 September; 56(9): 646. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10615299
•
Bizarre gyrate erythema associated with malignant thymoma. Author(s): Harwood CA, Lofts F, Mansi JL, Glees JP, Marsden RA. Source: The British Journal of Dermatology. 1997 January; 136(1): 144-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9039325
•
Bleomycin-induced flagellate erythema. Author(s): Duhra P, Ilchyshyn A, Das RN. Source: Clinical and Experimental Dermatology. 1991 May; 16(3): 216-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1718637
•
Borrelia burgdorferi isolates from erythema migrans. Author(s): Hercogova J, Tomankova M, Plch J, Jirous J, Hulinska D, Frosslova D, Bartak P. Source: Archives of Dermatological Research. 1993; 285(3): 171-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8503699
Studies
27
•
Bullous acral erythema and concomitant pigmentation on the face and occluded skin. Author(s): Ozkaya-Bayazit E, Diz-Kucukkaya R, Akasya E, Buyukbabani N, Oncu S, Pekcelen Y. Source: Journal of the European Academy of Dermatology and Venereology : Jeadv. 2000 March; 14(2): 139-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10972102
•
Bullous acral erythema secondary to high-dose methotrexate. Author(s): Morrell DS, Challgren E, Eapen M, Esterly NB. Source: Journal of Pediatric Hematology/Oncology : Official Journal of the American Society of Pediatric Hematology/Oncology. 2002 March-April; 24(3): 240. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11990316
•
Bullous erythema ab igne. Author(s): Kokturk A, Kaya TI, Baz K, Yazici AC, Apa DD, Ikizoglu G. Source: Dermatology Online Journal [electronic Resource]. 2003 August; 9(3): 18. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12952765
•
Bullous erythema ab igne. Author(s): Flanagan N, Watson R, Sweeney E, Barnes L. Source: The British Journal of Dermatology. 1996 June; 134(6): 1159-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8763454
•
Bullous erythema multiforme following herpes zoster and varicella-zoster virus infection. Author(s): Weisman K, Petersen CS, Blichmann CW, Nielsen NH, Hultberg BM. Source: Journal of the European Academy of Dermatology and Venereology : Jeadv. 1998 September; 11(2): 147-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9784041
•
Bullous erythema multiforme following topical diphenylcyclopropenone application. Author(s): Oh CW, Han KD, Kim TH. Source: Contact Dermatitis. 1998 April; 38(4): 220-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9565301
•
Bullous erythema nodosum leprosum (bullous type 2 reaction). Author(s): Sethuraman G, Jeevan D, Srinivas CR, Ramu G. Source: International Journal of Dermatology. 2002 June; 41(6): 362-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12100694
28
Erythema
•
Bullous pemphigoid mimicking bullous erythema multiforme: an untoward side effect of penicillins. Author(s): Alcalay J, David M, Ingber A, Hazaz B, Sandbank M. Source: Journal of the American Academy of Dermatology. 1988 February; 18(2 Pt 1): 345-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2964460
•
Bullous pemphigoid with figurate erythema associated with carcinoma of the bronchus. Author(s): Graham-Brown RA. Source: The British Journal of Dermatology. 1987 September; 117(3): 385-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3314968
•
Bullous variant of chemotherapy-induced acral erythema. Author(s): Waltzer JF, Flowers FP. Source: Archives of Dermatology. 1993 January; 129(1): 43-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8420487
•
Bupropion-induced erythema multiforme. Author(s): Lineberry TW, Peters GE Jr, Bostwick JM. Source: Mayo Clinic Proceedings. 2001 June; 76(6): 664-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11393509
•
Calcipotriol ointment and cream or their vehicles applied immediately before irradiation inhibit ultraviolet B-induced erythema. Author(s): De Rie MA, Di Nuzzo S, Brands S, Hansen AB, Bos JD. Source: The British Journal of Dermatology. 2000 June; 142(6): 1160-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10848740
•
Case 1: enlarging lesion on right inner thigh. Diagnosis: erythema chronicum migrans caused by Lyme disease. Author(s): Karim A, Robson A, Calonje E. Source: Clinical and Experimental Dermatology. 2003 May; 28(3): 335-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12780734
•
Case 2. Diagnosis: erythema multiforme as a presentation of autoimmune progesterone dermatitis. Author(s): Warin AP. Source: Clinical and Experimental Dermatology. 2001 January; 26(1): 107-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11260195
Studies
29
•
Cerebrospinal fluid findings in adult patients with multiple erythema migrans. Author(s): Maraspin V, Cimperman J, Lotric-Furlan S, Ruzic-Sabljic E, Jurca T, Strle F. Source: Wiener Klinische Wochenschrift. 2002 July 31; 114(13-14): 505-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12422591
•
Characteristics of erythema migrans in Borrelia afzelii and Borrelia garinii infections. Author(s): Carlsson SA, Granlund H, Jansson C, Nyman D, Wahlberg P. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(1): 31-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12685881
•
Characterization of Lyme borreliosis isolates from patients with erythema migrans and neuroborreliosis in southern Sweden. Author(s): Ornstein K, Berglund J, Nilsson I, Norrby R, Bergstrom S. Source: Journal of Clinical Microbiology. 2001 April; 39(4): 1294-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11283044
•
Characterization of port wine stain skin erythema and melanin content using crosspolarized diffuse reflectance imaging. Author(s): Jung B, Choi B, Durkin AJ, Kelly KM, Nelson JS. Source: Lasers in Surgery and Medicine. 2004; 34(2): 174-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15004831
•
Chemotherapy-induced acral erythema: report of a case and immunohistochemical findings. Author(s): Tsuruta D, Mochida K, Hamada T, Ishii M, Wakasa K, Hashimoto S, Takekawa KE. Source: Clinical and Experimental Dermatology. 2000 July; 25(5): 386-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11012591
•
Children with multiple erythema migrans: are there any pre-treatment symptoms and/or signs suggestive for central nervous system involvement? Author(s): Arnez M, Pleterski-Rigler D, Luznik-Bufon T, Ruzic-Sabljic E, Strle F. Source: Wiener Klinische Wochenschrift. 2002 July 31; 114(13-14): 524-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12422594
•
Clinical constellation of annular erythema associated with anti-Ro/La autoantibodies. Author(s): Lee CW. Source: Journal of Korean Medical Science. 2000 April; 15(2): 199-202. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10803698
30
Erythema
•
Clinical outcome of erythema migrans after treatment with phenoxymethyl penicillin. Author(s): Bennet L, Danell S, Berglund J. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(2): 129-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12693565
•
Clofarabine-induced acral erythema during the treatment of patients with myelodysplasia and acute leukemia: report of two cases. Author(s): Chiao N, Bumgardner A, Duvic M. Source: Leukemia & Lymphoma. 2003 August; 44(8): 1405-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12952235
•
Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans. Author(s): Salazar JC, Pope CD, Sellati TJ, Feder HM Jr, Kiely TG, Dardick KR, Buckman RL, Moore MW, Caimano MJ, Pope JG, Krause PJ, Radolf JD; Lyme Disease Network. Source: Journal of Immunology (Baltimore, Md. : 1950). 2003 September 1; 171(5): 266070. Erratum In: J Immunol. 2003 November 1; 171(9): 4934. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12928420
•
Coexistence of psoriasis vulgaris, systemic sclerosis, and annular erythema in association with Sjogren's syndrome. Author(s): Yamamoto T, Nishioka K. Source: The Journal of Dermatology. 2004 January; 31(1): 69-72. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14739510
•
Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans. Author(s): Arnez M, Radsel-Medvescek A, Pleterski-Rigler D, Ruzic-Sabljic E, Strle F. Source: Wiener Klinische Wochenschrift. 1999 December 10; 111(22-23): 916-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10666802
•
Comparison of erythema migrans caused by Borrelia afzelii and Borrelia garinii. Author(s): Logar M, Ruzic-Sabljic E, Maraspin V, Lotric-Furlan S, Cimperman J, Jurca T, Strle F. Source: Infection. 2004 February; 32(1): 15-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15007737
•
Correlating skin phototype and minimum erythema dose in Arab skin. Author(s): Venkataram MN, Haitham AA. Source: International Journal of Dermatology. 2003 March; 42(3): 191-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12653912
Studies
31
•
Dapsone-responsive persistent erythema multiforme. Author(s): Mahendran R, Grant JW, Norris PG. Source: Dermatology (Basel, Switzerland). 2000; 200(3): 281-2. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10828645
•
Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy. Author(s): Rea TH. Source: International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association. 2001 December; 69(4): 318-27. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12035293
•
Demographic features, clinical characteristics and laboratory findings in children with multiple erythema migrans in Slovenia. Author(s): Arnez M, Pleterski-Rigler D, Ahcan J, Ruzic-Sabljic E, Strle F. Source: Wiener Klinische Wochenschrift. 2001 February 15; 113(3-4): 98-101. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11253748
•
Dermacentor-borne necrosis erythema and lymphadenopathy: clinical and epidemiological features of a new tick-borne disease. Author(s): Oteo JA, Ibarra V, Blanco JR, Martinez de Artola V, Marquez FJ, Portillo A, Raoult D, Anda P. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2004 April; 10(4): 327-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15059122
•
Design and evaluation of a novel portable erythema-melanin-meter. Author(s): Dolotov LE, Sinichkin YP, Tuchin VV, Utz SR, Altshuler GB, Yaroslavsky IV. Source: Lasers in Surgery and Medicine. 2004; 34(2): 127-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15004824
•
Detection and genotyping of human herpes simplex viruses in cutaneous lesions of erythema multiforme by nested PCR. Author(s): Sun Y, Chan RK, Tan SH, Ng PP. Source: Journal of Medical Virology. 2003 November; 71(3): 423-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12966549
•
Detection of herpes simplex virus genomic DNA in various subsets of Erythema multiforme by polymerase chain reaction. Author(s): Ng PP, Sun YJ, Tan HH, Tan SH. Source: Dermatology (Basel, Switzerland). 2003; 207(4): 349-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14657624
32
Erythema
•
Detection of spirochaetal DNA simultaneously in skin biopsies, peripheral blood and urine from patients with erythema migrans. Author(s): Pauluzzi P, Bonin S, Gonzalez Inchaurraga MA, Stanta G, Trevisan G. Source: Acta Dermato-Venereologica. 2004; 84(2): 106-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15206688
•
Development of erythema migrans in spite of treatment with antibiotics after a tick bite. Author(s): Maraspin V, Lotric-Furlan S, Strle F. Source: Wiener Klinische Wochenschrift. 2002 July 31; 114(13-14): 616-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12422612
•
Diagnosis, classification, and management of erythema multiforme and StevensJohnson syndrome. Author(s): Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Taieb A. Source: Archives of Disease in Childhood. 2000 October; 83(4): 347-52. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10999875
•
Diagnosis: erythema nodosum or not? Author(s): White WL, Hitchcock MG. Source: Semin Cutan Med Surg. 1999 March; 18(1): 47-55. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10188842
•
Diagnostic value of PCR for detection of Borrelia burgdorferi DNA in clinical specimens from patients with erythema migrans and Lyme neuroborreliosis. Author(s): Lebech AM, Hansen K, Brandrup F, Clemmensen O, Halkier-Sorensen L. Source: Molecular Diagnosis : a Journal Devoted to the Understanding of Human Disease Through the Clinical Application of Molecular Biology. 2000 June; 5(2): 139-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11066015
•
Dietary tomato paste protects against ultraviolet light-induced erythema in humans. Author(s): Stahl W, Heinrich U, Wiseman S, Eichler O, Sies H, Tronnier H. Source: The Journal of Nutrition. 2001 May; 131(5): 1449-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11340098
•
Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans. Author(s): Mullegger RR, McHugh G, Ruthazer R, Binder B, Kerl H, Steere AC. Source: The Journal of Investigative Dermatology. 2000 December; 115(6): 1115-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11121150
Studies
33
•
Diffuse erythema multiforme-like contact dermatitis caused by disperse blue 124 in a 2 year old child. Author(s): Baldari U, Alessandrini F, Raccagni AA. Source: Journal of the European Academy of Dermatology and Venereology : Jeadv. 1999 March; 12(2): 180-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10343954
•
Diffuse esophageal stricture caused by erythema multiforme major. Author(s): Carucci LR, Levine MS, Rubesin SE. Source: Ajr. American Journal of Roentgenology. 2003 March; 180(3): 749-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12591689
•
Digital image analysis of erythema development after experimental thermal injury to human skin: effect of postburn topical local anesthetics (EMLA). Author(s): Mattsson U, Cassuto J, Jontell M, Jonsson A, Sinclair R, Tarnow P. Source: Anesthesia and Analgesia. 1999 May; 88(5): 1131-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10320183
•
Dimorphic exanthema manifested as reticular maculopapular exanthema and erythema multiforme major associated with pyrazolon derivatives. Author(s): Chen W, Hsieh FS. Source: European Journal of Dermatology : Ejd. 2002 September-October; 12(5): 488-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12370143
•
Disseminated granuloma annulare following erythema multiforme minor. Author(s): Abraham Z, Feuerman EJ, Schafer I, Feinmesser M. Source: The Australasian Journal of Dermatology. 2000 November; 41(4): 238-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11105369
•
Dysregulation of IL-4 expression in lepromatous leprosy patients with and without erythema nodosum leprosum. Author(s): Nath I, Vemuri N, Reddi AL, Bharadwaj M, Brooks P, Colston MJ, Misra RS, Ramesh V. Source: Lepr Rev. 2000 December; 71 Suppl: S130-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11201870
•
Ectopic erythema migrans in an adolescent with a skin disorder. Author(s): Flaitz CM. Source: Pediatr Dent. 2000 January-February; 22(1): 63-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10730290
34
Erythema
•
Erysipelas-like erythema of familial Mediterranean fever: clinicopathologic correlation. Author(s): Barzilai A, Langevitz P, Goldberg I, Kopolovic J, Livneh A, Pras M, Trau H. Source: Journal of the American Academy of Dermatology. 2000 May; 42(5 Pt 1): 791-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10775856
•
Erythema ab igne induced by a laptop computer. Author(s): Bilic M, Adams BB. Source: Journal of the American Academy of Dermatology. 2004 June; 50(6): 973-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15153907
•
Erythema ab ignis. Author(s): Dunford J, Crutchfield CE 3rd. Source: Dermatology Nursing / Dermatology Nurses' Association. 2004 April; 16(2): 182. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15148902
•
Erythema dyschromicum perstans: response to dapsone therapy. Author(s): Bahadir S, Cobanoglu U, Cimsit G, Yayli S, Alpay K. Source: International Journal of Dermatology. 2004 March; 43(3): 220-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15009398
•
Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis. Author(s): Schwartz RA. Source: International Journal of Dermatology. 2004 March; 43(3): 230-2. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15009400
•
Erythema elevatum diutinum associated with lupus panniculitis in a patient with discoid lesions of chronic cutaneous lupus erythematosus. Author(s): Hancox JG, Wallace CA, Sangueza OP, Graham GF. Source: Journal of the American Academy of Dermatology. 2004 April; 50(4): 652-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15034527
•
Erythema elevatum diutinum in an HIV+ hemophilic patient. Author(s): Sanz-Trelles A, Ayala-Carbonero A, Ojeda-Martos A. Source: The American Journal of Dermatopathology. 1999 December; 21(6): 587-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10608257
Studies
35
•
Erythema elevatum diutinum. Author(s): Gibson LE, el-Azhary RA. Source: Clinics in Dermatology. 2000 May-June; 18(3): 295-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10856661
•
Erythema elevatum diutinum/Sweet's syndrome overlap with gastrointestinal and oral involvement. Author(s): Evans AV, Sabroe RA, Setterfield J, Greaves MW. Source: The British Journal of Dermatology. 1999 October; 141(4): 766-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10583147
•
Erythema migrans and serodiagnosis by enzyme immunoassay and immunoblot with three borrelia species. Author(s): Stanek G, Breier F, Menzinger G, Schaar B, Hafner M, Partsch H. Source: Wiener Klinische Wochenschrift. 1999 December 10; 111(22-23): 951-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10666807
•
Erythema migrans in pregnancy. Author(s): Maraspin V, Cimperman J, Lotric-Furlan S, Pleterski-Rigler D, Strle F. Source: Wiener Klinische Wochenschrift. 1999 December 10; 111(22-23): 933-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10666804
•
Erythema migrans in the immunocompromised host. Author(s): Maraspin V, Lotric-Furlan S, Cimperman J, Ruzic-Sabljic E, Strle F. Source: Wiener Klinische Wochenschrift. 1999 December 10; 111(22-23): 923-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10666803
•
Erythema multiforme after application of aural Gentisone HC drops. Author(s): Siddiq MA. Source: The Journal of Laryngology and Otology. 1999 November; 113(11): 1002-3. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10696380
•
Erythema multiforme associated with hepatitis B immunization. Author(s): Loche F, Schwarze HP, Thedenat B, Carriere M, Bazex J. Source: Clinical and Experimental Dermatology. 2000 March; 25(2): 167-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10836849
•
Erythema multiforme from betalactams with positive cutaneous tests. Author(s): Alonso Gomez A, Barranco Sanz P, Cabanas R, Lopez-Serrano MC. Source: J Investig Allergol Clin Immunol. 1999 November-December; 9(6): 401-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10664937
36
Erythema
•
Erythema multiforme minor following vaccination with paediatric vaccines. Author(s): Frederiksen MS, Brenoe E, Trier J. Source: Scandinavian Journal of Infectious Diseases. 2004; 36(2): 154-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15061674
•
Erythema nodosum in Israeli children. Author(s): Garty BZ, Poznanski O. Source: Isr Med Assoc J. 2000 February; 2(2): 145-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10804940
•
Erythema nodosum: etiologic and predictive factors in a defined population. Author(s): Garcia-Porrua C, Gonzalez-Gay MA, Vazquez-Caruncho M, Lopez-Lazaro L, Lueiro M, Fernandez ML, Alvarez-Ferreira J, Pujol RM. Source: Arthritis and Rheumatism. 2000 March; 43(3): 584-92. Erratum In: Arthritis Rheum 2000 May; 43(5): 1061. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10728752
•
E-selectin polymorphism in erythema nodosum secondary to sarcoidosis. Author(s): Amoli MM, Llorca J, Gomez-Gigirey A, Garcia-Porrua C, Lueiro M, ElMagadmi M, Fernandez ML, Ollier WE, Gonzalez-Gay MA. Source: Clin Exp Rheumatol. 2004 March-April; 22(2): 230-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15083893
•
Facial erythema and pigmentation as an initial manifestation of chronic graft-versushost disease. Author(s): Tokura Y, Yagi H, Iwasaki K, Takigawa M. Source: The Journal of Dermatology. 1994 March; 21(3): 185-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8014272
•
Facial erythema as a result of benzophenone allergy. Author(s): Nedorost ST. Source: Journal of the American Academy of Dermatology. 2003 November; 49(5 Suppl): S259-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14576646
•
Facial flushing and/or generalized erythema after epidural steroid injection. Author(s): DeSio JM, Kahn CH, Warfield CA. Source: Anesthesia and Analgesia. 1995 March; 80(3): 617-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7864437
Studies
37
•
Factor XIIIa+ dermal dendrocytes in erythema elevatum diutinum and ordinary cutaneous leukocytoclastic vasculitis lesions. Author(s): Pacheco LS, Sotto MN. Source: Journal of Cutaneous Pathology. 2000 March; 27(3): 136-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10728816
•
Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behcet's disease. Author(s): Yucel AE, Kart-Koseoglu H, Akova YA, Demirhan B, Boyacioglu S. Source: Rheumatology (Oxford, England). 2004 March; 43(3): 394-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14963212
•
Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culturedocumented Lyme borreliosis associated with erythema migrans: report of a prospective study. Author(s): Nadelman RB, Nowakowski J, Forseter G, Bittker S, Cooper D, Goldberg N, McKenna D, Wormser GP. Source: The American Journal of Medicine. 1993 June; 94(6): 583-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8506882
•
Faint erythema. Another manifestation of cutaneous sarcoidosis? Author(s): Okano M, Nishimura H, Morimoto Y, Maeda H. Source: International Journal of Dermatology. 1997 September; 36(9): 681-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9352410
•
Famotidine-induced erythema multiforme: cross-sensitivity with cimetidine. Author(s): Horiuchi Y, Ikezawa K. Source: Annals of Internal Medicine. 1999 November 16; 131(10): 795. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10577316
•
Fast measurements of transmission of erythema effective irradiance through clothing fabrics. Author(s): Zhang Z, Thomas BW, Wong CF, Fleming RA. Source: Health Physics. 1997 February; 72(2): 256-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9003710
•
Fat necrosis with features of erythema nodosum in a patient with metastatic pancreatic carcinoma. Author(s): Durden FM, Variyam E, Chren MM. Source: International Journal of Dermatology. 1996 January; 35(1): 39-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8838928
38
Erythema
•
Febrile lady with acute renal failure and desquamating erythema. Author(s): Roth S, Andrassy K, Schmidt KH, Gunther E, Ritz E. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 1999 July; 34(1): 150-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10401030
•
Fenoterol-induced erythema exudativum multiforme-like exanthem: demonstration of drug-specific lymphocyte reactivity in vivo and in vitro. Author(s): Sachs B, Renn C, al Masaoudi T, Merk HF. Source: Acta Dermato-Venereologica. 2001 October-November; 81(5): 368-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11800149
•
Ferdinand von Hebra on Erythema multiforme. Author(s): Saavedra-Delgado AM. Source: Allergy Proc. 1992 May-June; 13(3): 155-7. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1505757
•
Figurate erythema with bullous pemphigoid: a true paraneoplastic phenomenon? Author(s): Gilmour E, Bhushan M, Griffiths CE. Source: Clinical and Experimental Dermatology. 1999 November; 24(6): 446-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10606944
•
Figurate erythema, photosensitivity, and conjunctival irritation of recent onset. Subacute cutaneous lupus erythematosus (SCLE) and keratoconjunctivitis sicca. Author(s): Naldi L, Bronzoni M, d'Oro LC, Locati F, Marchesi L, Cainelli T. Source: Archives of Dermatology. 1992 September; 128(9): 1265, 1268. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1519943
•
Fixed drug eruption presenting as erythema dyschromicum perstans: a flare without taking any medications. Author(s): Mizukawa Y, Shiohara T. Source: Dermatology (Basel, Switzerland). 1998; 197(4): 383-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9873180
•
Flagellate erythema after intraperitoneal bleomycin. Author(s): Zaki I, Haslam P, Scerri L. Source: Clinical and Experimental Dermatology. 1994 July; 19(4): 366. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7525126
Studies
39
•
Flagellate erythema and dermatomyositis. Author(s): Gomez Centeno P, Sanchez-Aguilar D, Pereiro M Jr, Toribio J. Source: Clinical and Experimental Dermatology. 1998 September; 23(5): 239-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10233616
•
Fluorescein and indocyanine green angiography findings in a case of poststreptococcal syndrome with erythema nodosum and posterior uveitis. Author(s): Caccavale A, Mignemi L. Source: Retina (Philadelphia, Pa.). 2001; 21(6): 669-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11756896
•
Furniture-induced erythema ab igne. Author(s): Meffert JJ, Davis BM. Source: Journal of the American Academy of Dermatology. 1996 March; 34(3): 516-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8609272
•
Ga-67 and Tc-99m HMPAO labeled WBC imaging in erythema nodosum leprosum reaction of leprosy. Author(s): Peng NJ, Wang JH, Hsieh SP, Jao GH, Tsay DG, Liu RS. Source: Clinical Nuclear Medicine. 1998 April; 23(4): 248-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9554203
•
Generalized pustular rash and erythema. Toxic pustuloderma. Author(s): Wollina U, Lustig A, Bocker T. Source: Archives of Dermatology. 1997 April; 133(4): 500-1, 503-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9126026
•
Generic carbamazepine and erythema multiforme: generic-drug nonequivalency. Author(s): Busch RL. Source: The New England Journal of Medicine. 1989 September 7; 321(10): 692-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2770798
•
Giant cell arteritis of the skin simulating erythema nodosum. Author(s): Goldberg JW, Lee ML, Sajjad SM. Source: Annals of the Rheumatic Diseases. 1987 September; 46(9): 706-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3675013
40
Erythema
•
Glucagon therapy as a possible cause of erythema necrolyticum migrans in two neonates with persistent hyperinsulinaemic hypoglycaemia. Author(s): Wald M, Lawrenz K, Luckner D, Seimann R, Mohnike K, Schober E. Source: European Journal of Pediatrics. 2002 November; 161(11): 600-3. Epub 2002 September 05. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12424585
•
Granulocyte colony-stimulating factor (G-CSF) induced disseminated erythema with CD68 positive histiocytes. Author(s): Tomita Y, Shimizu T, Shimizu H. Source: Acta Dermato-Venereologica. 2001 November-December; 81(6): 436-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11859953
•
Granulomatous mastitis--a rare cause of erythema nodosum. Author(s): Adams DH, Hubscher SG, Scott DG. Source: Postgraduate Medical Journal. 1987 July; 63(741): 581-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3658869
•
Gravitational erythema. Author(s): Perrett CM, Berth-Jones J, Dharma B. Source: The British Journal of Dermatology. 2003 June; 148(6): 1267. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12828761
•
Gravitational erythema. Author(s): Berth-Jones J, Graham-Brown RA. Source: Clinical and Experimental Dermatology. 1988 July; 13(4): 259. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3246094
•
Group specific component (Gc) in erythema nodosum leprosum (ENL). Author(s): Ghei SK, Agrewala JN, Sengupta U, Sudhakar KS. Source: Indian J Lepr. 1993 July-September; 65(3): 323-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8283068
•
Guidelines for measurement of skin colour and erythema. A report from the Standardization Group of the European Society of Contact Dermatitis. Author(s): Fullerton A, Fischer T, Lahti A, Wilhelm KP, Takiwaki H, Serup J. Source: Contact Dermatitis. 1996 July; 35(1): 1-10. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8896947
Studies
41
•
Halo naevus with histological changes resembling epidermal erythema multiforme. Author(s): Fabrizi G, Massi G. Source: The British Journal of Dermatology. 1999 August; 141(2): 369-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10468829
•
Has the presence or absence of Borrelia burgdorferi sensu lato as detected by skin culture any influence on the course of erythema migrans? Author(s): Logar M, Lotric-Furlan S, Maraspin V, Cimperman J, Jurca T, Ruzic-Sabljic E, Strle F. Source: Wiener Klinische Wochenschrift. 1999 December 10; 111(22-23): 945-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10666806
•
Hepatocellular carcinoma associated with paraneoplastic erythema nodosum and polyarthritis. Author(s): Glinkov S, Krasnaliev I, Atanassova M, Arnaudov P, Kirov K, Glinkova V. Source: Journal of Hepatology. 2003 October; 39(4): 656-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12971982
•
Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions. Author(s): Kokuba H, Aurelian L, Burnett J. Source: The Journal of Investigative Dermatology. 1999 November; 113(5): 808-15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10571738
•
Herpes simplex virus associated erythema multiforme in a prepartum woman without involvement of the newborn. Author(s): Amichai B, Meltzer S. Source: Journal of the European Academy of Dermatology and Venereology : Jeadv. 2002 September; 16(5): 546. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12428866
•
Herpes simplex virus-associated erythema multiforme in prepubertal children. Author(s): Weston WL, Morelli JG. Source: Archives of Pediatrics & Adolescent Medicine. 1997 October; 151(10): 1014-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9343012
•
Herpes simplex virus-induced recurrent erythema multiforme. Author(s): Cohen PR. Source: J Gt Houst Dent Soc. 1995 April-May; 66(9): 17-8. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9594805
42
Erythema
•
Herpes simplex-associated erythema multiforme (HAEM): a clinical therapeutic dilemma. Author(s): Katz J, Livneh A, Shemer J, Danon YL, Peretz B. Source: Pediatr Dent. 1999 September-October; 21(6): 359-62. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10509338
•
Herpes zoster laryngis with prelaryngeal skin erythema. Author(s): Wu CL, Linne OC, Chiang CW. Source: The Annals of Otology, Rhinology, and Laryngology. 2004 February; 113(2): 1134. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14994764
•
High-dose methotrexate-induced bullous variant of acral erythema. Author(s): Hellier I, Bessis D, Sotto A, Margueritte G, Guilhou JJ. Source: Archives of Dermatology. 1996 May; 132(5): 590-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8624164
•
High-dose systemic corticosteroids can arrest recurrences of severe mucocutaneous erythema multiforme. Author(s): Martinez AE, Atherton DJ. Source: Pediatric Dermatology. 2000 March-April; 17(2): 87-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10792793
•
Histological study of necrolytic acral erythema. Author(s): Abdallah MA, Ghozzi MY, Monib HA, Hafez AM, Hiatt KM, Smoller BR, Horn TD. Source: J Ark Med Soc. 2004 April; 100(10): 354-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15080276
•
Histopathologic features of erythema nodosum--like lesions in Behcet disease: a comparison with erythema nodosum focusing on the role of vasculitis. Author(s): Kim B, LeBoit PE. Source: The American Journal of Dermatopathology. 2000 October; 22(5): 379-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11048972
•
Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Author(s): Rzany B, Hering O, Mockenhaupt M, Schroder W, Goerttler E, Ring J, Schopf E. Source: The British Journal of Dermatology. 1996 July; 135(1): 6-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8776350
Studies
43
•
HLA-DRB1 associations in biopsy proven erythema nodosum. Author(s): Amoli MM, Thomson W, Hajeer AH, Garcia-Porrua C, Lueiro M, Ollier WE, Gonzalez-Gay MA. Source: The Journal of Rheumatology. 2001 December; 28(12): 2660-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11764214
•
Hot pop brown spot: erythema Ab igne induced by heated popcorn. Author(s): Donohue KG, Nahm WK, Badiavas E, Li L, Pedvis-Leftick A. Source: The Journal of Dermatology. 2002 March; 29(3): 172-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11990255
•
How accurate is a clinical diagnosis of erythema chronicum migrans? Prospective study comparing the diagnostic accuracy of general practitioners and dermatologists in an area where lyme borreliosis is endemic. Author(s): Lipsker D, Lieber-Mbomeyo A, Hedelin G. Source: Archives of Dermatology. 2004 May; 140(5): 620-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15148115
•
How do I treat erythema nodosum, aphthous ulcerations, and pyoderma gangrenosum? Author(s): Hanauer SB. Source: Inflammatory Bowel Diseases. 1998 February; 4(1): 70; Discussion 73. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9552231
•
HPLC analysis of vitamin E isoforms in human epidermis: correlation with minimal erythema dose and free radical scavenging activity. Author(s): Fuchs J, Weber S, Podda M, Groth N, Herrling T, Packer L, Kaufmann R. Source: Free Radical Biology & Medicine. 2003 February 1; 34(3): 330-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12543248
•
Images. Erythema nodosum. Author(s): Zafren K, Kercher E. Source: Wilderness Environ Med. 1999 Autumn; 10(3): 171-3. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10560312
•
Improved serodiagnosis of erythema migrans using novel recombinant borrelial BBK32 antigens. Author(s): Lahdenne P, Panelius J, Saxen H, Heikkila T, Sillanpaa H, Peltomaa M, Arnez M, Huppertz HI, Seppala IJ. Source: Journal of Medical Microbiology. 2003 July; 52(Pt 7): 563-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12808077
44
Erythema
•
In vitro determination of erythema and immunologic protection afforded by sunscreens do not accord with in vivo assessments. Author(s): Fourtanier A. Source: The Journal of Investigative Dermatology. 1999 January; 112(1): 119. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9886277
•
In vitro interferon-gamma release test in the diagnosis of drug-induced erythema nodosum. Author(s): Halevy S, Gold I, Cohen AD, Grossman N. Source: Isr Med Assoc J. 2004 January; 6(1): 59-60. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14740516
•
Increased blood flow and erythema in the posterior vestibular mucosa in vulvar vestibulitis(1). Author(s): Bohm-Starke N, Hilliges M, Blomgren B, Falconer C, Rylander E. Source: Obstetrics and Gynecology. 2001 December; 98(6): 1067-74. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11755555
•
Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Author(s): Micali G, Linthicum K, Han N, West DP. Source: Pharmacotherapy. 1999 February; 19(2): 223-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10030773
•
Inflammatory cytokine production predominates in early Lyme disease in patients with erythema migrans. Author(s): Glickstein L, Moore B, Bledsoe T, Damle N, Sikand V, Steere AC. Source: Infection and Immunity. 2003 October; 71(10): 6051-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14500528
•
Influence of UVA pre-exposure on UVB-induced erythema. A chromometric study. Author(s): Routaboul C, Marguery MC, Garigue J, Bazex J. Source: Photodermatology, Photoimmunology & Photomedicine. 1999 April; 15(2): 52-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10321516
•
Intense pulsed light treatment for chronic facial erythema of systemic lupus erythematosus: a case report. Author(s): Levy JL. Source: Journal of Cutaneous Laser Therapy. 2000 December; 2(4): 195-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11350676
Studies
45
•
Interaction of HSV-1 infected peripheral blood mononuclear cells with cultured dermal microvascular endothelial cells: a potential model for the pathogenesis of HSV-1 induced erythema multiforme. Author(s): Larcher C, Gasser A, Hattmannstorfer R, Obexer P, Furhapter C, Fritsch P, Sepp N. Source: The Journal of Investigative Dermatology. 2001 January; 116(1): 150-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11168811
•
Interferon-alpha 2b induced facial erythema in a woman with chronic hepatitis C infection. Author(s): Tursen U, Kaya TI, Ikizoglu G. Source: Journal of the European Academy of Dermatology and Venereology : Jeadv. 2002 May; 16(3): 285-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12195575
•
Intestinal bypass syndrome presenting as erythema nodosum. Author(s): Katugampola RP, Patel GK, Farrell AM. Source: Clinical and Experimental Dermatology. 2004 May; 29(3): 261-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15115506
•
Intraepidermal bile pigment in skin biopsy specimens for graft-versus-host disease versus erythema multiforme. Author(s): Dilday BR, Smoller BR. Source: Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. 1998 October; 11(10): 1005-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9796731
•
Intravenous lidocaine infusion in the treatment of experimental human skin burns digital colour image analysis of erythema development. Author(s): Mattsson U, Cassuto J, Tarnow P, Jonsson A, Jontell M. Source: Burns : Journal of the International Society for Burn Injuries. 2000 December; 26(8): 710-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11024603
•
Is erythema multiforme associated with bupropion use? Author(s): Drago F, Rebora A. Source: Archives of Internal Medicine. 2002 April 8; 162(7): 843. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11926865
46
Erythema
•
Is systemic autoimmune disease a risk factor for terbinafine-induced erythema multiforme? Author(s): Goeteyn V, Naeyaert JM, Lambert J, Monbaliu L, Vermander F. Source: The British Journal of Dermatology. 2000 March; 142(3): 578-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10777271
•
Isolation and species typing of Lyme borreliosis spirochaetes from UK patients with erythema migrans. Author(s): Robertson J, Murdoch S, Foster L, Green S. Source: European Journal of Epidemiology. 1999 May; 15(5): 499-500. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10442477
•
Isolation of Borrelia burgdorferi sensu lato from blood of children with solitary erythema migrans. Author(s): Arnez M, Ruzic-Sabljic E, Ahcan J, Radsel-Medvescek A, Pleterski-Rigler D, Strle F. Source: The Pediatric Infectious Disease Journal. 2001 March; 20(3): 251-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11303825
•
Isolation of Borrelia burgdorferi sensu lato from blood of patients with erythema migrans. Author(s): Maraspin V, Ruzic-Sabljic E, Cimperman J, Lotric-Furlan S, Jurca T, Picken RN, Strle F. Source: Infection. 2001 March-April; 29(2): 65-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11339477
•
Kawasaki disease characterized by erythema and induration at the Bacillus CalmetteGuerin and purified protein derivative inoculation sites. Author(s): Hsu YH, Wang YH, Hsu WY, Lee YP. Source: The Pediatric Infectious Disease Journal. 1987 June; 6(6): 576-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3615073
•
Key factors in the subjective and objective assessment of conjunctival erythema. Author(s): Papas EB. Source: Investigative Ophthalmology & Visual Science. 2000 March; 41(3): 687-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10711682
•
Kikuchi disease with facial rash and erythema multiforme. Author(s): Kaur S, Thami GP, Mohan H, Kanwar AJ. Source: Pediatric Dermatology. 2001 September-October; 18(5): 403-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11737685
Studies
47
•
Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: a comparison of different techniques. Author(s): Nowakowski J, Schwartz I, Liveris D, Wang G, Aguero-Rosenfeld ME, Girao G, McKenna D, Nadelman RB, Cavaliere LF, Wormser GP; Lyme Disease Study Group. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 December 15; 33(12): 2023-7. Epub 2001 November 07. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11700579
•
Lack of association between ICAM-1 gene polymorphisms and biopsy-proven erythema nodosum. Author(s): Amoli MM, Ollier WE, Lueiro M, Fernandez ML, Garcia-Porrua C, GonzalezGay MA. Source: The Journal of Rheumatology. 2004 February; 31(2): 403-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14760823
•
Large, patchy skin eruptions after a hiking trip. Erythema chronicum migrans hallmarks Lyme disease. Author(s): Ledbetter LS, Hsu S, Lee JB. Source: Postgraduate Medicine. 2000 May 1; 107(5): 51-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10844941
•
Laser treatment of erythema and telangiectasia associated with rosacea. Author(s): Clark SM, Lanigan SW, Marks R. Source: Lasers in Medical Science. 2002; 17(1): 26-33. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11845365
•
Late-onset erythema along a sterile functioning ventriculoperitoneal shunt: case report and review of the literature. Author(s): AbdelAziz H, Vassilyadi M, Ventureyra EC. Source: Child's Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery. 2002 May; 18(5): 235-7. Epub 2002 April 09. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12042923
•
Late-stage nodular erythema elevatum diutinum. Author(s): High WA, Hoang MP, Stevens K, Cockerell CJ. Source: Journal of the American Academy of Dermatology. 2003 October; 49(4): 764-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14512939
48
Erythema
•
Leukocytoclastic vasculitis presenting as an erythema gyratum repens--like eruption on a patient with systemic lupus erythematosus. Author(s): Pique E, Palacios S, Santana Z. Source: Journal of the American Academy of Dermatology. 2002 November; 47(5 Suppl): S254-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12399742
•
Lichen planopilaris coexisting with erythema dyschromicum perstans. Author(s): Metin A, Calka O, Ugras S. Source: The British Journal of Dermatology. 2001 September; 145(3): 522-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11531858
•
Linear erythema craquele due to acute oedema in anorexia nervosa. Author(s): Ishiguro N, Hirohara D, Hotta M, Takano K, Kawashima M. Source: The British Journal of Dermatology. 2001 August; 145(2): 357-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11531814
•
Linear gingival erythema in an HIV-seropositive man. Author(s): Lugo RI, Fornatora ML, Reich RF, Freedman PD. Source: Aids Read. 1999 March-April; 9(2): 97-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12728891
•
Linear IgA dermatosis presenting with erythema annulare centrifugum lesions: report of three cases in adults. Author(s): Dippel E, Orfanos CE, Zouboulis C. Source: Journal of the European Academy of Dermatology and Venereology : Jeadv. 2000 March; 15(2): 167-70. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11495529
•
Lipoatrophic lesions preceded by pain and erythema - a new clinical entity? Author(s): Imamura S, Taniguchi S. Source: European Journal of Dermatology : Ejd. 2000 October-November; 10(7): 540-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11056426
•
Localized erythema-multiforme-like contact dermatitis from rubber gloves. Author(s): Lu CY, Sun CC. Source: Contact Dermatitis. 2001 November; 45(5): 311-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11722502
Studies
49
•
Long-term follow-up of erythema nodosum. Author(s): Tantisirin O, Puavilai S. Source: J Med Assoc Thai. 2003 December; 86(12): 1095-100. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14971515
•
Long-term prognosis of patients treated for erythema migrans in France. Author(s): Lipsker D, Antoni-Bach N, Hansmann Y, Jaulhac B. Source: The British Journal of Dermatology. 2002 May; 146(5): 872-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12000387
•
Long-term serological follow-up of patients treated for chronic cutaneous borreliosis or culture-positive erythema migrans. Author(s): Lomholt H, Lebech AM, Hansen K, Brandrup F, Halkier-Sorensen L. Source: Acta Dermato-Venereologica. 2000 September-October; 80(5): 362-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11200835
•
Lupus erythematosus with an erythema multiforme-like eruption. Author(s): Roustan G, Salas C, Barbadillo C, Sanchez Yus E, Mulero J, Simon A. Source: European Journal of Dermatology : Ejd. 2000 August; 10(6): 459-62. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10980468
•
Lupus erythematosus with antiphospholipid syndrome and erythema multiformelike lesions. Author(s): Marzano AV, Berti E, Gasparini G, Caputo R. Source: The British Journal of Dermatology. 1999 October; 141(4): 720-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10583125
•
Lyme disease presenting with multiple erythema migrans lesions: an illustrative case. Author(s): Weed B, Davis MD. Source: International Journal of Dermatology. 2003 September; 42(9): 715-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12956686
•
Lyme disease without erythema migrans: cause for concern? Author(s): Stricker RB, Phillips SE. Source: The American Journal of Medicine. 2003 July; 115(1): 72-3; Author Reply 73-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12867241
50
Erythema
•
Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. Author(s): Amoli MM, Donn RP, Thomson W, Hajeer AH, Garcia-Porrua C, Lueiro M, Ollier WE, Gonzalez-Gay MA. Source: The Journal of Rheumatology. 2002 August; 29(8): 1671-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12180727
•
Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Author(s): Sampaio EP, Hernandez MO, Carvalho DS, Sarno EN. Source: Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2002 February; 56(1): 13-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11905505
•
Marked swollen erythema of the face together with sicca syndrome as a sign for chronic active Epstein-Barr virus infection. Author(s): Sato-Matsumura KC, Matsumura T, Kobayashi H, Fujimoto K, Itoh T, Shimizu M, Shimizu H. Source: The British Journal of Dermatology. 2000 December; 143(6): 1351-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11122068
•
Measurement of actinic erythema in healthy subjects and in subjects with polymorphous light eruption using a tristimulus colorimeter. Author(s): Taylor CR. Source: Dermatology (Basel, Switzerland). 1996; 193(2): 155-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8884159
•
Measurement of actinic erythema in healthy subjects and in subjects with polymorphous light eruption using a tristimulus colorimeter. Author(s): Garigue J, Marguery MC, Malmary MF, el Sayed F, Bazex J. Source: Dermatology (Basel, Switzerland). 1995; 190(1): 31-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7894092
•
Measurement of cutaneous erythema by means of photodensitometry: application to cutaneous photosensitivity. Author(s): Demange L, Leonard F, Morel M, Kalis B. Source: Photodermatology, Photoimmunology & Photomedicine. 1998 June-August; 14(3-4): 100-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9779496
Studies
51
•
Mediators of inflammation involved in UVB erythema. Author(s): Terui T, Tagami H. Source: Journal of Dermatological Science. 2000 March; 23 Suppl 1: S1-5. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10764982
•
Meloxicam-induced erythema multiforme. Author(s): Nikas SN, Kittas G, Karamaounas N, Drosos AA. Source: The American Journal of Medicine. 1999 November; 107(5): 532-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10569318
•
Methods for assessing erythema: a critique of parametric and nonparametric techniques. Author(s): Doshi A, Zaheer A, Stiller MJ. Source: International Journal of Dermatology. 1997 May; 36(5): 334-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9199978
•
Methotrexate-induced acral erythema with bullous reaction. Author(s): Feizy V, Namazi MR, Barikbin B, Ehsani A. Source: Dermatology Online Journal [electronic Resource]. 2003 February; 9(1): 14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12639472
•
Mid-dermal elastophagocytosis presenting as a persistent reticulate erythema. Author(s): Bannister MJ, Rubel DM, Kossard S. Source: The Australasian Journal of Dermatology. 2001 February; 42(1): 50-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11233723
•
Migratory necrolytic erythema and glucagonoma. Author(s): Echenique-Elizondo M, Elorza JL, De Delas JS. Source: Surgery. 2003 April; 133(4): 449-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12717367
•
Minimal erythema dose on the buttock and volar forearm in previously UV unexposed Caucasians. Author(s): Gambichler T, Poppe J, Schropl F. Source: Journal of the European Academy of Dermatology and Venereology : Jeadv. 1999 March; 12(2): 193-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10343963
•
Misdiagnosis of erythema migrans. Author(s): Feder HM Jr, Whitaker DL. Source: The American Journal of Medicine. 1995 October; 99(4): 412-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7573098
52
Erythema
•
Moraxella catarrhalis bacteremia as a cause of erythema nodosum. Author(s): Periyakoil V, Krasner C. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 1996 September; 23(3): 650-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8879804
•
Morbilliform erythema-multiforme-like eruption from desoxymethasone. Author(s): Stingeni L, Hansel K, Lisi P. Source: Contact Dermatitis. 1996 December; 35(6): 363-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9118633
•
Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Author(s): Denning DW, Griffiths CE. Source: Clinical and Experimental Dermatology. 2001 November; 26(8): 648-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11722447
•
Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). Author(s): Tay YK, Huff JC, Weston WL. Source: Journal of the American Academy of Dermatology. 1996 November; 35(5 Pt 1): 757-60. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8912572
•
Mycosis fungoides presenting as annular erythema. Author(s): Lim DS, Murphy GM, Egan CA. Source: The British Journal of Dermatology. 2003 March; 148(3): 591. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12653756
•
Naevocentric erythema multiforme associated with herpes labialis. Author(s): McKenna KE. Source: The British Journal of Dermatology. 1999 November; 141(5): 954-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10583204
•
Necrolytic acral erythema: response to combination therapy with interferon and ribavirin. Author(s): Hivnor CM, Yan AC, Junkins-Hopkins JM, Honig PJ. Source: Journal of the American Academy of Dermatology. 2004 May; 50(5 Suppl): S1214. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15097946
Studies
53
•
Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGFreceptor inhibition. Author(s): Trojan A, Jacky E, Follath F, Dummer R. Source: Swiss Medical Weekly : Official Journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology. 2003 January 11; 133(1-2): 22-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12596092
•
Necrolytic migratory erythema as the only presenting sign of a glucagonoma. Author(s): Johnson SM, Smoller BR, Lamps LW, Horn TD. Source: Journal of the American Academy of Dermatology. 2003 August; 49(2): 325-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12894090
•
Necrolytic migratory erythema: case report and clinical review. Author(s): Adam DN, Cohen PD, Ghazarian D. Source: Journal of Cutaneous Medicine and Surgery. 2003 July-August; 7(4): 333-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14738101
•
Necrolytic migratory erythema: clinicopathologic study of 13 cases. Author(s): Pujol RM, Wang CY, el-Azhary RA, Su WP, Gibson LE, Schroeter AL. Source: International Journal of Dermatology. 2004 January; 43(1): 12-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14693015
•
Neonatal erythema multiforme major. Author(s): Johnston GA, Ghura HS, Carter E, Graham-Brown RA. Source: Clinical and Experimental Dermatology. 2002 November; 27(8): 661-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12472541
•
Neutrophilic dermatosis of the dorsal hands: a variant of erythema elevatum diutinum? Author(s): Ayoub N, Tomb R. Source: Archives of Dermatology. 2003 January; 139(1): 102. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12533183
•
Nodular scleritis and panuveitis with erythema elevatum diutinum. Author(s): Mitamura Y, Fujiwara O, Miyanishi K, Sato H, Saga K, Ohtsuka K. Source: American Journal of Ophthalmology. 2004 February; 137(2): 368-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14962440
54
Erythema
•
Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Author(s): Mark KA, Sparacio RM, Voigt A, Marenus K, Sarnoff DS. Source: Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]. 2003 June; 29(6): 600-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12786702
•
Objective measurement of minimal erythema and melanogenic doses using natural and solar-simulated light. Author(s): Poon TS, Kuchel JM, Badruddin A, Halliday GM, Barnetson RS, Iwaki H, Hatao M. Source: Photochemistry and Photobiology. 2003 October; 78(4): 331-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14626659
•
Occupational erythema-multiforme-like dermatitis from sensitization to costus resinoid, followed by flare-up and systemic contact dermatitis from betacyclocostunolide in a chemistry student. Author(s): Le Coz CJ, Lepoittevin JP. Source: Contact Dermatitis. 2001 May; 44(5): 310-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11379984
•
Occurrence of neutrophils and activated Th1 cells in UVB-induced erythema. Author(s): Terui T, Takahashi K, Funayama M, Terunuma A, Ozawa M, Sasai S, Tagami H. Source: Acta Dermato-Venereologica. 2001 January-February; 81(1): 8-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11411937
•
On Japanese baseball and erythema induratum of Bazin. Author(s): White WL. Source: The American Journal of Dermatopathology. 1997 August; 19(4): 318-22. Erratum In: Am J Dermatopathol 1997 October; 19(5): 555. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9261465
•
Onset of erythema nodosum during pregnancy: a case report. Author(s): Coaccioli S, Donati L, Di Cato L, Puxeddu A, Villani C. Source: Clin Exp Obstet Gynecol. 1998; 25(1-2): 40-1. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9743879
•
Oral and cutaneous lesions. Erythema multiforme. Author(s): Fantasia JE, Damm DD. Source: Gen Dent. 2001 March-April; 49(2): 149, 221. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12004692
Studies
55
•
Oral manifestations of erythema multiforme. Author(s): Ayangco L, Rogers RS 3rd. Source: Dermatologic Clinics. 2003 January; 21(1): 195-205. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12622281
•
Oral pathology quiz #30. Case number two. Erythema multiforme. Author(s): Cleveland DB, Doyle JL, Rinaggio J, Schneider LC. Source: J N J Dent Assoc. 2000 Fall; 71(4): 16-7, 54. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11326405
•
Orf and erythema multiforme in a child. Author(s): Ferrando MF, Leaute-Labreze C, Fleury H, Taieb A. Source: Pediatric Dermatology. 1997 March-April; 14(2): 154-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9144706
•
Papules with minimal perilesional erythema. Intermittently painful, yellow-white "bumps" drain chalky substance. Author(s): Levine N. Source: Geriatrics. 2004 March; 59(3): 34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15035577
•
Patchy erythema on the breasts. Author(s): Susser WS, Perry AE, Spencer SK. Source: Archives of Dermatology. 2001 April; 137(4): 495-500. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11295935
•
Pemphigus foliaceus and figurate erythema in a patient with prostate cancer. Author(s): Ota M, Sato-Matsumura KC, Matsumura T, Tsuji Y, Ohkawara A. Source: The British Journal of Dermatology. 2000 April; 142(4): 816-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10792242
•
Pentoxifylline attenuates UVB-induced cutaneous erythema. Author(s): Lowitt MH. Source: Dermatology (Basel, Switzerland). 2001; 202(1): 44-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11244228
•
Photo quiz. Erythema infectiosum. Author(s): Torgerson S, Elston DM. Source: Cutis; Cutaneous Medicine for the Practitioner. 2000 February; 65(2): 64, 81-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10696555
56
Erythema
•
Photosensitizing drugs may lower the narrow-band ultraviolet B (TL-01) minimal erythema dose. Author(s): Cameron H, Dawe RS. Source: The British Journal of Dermatology. 2000 February; 142(2): 389-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10730791
•
Precipitants in 42 cases of erythema multiforme. Author(s): Villiger RM, von Vigier RO, Ramelli GP, Hassink RI, Bianchetti MG. Source: European Journal of Pediatrics. 1999 November; 158(11): 929-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10541951
•
Progeroid syndrome with facial teleangiectatic erythema, posterior subcapsular cataracts, calcification of basal ganglia and atrium septum defect type 2. Author(s): Fryns JP, Dumoulin M, Hens G. Source: Genet Couns. 1999; 10(4): 395-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10631929
•
Prolonged erythema after facial laser resurfacing or phenol peel secondary to corticosteroid addiction. Author(s): Rapaport MJ, Rapaport V. Source: Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]. 1999 October; 25(10): 781-4; Discussion 785. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10594579
•
Psoralen-ultraviolet A-induced erythema: sensitivity correlates with the concentrations of psoralen in suction blister fluid. Author(s): Yeo UC, Shin JH, Yang JM, Park KB, Kim MM, Bok HS, Lee ES. Source: The British Journal of Dermatology. 2000 April; 142(4): 733-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10792224
•
Quantification of allergic and irritant patch test reactions using laser-Doppler flowmetry and erythema index. Author(s): Gawkrodger DJ, McDonagh AJ, Wright AL. Source: Contact Dermatitis. 1991 March; 24(3): 172-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1868699
•
Quantification of erythema and pigmentation using a videomicroscope and a computer. Author(s): Takiwaki H, Shirai S, Kanno Y, Watanabe Y, Arase S. Source: The British Journal of Dermatology. 1994 July; 131(1): 85-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8043425
Studies
57
•
Quantification of erythema using digital camera and computer-based colour image analysis: a multicentre study. Author(s): Setaro M, Sparavigna A. Source: Skin Res Technol. 2002 May; 8(2): 84-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12060471
•
Quantification of patient to patient variation of skin erythema developing as a response to radiotherapy. Author(s): Russell NS, Knaken H, Bruinvis IA, Hart AA, Begg AC, Lebesque JV. Source: Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology. 1994 March; 30(3): 213-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8209004
•
Quantitative aspects of ultraviolet erythema. Author(s): Diffey BL, Farr PM. Source: Clin Phys Physiol Meas. 1991 November;12(4):311-25. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1778030
•
Quantitative assessment of UV-induced pigmentation and erythema. Author(s): Kollias N, Baqer AH. Source: Photodermatol. 1988 February; 5(1): 53-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3353319
•
Quantitative color analysis of laryngeal erythema in chronic posterior laryngitis. Author(s): Hanson DG, Jiang J, Chi W. Source: Journal of Voice : Official Journal of the Voice Foundation. 1998 March; 12(1): 7883. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9619981
•
Quantitative detection of Borrelia burgdorferi in 2-millimeter skin samples of erythema migrans lesions: correlation of results with clinical and laboratory findings. Author(s): Liveris D, Wang G, Girao G, Byrne DW, Nowakowski J, McKenna D, Nadelman R, Wormser GP, Schwartz I. Source: Journal of Clinical Microbiology. 2002 April; 40(4): 1249-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11923340
•
Quantitative evaluation of drug-induced erythema by using a tristimulus colour analyzer: experimental design and data analysis. Author(s): Chan SY, Li Wan Po A. Source: Skin Pharmacol. 1993; 6(4): 298-312. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8198816
58
Erythema
•
Quinolones-induced acral erythema. Author(s): Bonnetblanc JM, Bernard P. Source: Therapie. 1996 September-October; 51(5): 601-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9138405
•
Radiotherapy and erythema nodosum. Author(s): Fearfield LA, Bunker CB. Source: The British Journal of Dermatology. 2000 January; 142(1): 189. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10819553
•
Recurrent erythema multiforme and chronic hepatitis C: efficacy of interferon alpha. Author(s): Dumas V, Thieulent N, Souillet AL, Jullien D, Faure M, Claudy A. Source: The British Journal of Dermatology. 2000 June; 142(6): 1248-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10848764
•
Recurrent erythema multiforme in a child. Author(s): Chan LY, Tang WY, Leung CY, Lo KK. Source: Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi / Hong Kong Academy of Medicine. 2000 September; 6(3): 331. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11025858
•
Recurrent erythema multiforme/Stevens-Johnson syndrome: response to mycophenolate mofetil. Author(s): Davis MD, Rogers RS 3rd, Pittelkow MR. Source: Archives of Dermatology. 2002 December; 138(12): 1547-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12472339
•
Reduction of minimal erythema dose by sweating. Author(s): Moehrle M, Koehle W, Dietz K, Lischka G. Source: Photodermatology, Photoimmunology & Photomedicine. 2000 December; 16(6): 260-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11132129
•
Relapsing polychondritis and erythema elevatum diutinum: an unusual association refractory to dapsone. Author(s): Delgado J, Gomez-Cerezo J, Siguenza M, Barbado FJ, Dupond JL, Vazquez JJ. Source: The Journal of Rheumatology. 2001 March; 28(3): 634-5. Erratum In: J Rheumatol 2001 May; 28(5): 1200. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11296973
Studies
59
•
Reticular telangiectatic erythema associated with an implantable cardioverter defibrillator: an underpublished entity? Author(s): Herbst RA, Weiss J. Source: Archives of Dermatology. 2003 January; 139(1): 100-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12533181
•
Reticulated rash on the thighs. Erythema ab igne. Author(s): Lim DS, Egan CA. Source: Postgraduate Medicine. 2004 March; 115(3): 81-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15038259
•
Risk factors for erythema nodosum leprosum. Author(s): Manandhar R, LeMaster JW, Roche PW. Source: International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association. 1999 September; 67(3): 270-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10575406
•
Sarcoid and erythema nodosum arthropathies. Author(s): Pettersson T. Source: Bailliere's Best Practice & Research. Clinical Rheumatology. 2000 September; 14(3): 461-76. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10985981
•
Selection of treatment of cefaclor-associated urticarial, serum sickness-like reactions and erythema multiforme by emergency pediatricians: lack of a uniform standard of care. Author(s): Joubert GI, Hadad K, Matsui D, Gloor J, Rieder MJ. Source: Can J Clin Pharmacol. 1999 Winter; 6(4): 197-201. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10601753
•
Selective up-regulation of matrix metalloproteinase-9 expression in human erythema migrans skin lesions of acute lyme disease. Author(s): Zhao Z, Chang H, Trevino RP, Whren K, Bhawan J, Klempner MS. Source: The Journal of Infectious Diseases. 2003 October 15; 188(8): 1098-104. Epub 2003 Oct 06. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14551878
•
Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Author(s): Moraes MO, Sampaio EP, Nery JA, Saraiva BC, Alvarenga FB, Sarno EN. Source: The British Journal of Dermatology. 2001 January; 144(1): 175-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11167702
60
Erythema
•
Skin redness following minimal sun exposure. Immediate erythema and edema appear at sites unprotected by clothing. Author(s): Levine N. Source: Geriatrics. 2003 December; 58(12): 14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14682093
•
Solitary and multiple erythema migrans in children: comparison of demographic, clinical and laboratory findings. Author(s): Arnez M, Pleterski-Rigler D, Luznik-Bufon T, Ruzic-Sabljic E, Strle F. Source: Infection. 2003 December; 31(6): 404-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14735383
•
Solitary erythema migrans in Georgia and South Carolina. Author(s): Felz MW, Chandler FW Jr, Oliver JH Jr, Rahn DW, Schriefer ME. Source: Archives of Dermatology. 1999 November; 135(11): 1317-26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10566829
•
Sun protection factor measurement of sunscreens is dependent on minimal erythema dose. Author(s): Damian DL, Halliday GM, Stc Barnetson R. Source: The British Journal of Dermatology. 1999 September; 141(3): 502-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10583055
•
Sunscreens: photoprotection of non-erythema endpoints relevant to skin cancer. Author(s): Young AR, Walker SL. Source: Photodermatology, Photoimmunology & Photomedicine. 1999 December; 15(6): 221-5. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10599971
•
Taking aim at erythema multiforme. How to spot target lesions and less typical presentations. Author(s): Katta R. Source: Postgraduate Medicine. 2000 January; 107(1): 87-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10649667
•
Testing the validity of erythema detection algorithms. Author(s): Riordan B, Sprigle S, Linden M. Source: Journal of Rehabilitation Research and Development. 2001 January-February; 38(1): 13-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11322466
Studies
61
•
The close association of Lymphadenitis tuberculosa and Erythema induratum of Bazin in Japanese patients. Author(s): Shimizu A, Takahashi A, Negishi I, Tamura A, Ishikawa O. Source: Dermatology (Basel, Switzerland). 2003; 207(4): 426-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14657647
•
The effect of methoxsalen dose on ultraviolet-A-induced erythema. Author(s): Ibbotson SH, Dawe RS, Farr PM. Source: The Journal of Investigative Dermatology. 2001 May; 116(5): 813-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11348476
•
The influence of patch test size and design on the distribution of erythema induced by sodium lauryl sulfate. Author(s): Nicholson M, Willis CM. Source: Contact Dermatitis. 1999 November; 41(5): 264-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10554060
•
Topical all-trans retinoic acid does not influence minimal erythema doses for UVB light in normal skin. Author(s): Smit JV, de Jong EM, de Jongh GJ, van de Kerkhof PC. Source: Acta Dermato-Venereologica. 2000 January-February; 80(1): 66-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10721847
•
Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. Author(s): Alomar A, Puig L, Gallardo CM, Valenzuela N. Source: Contact Dermatitis. 2003 October; 49(4): 185-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14996065
•
Transient subungual erythema in a patient with idiopathic Sweet's syndrome. Author(s): Viseux V, Boulenger A, Jestin B, Plantin P. Source: Journal of the American Academy of Dermatology. 2003 September; 49(3): 554-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12963933
•
Treatment of eosinophilic annular erythema with chloroquine. Author(s): Kahofer P, Grabmaier E, Aberer E. Source: Acta Dermato-Venereologica. 2000 January-February; 80(1): 70-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10721850
62
Erythema
•
Tropical-wood-induced bullous erythema multiforme. Author(s): Shimizu S, Chen KR, Pratchyapruit WO, Shimizu H. Source: Dermatology (Basel, Switzerland). 2000; 200(1): 59-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10681619
•
Ultraviolet protection by summer textiles. Ultraviolet transmission measurements verified by determination of the minimal erythema dose with solar-simulated radiation. Author(s): Gambichler T, Avermaete A, Bader A, Altmeyer P, Hoffmann K. Source: The British Journal of Dermatology. 2001 March; 144(3): 484-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11260003
•
Ultraviolet radiation-induced erythema in human skin. Author(s): Harrison GI, Young AR. Source: Methods (San Diego, Calif.). 2002 September; 28(1): 14-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12231183
•
Ultraviolet-radiation-induced erythema and suppression of contact hypersensitivity responses in patients with polymorphic light eruption. Author(s): van de Pas CB, Kelly DA, Seed PT, Young AR, Hawk JL, Walker SL. Source: The Journal of Investigative Dermatology. 2004 February; 122(2): 295-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15009708
•
Underlying causes of erythema nodosum. Lesions may provide clue to systemic disease. Author(s): Brodell RT, Mehrabi D. Source: Postgraduate Medicine. 2000 November; 108(6): 147-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11098265
•
Unusual annular erythema associated with myelodysplastic syndrome. Author(s): Yamamoto T, Soejima K, Yokozeki H, Koyano T, Katayama I, Nishioka K. Source: Dermatology (Basel, Switzerland). 2001; 202(1): 70-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11244236
•
Unusual lymphoma manifestations: case 1. Natural killer cell leukemia with dermal erythema and vascular epidermal growth factor production. Author(s): Gear RB, Heffelfinger S, Flessa HC. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2004 February 1; 22(3): 557-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14752078
Studies
63
•
Use of human immunoglobulin for treatment of severe erythema multiforme in a cat. Author(s): Byrne KP, Giger U. Source: J Am Vet Med Assoc. 2002 January 15; 220(2): 197-201, 183-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12126130
•
Use of mycophenolate mofetil in erythema nodosum. Author(s): Boyd AS. Source: Journal of the American Academy of Dermatology. 2002 December; 47(6): 968-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12451393
•
UVB photoprotection with antioxidants: effects of oral therapy with d-alphatocopherol and ascorbic acid on the minimal erythema dose. Author(s): Mireles-Rocha H, Galindo I, Huerta M, Trujillo-Hernandez B, Elizalde A, Cortes-Franco R. Source: Acta Dermato-Venereologica. 2002; 82(1): 21-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12013192
•
Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Author(s): Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Source: Gastroenterology. 2002 September; 123(3): 714-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12198697
•
Varicella zoster virus infection associated with erythema multiforme in children. Author(s): Prais D, Grisuru-Soen G, Barzilai A, Amir J. Source: Infection. 2001 January-February; 29(1): 37-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11261757
•
Very low dose acyclovir can be effective as prophylaxis for post-herpetic erythema multiforme. Author(s): Williams RE, Lever R. Source: The British Journal of Dermatology. 1991 January; 124(1): 111. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1993137
•
Vesicular erythema migrans. Author(s): Goldberg NS, Forseter G, Nadelman RB, Schwartz I, Jorde U, McKenna D, Holmgren D, Bittker S, Montecalvo M, Wormser GP. Source: Archives of Dermatology. 1992 November; 128(11): 1495-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1444504
64
Erythema
•
Virus induced erythema multiforme and Stevens-Johnson syndrome. Author(s): Choy AC, Yarnold PR, Brown JE, Kayaloglou GT, Greenberger PA, Patterson R. Source: Allergy Proc. 1995 July-August; 16(4): 157-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8566721
•
Vulvar erythema and induration. Extraintestinal Crohn's disease of the vulva. Author(s): Patton LW, Elgart ML, Williams CM. Source: Archives of Dermatology. 1990 October; 126(10): 1351-2, 1354-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2221942
•
Vulvar erythema. Vulvitis chronica plasmacellularis (Zoon's vulvitis). Author(s): McCreedy CA, Melski JW. Source: Archives of Dermatology. 1990 October; 126(10): 1352-3, 1356. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2221943
•
What is erythema multiforme? Author(s): Weston WL. Source: Pediatric Annals. 1996 February; 25(2): 106-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8822035
•
What is going on in erythema multiforme? Author(s): Roujeau JC. Source: Dermatology (Basel, Switzerland). 1994; 188(4): 249-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8193394
•
What is your assessment? Erythema infectiosum. Author(s): Hayden-Difazio N. Source: Pediatric Nursing. 1994 November-December; 20(6): 616-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7708465
•
What's your assessment? Erythema multiforme. Author(s): Bielan B. Source: Dermatology Nursing / Dermatology Nurses' Association. 2003 February; 15(1): 41-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12656002
65
CHAPTER 2. NUTRITION AND ERYTHEMA Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and erythema.
Finding Nutrition Studies on Erythema The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “erythema” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
66
Erythema
The following information is typical of that found when using the “Full IBIDS Database” to search for “erythema” (or a synonym): •
Allergic contact dermatitis to tea tree oil with erythema multiforme-like id reaction. Author(s): Division of Dermatology, McGill University Health Center, Royal Victoria Hospital, Montreal, Quebec, Canada. Source: Khanna, M Qasem, K Sasseville, D Am-J-Contact-Dermat. 2000 December; 11(4): 238-42 1046-199X
•
Aloe vera does not affect cutaneous erythema and blood flow following ultraviolet B exposure. Author(s): Department of Dermatology, University of Miami School of Medicine, Florida. Source: Crowell, J Hilsenbeck, S Penneys, N Photodermatol. 1989 October; 6(5): 237-9 0108-9684
•
Anti-inflammatory action of pale sulfonated shale oil (ICHTHYOL pale) in UVB erythema test. Source: Warnecke, J Wendt, A Inflamm-Res. 1998 February; 47(2): 75-8 1023-3830
•
Common triggers of facial erythema in adults. Source: Heiberger, K Brenman, S JAAPA. 2001 September; 14(9): 49-50, 53-4
•
Contact dermatitis associated with an erythema multiforme-like eruption. Author(s): The Dermatology Clinic, Aalborg, Denmark. Source: Veien, N K Hausen, B M Am-J-Contact-Dermat. 2000 December; 11(4): 235-7 1046-199X
•
High incidence of chemotherapy-induced acral erythema in female patients with nonHodgkin's lymphoma treated with the VACOP-B regimen. Author(s): Department of Medicine III, Osaka University Medical School, Japan. Source: Ogawa, H Sugiyama, H Tani, Y Soma, T Yamagami, T Tatekawa, T Oji, Y Kubota, T Kimura, T Inoue, K Nakagawa, M Sasaki, K Matsunashi, T Miyake, S Kishimoto, T Leuk-Lymphoma. 1998 March; 29(1-2): 171-7 1042-8194
•
Influence of fish oil supplementation on the minimal erythema dose in humans. Author(s): Department of Dermatology, Baylor College of Medicine Houston, Tex. Source: Orengo, I F Black, H S Wolf, J E Arch-Dermatol-Res. 1992; 284(4): 219-21 03403696
•
Linear IgA dermatosis presenting with erythema annulare centrifugum lesions: report of three cases in adults. Author(s): Department of Dermatology, University Medical Center Benjamin Franklin, The Free University of Berlin, Germany. Source: Dippel, E Orfanos, C E Zouboulis, C J-Eur-Acad-Dermatol-Venereol. 2000 March; 15(2): 167-70 0926-9959
•
Suppression of UV-induced erythema by topical treatment with melatonin. Influence of the application time point. Author(s): Department of Dermatology, Friedrich-Schiller-University Jena, Jena,
[email protected] Source: Fischer, T Bangha, E Elsner, P Kistler, G S Biol-Signals-Recept. 1999 Jan-April; 8(1-2): 132-5 1422-4933
•
Suspected necrolytic migratory erythema associated with chronic hepatopathy in a cat. Author(s): Nine Lives Veterinary Practice for Cats, Hockley Heath, West Midlands. Source: Godfrey, D R Rest, J R J-Small-Anim-Pract. 2000 July; 41(7): 324-8 0022-4510
Nutrition
67
•
Terrien's marginal degeneration associated with erythema elevatum diutinum. Author(s): Department of Ophthalmology, Tokyo Dental College, Chiba, Japan. Source: Shimazaki, J Yang, H Y Shimmura, S Tsubota, K Cornea. 1998 May; 17(3): 342-4 0277-3740
•
The effect of topical L-selenomethionine on minimal erythema dose of ultraviolet irradiation in humans. Author(s): Department of Pathology, Scripps Clinic and Research Foundation, La Jolla, California. Source: Burke, K E Burford, R G Combs, G F French, I W Skeffington, D R Photodermatol-Photoimmunol-Photomed. 1992 April; 9(2): 52-7 0905-4383
•
UV-induced erythema model: a tool in dermatopharmacology for testing the topical activity of non-steroidal anti-inflammatory agents in man. Author(s): Clinical Pharmacology Research Unit, Hospital Sant Pau, Autonomous University of Barcelona, Spain. Source: Torrent, J Izquierdo, I Barbanoj, M J Moreno, J Lauroba, J Jane, F Methods-FindExp-Clin-Pharmacol. 1988 May; 10(5): 341-5 0379-0355
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
68
Erythema
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMDHealth: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
The following is a specific Web list relating to erythema; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Minerals Iron Source: Healthnotes, Inc.; www.healthnotes.com Magnesium Source: Integrative Medicine Communications; www.drkoop.com Zinc Source: Integrative Medicine Communications; www.drkoop.com
69
CHAPTER 3. ALTERNATIVE MEDICINE AND ERYTHEMA Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to erythema. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to erythema and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “erythema” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to erythema: •
A fatal case of erythema necroticans. Author(s): Davis SV, Shenoi SD, Balachandran C, Pai SB. Source: Indian J Lepr. 2002 April-June; 74(2): 145-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12708733
•
A placebo controlled clinical trial investigating the efficacy of a homeopathic afterbite gel in reducing mosquito bite induced erythema. Author(s): Hill N, Stam C, Tuinder S, van Haselen RA. Source: European Journal of Clinical Pharmacology. 1995; 49(1-2): 103-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8751030
•
Airborne erythema-multiforme-like eruption due to pyrethrum. Author(s): Garcia-Bravo B, Rodriguez-Pichardo A, de Pierola SF, Camacho F.
70
Erythema
Source: Contact Dermatitis. 1995 December; 33(6): 433. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8706408 •
Allergic contact dermatitis to tea tree oil with erythema multiforme-like id reaction. Author(s): Khanna M, Qasem K, Sasseville D. Source: American Journal of Contact Dermatitis : Official Journal of the American Contact Dermatitis Society. 2000 December; 11(4): 238-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11123417
•
Aloe vera does not affect cutaneous erythema and blood flow following ultraviolet B exposure. Author(s): Crowell J, Hilsenbeck S, Penneys N. Source: Photodermatol. 1989 October; 6(5): 237-9. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2616366
•
Anti-inflammatory effect of hamamelis lotion in a UVB erythema test. Author(s): Hughes-Formella BJ, Bohnsack K, Rippke F, Benner G, Rudolph M, Tausch I, Gassmueller J. Source: Dermatology (Basel, Switzerland). 1998; 196(3): 316-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9621139
•
Anti-inflammatory efficacy of topical preparations with 10% hamamelis distillate in a UV erythema test. Author(s): Hughes-Formella BJ, Filbry A, Gassmueller J, Rippke F. Source: Skin Pharmacology and Applied Skin Physiology. 2002 March-April; 15(2): 12532. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11867970
•
Carotenoid supplementation reduces erythema in human skin after simulated solar radiation exposure. Author(s): Lee J, Jiang S, Levine N, Watson RR. Source: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.). 2000 February; 223(2): 170-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10654620
•
Carotenoids and carotenoids plus vitamin E protect against ultraviolet light-induced erythema in humans. Author(s): Stahl W, Heinrich U, Jungmann H, Sies H, Tronnier H. Source: The American Journal of Clinical Nutrition. 2000 March; 71(3): 795-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10702175
•
Changes of minimal erythema dose after water and salt water baths. Author(s): Gambichler T, Schropl F.
Alternative Medicine 71
Source: Photodermatology, Photoimmunology & Photomedicine. 1998 June-August; 14(3-4): 109-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9779497 •
Contact dermatitis associated with an erythema multiforme-like eruption. Author(s): Veien NK, Hausen BM. Source: American Journal of Contact Dermatitis : Official Journal of the American Contact Dermatitis Society. 2000 December; 11(4): 235-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11187214
•
Dietary fish-oil supplementation in humans reduces UVB-erythemal sensitivity but increases epidermal lipid peroxidation. Author(s): Rhodes LE, O'Farrell S, Jackson MJ, Friedmann PS. Source: The Journal of Investigative Dermatology. 1994 August; 103(2): 151-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8040603
•
Effect of oral administration ofHypericum perforatum extract (St. John's Wort) on skin erythema and pigmentation induced by UVB, UVA, visible light and solar simulated radiation. Author(s): Schempp CM, Winghofer B, Muller K, Schulte-Monting J, Mannel M, Schopf E, Simon JC. Source: Phytotherapy Research : Ptr. 2003 February; 17(2): 141-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12601676
•
Effects of hypnotic suggestions on ultraviolet B radiation-induced erythema and skin blood flow. Author(s): Zachariae R, Oster H, Bjerring P. Source: Photodermatology, Photoimmunology & Photomedicine. 1994 August; 10(4): 154-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7803226
•
Environmental influences on UVB erythema. Author(s): Gollhausen R, Przybilla B, Galosi A, Kohler K, Ring J. Source: Photodermatol. 1987 June; 4(3): 148-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3684737
•
Erythema ab igne caused by frequent hot bathing. Author(s): Lin SJ, Hsu CJ, Chiu HC. Source: Acta Dermato-Venereologica. 2002; 82(6): 478-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12575865
•
Erythema and desquamation after high-dose methotrexate. Author(s): Doyle LA, Berg C, Bottino G, Chabner B.
72
Erythema
Source: Annals of Internal Medicine. 1983 May; 98(5 Pt 1): 611-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=6601925 •
Erythema annulare centrifugum and Hodgkin's disease: association with disease activity. Author(s): Leimert JT, Corder MP, Skibba CA, Gingrich RD. Source: Archives of Internal Medicine. 1979 April; 139(4): 486-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=435007
•
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip. Author(s): Rosenbaum MR, Kerlin RL. Source: J Am Vet Med Assoc. 1995 November 15; 207(10): 1315-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7591926
•
Erythema multiforme-like eruptions due to exotic woods and ordinary plants: Part I. Author(s): Fisher AA. Source: Cutis; Cutaneous Medicine for the Practitioner. 1986 February; 37(2): 101-2, 104. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2937616
•
Erythema multiforme-like eruptions due to topical medications: Part II. Author(s): Fisher AA. Source: Cutis; Cutaneous Medicine for the Practitioner. 1986 March; 37(3): 158, 160-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2937617
•
Erythema nodosum and non-Hodgkin's lymphoma. Author(s): Thomson GT, Keystone EC, Sturgeon JF, Fornasier V. Source: The Journal of Rheumatology. 1990 March; 17(3): 383-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2332863
•
Erythema-multiforme-like contact dermatitis due to capsicum. Author(s): Raccagni AA, Bardazzi F, Baldari U, Righini MG. Source: Contact Dermatitis. 1995 November; 33(5): 353-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8565498
•
Erythema-multiforme-like eruption following allergic contact dermatitis from sesquiterpene lactones in herbal medicine. Author(s): Mateo MP, Velasco M, Miquel FJ, de la Cuadra J. Source: Contact Dermatitis. 1995 December; 33(6): 449-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8706423
Alternative Medicine 73
•
Etoposide-related acral erythema. Author(s): Portal I, Cardenal F, Garcia-del-Muro X. Source: Cancer Chemotherapy and Pharmacology. 1994; 34(2): 181. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8194170
•
Generalized erythema-multiforme-like eruption following allergic contact dermatitis. Author(s): Torinuki W. Source: Contact Dermatitis. 1990 September; 23(3): 202-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2149331
•
High incidence of chemotherapy-induced acral erythema in female patients with nonHodgkin's lymphoma treated with the VACOP-B regimen. Author(s): Ogawa H, Sugiyama H, Tani Y, Soma T, Yamagami T, Tatekawa T, Oji Y, Kubota T, Kimura T, Inoue K, Nakagawa M, Sasaki K, Matsunashi T, Miyake S, Kishimoto T. Source: Leukemia & Lymphoma. 1998 March; 29(1-2): 171-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9638986
•
Influence of fish oil supplementation on the minimal erythema dose in humans. Author(s): Orengo IF, Black HS, Wolf JE Jr. Source: Archives of Dermatological Research. 1992; 284(4): 219-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1417068
•
Interstitial and granulomatous drug reaction presenting as erythema nodosum-like lesions. Author(s): Lee MW, Choi JH, Sung KJ, Moon KC, Koh JK. Source: Acta Dermato-Venereologica. 2002; 82(6): 473-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12575862
•
Local erythematous dermatitis after intravenous docetaxel. Author(s): Hirai K, Ishiko O, Nakajima S, Kanaoka Y, Nakamura Y, Oiso N, Ishii M, Ogita S. Source: Gynecologic and Obstetric Investigation. 2002; 53(2): 118-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11961387
•
Localized epidermal necrolysis (erythema multiforme-like reaction) following intravenous injection of vinblastine. Author(s): Arias D, Requena L, Hasson A, Gutierrez M, Domine M, Martin L, Barat A. Source: Journal of Cutaneous Pathology. 1991 October; 18(5): 344-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1761786
74
Erythema
•
Necrolytic migratory erythema without glucagonoma: the role of dietary essential fatty acids. Author(s): Blackford S, Wright S, Roberts DL. Source: The British Journal of Dermatology. 1991 November; 125(5): 460-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1751353
•
Nummular erythema in a patient with chronic daily headache. Author(s): Campbell WW, Sartori RJ. Source: Headache. 2003 November-December; 43(10): 1112. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14629249
•
Palmar-plantar erythema associated with combination chemotherapy. Author(s): Pagliuca A, Kaczmarski R, Mufti GJ. Source: Postgraduate Medical Journal. 1990 March; 66(773): 242-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1694580
•
Penetration of solar erythemal UV radiation in the shade of two common Australian trees. Author(s): Parisi AV, Willey A, Kimlin MG, Wong JC. Source: Health Physics. 1999 June; 76(6): 682-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10334585
•
Pericarditis associated with acral erythema of chemotherapy: a syndrome of cutaneous and serosal toxicities? Author(s): Vukelja SJ, Sharkey MJ, Baker WJ, Berger TC. Source: Cutis; Cutaneous Medicine for the Practitioner. 1993 August; 52(2): 89-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8404022
•
Prevention of experimentally induced irritant contact dermatitis by extracts of Isatis tinctoria compared to pure tryptanthrin and its impact on UVB-induced erythema. Author(s): Heinemann C, Schliemann-Willers S, Oberthur C, Hamburger M, Elsner P. Source: Planta Medica. 2004 May; 70(5): 385-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15124080
•
Recurrent erythema nodosum associated with Echinacea herbal therapy. Author(s): Soon SL, Crawford RI. Source: Journal of the American Academy of Dermatology. 2001 February; 44(2): 298-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11174391
•
Reduction in 8-methoxypsoralen immersion time alters the erythemal response to bath PUVA. Author(s): Azurdia RM, Dean MP, Rhodes LE.
Alternative Medicine 75
Source: Photodermatology, Photoimmunology & Photomedicine. 2000 August; 16(4): 186-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11019945 •
Salt water bathing prior to UVB irradiation leads to a decrease of the minimal erythema dose and an increased erythema index without affecting skin pigmentation. Author(s): Schempp CM, Muller K, Schulte-Monting J, Schopf E, Simon JC. Source: Photochemistry and Photobiology. 1999 March; 69(3): 341-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10089826
•
Single dose erythemas of skin in hyperbaric radiation therapy. Author(s): Parker RG, Wootton P. Source: Radiol Clin Biol. 1967; 36(1): 24-6. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=6030091
•
Solar ultraviolet-induced erythema in human skin and nuclear factor-kappa-Bdependent gene expression in keratinocytes are modulated by a French maritime pine bark extract. Author(s): Saliou C, Rimbach G, Moini H, McLaughlin L, Hosseini S, Lee J, Watson RR, Packer L. Source: Free Radical Biology & Medicine. 2001 January 15; 30(2): 154-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11163532
•
Sunbed use in relation to phenotype, erythema, sunscreen use and skin diseases. A questionnaire survey among Swedish adolescents. Author(s): Boldeman C, Beitner H, Jansson B, Nilsson B, Ullen H. Source: The British Journal of Dermatology. 1996 November; 135(5): 712-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8977669
•
Supplementation with beta-carotene or a similar amount of mixed carotenoids protects humans from UV-induced erythema. Author(s): Heinrich U, Gartner C, Wiebusch M, Eichler O, Sies H, Tronnier H, Stahl W. Source: The Journal of Nutrition. 2003 January; 133(1): 98-101. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12514275
•
Taxol-induced acral erythema. Author(s): de Argila D, Dominguez JD, Iglesias L. Source: Dermatology (Basel, Switzerland). 1996; 192(4): 377-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8864381
•
The spectrum of contact urticaria. Wheals, erythema, and pruritus. Author(s): Kligman AM.
76
Erythema
Source: Dermatologic Clinics. 1990 January; 8(1): 57-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2302863 •
Treatment of cold erythema multiforme with jia wei gui zhi tang (reinforced decoction of Ramulus Cinnamomi). Author(s): Jiang C. Source: J Tradit Chin Med. 1986 March; 6(1): 27-8. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3736097
•
Unusual erythema of the proximal nail fold and onychodermal band. Author(s): Kowal-Vern A, Eng A. Source: Cutis; Cutaneous Medicine for the Practitioner. 1993 July; 52(1): 43-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8354087
•
Zinc and essential fatty acid therapy for necrolytic migratory erythema. Author(s): Burton JL. Source: Archives of Dermatology. 1993 February; 129(2): 246. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8434987
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMDHealth: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
Alternative Medicine 77
The following is a specific Web list relating to erythema; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Angioedema Source: Integrative Medicine Communications; www.drkoop.com Burns Source: Healthnotes, Inc.; www.healthnotes.com Cellulitis Source: Integrative Medicine Communications; www.drkoop.com Cold Sores Source: Healthnotes, Inc.; www.healthnotes.com Food Poisoning Source: Integrative Medicine Communications; www.drkoop.com Genital Herpes Source: Healthnotes, Inc.; www.healthnotes.com Inflammatory Bowel Disease Source: Integrative Medicine Communications; www.drkoop.com Lupus Source: Integrative Medicine Communications; www.drkoop.com Pancreatic Insufficiency Source: Healthnotes, Inc.; www.healthnotes.com Photodermatitis Source: Integrative Medicine Communications; www.drkoop.com Photosensitivity Source: Healthnotes, Inc.; www.healthnotes.com Raynaud's Phenomenon Source: Integrative Medicine Communications; www.drkoop.com Skin Infection Source: Integrative Medicine Communications; www.drkoop.com Sunburn Source: Integrative Medicine Communications; www.drkoop.com Systemic Lupus Erythematosus Source: Healthnotes, Inc.; www.healthnotes.com
78
Erythema
Systemic Lupus Erythematosus Source: Integrative Medicine Communications; www.drkoop.com Ulcerative Colitis Source: Integrative Medicine Communications; www.drkoop.com •
Alternative Therapy Cupping Alternative names: cupping method cupping therapy; called the "horn method" in ancient China Source: The Canoe version of A Dictionary of Alternative-Medicine Methods, by Priorities for Health editor Jack Raso, M.S., R.D. Hyperlink: http://www.canoe.ca/AltmedDictionary/c.html
•
Herbs and Supplements Alfalfa Alternative names: Medicago sativa Source: Healthnotes, Inc.; www.healthnotes.com Aloe Alternative names: Aloe vera L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Androstenedione Source: Healthnotes, Inc.; www.healthnotes.com Astragalus Alternative names: Astragalus membranaceus Source: Healthnotes, Inc.; www.healthnotes.com Corticosteroids Source: Prima Communications, Inc.www.personalhealthzone.com Dehydroepiandrosterone (DHEA) Source: Healthnotes, Inc.; www.healthnotes.com Dehydroepiandrosterone (DHEA) Source: Integrative Medicine Communications; www.drkoop.com DHEA Source: Integrative Medicine Communications; www.drkoop.com DHEA (Dehydroepiandrosterone) Source: Prima Communications, Inc.www.personalhealthzone.com Echinacea Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
Alternative Medicine 79
Glycyrrhiza Alternative names: Licorice; Glycyrrhiza glabra L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org PABA Source: Healthnotes, Inc.; www.healthnotes.com Pregnenolone Source: Healthnotes, Inc.; www.healthnotes.com Pygeum Alternative names: African Prune; Pygeum africanum Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Sanguinaria Alternative names: Bloodroot; Sanguinaria canadensis L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Uncaria Catclaw Alternative names: Cat's Claw, Uno de Gato; Uncaria tomentosa (Willd.) D.C. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
81
CHAPTER 4. PATENTS ON ERYTHEMA Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.8 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “erythema” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on erythema, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Erythema By performing a patent search focusing on erythema, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We
8Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
82
Erythema
will tell you how to obtain this information later in the chapter. The following is an example of the type of information that you can expect to obtain from a patent search on erythema: •
Composition and method of treating depigmentation disorders Inventor(s): Schallreuter; Karin U. (Quickborn, DE), Wood; John M. (Quickborn, DE) Assignee(s): Stiefel Laboratories, Inc. (Coral Gables, FL) Patent Number: 5,433,942 Date filed: November 15, 1993 Abstract: Vitiligo and other tyrosinase-positive depigmentation disorders are treated by topical application of a pseudocatalase and subsequent exposure to a sub-minimal erythema dose of UVB light. After a course of treatment, pigmentation of the affected areas can be maintained by treatment with the pseudocatalases without UVB light treatment. The preferred pseudocatalases are transition metal co-ordination complexes, especially manganese (II) bicarbonate. Excerpt(s): This application was filed under 35 USC.sctn. 371 through PCT/GB92/00878, filed May 15, 1992. The present invention relates to the treatment of tyrosinase-positive depigmentation disorders and has particular application to the treatment of vitiligo. It provides compositions for said treatment and methods of said treatment. Vitiligo is a chronic depigmentation disorder in which the patient has unsightly white patches or spots which are caused by localized loss of pigment and are very liable to sunburn. Although the condition is not debilitating, it is often emotionally stressful to the patient. The cause presently is unknown but it has been speculated that it results from an autoimmune response, involvement of the nervous system or a toxic effect on melanocytes. Usually, the only treatment is the use of skin-colouring cosmetics to disguise the patches or, in the case of Blacks and Indians, of depigmenting agents such as hydroquinone to depigment the remaining pigmented skin. Some limited success in treatment has been reported using the so-called PUVA method. Web site: http://www.delphion.com/details?pn=US05433942__
•
Compositions and methods for inhibiting photoaging of skin Inventor(s): Fisher; Gary J. (Ann Arbor, MI), Kang; Sewon (Ann Arbor, MI), Voorhees; John J. (Ann Arbor, MI) Assignee(s): Regents of the University of Michigan () Patent Number: 6,365,630 Date filed: July 13, 2000 Abstract: Compositions and methods are provided for ameliorating various effects of UVA and UVB radiation from the sun. The compositions including an ingredient that prevents photoaging from MED and subMED radiation, such as a retinoid, certain other compounds (such as N-acetylcysteine, 2-furildioxime, and vitamin C) and optionally other MMP inhibitors such as tetracyclines and/or compounds that inhibit the P-450mediated metabolism of retinoids such as ketoconazole and other azole compounds. In the method, the composition is applied prior to exposure to the sun; depending upon the ingredients used in the composition, application should be from 7 to 48 hours prior to exposure. Compounds that prevent erythema (skin reddening, sunburn) do not necessarily protect against UV-mediated elevation of MMP levels and activity, and
Patents 83
similarly compounds that prevent UV-mediated elevation of MMP levels and activity are not necessarily effective against UV-induced erythema. Excerpt(s): This invention involves photoprotection of human skin. More particularly, the invention relates to compositions for topical application and to methods for using the same to inhibit photoaging of skin, especially as induced by exposure to incidential and/or direct radiation as would occur daily. Separately, this invention provides novel methods and compositions for reducing UV-induced erythema (skin reddening). Photoaging is a term presently used to describe the changes in appearance and/or function of human skin as a result of repeated exposure to sunlight, and especially regarding wrinkles and other changes in the appearance of the skin. Solar radiation reaching the earth's surface that effects and enables various animals, including humans, comprises ultraviolet (UV) (.lambda.<400 nm), visible (400 nm<.lambda.<700 nm), and infrared (IR) (.lambda.>700 nm). UV radiation is generally divided into UVA (320-400 nm), UVB (290-320 nm), and UVC (<290 nm); UVC radiation is blocked from reaching the earth's surface by stratospheric ozone. The ultraviolet (UV) component of sunlight, particularly UVB, is generally believed to be the principal causative agent in photoaging. Web site: http://www.delphion.com/details?pn=US06365630__ •
Cosmetic composition containing spindle shaped fine particles of titanium dioxide Inventor(s): Kumagaya; Shigenori (Yokohama, JP), Ogawa; Katsuki (Yokohama, JP), Takata; Sadaki (Yokohama, JP) Assignee(s): Shiseido Company, Ltd. (Tokyo, JP) Patent Number: 6,123,927 Date filed: July 14, 1997 Abstract: This invention relates to a cosmetic composition having a UV blocking action in a wide region from UVB to UVA and capable of preventing erythema and melanism due to burning by the sun.The conventional fine particles of titanium dioxide are insufficient in the effect for blocking ultraviolet ray and, furthermore, the feeling to the skin becomes poorer, and the finish becomes powdery.This invention resides in the formulation, into a cosmetic composition, of spindle shaped fine particles of titanium dioxide having an average short diameter of 0.03 to 0.06.mu.m, an average long diameter of 0.08 to 0.12.mu.m, and an aspect ratio (long diameter/short diameter) of 2 to 4 or the spindle shaped fine particles and a metal oxide having an average particle size of 0.2.mu.m or more. Excerpt(s): The present invention relates to a cosmetic composition having a UV blocking action in a wide region from UVB to UVA and capable of preventing erythema and melanism due to burning by the sun. In the past, sun screens, foundations, etc. have been known as cosmetic compositions for preventing sunburn. In these cosmetic compositions UV absorbents and UV blocking agents are formulated as substances for blocking UV rays. In these, fine particles of titanium dioxide having an average particle size of 0.03 to 0.05.mu.m have been generally used as UV blocking agents. The applicant of the present invention previously obtained a cosmetic composition having a high UV protective effect by formulating a combination of spherical fine particles of titanium dioxide having an average particle size of 0.01 to 0.10.mu.m and needle type (spindle shaped) fine particles of titanium dioxide having a short diameter of 0.005 to 0.02.mu.m and a long diameter of 0.01 to 0.10.mu.m (Japanese Patent Application No. 5-340571 (i.e.,
84
Erythema
JP-A-7-165532)). However, these fine particles of titanium dioxide are hard to disperse in the single particle state in a cosmetic composition since the particle size is small. Therefore, in actuality, they exist as considerably large aggregates. Further, when metal oxides having a large relative particle size are formulated in a cosmetic composition, the metal oxides form the nucleus for easy formation of aggregates and the effect for preventing UV rays inherently exhibited remarkably falls. In particular, in a solid foundation, since the components are a powder and oil in a paste composition, the fine particles of powder easily aggregate as nuclei the relatively large particle size powder. The above trend becomes particularly conspicuous. Accordingly, even if fine particles of titanium dioxide are formulated in the cosmetic composition, it is hard to obtain the desired UV protecting effect. Even if the amount of formulation is increased, the effect for protecting the UV rays will not rise, the feeling to the skin will become poorer, the finish will become powdery, and other defects will appear. Web site: http://www.delphion.com/details?pn=US06123927__ •
Cream composition for skin care Inventor(s): Jeong; Jee Hean (Suwon, KR), Kim; Jin Wook (Yongin, KR), Park; Chang Seo (Kwachon, KR) Assignee(s): Doosan Corporation (KR) Patent Number: 6,372,236 Date filed: October 18, 2000 Abstract: Disclosed are compositions for skin care and their medicinal uses. The compositions are identical in lipid constituents and structural properties to that of human stratum corneum. They comprise the major constituents for the lipid lamellar of the stratum corneum, including ceramides, cholesterol and fatty acids, the major constituents for epidermal cell membranes, including phospholipids, and physiologically active substances, including phytosphingosine and its derivatives. Without causing side effects, the cream composition for skin care is of much better skin penetration and water-retention capacity than are conventional compositions comprised of ceramide and other components in forms different from those of human skin. In addition to providing inhibitory activity against skin microorganisms, the cream composition brings about an improvement in the wrinkle condition of the skin, so that it can be applied to cosmetics. Also, it can be used as a medicinal material for the therapeutic treatment of inflammation, such as thermic erythema caused by IR and/or UV light. Excerpt(s): The present invention relates to a composition for skin care, which is identical in lipid composition and structural properties to intercellular lipid lamella of stratum corneum. In terms of structure, the skin can be divided into dermis, epidermis, and stratum corneum in accordance with the differentiation of keratinocyte cells from a basal layer. Particularly, the stratum corneum, which is the outermost layer of the skin, is primarily responsible for protecting the skin from external physical and chemical damage as well as functioning as a barrier to prevent the loss of internal water. Deeply understanding the structure of the skin and the physical and chemical properties of epidermal lipid constituents is indispensable for and helpful in developing skin applications for maintaining the skin in healthy condition. Web site: http://www.delphion.com/details?pn=US06372236__
Patents 85
•
Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition and composition obtained Inventor(s): Breton; Lionel (Versailles, FR), Cohen; Catherine (Paris, FR), De Lacharriere; Olivier (Paris, FR) Assignee(s): L'Oreal (Paris, FR) Patent Number: 5,658,581 Date filed: December 28, 1995 Abstract: The invention relates to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha anlagonist in a cosmetic, pharmaceutical or dermatological composition for treating sensitive skins. It relates especially to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist for preventing and/or combating skin irritations and/or sores and/or erythema and/or dysaesthetic sensations and/or sensations of inflammation and/or pruritus and/or prickling and/or tingling and/or discomfort and/or tightness of the skin and/or mucosae. It also relates to a composition containing a histamine antagonist, an interleukin-1 anlagonist and/or a TNF alpha antagonist which limits or eliminates the irritant side-effects of certain products, and in particular of certain cosmetic, dermatological or pharmaceutical active agents. Excerpt(s): The present invention relates to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition for topical application, intended, in particular, for the treatment of sensitive skins, as well as to a composition containing a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist for the purpose of decreasing or even abolishing the irritant effects of certain products, and in particular of certain active agents used in the cosmetics, pharmaceutical or dermatological field. It is known that some skins are more sensitive than others. The symptoms of sensitive skin were hitherto poorly characterized and the problem of these skins was, as a result, poorly defined; nobody understood precisely the process involved in sensitivity--nonallergic cutaneous hyperreactivity--of the skin. Some workers believed that a sensitive skin was a skin which reacted to cosmetic products, others that such a skin was one which reacted to several external factors, not necessarily associated with cosmetic products. Some tests have been tried in an effort to pinpoint sensitive skins, for example tests involving lactic acid and DMSO, which are known to be irritant substances: see, for example, the paper by K. Lammintausta et al., Dermatoses. 1988, 36, pages 45-49; and the paper by T. Agner and J. Serup, Clinical and Experimental Dermatology, 1989, 14, pages 214-217. However, these tests did not enable sensitive skins to be characterized completely. Web site: http://www.delphion.com/details?pn=US05658581__
•
Low-pressure mercury discharge lamp for tanning Inventor(s): Jalink; Cornelis J. (Eindhoven, NL), Justel; Thomas (Aachen, DE), Nikol; Hans (Aachen, DE), Ronda; Cornelis R. (Aachen, DE), Van Der Voort; Dick (Maarheeze, NL) Assignee(s): U.S. Philips Corporation (New York, NY) Patent Number: 6,208,069 Date filed: December 9, 1998
86
Erythema
Abstract: A lamp vessel is made from a material which absorbs short-wave UV radiation. In addition, the luminescent screen comprises cerium-activated lunthanum phosphate and a luminescent substance having an emission band whose maximum is situated in the wavelength range from 340 nm and whose half-value ranges between 35 nm and 80 nm. The emission spectrum of the lamp for wavelengths below 400 nm corresponds closely to the solar spectrum while the lamp also has a high erythema L light output. Excerpt(s): means for maintaining a discharge in the lamp vessel, during operation of the lamp. Such a low-pressure mercury discharge lamp, hereinafter also referred to as lamp, is known from U.S. Pat. No. 4,703,224. This lamp comprises a lamp vessel formed from an "open" glass having a relatively high transmission for UV-radiation of a relatively short wavelength. The luminescent screen of the known lamp comprises a mixture of cerium-activated strontium magnesium aluminate, europium-activated strontium pyrophosphate and europium-activated barium pyrophosphate. The emission spectrum of this luminescent screen for wavelengths below 400 nm corresponds substantially to the spectrum of sunlight. Since the UV-radiation acting on the skin is situated mainly in this wavelength range, the emission spectrum of the known lamp has biological effects which also correspond substantially to those of sunlight. More particularly, the lamp has advantageous properties as regards tanning and thickening of the skin so that an increased resistance against reddening of the skin caused by overexposure to sunlight is brought about. A drawback of the known lamp, however, is that the luminescent substances included in the luminescent screen demonstrate a certain degree of optical interaction with each other, so that a part of the light emitted by these luminescent substances is absorbed again by the luminescent screen. This optical interaction causes a relatively low effectiveness of the lamp. Since the degree to which optical interaction occurs depends substantially on the thickness of the luminescent screen, and in practice this thickness varies relatively substantially within a lamp, the optical interaction causes relatively large differences between the emission spectra of different parts of the luminescent screen. It is an object of the invention to provide a lowpressure mercury discharge lamp for tanning purposes whose emission spectrum for wavelengths below 400 nm corresponds substantially to the spectrum of sunlight, the lamp also having a relatively high effectiveness, and the difference between the emission spectra of different parts of the luminescent screen being relatively small. Web site: http://www.delphion.com/details?pn=US06208069__ •
Opto-electronic ultra-violet radiation dosimeter Inventor(s): Wuest; Martin P. (San Antonio, TX) Assignee(s): Southwest Research Institute (San Antonio, TX) Patent Number: 6,426,503 Date filed: June 9, 2000 Abstract: A dosimeter 10, which may be easily implemented as a monolithic device, using all-silicon semiconductor fabrication techniques. The dosimeter 10 has a UV filter 11a, whose transmission characteristics match those of the erythema action curve. The filtered radiation is detected by a photodiode, and appropriate signal processing is performed to provide some sort of output indicating UV dosage. Other embodiments use a UV sensitive photodiode without a filter.
Patents 87
Excerpt(s): This invention relates to detection of electromagnetic radiation, and more particularly to a personal device for measuring ultraviolet radiation. Ultraviolet (UV) radiation adversely affects human skin from birth to death. In addition to acute adverse effects such as sunburn, chronic exposure can cause premature aging of the skin, actinic keratoses, and basal carcinoma. With the reduction of the stratospheric ozone layer through anthropogenic influences, the problem of UV effects on the human skin may become even more severe. Ultraviolet radiation can cause damage at the molecular level to organisms. The sensitivity of biological organisms increases with shorter wavelengths because of the higher photon energy. A sensitivity curve for reddening of the skin (erythema action spectra) has been defined by the Commission Internationale de l' Eclairage (CIE). Web site: http://www.delphion.com/details?pn=US06426503__ •
Percutaneous laser treatment Inventor(s): Damasco; Sanford (Long Beach, CA), Loeb; Marvin P. (Huntington Beach, CA) Assignee(s): Trimedyne, Inc. (Irvine, CA) Patent Number: 5,984,915 Date filed: October 8, 1997 Abstract: A method of percutaneous and subcutaneous laser treatment of the tissue of a patient is provided. The tip of an optical fiber is be passed through the skin, advanced through the tissue subcutaneously to a desired treatment area and withdrawn. Laser energy can be emitted at different levels during any or all of the skin penetration, advancement, tissue treatment and withdrawal phases. The present invention is useful for surgical treatments, and is especially suitable for minimally invasive plastic or cosmetic surgical and dermatological procedures without bleeding and with less edema, erythema and swelling and faster healing than conventional surface laser energy application, abrasion, scalpel surgery or chemical peel procedures. Excerpt(s): The present invention relates to methods and procedures for the amelioration of cosmetic flaws and the like by the application of laser energy to a selected target region or site. The present invention is useful in the practice of surgery, especially plastic and cosmetic surgery, as well as dermatology. The present invention is especially suitable for minimally invasive surgical treatments in which a percutaneous approach is desired. Biological tissue comprises cells embedded in a primarily proteinaceous extracellular matrix. Collagen is one of the predominant proteins found in the extracellular matrix. Collagen can be altered by the application of thermal energy to become denatured and act as a biological glue. Thermal energy can also cause collagen fibers to become cross-linked, reducing the volume of the thermally treated collagen. The thermal effect may be conveniently produced by the interaction of laser generated light energy with tissue. Laser energy of the appropriate wavelength, energy and geometry can thus be used to weld together opposed tissue surfaces and shrink collagen-containing tissues. The use of laser devices in various types of surgery is known. Such devices cause thermal coagulation and/or ablation of tissue by emission of a predetermined level of laser energy for a predetermined time. The unwanted tissue can be coagulated to the desired depth by laser energy at low energy density, or ablated by subjecting the tissue to a higher level of energy density. However, when laser energy is applied to the skin from an external source, erythema or sun-burning frequently
88
Erythema
occurs. The erythema can take weeks or months to subside, and discoloration or scarring of the skin may be a lasting result. Web site: http://www.delphion.com/details?pn=US05984915__ •
Prevention or treatment of sunburn using the S(+) isomer of ibuprofen Inventor(s): Laska; Eugene M. (Larchmont, NY), Sunshine; Abraham (New York, NY) Assignee(s): Sterling Drug, Inc. (New York, NY) Patent Number: 5,100,918 Date filed: October 5, 1990 Abstract: Ultraviolet radiation induced erythema is prevented or treated in a human mammal in need of such prevention or treatment, i.e., a mammal suffering from or seeking to avoid sunburn, by topically administering thereto a unit dosage erythemapreventing or treating effective amount of the S(+) ibuprofen enantiomer, said enantiomer being substantially free of its R(-) ibuprofen antipode. Excerpt(s): The present invention relates to the use of topically administered S(+) ibuprofen to prevent or treat erythema induced by ultraviolet irradiation in mammalian organisms in need of such prevention or treatment, and to certain topical pharmaceutical compositions comprising unit dosage effective amounts of S(+) ibuprofen. The compound is well-known as a nonsteroidal anti-inflammatory drug having analgesic and antipyretic activity. Ibuprofen is currently marketed by prescription in the United States generically, as well as under tradenames such as Motrin.RTM., which is available in 400, 600 and 800 mg tablets for oral administration. Ibuprofen has recently also become available in this country in non-prescription strength (200 mg) under a variety of tradenames, including Advil.RTM. and Nuprin.RTM., as well as in generic form. For the treatment of mild to moderate pain, 400 mg every 4 to 6 hours, not to exceed 3200 mg daily, is generally recommended for Motrin.RTM. The lower dose over-the-counter products are generally recommended for minor aches and pains, to be used orally at the 200 to 400 mg level, every 4 to 6 hours, not to exceed 1200 mg daily unless directed by a physician. See also Physician's Desk Reference, 40th edition, 1990, publisher Edward R. Barnhart, Medical Economics Company, Inc., Oradell, NJ 07649. As is apparent from its chemical nomenclature, ibuprofen is a racemic mixture. It is only the racemic mixture which has in fact ever been marketed. There have, however, been some studies of the individual S(+) and R(-) isomers reported in the literature. These generally reflect that the R(-) isomer is converted in vivo but not in vitro to the S(+) enantiomer, which is the active form of ibuprofen. Web site: http://www.delphion.com/details?pn=US05100918__
•
Skin evaluation apparatus Inventor(s): Bain; Duncan Shirreffs (Hertfordshire, GB), Ferguson-Pell; Martin William (Chesham Bois, GB), Mcleod; Alastair George (Rugby, GB) Assignee(s): Huntleigh Technology, PLC (GB) Patent Number: 6,631,288 Date filed: December 6, 2000
Patents 89
Abstract: A skin evaluation apparatus and method for rapidly assessing the degree of erythema of the skin and the skin's response to blanching. The apparatus includes a housing comprising a probe head having an emitter and sensor and a blanching edge. The emitter consists of bundles of optical fibers by means of which light from LEDs is delivered to and recovered from the skin. In use, the probe head is held flush with the skin surface causing the blanching edge to indent a fixed area of skin causing a local blanche. As the probe head is moved, the blanching edge slides along the skin surface evacuating blood as it moves. During the blanche, the LEDs are switched on and the scattered signal collected using a photodiode. A processor measures the attenuation of scattered light and gives a display of blood content against time, providing an indication of the blood circulation in that area. Excerpt(s): The present invention relates to a tissue evaluation apparatus and method for rapidly assessing non-invasively the tissue status particularly with respect to the quality of microcirculation, susceptibility to mechanical force related damage and differentiation of bruised or necrotic dermal or sub-dermal tissue from that which is healthy or erythemous. The apparatus and method of the present invention is particularly effective in, but not limited to, the early detection of a pressure ulcer. Any medical condition or disease which can be assessed by measuring the competence of microcirculatory supply and drainage will also be a potential application for this technique. The first sign of a pressure ulcer is as an area of persistent redness which may be visible on some skins and not others depending upon their pigmentation. This persistent redness is due to soft tissue being compressed for a long period of time between a bone and a firm surface such as a mattress causing an interruption of the blood supply which the body corrects by means of a temporary elevation of the blood flow to the area. Web site: http://www.delphion.com/details?pn=US06631288__ •
Therapeutic treatment for skin disorders Inventor(s): Jirousek; Michael Robert (Indianapolis, IN), Stramm; Lawrence E. (Indianapolis, IN), Vignati; Louis (Indianapolis, IN), Ways; Douglas Kirk (Indianapolis, IN) Assignee(s): Eli Lilly and Company (Indianapolis, IN) Patent Number: 6,093,740 Date filed: April 9, 1998 Abstract: A method for reducing or inhibiting vascular permeability especially the increased vascular permeability associated with VPF/VEGF, and dermal edema exhibited with bullous phemigoid, erythema multiforme, dermatitis herpetiformis, contact dermatitis/delayed hypersensitivity is disclosed, particularly using the.beta.isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,Ndimethylamino)-butane)-bis -(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts. Excerpt(s): The present invention is broadly directed to a method of inhibiting or decreasing vascular permeability associated with dermal edema, e.g., induration, and especially the increased vascular permeability induced by vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF). The present invention is particularly directed to the use of Protein Kinase C (PKC) inhibitors, especially a particular class of isozyme selective PKC inhibitors for treating bullous phemigoid, erythema multiforme,
90
Erythema
dermatitis herpetiformis, contact dermatitis/delayed hypersensitivity, and allergic skin conditions. Dermatological disorders such as bullous phemigoid, erythema multiforme, dermatitis herpetiformis, contact dermatitis, and allergic skin conditions are characterized by dermal edema. Bullous pemphigoid usually occurs in the elderly and may affect any of or all the skin and mucosal surfaces. Dermatitis herpetiformis is characterized by intensely pruritic, grouped vesicles which tend to be symmetrically distributed on the extensor surfaces of the limbs and over the scalp, buttocks, and back. Erythema multiforme syndrome is a characteristic response of the skin and mucous membranes that is related to a number of possible etiologies, including infectious agents (herpesvirus hominis, Mycoplasma pneumoniae) and drugs (especially penicillin, antipyretics, barbiturates, hydantoins, and sulfonamides). In 50 percent of patients no etiology is ascertained. The major pathologic change in erythema multiforme is an acute lymphohistiocytic inflammatory infiltrate around blood vessels and may include degenerative changes in the endothelial cells of the capillaries and marked papillary dermal edema. The lesions occur in a characteristic symmetrical distribution and the syndrome may also include severe toxemia and prostration, high fever, cough, and "patchy" inflammation of the lungs. Web site: http://www.delphion.com/details?pn=US06093740__ •
Therapeutic/cosmetic compositions comprising CGRP antagonists for treating skin redness/rosacea/discrete erythema Inventor(s): Breton; Lionel (Versailles, FR), de Lacharriere; Olivier (Paris, FR) Assignee(s): Societe L'Oreal S.A. (Paris, FR) Patent Number: 5,932,215 Date filed: March 28, 1996 Abstract: Skin redness, rosacea and/or discreet erythema afflicting a mammalian, notably human patient, are therapeutically treated by administrating to such patient a therapeutically/cosmetically effective amount of at least one CGRP antagonist, advantageously in combinatory immixture with at least one antagonist of a neuropeptide other than CGRP, e.g., a substance P antagonist, and/or at least one inflammation mediator antagonist. Excerpt(s): The present invention relates to the formulation of an antagonist of CGRP (peptide derived from the calcitonin gene: Calcitonin Gene Related Peptide, or "CGRP") into cosmetic/pharmaceutical/dermatological compositions, in particular for topical application, for treating rosacea and/or discreet erythema. More especially, this invention relates to the topical, ingestible or injectable treatment of rosacea or discreet erythema. It is known to this art that rosacea is a skin affliction characterized by erythema of the face, predominantly on the cheeks, the forehead and the nose, hyperseborrhoea of the face on the forehead, the nose and the cheeks, and an infectious component manifesting acneiform pustules. Web site: http://www.delphion.com/details?pn=US05932215__
Patents 91
•
Topical composition containing capsazepine Inventor(s): Breton; Lionel (Versailles, FR), De Lacharriere; Olivier (Paris, FR) Assignee(s): Societe L'Oreal S.A. (Paris, FR) Patent Number: 6,048,855 Date filed: June 18, 1998 Abstract: A topical composition containing capsazepine and particularly suitable for treating neurogenic skin disorders and diseases, especially painful and/or pruriginous diseases, as well as for treating sensitive skin and eyes. In particular, the composition is useful for preventing and/or controlling skin and/or eye irritation, itching, erythema and dysaesthesia and heating of the skin, eyes and mucosa, as well as for reducing the irritancy of an active substance having an irritant side-effect. Excerpt(s): The present invention relates to a cosmetic, dermatological and/or pharmaceutical composition intended in particular for the treatment in man of certain cutaneous disorders and/or skin diseases, in particular painful and/or pruriginous diseases. Some of these diseases are currently treated by means of local corticoids or of PUVA therapy. Corticoids are very effective in soothing the symptoms of these diseases but, unfortunately, they exhibit side effects which are often highly disadvantageous, such as atrophies or infections, in particular mycotic or bacterial infections. PUVA therapy is, for its part, the local irradiation of the diseased skin with UVA radiation, after absorption of a photosensitizing substance. This technique exhibits the serious disadvantages of a photoageing, which can very often result in cancers of the skin. Moreover, this treatment is not ambulatory, obliging the patients commonly to go to a specialist centre throughout the duration of the treatment, which is highly restricting and limits their occupational employment and their leisure activities. The precise subject of the present invention is a topical composition which makes it possible to effectively treat these cutaneous diseases, while overcoming these disadvantages. Web site: http://www.delphion.com/details?pn=US06048855__
•
Ultraviolet radiation protection evaluator Inventor(s): Kaminski; Ray (Brick, NJ), Kollias; Nikiforos (Belmont, MA) Assignee(s): Instruments SA, Inc. (Edison, NJ) Patent Number: 5,640,957 Date filed: June 9, 1995 Abstract: An ultraviolet radiation protection evaluator for determining the effectiveness and protection rating of sunscreen. The apparatus contains a fiber optic probe for delivering Ultraviolet radiation directly to skin. The probe receives reflected and diffused ultraviolet radiation from the skin and transmits the same to a monochromator which performs a spectral analysis and evaluation on the reflected radiation. This information is transmitted to a computer having software for evaluating the readings. The readings are taken first on untreated skin then again on skin treated with a sunscreen. The software, via variables inputted to the computer, computes the ratio of the sunscreen data obtained from both the treated and untreated skin along with the product of the spectrum of the light and radiation source and the action spectrum of UV induced erythema and qualitively characterizes the sunscreen in relation to natural skin protection.
92
Erythema
Excerpt(s): This invention relates to lotion and other types of sunscreens, and more particularly, to an apparatus for evaluating the effectiveness and determining the appropriate sun protection factor (SPF) rating of such sunscreens. Recent discoveries in the medical field regarding skin cancer and the role of the sun in causing the same have made sunscreens more popular than ever. Moreover, the alarming rate at which the ozone layer was depleted and the slow rate of recovery makes advances in sunscreen technology an important and potentially lifesaving science. Commercially available sunscreens range in potency from two times the skin's naturally occurring UV protection to thirty five and more times the natural state. Measuring the effectiveness of sunscreens is imperative to rating existing sunscreens with relation to their improvement of the skin's natural abilities and for determining the value of new compositions with regard to the same. The most popular techniques for evaluating sunscreens include in vivo phoyo testing or in vitro transmission methods. Web site: http://www.delphion.com/details?pn=US05640957__ •
Ultraviolet ray-absorbing cosmetic composition Inventor(s): Sugiura; Fumitoshi (Gamagori, JP), Sugiura; Masato (Gamagori, JP), Yoshida; Norio (Ibaraki, JP) Assignee(s): Takemoto Oil & Fat Co., Ltd. (Aichi, JP), Teijin Limited (Osaka, JP) Patent Number: 5,234,681 Date filed: March 20, 1992 Abstract: The cosmetic composition of this is an ultraviolet ray-absorbing cosmetic composition containing particles of cyclic imino ester which is excellent in ultraviolet ray absorbability, stable against water, sparingly soluble in organic solvents, fats and oils, sebum, etc., and further has only a low skin-irritating property. When this cosmetic composition is applied onto the skin, erythema is not formed on/in the skin even if it is exposed to sunlight for a long period, and further aging of the skin can be prevented. Excerpt(s): This invention relates to an ultraviolet ray-absorbing cosmetic composition. More specifically, this invention relates to an ultraviolet ray-absorbing cosmetic composition for application to skin containing a certain kind of cyclic imino ester as an ultraviolet absorber. Although sunbathing is frequently performed for improvement of health, it is known that erythema is formed by excessively exposing the skin to sunlight and that this phenomenon is caused mainly by light beam of a wavelength of 280 to 320 nm, so-called UV-B. For the purpose of prevention of occurrence of such a burn symptom, it is proposed to compound ultraviolet absorber having absorption in the region of UV-B (Please refer to the gazette of Japanese Patent Publication No. 39404/1984 and the specification of the corresponding U.S. Pat. No. 4,061,730). On the other hand, it has been thought that light beam having a wavelength of 320 to 400 nm (UV-A), which makes the skin brown without causing erythema, is a desirable light. However, it has been revealed that while UV-B reaches only up to the epithelial layer, UV-A reaches up to the dermal layer, a deeper layer, and therefore, aging of skin is accelerated by long-term exposure to UV-A. Web site: http://www.delphion.com/details?pn=US05234681__
Patents 93
Patent Applications on Erythema As of December 2000, U.S. patent applications are open to public viewing.9 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to erythema: •
Blanching response pressure sore detector apparatus and method Inventor(s): Taylor, Geoffrey L.; (Winnipeg, CA) Correspondence: Law Offices OF William L. Chapin; 16791 Sea Witch Lane; Huntington Beach; CA; 92649; US Patent Application Number: 20040054303 Date filed: July 29, 2002 Abstract: A portable, hand-holdable Blanching Response Tester apparatus (BRT) pressable against the skin of a human patient to provide an indication of a nonblanchable erythema indicative of an incipient pressure sore includes a housing having in a front end wall thereof an optically transmissive window and within the housing a broad-band light source electrically energizable to emit light including energy in the near infrared (0.8.mu. to 1.5.mu.) outwards through the window. A first, leading photodetector spaced laterally apart from the light source and a second, trailing photodetector spaced equidistant from the light source in an opposite direction have fields of view which include regions of the skin ahead of an behind a central area of the skin illuminated by the light source. Electronic signal processing circuitry within the BRT housing includes a pair of differential amplifiers having opposite pairs of inputs connected to the pair of photodetectors, one amplifier driving a first, "NO-GO" red, light-emitting diode mounted in an upper wall panel of the housing, and the other amplifier driving a second, "GO" green LED. When the BRT window is pressed against the skin and the light source energized, if light reflected from the skin by leading photodetector over a questionable area of the skin exceeds light reflected from a known healthy sample area of skin beneath the trailing photodetector the red, NO-GO LED is illuminated if the difference in light values exceeds a first threshold values signifying a pressure sore, and if light received by the trailing photodetector exceeds that received by the leading photodetector by a second threshold value, the green, GO LED is illuminated. Excerpt(s): The present invention relates to methods and apparatus for detecting incipient or first stage pressure sores in humans. More particularly, the invention relates to a hand-held detector apparatus which is pressed against the skin of a patient to provide detection of non-blanchable erythemas which are indicative of existing or potential pressure sores, and a method for detecting pressure sores. If an external part of a person's body is subjected to a localized external pressure sufficient to inhibit blood flow to tissue below the skin for substantially long periods of time, a sore or lesion can develop at the area of the skin where the pressure is applied. Such sores are referred to as pressure sores, and are common among medical patients and elderly persons who are required to lie in a hospital bed or be seated in a wheel chair for extended time periods. Typically, pressure sores develop in areas of tissue which overlie a bony prominence of the body. Even a relatively light pressure exerted by covering bed clothes on the toes of a recumbent patient is sufficient to cause a pressure sore on the toe, if exerted for a long
9
This has been a common practice outside the United States prior to December 2000.
94
Erythema
period of time. The probability of a pressure sore forming is proportional to both the magnitude of the pressure and the time period which the pressure is exerted. Accordingly, areas of the body on which large portions of a patient's weight are supported by a bed or wheel chair are particularly likely candidate areas for the formation of a pressure sore in a relatively short period of time. These include the heels, ischial tuberosities at the ends of the hip bones, sacrum, scapula, and occiput (back part of the skull). While the exact mechanism for the formation of the beginning or first stage pressure sore is not known, it is known that a prolonged deficiency of oxygenated blood supplied to tissues is a primary cause of the pathology. Prolonged here means longer than a localized and temporary deficiency of blood supply to an area of tissue caused by obstruction of blood flow to that area, a condition known as ischemia, which can cause a temporary whitening or blanching of the skin. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Compositions and methods using direct MMP inhibitors for inhibiting photoaging of skin Inventor(s): Fisher, Gary J.; (Ann Arbor, MI), Kang, Sewon; (Ann Arbor, MI), Voorhees, John J.; (Ann Arbor, MI) Correspondence: Bradley N. Ruben; Suite 5A; 463 First Street; Hoboken; NJ; 07030; US Patent Application Number: 20020106339 Date filed: April 2, 2002 Abstract: Compositions and methods are provided for ameliorating various effects of UVA and UVB radiation from the sun. The compositions include an ingredient that prevents photoaging from MED and subMED radiation, namely a direct acting MMP (matrix metalloproteinase) inhibitor. The compositions can include another, indirect MMP inhibitor, such as a retinoid, certain other compounds (such as N-acetylcysteine, 2furildioxime, and vitamin C), tetracyclines, and if a retinoid is used then in addition optional compounds that inhibit the CYP-26 (chytochrome P-450) mediated metabolism of retinoids such as ketoconazole and other azole compounds. In the method, the composition is applied prior to exposure to the sun; for direct acting MMP inhibitors, application should be just prior to exposure, and if indirect inhibitors such as retinoids are used in addition, then application of the indirect inhibitor should be at least about seven hours prior to exposure. Compounds that prevent erythema (skin reddening, sunburn) do not necessarily protect against UV-mediated elevation of MMP levels and activity, and similarly compounds that prevent UV-mediated elevation of MMP levels and activity are not necessarily effective against UV-induced erythema. Excerpt(s): This application is a division of application 09/615,218, filed Jul. 13, 2000, now U.S. Pat. No. 6,365,630, which is a division of application 09/089,914, filed Jun. 3, 1998, now U.S. Pat. No. 6,130,254, which is a based on provisional applications 60/048,520, filed Jun. 4, 1997 and 60/057,976, filed Sep. 5, 1997. This invention involves photoprotection of human skin. More particularly, the invention relates to compositions for topical application and to methods for using the same to inhibit photoaging of skin, especially as induced by exposure to incidential and/or direct radiation as would occur daily. Separately, this invention provides novel methods and compositions for reducing UV-induced erythema (skin reddening). Photoaging is a term presently used to describe the changes in appearance and/or function of human skin as a result of repeated exposure to sunlight, and especially regarding wrinkles and other changes in the appearance of the skin.
Patents 95
Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Cosmetic, pharmaceutical or dermatological composition comprising a histamine antagonist, an interleukin-1 antagonist and/or a TNF-alpha antagonist Inventor(s): Breton, Lionel; (Versailles, FR), Cohen, Catherine; (Paris, FR), Lacharriere, Olivier De; (Paris, FR) Correspondence: Norman H. Stepno; Burns, Doane, Swecker & Mathis, L.L.P.; P.O. Box 1404; Alexandria; VA; 22313-1404; US Patent Application Number: 20010022978 Date filed: April 25, 2001 Abstract: The invention relates to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF-alpha antagonist in a cosmetic, pharmaceutical or dermatological composition for treating sensitive skins. It relates especially to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF-alpha antagonist for preventing and/or combating skin irritations and/or sores and/or erythema and/or dysaesthesic sensations and/or sensations of inflammation and/or pruritus and/or prickling and/or tingling and/or discomfort and/or tightness of the skin and/or mucosae. It also relates to a composition containing a histamine antagonist, an interleukin-1 antagonist and/or a TNF-alpha antagonist which limits or eliminates the irritant side-effects of certain products, and in particular of certain cosmetic, dermatological or pharmaceutical active agents. Excerpt(s): This application is a divisional of copending U.S. application Ser. No. 09/391,394, filed Sep. 8, 1999, now allowed, incorporated by reference herein in its entirety and relied upon, which is a continuation of application Ser. No. 08/879,889, filed Jun. 20, 1997, now U.S. Pat. No. 5,993,833, which is a divisional of application Ser. No. 08/580,291, filed Dec. 28, 1995, now U.S. Pat. No. 5,658,581. The present invention relates to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNFalpha antagonist in a cosmetic, pharmaceutical or dermatological composition for topical application, intended, in particular, for the treatment of sensitive skins, as well as to a composition containing a histamine antagonist, an interleukin-1 antagonist and/or a TNF-alpha antagonist for the purpose of decreasing or even abolishing the irritant effects of certain products, and in particular of certain active agents used in the cosmetics, pharmaceutical or dermatological field. It is known that some skins are more sensitive than others. The symptoms of sensitive skin were hitherto poorly characterized and the problem of these skins was, as a result, poorly defined; nobody understood precisely the process involved in sensitivity--non-allergic cutaneous hyperreactivity--of the skin. Some workers believed that a sensitive skin was a skin which reacted to cosmetic products, others that such a skin was one which reacted to several external factors, not necessarily associated with cosmetic products. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
96
•
Erythema
Erythema measuring device Inventor(s): Davis, Matthew J.; (Concord, NC), Lockhart, Peter; (Charlotte, NC), Splinter, Robert; (Huntersville, NC) Correspondence: Hancock & Estabrook, Llp; 1500 Mony Tower I; PO Box 4976; Syracuse; NY; 13221-4976; US Patent Application Number: 20030135098 Date filed: January 17, 2002 Abstract: The present invention provides an erythema meter comprising a light guide that carries light of two specific wavelengths (probing and reference) at two distinct frequencies that are generated and modulated by a either a single or multiple source(s), a photodetector mounted in the tip of the guide that receives light reflected from the surface being examined, and circuitry electrically coupled to the guide for processing the light data, and determining the level of erythema present on the examined surface. The probing and reference wavelengths are delivered in sinusoidal or amplitude modulated fashion, thereby permitting electronic filtering of the received data. A calculating circuit determines the quotient of the two wavelengths after having been reflected off of a surface, such as mucosal or dermal surfaces, which is representative of the severity of erythema present in the surface Excerpt(s): The present invention relates generally to meters for detecting erythema, and more particularly to such meters that utilize two different wavelengths of light to measure the erythema. A more common, almost universal disease affecting mankind, and which has an erythematous component is periodontal disease. Periodontitis is a term used to describe an inflammatory disease affecting the tissues surrounding and supporting the teeth. In mild cases (i.e., gingivitis), only the soft gum tissue is affected. Erythema, along with a swelling of the gums, is caused by an underlying bacterial infection. If not detected early, this condition can progress to periodontitis and result in active destruction of the supporting bone tissues around the teeth, resulting in their loss. The determination of the degree of erythema has always been problematic for researchers who develop and clinicians who use medications to prevent or decrease erythema in these patients. Current methods for detecting erythema on mucosal and skin are highly subjective, not re-produceable, and often do not detect disease in an early stage when treatment and preventive strategies are most effective. In addition, these methods do not provide a baseline for a particular patient, and are dependent upon patient cooperation, examiner direct line of sight, and the available lighting. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Erythema measuring device and method Inventor(s): Brennan, Michael T.; (Charlotte, NC), Fox, Philip C.; (Cabin John, MD), Lockhart, Peter B.; (Charlotte, NC), Splinter, Robert; (Huntersville, NC) Correspondence: George R. Mcguire, Bond Schoeneck & King, Pllc; One Lincoln Center; Syracuse; NY; 13202; US Patent Application Number: 20040073374 Date filed: October 8, 2003 Abstract: An erythema meter includes a probe, a light source of one or more specific probing and reference wavelengths, and an acoustic detector which determines the level
Patents 97
of erythema present in the dental pulp chamber of a tooth. The probing and reference wavelengths are delivered in pulsed or amplitude modulated fashion through the probe, thereby permitting electronic identification and filtering of the received data. The absorption of the light wave raises the temperature of the material in the tooth and causes it to expand, thus creating tiny shockwaves which are picked up with the acoustic detector, revealing information on the location of blood and the quantity of blood inside the tooth. The erythema meter accurately measures the erythema, or inflammation, within the tooth in a qualitative and quantitative manner. Excerpt(s): This application is a continuation-in-part of U.S. application Ser. No. 10/053,103 filed Jan. 17, 2002 entitled ERYTHEMA MEASURING DEVICE, incorporated herein by reference. This invention relates generally to the field of devices for detecting the health status of the pulp tissue within a tooth, and more particularly to a device and method for using a combination of light and acoustics to measure the degree of erythema in a tooth. Erythema refers to redness, or inflammation of vascularized areas of the body, which can increase as a result of various causes including diseases and disorders of the mucosa and skin, and of the dental pulp ("tooth nerve") tissue. There is a long-standing problem of determining the health status of the contents of the dental pulp chamber within teeth. The pulp consists of different tissues, including a dense network of small blood vessels. In the healthy state, the pulp tissue is red in color due to a rich blood supply. When a tooth becomes diseased from caries (decay), or injured from trauma, the dental pulp becomes inflamed, and in the case of caries, the degree of erythema might increase, first near the area of disease (caries) in the crown portion of the tooth, and ultimately progressing throughout the pulp chamber and root canal(s) to the apex of the tooth, where the pulp tissue joins the systemic circulation in the surrounding alveolar bone. This increased erythema eventually disappears as the pulp becomes overwhelmed by the inflammatory process, loses its blood supply, and becomes necrotic. This can be painful, but in many cases it is a silent process. The resulting infection can ultimately spread to the soft tissues of the face, involving vital structures of the head and neck, and on rare occasions can result in death. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration Inventor(s): Martin, Alain; (Ringoes, NJ) Correspondence: Craig M. Bell; 1794 Jennings Way; Paoli; PA; 19301; US Patent Application Number: 20030165457 Date filed: September 11, 2001 Abstract: A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response is disclosed. Mammalian cells participating in the inflammatory response are contacted with an inflammatory suppressor selected from the group consisting of alpha-keto acids and their salts which reduce the undesired inflammatory response and is an antioxidant. The inflammatory suppressor may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response such as pain, swelling, erythema, crusting, scarring, itching, also disclosed.
98
Erythema
Excerpt(s): This invention pertains to therapeutic methods of preventing, and the treatment and repair of damaged cells and tissues from injuries and the resulting disease states in mammals caused by the inflammatory production of pain, erythema, itching, crusting, swelling, an inflammatory response to radiation, excess angiogenesis (capillary formation), tissue ischemia and scarring which produce uncontrolled scarring and reduced healing. This invention also pertains to compositions used in the therapeutic methods to enhance the proper collagen and elastin deposition in wounds and injuries. Wounds are internal or external bodily injuries or lesions caused by mechanical, chemical, viral, bacterial or thermal means, which disrupt the normal continuity of structures. Such bodily injuries include contusions, which are wounds in which the skin is unbroken, incisions, i.e., wounds in which the skin is broken by a cutting instrument, and lacerations, which are wounds in which the skin is broken by a dull or blunt instrument. Patients who suffer major wounds could benefit from an antiscarring wound healer enhancer, that protects and enhances repair while reducing the pain, swelling, tissue ischemia, excess angiogenesis, erythema (redness), crusting, itching, and fibrotic conditions (scarring) which accompany most wounds. Wound healing consists of a series of processes whereby injured tissues are repaired, specialized tissue is generated, and new tissue is reorganized. Wound healing consists of three major phases: (a) an inflammation phase (0-3 days), (b) a cellular proliferation phase (312 days), and (c) a remodeling phase (3-6 months). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Method for monitoring wounds Inventor(s): Gutenev, Alexander; (North Narrabeen, AU) Correspondence: Gottlieb Rackman & Reisman PC; 270 Madison Avenue; 8th Floor; New York; NY; 100160601 Patent Application Number: 20040136579 Date filed: November 12, 2003 Abstract: A method of quantifying the extent of erythema around a wound of a patient is disclosed. An image (200) is captured that includes the wound, the erythema and surrounding skin. A border of the wound is identified (step 232) and a distance transform is performed (step 234) on an area of the image between the wound border and a boundary of the image to determine bands of pixels (226,228,230), wherein the pixels within each band are equidistant from the wound border. A representative value such as average brightness is calculated for each band (step 238), and a threshold level is defined relative to the representative value of the surrounding skin (step 240). The extent of the erythema is then calculated. Excerpt(s): The present invention relates generally to the monitoring of wounds and, in particular, to quantifying the extent of erythema around a wound. When a patient suffers a wound to the body, the typical symptoms of inflammation include change of color (erythema), swelling (oedema), local increase in temperature and pain. Most of these symptoms result from changes in blood vessels caused by the release of inflammatory agents at the location of the damaged cells. From a diagnostic point of view, change of color is one of the most important manifestations of inflammation. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 99
•
Method of optimizing the use of a tanning-related device, device for performing such a method, and tanning-related device Inventor(s): Lenderink, Egbert; (Eindhoven, NL), Schoenmakers, Theodorus Johanna Maria; (Eindhoven, NL) Correspondence: Philips Electronics North America Corporation; 580 White Plains Road; Tarrytown; NY; 10591; US Patent Application Number: 20020022868 Date filed: July 2, 2001 Abstract: Method comprising steps of: A) determining a quantity related to a person's personal minimum erythema dose (MED), B) using said quantity as an input for a tanning-related device, thus influencing its operation, and comprising for the purpose of step A), C) non-invasively measuring a feature of the person's skin related to the person's personal MED, and D) electronically deducing the person's personal MED from the measured feature. Furthermore, a device for use with a tanning-related device (12) comprising measuring means (1) for non-invasively measuring a feature of the person's skin (3) related to the person's personal MED, deduction means (5) for deducting the person's personal MED from the measured feature, and communication means (7) for electronically communicating a signal representing the deduced MED to a tanningrelated device. Thus, it is possible to use information coming from an objective measurement for controlling a tanning-related device with no risk of skin damage. Excerpt(s): B) using said quantity as an input for a tanning-related device, thus influencing its operation. Tanning is induced by irradiation with ultraviolet (UV) light, either from natural sunlight or from a solarium. As is known, large doses of ultraviolet light are harmful. However, the dose that is harmful differs from one person to the next and even from one time to another for a single person. The parameter currently used to quantify a person's sensitivity to ultraviolet light is the minimum erythema dose (MED), the smallest dose that induces visible redness of the skin. In order to avoid radiation damage, it is generally accepted that this MED should not be exceeded. For efficient tanning, on the other hand, a person wants as high a dose of ultraviolet light as possible. The problem is that the person does not know his MED exactly. Currently, MED can be estimated or measured. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Methods, compositions and articles for reducing or preventing the effects of inflammation Inventor(s): Fsadni, Mario G.; (Bulach, CH), Hariton, Claude A. A.; (Sillery, CA), Huber, Gustave; (Rafz, CH), Levy, Julia G.; (Vancouver, CA), Richter, Anna M.; (Vancouver, CA), Stewart, William C.; (James Island, SC) Correspondence: Kawai Lau; Morrison & Foerster Llp; Suite 500; 3811 Valley Centre Drive; San Diego; CA; 92130-2332; US Patent Application Number: 20020103180 Date filed: August 13, 2001 Abstract: A method for reducing or preventing the effects of inflammation arising from injured tissue, which method comprises the steps of:a. bringing the injured tissue, or pre-injured tissue, into contact with a photosensitizing agent capable of penetrating into
100
Erythema
the tissue, resulting in the desired degree of biodistribution in less than one hour; andb. exposing the tissue thus contacted to light having a wavelength absorbed by the photosensitizing agent for a time sufficient to reduce or prevent inflammation in the exposed tissue, but not so long as to cause necrosis or erythema of the exposed tissue,or a pharmaceutical composition or an article for reducing or preventing the effects of inflammation arising from injured tissue.The composition comprises:a. from about 1.mu.g/mL to about 2 mg/mL of a photosensitizing agent capable of penetrating into the injured tissue, or pre-injured tissue, resulting in the desired degree of biodistribution less than one hour; andb. a pharmaceutically acceptable carrier.The article comprises:a. a photosensitizing agent capable of penetrating into the injured tissue, or pre-injured tissue, resulting in the desired degree of biodistribution in less than one hour; andb. an absorbent applicator. Excerpt(s): This invention relates generally to the field of pharmacotherapeutics and the use of photodynamic therapy ("PDT") to reduce or prevent inflammation due to injured tissue, whether by intestinal injury, such as surgery, or by accidental injury, such as skin lacerations, injuries to joints and tendons, and the treatment of burn victims. In a preferred embodiment, the invention relates to the use of "low dose" PDT to treat ocular tissue where inflammation is due to the manipulation of eye tissue, especially when the inflammation presents a complicating factor in the patient's recovery from a necessary procedure. Common applications include inflammatory eye disease and various types of ocular surgery or laser treatment, such as transplantation and the filtration ocular surgery commonly used to treat glaucoma. In a particularly preferred embodiment, the invention relates to the extension of filtration bleb survival to improve the outcome of filtration surgery. The four cardinal signs commonly associated with inflammation are: (1) redness, (2) swelling, (3) heat and (4) pain, with an optional fifth cardinal sign being loss of function of the affected part. While injury triggers a complex series of events, many of which occur simultaneously and are interrelated in a variety of ways, it is known that small blood vessels participate in an important way in the induction of inflammation. In fact, inflammation is one of the body's valuable defense mechanisms and is generally thought of as having three phases: the degenerative phase, the vascular phase, and the healing phase. See Klein, "Defense Reactions in Action", Immunology, The Science of Self-Nonself Discrimination, Chapter 14, 577-84 (1982), the disclosure of which is hereby incorporated by reference. Specifically, in the degenerative phase, the affected cells, primarily epidermal cells and fibroblasts become swollen, with their cytoplasms becoming vacuolized and their nuclei enlarging and fragmenting. Some of the platelets in the damaged blood vessels disintegrate and release serotonin and other mediators acting on sympathetic nerve endings. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Therapeutic composition for broad spectrum dermal disease Inventor(s): Choi, Jin Hee; (Seoul, KR), Kim, Jin Wook; (Kyonggi-do, KR), Koh, Ui Chan; (Seoul, KR), Park, Chang Seo; (Kyonggi-do, KR) Correspondence: Knobbe Martens Olson & Bear Llp; 2040 Main Street; Fourteenth Floor; Irvine; CA; 92614; US Patent Application Number: 20040138177 Date filed: September 12, 2003 Abstract: The invention relates to a therapeutic composition for broad spectrum dermal disease and in particular, to a composition comprising principal lipid components of
Patents 101
skin, preferably having about 30 to 90% by weight of a carrier for applying to skin; 0.01 to 5.0% by weight of sphingolipid long-chain base; 0.001 to 1.0% by weight of lysophosphatidic acid; and 1 to 40% by weight of organic or inorganic additives. The composition is useful for the treatment and improvement of atopic dermatitis, psoriasis, acne, ichthyosis, infectious dermatitis, pruritus, erythema derived from pruritus, vulnus, chapping of skin and ulcer, etc. Excerpt(s): This application is a continuation of International Application No. PCT/KR02/00428, filed Mar. 12, 2002, which claims priority to Korean Patent Application No. KR 2001-12591, filed Mar. 12, 2001, the disclosures of which are incorporated by reference herein in their entireties. The present invention relates to a pharmaceutical composition which can be employed as an essential therapeutic agent for dermal disease caused by damage of a skin barrier, such as atopic dermatitis, and specifically, it concerns a composition which repair a damaged skin barrier to a normal condition so as to recover the skin's properties of moisture-retaining capacity and selective permeability, thereby maximizing inhibition or alleviation of skin irritation due to external irritants. More particularly, the invention relates to a therapeutic composition for a broad spectrum of skin diseases, comprising sphingolipid long-chain base selected from the group consisting of phytosphingosine, acetylphytosphingosine, tetraacetyl phytosphingosine, hexanoylphytosphingosine and acetylphytosphingosine phosphate, andlysophosphatidic acid selected from the group consisting of lyso-stearoyl phosphatidic acid (18:0), lyso-oleoyl phosphatidic acid (18:1), lyso-palmitoyl phosphatidic acid (16:0) and natural lyso-phosphatidic acid derived from egg yolk or beans, with respect to the total weight of the composition. Many skin diseases such as psoriasis and atopic dermatitis are known to be diseases which are hard to cure, like cancers, AIDS and dementia, and thereby plague the human race. The reasons for these diseases are still not clearly understood, and a fundamental therapy is not yet developed. It is believed that a combination of multiple factors including genetic, environmental and immunological causes, may cause skin diseases. Such diseases have characteristics of chronic and periodic onset and recurrence. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Thermal quenching of tissue Inventor(s): Baumgardner, Jonathan M.; (Auburn, CA), Koop, Dale E.; (Woodside, CA), Weiss, Robert A.; (Hunt Valley, MD) Correspondence: Rutan & Tucker Llp; Suite 1400; 611 Anton BLVD.; Costa Mesa; CA; 92626; US Patent Application Number: 20030065313 Date filed: May 31, 2002 Abstract: The present invention provides a system for achieving erythema and/or mild edema in an upper layer of skin, without causing blisters, and without the risk of high fluence levels or critical need for cooling. Excerpt(s): This application claims the benefit of U.S. patent application Ser. No. 09/364,275 filed Jul. 29, 1999 incorporated herein by reference in its entirety. This invention is related to the delivery of laser or other source of thermal energy to biological or other tissue for treatment therein. It is sometimes desirable to cause heat affected changes in a selected structure in tissue, such as a vein or hair follicle without causing heat affected changes in tissue adjacent to the selected structure. Selective
102
Erythema
photothermalysis is a method of irradiating with a laser or pulsed light source that is preferentially absorbed by a pre-selected target. The amount of energy or fluence delivered to the target is chosen such that the temperature rise in the targeted region results in an intended thermal treatment of the target. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Use of a composition containing an effective quantity of at least one chelating agent for partially or totally reducing the symptoms associated with histamine release in the organism Inventor(s): De Lacharriere, Olivier; (Paris, FR), Jourdain, Roland; (Meudon la Foret, FR) Correspondence: Oblon Spivak Mcclelland Maier & Neustadt PC; Fourth Floor; 1755 Jefferson Davis Highway; Arlington; VA; 22202; US Patent Application Number: 20030039669 Date filed: April 23, 2002 Abstract: Use to partially or totally reduce the symptoms associated with histamine release in the organism, particularly pruritus and erythema, which comprises the topical application of a cosmetic and/or dermatological and/or hygiene composition containing an effective quantity of at least one ion chelating agent, said composition being essentially free of flavones, flavonones and/or flavonoids, and free of sequestring agents such as polyaspartic acid and its salts, cellulose derivatives and copolymers containing maleic or hydrosuccinic acid as monomeric building blocks and salts thereof. Excerpt(s): The present invention relates to the use of a composition containing an effective quantity of at least one chelating agent for partially or totally eliminating the symptoms associated with histamine release, particularly erythema and pruritus. Histamine is an amine derived from histidine, present in animal tissue. Histamine is a chemical mediator of phenomena such as gastric secretions, allergies, etc. A chemical mediator should be understood to mean a substance released by a cell and involved in a process in the organism (nerve conduction, inflammation). Histamine is released in the organism from mastocytes, which are connective tissue cells which secrete chemical substances participating in immune reactions and blood coagulation, and are involved in allergic phenomena. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Use of a dispersion based on lipid vesicles as an anti-inflammatory composition Inventor(s): Simonnet, Jean-Thierry; (Paris, FR) Correspondence: Oblon Spivak Mcclelland Maier & Neustadt PC; Fourth Floor; 1755 Jefferson Davis Highway; Arlington; VA; 22202; US Patent Application Number: 20010031273 Date filed: May 18, 2001 Abstract: The present invention relates to the use of an aqueous dispersion of oily globules which have a monolamellar or oligolamellar liquid crystal coating, in a cosmetic composition, or for the preparation of a dermatological composition, for preventing and/or combating skin disorders involving an inflammatory process, in
Patents 103
particular for preventing and/or treating skin irritation and/or for preventing and/or treating solar erythema. Excerpt(s): The present invention relates to the use of an aqueous dispersion of oily globules, each provided with a monolamellar or oligolamellar liquid crystal coating, in a cosmetic composition, or for the preparation of a dermatological composition, for preventing and/or combating skin disorders involving an inflammatory process, in particular for preventing and/or treating skin irritation and/or for preventing and/or treating solar erythema. The invention also relates to a process for the cosmetic treatment of inflammation, irritation and/or solar erythema by applying such a dispersion. Inflammation (or the inflammatory process) is a set of biological reactions found throughout the animal kingdom. In man, two out of every three patients exhibit an inflammatory syndrome. Inflammation can be localized. It can be defined as the first response to any local attack by a series of non-specific reactions which are triggered irrespective of the initial cause, and taking place in three stages: vascular, cellulovascular and tissue fibrosis. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
UVA (> 360-400) and UVB (300-325) specific sunscreens Inventor(s): Fisher, Gary J.; (Ypsilanti, MI), Kang, Sewon; (Ann Arbor, MI), Voorhees, John J.; (Ann Arbor, MI) Correspondence: Hopgood, Calimafde; Judlowe & Mondolino; 60 East 42nd Street; New York; NY; 10165; US Patent Application Number: 20020028185 Date filed: July 6, 2001 Abstract: UVB radiation of about 300-310 nm wavelength and UVA radiation of about 380-390 nm wavelength, each of which exists in solar light, induces MMPs (matrix metalloproteinases) in human skin that degrade the collagen of the dermal matrix. This degradation contributes to photoaging of human skin, which can be prevented by blocking these wavelengths of solar radiation. In contrast, diseases that result in the overproduction of collagen can be treated by exposing the affected with to radiation having wavelengths in those regions, for these wavelengths not only induce MMPs but also inhibit collagen biosynthesis. For lighter skinned people so affected, the UVA wavelengths are preferred because of the reduced amount of erythema, whereas dark skinned people can be treated with the UVB radiation because they generally do not suffer from erythema. Excerpt(s): This application is based on provisional application No. 60/216244, filed Jul. 6, 2000, the disclosure of which is incorporated herein by reference. This invention relates to sunscreens that absorb specific wavelengths that we have found induce destructive enzymes in the skin, and to the use of these specific wavelengths in treating skin conditions. With regard to photodamage to skin from the sun, the prevailing view is now that both UVB and UVA radiation should be blocked to prevent damage to the skin. It has been known for some time that UVB, while enabling the skin to produce Vit. D.sub.3, nevertheless also produces erythema (sunburn). If the UVB radiation reaches a threshold dose level termed the minimum erythemal dose (MED), then sufficient UVB radiation has been delivered to the skin to cause visible erythema. UVA radiation is orders of magnitude less erythmogenic than UVB radiation, but is nevertheless damaging to the skin. The art generally considers the damaging regions to be 280-320
104
Erythema
nm for UVB, and 320-360 nm for UVA. UVB sunscreens are typically evaluated by their ability to prevent erythema, and that is how the Sun Protection Factor (SPF) is typically defined. Although less erythmogenic, UVA sunscreens are often tested in the same manner, or analogously to determine whether the compound screens against induction of pigment in the skin upon UVA exposure. See generally, Sunscreens: Development, Evaluation, and Regulatory Aspects, ed. by N. J. Lowe et al. (N.Y.: Marcel Dekker, Inc., 1997), the disclosure of which is incorporated herein by reference. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Keeping Current In order to stay informed about patents and patent applications dealing with erythema, you can access the U.S. Patent Office archive via the Internet at the following Web address: http://www.uspto.gov/patft/index.html. You will see two broad options: (1) Issued Patent, and (2) Published Applications. To see a list of issued patents, perform the following steps: Under “Issued Patents,” click “Quick Search.” Then, type “erythema” (or synonyms) into the “Term 1” box. After clicking on the search button, scroll down to see the various patents which have been granted to date on erythema. You can also use this procedure to view pending patent applications concerning erythema. Simply go back to http://www.uspto.gov/patft/index.html. Select “Quick Search” under “Published Applications.” Then proceed with the steps listed above.
105
CHAPTER 5. BOOKS ON ERYTHEMA Overview This chapter provides bibliographic book references relating to erythema. In addition to online booksellers such as www.amazon.com and www.bn.com, excellent sources for book titles on erythema include the Combined Health Information Database and the National Library of Medicine. Your local medical library also may have these titles available for loan.
Book Summaries: Federal Agencies The Combined Health Information Database collects various book abstracts from a variety of healthcare institutions and federal agencies. To access these summaries, go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. You will need to use the “Detailed Search” option. To find book summaries, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer. For the format option, select “Monograph/Book.” Now type “erythema” (or synonyms) into the “For these words:” box. You should check back periodically with this database which is updated every three months. The following is a typical result when searching for books on erythema: •
Cutaneous and Oral Manifestations of Reactions to Anti-infective Drugs: A Monograph Source: Research Triangle Park, NC: Glaxo, Inc. 1993. 31 p. Contact: Available from Glaxo-Wellcome Education Resource Center. 5 Moore Drive, Research Triangle Park, NC 27709. (800) 824-2896. PRICE: Single copy free. Stock Number GVL290. Summary: As patients receive multiple drugs, identifying drug-induced reactions becomes increasingly complex and pinpointing a specific drug as the cause is even more challenging. This professional education monograph focuses on the dermatologic signs that can be used to identify the anti-infective agents, primary antibacterial and antifungal drugs, responsible for skin and oral reactions. Topics include the role of the medication history, clinical assessment, epidemiology, pathophysiology, and diagnostic tests. The monograph then presents six case scenarios covering toxic epidermal
106
Erythema
necrolysis in HIV infection, erythema multiform in a young woman, tetracyclineinduced photosensitivity reaction, erythema nodosum in a young woman, ampicillininduced eruption in mononucleosis, and a bone marrow transplant recipient with papular urticarial eruptions. The monograph concludes with a list of educational objectives, a list of references, and a self-test and directions for registering for continuing medical education credits. 12 figures. 6 tables. 11 references. (AA-M). •
Atlas of Diseases of the Oral Cavity in HIV Infection Source: Copenhagen, Denmark: Munksgaard. 1995. 152 p. Contact: Available from Munksgaard. 35 Norre Sogade, P.O. Box 2148, DK-1016, Copenhagen K, Denmark. Telephone +45 33 12 70 30; Fax +45 33 12 93 87; E-mail:
[email protected]; http://www.munksgaard.dk/publishers/. PRICE: DKK 400,000 plus postage; contact directly for current price in US dollars. ISBN: 8716115090. Summary: This atlas of oral diseases in HIV infection depicts and describes the oral manifestations of HIV in three sections. The authors stress that oral manifestations are often the key to an initial clinical diagnosis of HIV infection. The introductory material discusses epidemiology, the global aspects of HIV seropositivity, predictions for the future, and the classification of oral lesions associated with HIV infection. The first section covers lesions strongly associated with HIV infection including candidiasis, hyperplasia, angular cheilitis, hairy leukoplakia, periodontal diseases, linear gingival erythema, necrotizing gingivitis, stomatitis and periodontitis, Kaposi's sarcoma, and non-Hodgkin's lymphoma. The second section covers lesions less commonly associated with HIV infection including tuberculosis, hyperpigmentation, pigmentation of the nails, enlargement of major salivary glands, lymphoepithelial lesion, thrombocytopenia, atypical ulceration, herpes labialis, herpetic stomatitis, herpes zoster, varicella, condyloma acuminatum, focal epithelial hyperplasis, and verruca vulgaris. The third section outlines lesions seen in HIV infection, notably Klebsiella pneumonia infection, bacillar epithelioid angiomatosis, toxic epidermal necrolysis, drug-induced ulcerations, cryptococcoses, mucormycosis, penicilliosis, facial nerve paralysis, aphthous ulceration, cytomegalovirus-induced oral ulceration, and molluscum contagiosum. A final section describes other lesions, including exfoliative cheilitis, impetigo contagiosa, secondary syphilis, lichenoid lesions of buccal mucosa, and oral cancer. The atlas depicts each manifestation with a full-color photograph and provides brief descriptions. The book concludes with a list of references, coding according to the international classification of diseases, and a subject index. 111 figures. 193 references.
•
Diseases of the Oral Mucosa and the Lips Source: Orlando, FL: W.B. Saunders Company. 1993. 389 p. Contact: Available from W.B. Saunders Company. Order Fulfillment, 6277 Sea Harbor Drive, Orlando, FL 32887-4430. (800) 545-2522 (individuals) or (800) 782-4479 (schools); Fax (800) 874-6418 or (407) 352-3445; http://www.wbsaunders.com. PRICE: $99.00 plus shipping and handling. ISBN: 0721640397. Summary: This book is a clinically oriented atlas and text covering the symptoms and diseases of the oral mucosa and perioral skin. The authors focus on the essential aspects of each illness, concentrating on the clinical features that are important in the differential diagnosis. The authors include not only diseases confined to the oral mucosa but also those oral problems that may be signs of accompanying cutaneous (skin) or systemic diseases. Sixty-seven chapters are presented in three sections: the normal oral mucosa,
Books
107
general aspects of oral pathology, and diseases of the oral mucosa and the lips. Specific topics are inflammation of the lips, acquired diseases of the tongue, gingival hyperplasia, enlargement of the parotid gland, aphthous ulcers (stomatitis), pyostomatitis vegetans, disorders of pigmentation, urticaria and angioedema, psoriasis, Reiter's syndrome, lichen planus, graft-versus-host disease, rosacea, perioral dermatitis, erythema multiforme, acute febrile neutrophilic dermatosis (Sweet's syndrome), vesicular and bullous autoimmune diseases, desquamative gingivitis, necrotizing sialometaplasia, oral mucosal hemorrhage, viral diseases, bacterial diseases, fungal diseases, protozoal and parasitic diseases, mechanical damage, trauma, allergic and toxic contact stomatitis, occupational diseases of the oral mucosa, drug reactions and side effects, morphea and scleroderma, lichen sclerosus et atrophicus, dermatomyositis, lupus erythematosus, Sjogren's syndrome, polyarteritis nodosa, giant cell arteritis, plasma cell gingivitis, oral submucous fibrosis, halitosis, xerostomia, sialorrhea, selfinduced mucosal injuries, benign granulomatous processes, malignant granulomatoses, heterotopias and congenital malformations, genodermatoses and congenital syndromes, benign and malignant tumors, actinic keratosis, leukoplakia, paraneoplastic disorders, and oral signs of hematologic, nutritional, metabolic, and endocrine disorders. Each chapter includes full-color photographs and references are provided in individual sections. A subject index concludes the volume. (AA-M). •
Lip Complaints Source: in Scully, C. Handbook of Oral Disease: Diagnosis and Management. New York, NY: Thieme New York. 2001. p.300-338. Contact: Available from Thieme New York. 333 Seventh Avenue, New York, NY 10001. (212) 760-0888, ext 110. PRICE: $35.00 plus shipping and handling. ISBN: 1841840874. Summary: This chapter on lip complaints is from a handbook of oral disease that is intended to be used by all members of the dental team who need a ready office reference. The handbook covers the more common and important soft tissue orofacial disorders and gives clinically relevant aspects of the etiology, diagnosis, treatment, and prevention. The chapter covers bleeding, blisters, chapping, cheilitis (inflammation of the lips), colored lesions, macrostomia (swelling of the lip), microstomia (reduction in the mouth opening), white lesions, abnormal labial frenum, actinic cheilitis, angioedema, carcinoma (cancer of the lip), cleft lip and palate, double lip, erythema multiforme, herpes labialis, Kawasaki disease, labial melanotic macule, lip pit and fistula, plasma cell cheilitis, and venous lake. For each condition, the authors note etiology (cause), diagnosis, symptoms, epidemiology, risk factors, treatment, and prevention (where possible). Much of the information is provided in table or outline format for ease of reference. Full color photographs illustrate some conditions. 28 figures. 4 tables. 29 references.
•
Tongue Complaints Source: in Scully, C. Handbook of Oral Disease: Diagnosis and Management. New York, NY: Thieme New York. 2001. p.356-384. Contact: Available from Thieme New York. 333 Seventh Avenue, New York, NY 10001. (212) 760-0888, ext 110. PRICE: $35.00 plus shipping and handling. ISBN: 1841840874. Summary: This chapter on tongue complaints is from a handbook of oral disease that is intended to be used by all members of the dental team who need a ready office reference. The handbook covers the more common and important soft tissue orofacial disorders and gives clinically relevant aspects of the etiology, diagnosis, treatment, and
108
Erythema
prevention. This chapter covers amyloidosis, ankyloglossia (tongue tie), black hairy tongue, candidal glossitis (associated with fungal infection, thrush), coated tongue (white hairy tongue), deficiency glossitis, eosinophilic ulcer, erythema migrans (geographic tongue), fissured tongue, foliate papillitis, granular cell tumor, hairy leukoplakia, lingual thyroid, median rhomboid glossitis, oral-facial-digital syndrome, sublingual (under the tongue) keratosis, swelling, and syphilitic leukoplakia. For each condition, the authors note etiology (cause), diagnosis, symptoms, epidemiology, risk factors, treatment, and prevention (where possible). Much of the information is provided in table or outline format for ease of reference. Full color photographs illustrate some conditions. 39 figures. 9 references. •
Oral Medicine and Hospital Practice Source: Chicago, IL: Special Care Dentistry. 1997. 362 p. Contact: Available from Special Care Dentistry. 211 East Chicago Avenue, Chicago, IL 60611. (312) 440-2660. Fax (312) 440-2824. PRICE: $27.00 (member) or $30.00 (nonmember), plus shipping and handling; institutional prices and bulk orders available. ISBN: 0965719103. Summary: This manual is designed to help dental residents, students, and practitioners engaged in the care of both ambulatory and nonambulatory patients. The ten chapters provide information on questions that arise concerning a patient's medical history, medications, lab values, risk assessment, and clinical management. Topics include hospital structure and function, in-hospital care of dental patients, outpatient management of medically compromised patients, consultations, dental emergencies, medical emergencies, problems of the oral mucosa, treatment protocol, principles of drug therapy and formulary, and laboratory tests. The chapter on dental emergencies covers intraoral emergencies, postoperative emergencies, odontogenic infections, salivary gland emergencies, maxillofacial trauma, and temporomandibular joint emergencies. The chapter on problems of the oral mucosa covers angular cheilitis, bleeding, burning mouth, desquamative gingivitis, dry mouth, erythema of the mucosa, glossitis, odor, pain, pigmented lesions, ulcers, vesiculobullous disorders, and white patches. Most information is presented in outline format, for ease of access.
•
Oral and Cutaneous Manifestations of Hematogenously Disseminated Systemic Infections: A Monograph Source: Research Triangle Park, NC: Glaxo, Inc. 1993. 79 p. Contact: Available from Glaxo-Wellcome Education Resource Center. 5 Moore Drive, Research Triangle Park, NC 27709. (800) 824-2896. PRICE: Single copy free. Stock Number GVL251. Summary: This monograph describes oral and dermatologic manifestations resulting from systemic infections. Written as a continuing education tool for physicians, the monograph features 26 sections, each of which includes a description of dermatologic manifestations, other clinical features, laboratory findings, and epidemiologic factors. Diseases covered include AIDS, blastomycosis, candidiasis, coccidioidomycosis, cryptococcoses, erythema infectiousum (Fifth disease), gonococcemia, gram-negative bacterial sepsis, hand-foot-and-mouth disease, infectious mononucleosis, infective endocarditis, Kawasaki syndrome, leprosy, lyme disease, meningococcemia, Rocky Mountain spotted fever, roseola, rubella (German measles), rubeola (measles), scarlet fever, secondary (disseminated) syphilis, staphylococcal scalded skin syndrome, toxic shock syndrome, typhoid fever, varicella (chickenpox), and Vibrio vulnificus infection.
Books
109
Each section is illustrated with full-color photographs depicting patients with manifestations of the disease under consideration. The monograph includes a glossary of illustrations to help with diagnosis and classification. The monograph concludes with a self-test and instructions for receiving continuing medical education credits. A subject index is also included. 12 references.
Book Summaries: Online Booksellers Commercial Internet-based booksellers, such as Amazon.com and Barnes&Noble.com, offer summaries which have been supplied by each title’s publisher. Some summaries also include customer reviews. Your local bookseller may have access to in-house and commercial databases that index all published books (e.g. Books in Print). IMPORTANT NOTE: Online booksellers typically produce search results for medical and non-medical books. When searching for “erythema” at online booksellers’ Web sites, you may discover non-medical books that use the generic term “erythema” (or a synonym) in their titles. The following is indicative of the results you might find when searching for “erythema” (sorted alphabetically by title; follow the hyperlink to view more details at Amazon.com): •
21st Century Complete Medical Guide to Lyme Disease, Deer Ticks, B. Burgdorferi, Erythema Migrans, Authoritative CDC, NIH, and FDA Documents, Clinical References, and Practical Information for Patients and Physicians (CD-ROM) by PM Medical Health News; ISBN: 1592486630; http://www.amazon.com/exec/obidos/ASIN/1592486630/icongroupinterna
The National Library of Medicine Book Index The National Library of Medicine at the National Institutes of Health has a massive database of books published on healthcare and biomedicine. Go to the following Internet site, http://locatorplus.gov/, and then select “Search LOCATORplus.” Once you are in the search area, simply type “erythema” (or synonyms) into the search box, and select “books only.” From there, results can be sorted by publication date, author, or relevance. The following was recently catalogued by the National Library of Medicine:10 •
Case of universal erythema multiforme. Author: Duhring, Louis Adolphus, 1845-1913; Year: 1891
•
Enige onderzoekingen over ultraviolet erytheem en experimentele reproductie van enkele lichtdermatosen = Some investigations on ultraviolet erythema and experimental reproduction of some lightdermatoses. Author: door Abraham Hein Waterman; Year: 1967
•
Syfilis och erythema multiforme. Author: Oedmansson, Ernst Ludwig Wilhelm, 1831-; Year: 1874
10
In addition to LOCATORPlus, in collaboration with authors and publishers, the National Center for Biotechnology Information (NCBI) is currently adapting biomedical books for the Web. The books may be accessed in two ways: (1) by searching directly using any search term or phrase (in the same way as the bibliographic database PubMed), or (2) by following the links to PubMed abstracts. Each PubMed abstract has a "Books" button that displays a facsimile of the abstract in which some phrases are hypertext links. These phrases are also found in the books available at NCBI. Click on hyperlinked results in the list of books in which the phrase is found. Currently, the majority of the links are between the books and PubMed. In the future, more links will be created between the books and other types of information, such as gene and protein sequences and macromolecular structures. See http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Books.
110
•
Erythema
Vóórkomen van tekebeten en erythema migrans in de huisartsenpraktijken in Nederland. Author: E.L. de Mik. [et al.]; Year: 1995
Chapters on Erythema In order to find chapters that specifically relate to erythema, an excellent source of abstracts is the Combined Health Information Database. You will need to limit your search to book chapters and erythema using the “Detailed Search” option. Go to the following hyperlink: http://chid.nih.gov/detail/detail.html. To find book chapters, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Book Chapter.” Type “erythema” (or synonyms) into the “For these words:” box. The following is a typical result when searching for book chapters on erythema: •
Erythema Multiforme Source: in Bork, K., et al. Diseases of the Oral Mucosa and the Lips. Orlando, FL: W.B. Saunders Company. 1993. p. 68-70. Contact: Available from W.B. Saunders Company. Order Fulfillment, 6277 Sea Harbor Drive, Orlando, FL 32887-4430. (800) 545-2522 (individuals) or (800) 782-4479 (schools); Fax (800) 874-6418 or (407) 352-3445; http://www.wbsaunders.com. PRICE: $99.00 plus shipping and handling. ISBN: 0721640397. Summary: This chapter, from a textbook on diseases of the oral mucosa and the lips, discusses erythema multiforme (EM), a common complex skin disease. As the name suggests, the clinical lesions can take many forms. About 40 percent of EM patients have mucosal involvement. Typically, there may be oral mucosal blisters and erosions; ocular changes including conjunctivitis, uveitis, and scarring; and urethral and genital erosions leading to bowel and urinary retention. EM is self-limited and tends to resolve after two to three weeks. When it is recurrent, it is almost always connected with recurrent herpes simplex. The chapter covers etiology, clinical features, histopathology, diagnosis, differential diagnosis, and therapy. The authors caution that stomatitis caused by medications may appear similar to localized EM. Full-color photographs illustrate the chapter. 5 figures. 13 references. (AA-M).
111
CHAPTER 6. PERIODICALS AND NEWS ON ERYTHEMA Overview In this chapter, we suggest a number of news sources and present various periodicals that cover erythema.
News Services and Press Releases One of the simplest ways of tracking press releases on erythema is to search the news wires. In the following sample of sources, we will briefly describe how to access each service. These services only post recent news intended for public viewing. PR Newswire To access the PR Newswire archive, simply go to http://www.prnewswire.com/. Select your country. Type “erythema” (or synonyms) into the search box. You will automatically receive information on relevant news releases posted within the last 30 days. The search results are shown by order of relevance. Reuters Health The Reuters’ Medical News and Health eLine databases can be very useful in exploring news archives relating to erythema. While some of the listed articles are free to view, others are available for purchase for a nominal fee. To access this archive, go to http://www.reutershealth.com/en/index.html and search by “erythema” (or synonyms). The following was recently listed in this archive for erythema: •
Bupropion use associated with erythema multiforme Source: Reuters Industry Breifing Date: July 03, 2001
•
FDA Says Thalidomide "Approvable" For Erythema Nodosum Leprosum Source: Reuters Medical News Date: September 23, 1997
112
Erythema
•
FDA Panel Urges Approval Of Thalidomide For Erythema Nodosum Leprosum Source: Reuters Medical News Date: September 08, 1997
•
Amoxicillin Superior To Azithromycin Against Erythema Migrans Source: Reuters Medical News Date: May 07, 1996 The NIH
Within MEDLINEplus, the NIH has made an agreement with the New York Times Syndicate, the AP News Service, and Reuters to deliver news that can be browsed by the public. Search news releases at http://www.nlm.nih.gov/medlineplus/alphanews_a.html. MEDLINEplus allows you to browse across an alphabetical index. Or you can search by date at the following Web page: http://www.nlm.nih.gov/medlineplus/newsbydate.html. Often, news items are indexed by MEDLINEplus within its search engine. Business Wire Business Wire is similar to PR Newswire. To access this archive, simply go to http://www.businesswire.com/. You can scan the news by industry category or company name. Market Wire Market Wire is more focused on technology than the other wires. To browse the latest press releases by topic, such as alternative medicine, biotechnology, fitness, healthcare, legal, nutrition, and pharmaceuticals, access Market Wire’s Medical/Health channel at http://www.marketwire.com/mw/release_index?channel=MedicalHealth. Or simply go to Market Wire’s home page at http://www.marketwire.com/mw/home, type “erythema” (or synonyms) into the search box, and click on “Search News.” As this service is technology oriented, you may wish to use it when searching for press releases covering diagnostic procedures or tests. Search Engines Medical news is also available in the news sections of commercial Internet search engines. See the health news page at Yahoo (http://dir.yahoo.com/Health/News_and_Media/), or you can use this Web site’s general news search page at http://news.yahoo.com/. Type in “erythema” (or synonyms). If you know the name of a company that is relevant to erythema, you can go to any stock trading Web site (such as http://www.etrade.com/) and search for the company name there. News items across various news sources are reported on indicated hyperlinks. Google offers a similar service at http://news.google.com/.
Periodicals and News
113
BBC Covering news from a more European perspective, the British Broadcasting Corporation (BBC) allows the public free access to their news archive located at http://www.bbc.co.uk/. Search by “erythema” (or synonyms).
Newsletter Articles Use the Combined Health Information Database, and limit your search criteria to “newsletter articles.” Again, you will need to use the “Detailed Search” option. Go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. Go to the bottom of the search page where “You may refine your search by.” Select the dates and language that you prefer. For the format option, select “Newsletter Article.” Type “erythema” (or synonyms) into the “For these words:” box. You should check back periodically with this database as it is updated every three months. The following is a typical result when searching for newsletter articles on erythema: •
Nasopharyngeal Carcinoma Source: News from SPOHNC. News from Support for People with Oral and Head and Neck Cancer, Inc. 11(2): 1-3. October 2001. Contact: Available from Support for People with Oral and Head and Neck Cancer, Inc. (SPOHNC). P.O. Box 53, Locust Valley, NY 11560-0053. (516) 759-5333. E-mail:
[email protected]. Website: www.spohnc.org. Summary: This article, from a newsletter for people with oral and head and neck cancer, reviews nasopharyngeal cancer. The nasopharynx is an open chamber located behind the nasal cavity and below the base of the skull. The authors discuss the etiology (cause) and risk factors, clinical presentation (symptoms), routes of spread, physical and diagnostic evaluation, staging, complications, and treatment recommendations. The most common side effects occurring during and shortly after treatment are breakdown of the mucosa of the pharynx, dry mouth (xerostomia), and reddening (erythema) of the skin. The most common long term side effect is xerostomia, although its incidence decreases tremendously with IMRT (intensity modulated radiation therapy). Trismus (difficulty opening the mouth) may occur. The authors note that patients who present with early T1-2 N0-1 staged disease are good candidates for external beam radiotherapy alone. Combined modality treatment is recommended for all other lesions. 20 references.
Academic Periodicals covering Erythema Numerous periodicals are currently indexed within the National Library of Medicine’s PubMed database that are known to publish articles relating to erythema. In addition to these sources, you can search for articles covering erythema that have been published by any of the periodicals listed in previous chapters. To find the latest studies published, go to http://www.ncbi.nlm.nih.gov/pubmed, type the name of the periodical into the search box, and click “Go.” If you want complete details about the historical contents of a journal, you can also visit the following Web site: http://www.ncbi.nlm.nih.gov/entrez/jrbrowser.cgi. Here, type in the
114
Erythema
name of the journal or its abbreviation, and you will receive an index of published articles. At http://locatorplus.gov/, you can retrieve more indexing information on medical periodicals (e.g. the name of the publisher). Select the button “Search LOCATORplus.” Then type in the name of the journal and select the advanced search option “Journal Title Search.”
115
CHAPTER 7. RESEARCHING MEDICATIONS Overview While a number of hard copy or CD-ROM resources are available for researching medications, a more flexible method is to use Internet-based databases. Broadly speaking, there are two sources of information on approved medications: public sources and private sources. We will emphasize free-to-use public sources.
U.S. Pharmacopeia Because of historical investments by various organizations and the emergence of the Internet, it has become rather simple to learn about the medications recommended for erythema. One such source is the United States Pharmacopeia. In 1820, eleven physicians met in Washington, D.C. to establish the first compendium of standard drugs for the United States. They called this compendium the U.S. Pharmacopeia (USP). Today, the USP is a nonprofit organization consisting of 800 volunteer scientists, eleven elected officials, and 400 representatives of state associations and colleges of medicine and pharmacy. The USP is located in Rockville, Maryland, and its home page is located at http://www.usp.org/. The USP currently provides standards for over 3,700 medications. The resulting USP DI Advice for the Patient can be accessed through the National Library of Medicine of the National Institutes of Health. The database is partially derived from lists of federally approved medications in the Food and Drug Administration’s (FDA) Drug Approvals database, located at http://www.fda.gov/cder/da/da.htm. While the FDA database is rather large and difficult to navigate, the Phamacopeia is both user-friendly and free to use. It covers more than 9,000 prescription and over-the-counter medications. To access this database, simply type the following hyperlink into your Web browser: http://www.nlm.nih.gov/medlineplus/druginformation.html. To view examples of a given medication (brand names, category, description, preparation, proper use, precautions, side effects, etc.), simply follow the hyperlinks indicated within the United States Pharmacopeia (USP). Below, we have compiled a list of medications associated with erythema. If you would like more information on a particular medication, the provided hyperlinks will direct you to ample documentation (e.g. typical dosage, side effects, drug-interaction risks, etc.). The
116
Erythema
following drugs have been mentioned in the Pharmacopeia and other sources as being potentially applicable to erythema: Azathioprine •
Systemic - U.S. Brands: Imuran http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202077.html
Chloroquine •
Systemic - U.S. Brands: Aralen; Aralen HCl http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202133.html
Cyclophosphamide •
Systemic - U.S. Brands: Cytoxan; Neosar http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202174.html
Hydroxychloroquine •
Systemic - U.S. Brands: Plaquenil http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202288.html
Thalidomide •
Systemic - U.S. Brands: THALOMID http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202692.html
Commercial Databases In addition to the medications listed in the USP above, a number of commercial sites are available by subscription to physicians and their institutions. Or, you may be able to access these sources from your local medical library.
Mosby’s Drug Consult Mosby’s Drug Consult database (also available on CD-ROM and book format) covers 45,000 drug products including generics and international brands. It provides prescribing information, drug interactions, and patient information. Subscription information is available at the following hyperlink: http://www.mosbysdrugconsult.com/. PDRhealth The PDRhealth database is a free-to-use, drug information search engine that has been written for the public in layman’s terms. It contains FDA-approved drug information adapted from the Physicians’ Desk Reference (PDR) database. PDRhealth can be searched by brand name, generic name, or indication. It features multiple drug interactions reports. Search PDRhealth at http://www.pdrhealth.com/drug_info/index.html.
Researching Medications
117
Other Web Sites Drugs.com (www.drugs.com) reproduces the information in the Pharmacopeia as well as commercial information. You may also want to consider the Web site of the Medical Letter, Inc. (http://www.medletter.com/) which allows users to download articles on various drugs and therapeutics for a nominal fee.
Researching Orphan Drugs Although the list of orphan drugs is revised on a daily basis, you can quickly research orphan drugs that might be applicable to erythema by using the database managed by the National Organization for Rare Disorders, Inc. (NORD), at http://www.rarediseases.org/. Scroll down the page, and on the left toolbar, click on “Orphan Drug Designation Database.” On this page (http://www.rarediseases.org/search/noddsearch.html), type “erythema” (or synonyms) into the search box, and click “Submit Query.” When you receive your results, note that not all of the drugs may be relevant, as some may have been withdrawn from orphan status. Write down or print out the name of each drug and the relevant contact information. From there, visit the Pharmacopeia Web site and type the name of each orphan drug into the search box at http://www.nlm.nih.gov/medlineplus/druginformation.html. You may need to contact the sponsor or NORD for further information. NORD conducts “early access programs for investigational new drugs (IND) under the Food and Drug Administration’s (FDA’s) approval ‘Treatment INDs’ programs which allow for a limited number of individuals to receive investigational drugs before FDA marketing approval.” If the orphan product about which you are seeking information is approved for marketing, information on side effects can be found on the product’s label. If the product is not approved, you may need to contact the sponsor. The following is a list of orphan drugs currently listed in the NORD Orphan Drug Designation Database for erythema: •
Thalidomide (trade name: Thalomid) http://www.rarediseases.org/nord/search/nodd_full?code=31
•
Dehydroepiandrosterone http://www.rarediseases.org/nord/search/nodd_full?code=458
•
Clofazimine (trade name: Lamprene) http://www.rarediseases.org/nord/search/nodd_full?code=651
•
Recombinant humanized monoclonal antibody 5c8 http://www.rarediseases.org/nord/search/nodd_full?code=906
•
Humanized MAb (IDEC-131) to CD40L http://www.rarediseases.org/nord/search/nodd_full?code=966
If you have any questions about a medical treatment, the FDA may have an office near you. Look for their number in the blue pages of the phone book. You can also contact the FDA through its toll-free number, 1-888-INFO-FDA (1-888-463-6332), or on the World Wide Web at www.fda.gov.
119
APPENDICES
121
APPENDIX A. PHYSICIAN RESOURCES Overview In this chapter, we focus on databases and Internet-based guidelines and information resources created or written for a professional audience.
NIH Guidelines Commonly referred to as “clinical” or “professional” guidelines, the National Institutes of Health publish physician guidelines for the most common diseases. Publications are available at the following by relevant Institute11: •
Office of the Director (OD); guidelines consolidated across agencies available at http://www.nih.gov/health/consumer/conkey.htm
•
National Institute of General Medical Sciences (NIGMS); fact sheets available at http://www.nigms.nih.gov/news/facts/
•
National Library of Medicine (NLM); extensive encyclopedia (A.D.A.M., Inc.) with guidelines: http://www.nlm.nih.gov/medlineplus/healthtopics.html
•
National Cancer Institute (NCI); guidelines available at http://www.cancer.gov/cancerinfo/list.aspx?viewid=5f35036e-5497-4d86-8c2c714a9f7c8d25
•
National Eye Institute (NEI); guidelines available at http://www.nei.nih.gov/order/index.htm
•
National Heart, Lung, and Blood Institute (NHLBI); guidelines available at http://www.nhlbi.nih.gov/guidelines/index.htm
•
National Human Genome Research Institute (NHGRI); research available at http://www.genome.gov/page.cfm?pageID=10000375
•
National Institute on Aging (NIA); guidelines available at http://www.nia.nih.gov/health/
11
These publications are typically written by one or more of the various NIH Institutes.
122
Erythema
•
National Institute on Alcohol Abuse and Alcoholism (NIAAA); guidelines available at http://www.niaaa.nih.gov/publications/publications.htm
•
National Institute of Allergy and Infectious Diseases (NIAID); guidelines available at http://www.niaid.nih.gov/publications/
•
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); fact sheets and guidelines available at http://www.niams.nih.gov/hi/index.htm
•
National Institute of Child Health and Human Development (NICHD); guidelines available at http://www.nichd.nih.gov/publications/pubskey.cfm
•
National Institute on Deafness and Other Communication Disorders (NIDCD); fact sheets and guidelines at http://www.nidcd.nih.gov/health/
•
National Institute of Dental and Craniofacial Research (NIDCR); guidelines available at http://www.nidr.nih.gov/health/
•
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); guidelines available at http://www.niddk.nih.gov/health/health.htm
•
National Institute on Drug Abuse (NIDA); guidelines available at http://www.nida.nih.gov/DrugAbuse.html
•
National Institute of Environmental Health Sciences (NIEHS); environmental health information available at http://www.niehs.nih.gov/external/facts.htm
•
National Institute of Mental Health (NIMH); guidelines available at http://www.nimh.nih.gov/practitioners/index.cfm
•
National Institute of Neurological Disorders and Stroke (NINDS); neurological disorder information pages available at http://www.ninds.nih.gov/health_and_medical/disorder_index.htm
•
National Institute of Nursing Research (NINR); publications on selected illnesses at http://www.nih.gov/ninr/news-info/publications.html
•
National Institute of Biomedical Imaging and Bioengineering; general information at http://grants.nih.gov/grants/becon/becon_info.htm
•
Center for Information Technology (CIT); referrals to other agencies based on keyword searches available at http://kb.nih.gov/www_query_main.asp
•
National Center for Complementary and Alternative Medicine (NCCAM); health information available at http://nccam.nih.gov/health/
•
National Center for Research Resources (NCRR); various information directories available at http://www.ncrr.nih.gov/publications.asp
•
Office of Rare Diseases; various fact sheets available at http://rarediseases.info.nih.gov/html/resources/rep_pubs.html
•
Centers for Disease Control and Prevention; various fact sheets on infectious diseases available at http://www.cdc.gov/publications.htm
Physician Resources
123
NIH Databases In addition to the various Institutes of Health that publish professional guidelines, the NIH has designed a number of databases for professionals.12 Physician-oriented resources provide a wide variety of information related to the biomedical and health sciences, both past and present. The format of these resources varies. Searchable databases, bibliographic citations, full-text articles (when available), archival collections, and images are all available. The following are referenced by the National Library of Medicine:13 •
Bioethics: Access to published literature on the ethical, legal, and public policy issues surrounding healthcare and biomedical research. This information is provided in conjunction with the Kennedy Institute of Ethics located at Georgetown University, Washington, D.C.: http://www.nlm.nih.gov/databases/databases_bioethics.html
•
HIV/AIDS Resources: Describes various links and databases dedicated to HIV/AIDS research: http://www.nlm.nih.gov/pubs/factsheets/aidsinfs.html
•
NLM Online Exhibitions: Describes “Exhibitions in the History of Medicine”: http://www.nlm.nih.gov/exhibition/exhibition.html. Additional resources for historical scholarship in medicine: http://www.nlm.nih.gov/hmd/hmd.html
•
Biotechnology Information: Access to public databases. The National Center for Biotechnology Information conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information for the better understanding of molecular processes affecting human health and disease: http://www.ncbi.nlm.nih.gov/
•
Population Information: The National Library of Medicine provides access to worldwide coverage of population, family planning, and related health issues, including family planning technology and programs, fertility, and population law and policy: http://www.nlm.nih.gov/databases/databases_population.html
•
Cancer Information: Access to cancer-oriented databases: http://www.nlm.nih.gov/databases/databases_cancer.html
•
Profiles in Science: Offering the archival collections of prominent twentieth-century biomedical scientists to the public through modern digital technology: http://www.profiles.nlm.nih.gov/
•
Chemical Information: Provides links to various chemical databases and references: http://sis.nlm.nih.gov/Chem/ChemMain.html
•
Clinical Alerts: Reports the release of findings from the NIH-funded clinical trials where such release could significantly affect morbidity and mortality: http://www.nlm.nih.gov/databases/alerts/clinical_alerts.html
•
Space Life Sciences: Provides links and information to space-based research (including NASA): http://www.nlm.nih.gov/databases/databases_space.html
•
MEDLINE: Bibliographic database covering the fields of medicine, nursing, dentistry, veterinary medicine, the healthcare system, and the pre-clinical sciences: http://www.nlm.nih.gov/databases/databases_medline.html
12
Remember, for the general public, the National Library of Medicine recommends the databases referenced in MEDLINEplus (http://medlineplus.gov/ or http://www.nlm.nih.gov/medlineplus/databases.html). 13 See http://www.nlm.nih.gov/databases/databases.html.
124
Erythema
•
Toxicology and Environmental Health Information (TOXNET): Databases covering toxicology and environmental health: http://sis.nlm.nih.gov/Tox/ToxMain.html
•
Visible Human Interface: Anatomically detailed, three-dimensional representations of normal male and female human bodies: http://www.nlm.nih.gov/research/visible/visible_human.html
The NLM Gateway14 The NLM (National Library of Medicine) Gateway is a Web-based system that lets users search simultaneously in multiple retrieval systems at the U.S. National Library of Medicine (NLM). It allows users of NLM services to initiate searches from one Web interface, providing one-stop searching for many of NLM’s information resources or databases.15 To use the NLM Gateway, simply go to the search site at http://gateway.nlm.nih.gov/gw/Cmd. Type “erythema” (or synonyms) into the search box and click “Search.” The results will be presented in a tabular form, indicating the number of references in each database category. Results Summary Category Journal Articles Books / Periodicals / Audio Visual Consumer Health Meeting Abstracts Other Collections Total
Items Found 23074 86 404 119 1055 24738
HSTAT16 HSTAT is a free, Web-based resource that provides access to full-text documents used in healthcare decision-making.17 These documents include clinical practice guidelines, quickreference guides for clinicians, consumer health brochures, evidence reports and technology assessments from the Agency for Healthcare Research and Quality (AHRQ), as well as AHRQ’s Put Prevention Into Practice.18 Simply search by “erythema” (or synonyms) at the following Web site: http://text.nlm.nih.gov.
14
Adapted from NLM: http://gateway.nlm.nih.gov/gw/Cmd?Overview.x.
15
The NLM Gateway is currently being developed by the Lister Hill National Center for Biomedical Communications (LHNCBC) at the National Library of Medicine (NLM) of the National Institutes of Health (NIH). 16 Adapted from HSTAT: http://www.nlm.nih.gov/pubs/factsheets/hstat.html. 17 18
The HSTAT URL is http://hstat.nlm.nih.gov/.
Other important documents in HSTAT include: the National Institutes of Health (NIH) Consensus Conference Reports and Technology Assessment Reports; the HIV/AIDS Treatment Information Service (ATIS) resource documents; the Substance Abuse and Mental Health Services Administration's Center for Substance Abuse Treatment (SAMHSA/CSAT) Treatment Improvement Protocols (TIP) and Center for Substance Abuse Prevention (SAMHSA/CSAP) Prevention Enhancement Protocols System (PEPS); the Public Health Service (PHS) Preventive Services Task Force's Guide to Clinical Preventive Services; the independent, nonfederal Task Force on Community Services’ Guide to Community Preventive Services; and the Health Technology Advisory Committee (HTAC) of the Minnesota Health Care Commission (MHCC) health technology evaluations.
Physician Resources
125
Coffee Break: Tutorials for Biologists19 Coffee Break is a general healthcare site that takes a scientific view of the news and covers recent breakthroughs in biology that may one day assist physicians in developing treatments. Here you will find a collection of short reports on recent biological discoveries. Each report incorporates interactive tutorials that demonstrate how bioinformatics tools are used as a part of the research process. Currently, all Coffee Breaks are written by NCBI staff.20 Each report is about 400 words and is usually based on a discovery reported in one or more articles from recently published, peer-reviewed literature.21 This site has new articles every few weeks, so it can be considered an online magazine of sorts. It is intended for general background information. You can access the Coffee Break Web site at the following hyperlink: http://www.ncbi.nlm.nih.gov/Coffeebreak/.
Other Commercial Databases In addition to resources maintained by official agencies, other databases exist that are commercial ventures addressing medical professionals. Here are some examples that may interest you: •
CliniWeb International: Index and table of contents to selected clinical information on the Internet; see http://www.ohsu.edu/cliniweb/.
•
Medical World Search: Searches full text from thousands of selected medical sites on the Internet; see http://www.mwsearch.com/.
19 Adapted 20
from http://www.ncbi.nlm.nih.gov/Coffeebreak/Archive/FAQ.html.
The figure that accompanies each article is frequently supplied by an expert external to NCBI, in which case the source of the figure is cited. The result is an interactive tutorial that tells a biological story. 21 After a brief introduction that sets the work described into a broader context, the report focuses on how a molecular understanding can provide explanations of observed biology and lead to therapies for diseases. Each vignette is accompanied by a figure and hypertext links that lead to a series of pages that interactively show how NCBI tools and resources are used in the research process.
127
APPENDIX B. PATIENT RESOURCES Overview Official agencies, as well as federally funded institutions supported by national grants, frequently publish a variety of guidelines written with the patient in mind. These are typically called “Fact Sheets” or “Guidelines.” They can take the form of a brochure, information kit, pamphlet, or flyer. Often they are only a few pages in length. Since new guidelines on erythema can appear at any moment and be published by a number of sources, the best approach to finding guidelines is to systematically scan the Internet-based services that post them.
Patient Guideline Sources The remainder of this chapter directs you to sources which either publish or can help you find additional guidelines on topics related to erythema. Due to space limitations, these sources are listed in a concise manner. Do not hesitate to consult the following sources by either using the Internet hyperlink provided, or, in cases where the contact information is provided, contacting the publisher or author directly. The National Institutes of Health The NIH gateway to patients is located at http://health.nih.gov/. From this site, you can search across various sources and institutes, a number of which are summarized below. Topic Pages: MEDLINEplus The National Library of Medicine has created a vast and patient-oriented healthcare information portal called MEDLINEplus. Within this Internet-based system are “health topic pages” which list links to available materials relevant to erythema. To access this system, log on to http://www.nlm.nih.gov/medlineplus/healthtopics.html. From there you can either search using the alphabetical index or browse by broad topic areas. Recently, MEDLINEplus listed the following when searched for “erythema”:
128
Erythema
Behcet's Syndrome http://www.nlm.nih.gov/medlineplus/behcetssyndrome.html Crohn's Disease http://www.nlm.nih.gov/medlineplus/crohnsdisease.html Infant and Toddler Health http://www.nlm.nih.gov/medlineplus/infantandtoddlerhealth.html Lyme Disease http://www.nlm.nih.gov/medlineplus/lymedisease.html Skin Diseases http://www.nlm.nih.gov/medlineplus/skindiseases.html You may also choose to use the search utility provided by MEDLINEplus at the following Web address: http://www.nlm.nih.gov/medlineplus/. Simply type a keyword into the search box and click “Search.” This utility is similar to the NIH search utility, with the exception that it only includes materials that are linked within the MEDLINEplus system (mostly patient-oriented information). It also has the disadvantage of generating unstructured results. We recommend, therefore, that you use this method only if you have a very targeted search. The Combined Health Information Database (CHID) CHID Online is a reference tool that maintains a database directory of thousands of journal articles and patient education guidelines on erythema. CHID offers summaries that describe the guidelines available, including contact information and pricing. CHID’s general Web site is http://chid.nih.gov/. To search this database, go to http://chid.nih.gov/detail/detail.html. In particular, you can use the advanced search options to look up pamphlets, reports, brochures, and information kits. The following was recently posted in this archive: •
Q and A. Crohn's Disease and Ulcerative Colitis: Complications Source: New York, NY: Crohn's and Colitis Foundation of America. 2002. 8 p. Contact: Available from Crohn's and Colitis Foundation of America (CCFA). 386 Park Avenue South, 17th Floor, New York, NY 10016-8804. (800) 932-2423. E-mail:
[email protected]. Website: www.ccfa.org. PRICE: Single copy free. Summary: Crohn's disease and ulcerative colitis are chronic digestive diseases of the small and large intestines, collectively known as inflammatory bowel disease (IBD). This brochure answers common questions about the complications of these diseases. Symptoms of IBD can include diarrhea, abdominal pain, rectal bleeding, and fever; loss of appetite and weight loss are also common. If medications fail to control the symptoms of the disease, or if certain complications occur, surgery may be required. Yet, in spite of the physical and emotional demands of coping with IBD, most patients are able to lead full, satisfying lives. Complications are categorized as local (a complication involving the intestinal tract itself) or systemic (complications involving other organs or complications that affect the patient as a whole). The brochure covers specific topics including how commonly complications occur in IBD; systemic complications including fever, weakness, and loss of appetite; joint, eye and skin complications, including arthritis; the causes of the extraintestinal manifestations of IBD; which joints are commonly involved; the most common skin disorders associated with IBD, including
Patient Resources
129
erythema nodosum, pyoderma gangrenosum, and aphthous stomatitis; the manifestations of liver disease, including sclerosing cholangitis; the symptoms of bone loss; the more important local complications of ulcerative colitis, including toxic megacolon; how the complications of ulcerative colitis differ from those seen in Crohn's disease; the symptoms of intestinal obstruction; the indications for surgery; fistulas and how they are treated; concerns about malnutrition in patients with IBD; complications that affect children and adolescents with IBD; and the risk factors for cancer. The brochure includes a brief description of the goals and activities of the Crohn's and Colitis Foundation of American (www.ccfa.org). •
Otitis Externa (OE) Source: American Family Physician. 63(5): 941. March 1, 2001. Contact: Available from American Academy of Family Physicians. 11400 Tomahawk Creek Parkway, Leawood, KS 66211-2672. (800) 274-2237. Website: www.aafp.org. Summary: Otitis externa (OE) is an infection of the ear canal. Because the canal is dark and warm, it can easily get infected with bacteria (germs) and fungus. This patient education fact sheet offers practical information about the treatment and prevention of otitis externa. The most characteristic symptom is discomfort that is limited to the external auditory canal, while the most characteristic signs are erythema (redness) and swelling of the canal with variable discharge (drainage of fluid from the ear). The fact sheet notes that most OE infections can be treated with ear drops, but sometimes oral medications are needed. In addition, patients with OE are advised to keep their ear as dry as possible for seven to ten days, and not to put anything except the prescribed ear drops into the ear. The fact sheet then focuses on preventive strategies, including: never put anything in the ear canal, leave ear wax in the canal (or have a physician or nurse remove it if necessary), keep the ears as dry as possible (use a hair dryer to gently dry ears after swimming or showering), and do not use earplugs (they can irritate the ear canal). Readers are encouraged to consult with their own physician (or visit www.familydoctor.org) for more information.
•
Stomatology Center, Baylor College of Dentistry Source: Dallas, TX: Baylor College of Dentistry. 199x. 3 p. Contact: Available from Terry Rees, D.D.S., M.S.D., Director, Stomatology Center. Department of Periodontics, Baylor College of Dentistry, 3302 Gaston Avenue, Dallas, TX 75246. (214) 828-8144. Price: Single copy free. Summary: This brochure describes the Stomatology Center of the Baylor College of Dentistry, located in Dallas, Texas. The Stomatology Center was established to serve as a referral site for the treatment of severe mouth problems that are difficult to diagnose and difficult to manage. The stomatopathologic conditions of concern are chronic, painful, ulcerative or debilitating diseases of the oral mucosa. Their focus includes, but is not limited to: lichen planus, pemphigoid, pemphigus, hormonally-mediated desquamative gingivitis, recurrent oral ulcerations, erythema multiforme, candidosis, xerostomia, burning mouth and tongue syndrome, and problems resulting from chemotherapy. The brochure is illustrated with full-color photographs of the Center.
130
Erythema
The NIH Search Utility The NIH search utility allows you to search for documents on over 100 selected Web sites that comprise the NIH-WEB-SPACE. Each of these servers is “crawled” and indexed on an ongoing basis. Your search will produce a list of various documents, all of which will relate in some way to erythema. The drawbacks of this approach are that the information is not organized by theme and that the references are often a mix of information for professionals and patients. Nevertheless, a large number of the listed Web sites provide useful background information. We can only recommend this route, therefore, for relatively rare or specific disorders, or when using highly targeted searches. To use the NIH search utility, visit the following Web page: http://search.nih.gov/index.html. Additional Web Sources A number of Web sites are available to the public that often link to government sites. These can also point you in the direction of essential information. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=168&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/specific.htm
•
Google: http://directory.google.com/Top/Health/Conditions_and_Diseases/
•
Med Help International: http://www.medhelp.org/HealthTopics/A.html
•
Open Directory Project: http://dmoz.org/Health/Conditions_and_Diseases/
•
Yahoo.com: http://dir.yahoo.com/Health/Diseases_and_Conditions/
•
WebMDHealth: http://my.webmd.com/health_topics
Finding Associations There are several Internet directories that provide lists of medical associations with information on or resources relating to erythema. By consulting all of associations listed in this chapter, you will have nearly exhausted all sources for patient associations concerned with erythema. The National Health Information Center (NHIC) The National Health Information Center (NHIC) offers a free referral service to help people find organizations that provide information about erythema. For more information, see the NHIC’s Web site at http://www.health.gov/NHIC/ or contact an information specialist by calling 1-800-336-4797. Directory of Health Organizations The Directory of Health Organizations, provided by the National Library of Medicine Specialized Information Services, is a comprehensive source of information on associations. The Directory of Health Organizations database can be accessed via the Internet at
Patient Resources
131
http://www.sis.nlm.nih.gov/Dir/DirMain.html. It is composed of two parts: DIRLINE and Health Hotlines. The DIRLINE database comprises some 10,000 records of organizations, research centers, and government institutes and associations that primarily focus on health and biomedicine. To access DIRLINE directly, go to the following Web site: http://dirline.nlm.nih.gov/. Simply type in “erythema” (or a synonym), and you will receive information on all relevant organizations listed in the database. Health Hotlines directs you to toll-free numbers to over 300 organizations. You can access this database directly at http://www.sis.nlm.nih.gov/hotlines/. On this page, you are given the option to search by keyword or by browsing the subject list. When you have received your search results, click on the name of the organization for its description and contact information. The Combined Health Information Database Another comprehensive source of information on healthcare associations is the Combined Health Information Database. Using the “Detailed Search” option, you will need to limit your search to “Organizations” and “erythema”. Type the following hyperlink into your Web browser: http://chid.nih.gov/detail/detail.html. To find associations, use the drop boxes at the bottom of the search page where “You may refine your search by.” For publication date, select “All Years.” Then, select your preferred language and the format option “Organization Resource Sheet.” Type “erythema” (or synonyms) into the “For these words:” box. You should check back periodically with this database since it is updated every three months. The National Organization for Rare Disorders, Inc. The National Organization for Rare Disorders, Inc. has prepared a Web site that provides, at no charge, lists of associations organized by health topic. You can access this database at the following Web site: http://www.rarediseases.org/search/orgsearch.html. Type “erythema” (or a synonym) into the search box, and click “Submit Query.”
133
APPENDIX C. FINDING MEDICAL LIBRARIES Overview In this Appendix, we show you how to quickly find a medical library in your area.
Preparation Your local public library and medical libraries have interlibrary loan programs with the National Library of Medicine (NLM), one of the largest medical collections in the world. According to the NLM, most of the literature in the general and historical collections of the National Library of Medicine is available on interlibrary loan to any library. If you would like to access NLM medical literature, then visit a library in your area that can request the publications for you.22
Finding a Local Medical Library The quickest method to locate medical libraries is to use the Internet-based directory published by the National Network of Libraries of Medicine (NN/LM). This network includes 4626 members and affiliates that provide many services to librarians, health professionals, and the public. To find a library in your area, simply visit http://nnlm.gov/members/adv.html or call 1-800-338-7657.
Medical Libraries in the U.S. and Canada In addition to the NN/LM, the National Library of Medicine (NLM) lists a number of libraries with reference facilities that are open to the public. The following is the NLM’s list and includes hyperlinks to each library’s Web site. These Web pages can provide information on hours of operation and other restrictions. The list below is a small sample of
22
Adapted from the NLM: http://www.nlm.nih.gov/psd/cas/interlibrary.html.
134
Erythema
libraries recommended by the National Library of Medicine (sorted alphabetically by name of the U.S. state or Canadian province where the library is located)23: •
Alabama: Health InfoNet of Jefferson County (Jefferson County Library Cooperative, Lister Hill Library of the Health Sciences), http://www.uab.edu/infonet/
•
Alabama: Richard M. Scrushy Library (American Sports Medicine Institute)
•
Arizona: Samaritan Regional Medical Center: The Learning Center (Samaritan Health System, Phoenix, Arizona), http://www.samaritan.edu/library/bannerlibs.htm
•
California: Kris Kelly Health Information Center (St. Joseph Health System, Humboldt), http://www.humboldt1.com/~kkhic/index.html
•
California: Community Health Library of Los Gatos, http://www.healthlib.org/orgresources.html
•
California: Consumer Health Program and Services (CHIPS) (County of Los Angeles Public Library, Los Angeles County Harbor-UCLA Medical Center Library) - Carson, CA, http://www.colapublib.org/services/chips.html
•
California: Gateway Health Library (Sutter Gould Medical Foundation)
•
California: Health Library (Stanford University Medical Center), http://wwwmed.stanford.edu/healthlibrary/
•
California: Patient Education Resource Center - Health Information and Resources (University of California, San Francisco), http://sfghdean.ucsf.edu/barnett/PERC/default.asp
•
California: Redwood Health Library (Petaluma Health Care District), http://www.phcd.org/rdwdlib.html
•
California: Los Gatos PlaneTree Health Library, http://planetreesanjose.org/
•
California: Sutter Resource Library (Sutter Hospitals Foundation, Sacramento), http://suttermedicalcenter.org/library/
•
California: Health Sciences Libraries (University of California, Davis), http://www.lib.ucdavis.edu/healthsci/
•
California: ValleyCare Health Library & Ryan Comer Cancer Resource Center (ValleyCare Health System, Pleasanton), http://gaelnet.stmarysca.edu/other.libs/gbal/east/vchl.html
•
California: Washington Community Health Resource Library (Fremont), http://www.healthlibrary.org/
•
Colorado: William V. Gervasini Memorial Library (Exempla Healthcare), http://www.saintjosephdenver.org/yourhealth/libraries/
•
Connecticut: Hartford Hospital Health Science Libraries (Hartford Hospital), http://www.harthosp.org/library/
•
Connecticut: Healthnet: Connecticut Consumer Health Information Center (University of Connecticut Health Center, Lyman Maynard Stowe Library), http://library.uchc.edu/departm/hnet/
23
Abstracted from http://www.nlm.nih.gov/medlineplus/libraries.html.
Finding Medical Libraries
135
•
Connecticut: Waterbury Hospital Health Center Library (Waterbury Hospital, Waterbury), http://www.waterburyhospital.com/library/consumer.shtml
•
Delaware: Consumer Health Library (Christiana Care Health System, Eugene du Pont Preventive Medicine & Rehabilitation Institute, Wilmington), http://www.christianacare.org/health_guide/health_guide_pmri_health_info.cfm
•
Delaware: Lewis B. Flinn Library (Delaware Academy of Medicine, Wilmington), http://www.delamed.org/chls.html
•
Georgia: Family Resource Library (Medical College of Georgia, Augusta), http://cmc.mcg.edu/kids_families/fam_resources/fam_res_lib/frl.htm
•
Georgia: Health Resource Center (Medical Center of Central Georgia, Macon), http://www.mccg.org/hrc/hrchome.asp
•
Hawaii: Hawaii Medical Library: Consumer Health Information Service (Hawaii Medical Library, Honolulu), http://hml.org/CHIS/
•
Idaho: DeArmond Consumer Health Library (Kootenai Medical Center, Coeur d’Alene), http://www.nicon.org/DeArmond/index.htm
•
Illinois: Health Learning Center of Northwestern Memorial Hospital (Chicago), http://www.nmh.org/health_info/hlc.html
•
Illinois: Medical Library (OSF Saint Francis Medical Center, Peoria), http://www.osfsaintfrancis.org/general/library/
•
Kentucky: Medical Library - Services for Patients, Families, Students & the Public (Central Baptist Hospital, Lexington), http://www.centralbap.com/education/community/library.cfm
•
Kentucky: University of Kentucky - Health Information Library (Chandler Medical Center, Lexington), http://www.mc.uky.edu/PatientEd/
•
Louisiana: Alton Ochsner Medical Foundation Library (Alton Ochsner Medical Foundation, New Orleans), http://www.ochsner.org/library/
•
Louisiana: Louisiana State University Health Sciences Center Medical LibraryShreveport, http://lib-sh.lsuhsc.edu/
•
Maine: Franklin Memorial Hospital Medical Library (Franklin Memorial Hospital, Farmington), http://www.fchn.org/fmh/lib.htm
•
Maine: Gerrish-True Health Sciences Library (Central Maine Medical Center, Lewiston), http://www.cmmc.org/library/library.html
•
Maine: Hadley Parrot Health Science Library (Eastern Maine Healthcare, Bangor), http://www.emh.org/hll/hpl/guide.htm
•
Maine: Maine Medical Center Library (Maine Medical Center, Portland), http://www.mmc.org/library/
•
Maine: Parkview Hospital (Brunswick), http://www.parkviewhospital.org/
•
Maine: Southern Maine Medical Center Health Sciences Library (Southern Maine Medical Center, Biddeford), http://www.smmc.org/services/service.php3?choice=10
•
Maine: Stephens Memorial Hospital’s Health Information Library (Western Maine Health, Norway), http://www.wmhcc.org/Library/
136
Erythema
•
Manitoba, Canada: Consumer & Patient Health Information Service (University of Manitoba Libraries), http://www.umanitoba.ca/libraries/units/health/reference/chis.html
•
Manitoba, Canada: J.W. Crane Memorial Library (Deer Lodge Centre, Winnipeg), http://www.deerlodge.mb.ca/crane_library/about.asp
•
Maryland: Health Information Center at the Wheaton Regional Library (Montgomery County, Dept. of Public Libraries, Wheaton Regional Library), http://www.mont.lib.md.us/healthinfo/hic.asp
•
Massachusetts: Baystate Medical Center Library (Baystate Health System), http://www.baystatehealth.com/1024/
•
Massachusetts: Boston University Medical Center Alumni Medical Library (Boston University Medical Center), http://med-libwww.bu.edu/library/lib.html
•
Massachusetts: Lowell General Hospital Health Sciences Library (Lowell General Hospital, Lowell), http://www.lowellgeneral.org/library/HomePageLinks/WWW.htm
•
Massachusetts: Paul E. Woodard Health Sciences Library (New England Baptist Hospital, Boston), http://www.nebh.org/health_lib.asp
•
Massachusetts: St. Luke’s Hospital Health Sciences Library (St. Luke’s Hospital, Southcoast Health System, New Bedford), http://www.southcoast.org/library/
•
Massachusetts: Treadwell Library Consumer Health Reference Center (Massachusetts General Hospital), http://www.mgh.harvard.edu/library/chrcindex.html
•
Massachusetts: UMass HealthNet (University of Massachusetts Medical School, Worchester), http://healthnet.umassmed.edu/
•
Michigan: Botsford General Hospital Library - Consumer Health (Botsford General Hospital, Library & Internet Services), http://www.botsfordlibrary.org/consumer.htm
•
Michigan: Helen DeRoy Medical Library (Providence Hospital and Medical Centers), http://www.providence-hospital.org/library/
•
Michigan: Marquette General Hospital - Consumer Health Library (Marquette General Hospital, Health Information Center), http://www.mgh.org/center.html
•
Michigan: Patient Education Resouce Center - University of Michigan Cancer Center (University of Michigan Comprehensive Cancer Center, Ann Arbor), http://www.cancer.med.umich.edu/learn/leares.htm
•
Michigan: Sladen Library & Center for Health Information Resources - Consumer Health Information (Detroit), http://www.henryford.com/body.cfm?id=39330
•
Montana: Center for Health Information (St. Patrick Hospital and Health Sciences Center, Missoula)
•
National: Consumer Health Library Directory (Medical Library Association, Consumer and Patient Health Information Section), http://caphis.mlanet.org/directory/index.html
•
National: National Network of Libraries of Medicine (National Library of Medicine) provides library services for health professionals in the United States who do not have access to a medical library, http://nnlm.gov/
•
National: NN/LM List of Libraries Serving the Public (National Network of Libraries of Medicine), http://nnlm.gov/members/
Finding Medical Libraries
137
•
Nevada: Health Science Library, West Charleston Library (Las Vegas-Clark County Library District, Las Vegas), http://www.lvccld.org/special_collections/medical/index.htm
•
New Hampshire: Dartmouth Biomedical Libraries (Dartmouth College Library, Hanover), http://www.dartmouth.edu/~biomed/resources.htmld/conshealth.htmld/
•
New Jersey: Consumer Health Library (Rahway Hospital, Rahway), http://www.rahwayhospital.com/library.htm
•
New Jersey: Dr. Walter Phillips Health Sciences Library (Englewood Hospital and Medical Center, Englewood), http://www.englewoodhospital.com/links/index.htm
•
New Jersey: Meland Foundation (Englewood Hospital and Medical Center, Englewood), http://www.geocities.com/ResearchTriangle/9360/
•
New York: Choices in Health Information (New York Public Library) - NLM Consumer Pilot Project participant, http://www.nypl.org/branch/health/links.html
•
New York: Health Information Center (Upstate Medical University, State University of New York, Syracuse), http://www.upstate.edu/library/hic/
•
New York: Health Sciences Library (Long Island Jewish Medical Center, New Hyde Park), http://www.lij.edu/library/library.html
•
New York: ViaHealth Medical Library (Rochester General Hospital), http://www.nyam.org/library/
•
Ohio: Consumer Health Library (Akron General Medical Center, Medical & Consumer Health Library), http://www.akrongeneral.org/hwlibrary.htm
•
Oklahoma: The Health Information Center at Saint Francis Hospital (Saint Francis Health System, Tulsa), http://www.sfh-tulsa.com/services/healthinfo.asp
•
Oregon: Planetree Health Resource Center (Mid-Columbia Medical Center, The Dalles), http://www.mcmc.net/phrc/
•
Pennsylvania: Community Health Information Library (Milton S. Hershey Medical Center, Hershey), http://www.hmc.psu.edu/commhealth/
•
Pennsylvania: Community Health Resource Library (Geisinger Medical Center, Danville), http://www.geisinger.edu/education/commlib.shtml
•
Pennsylvania: HealthInfo Library (Moses Taylor Hospital, Scranton), http://www.mth.org/healthwellness.html
•
Pennsylvania: Hopwood Library (University of Pittsburgh, Health Sciences Library System, Pittsburgh), http://www.hsls.pitt.edu/guides/chi/hopwood/index_html
•
Pennsylvania: Koop Community Health Information Center (College of Physicians of Philadelphia), http://www.collphyphil.org/kooppg1.shtml
•
Pennsylvania: Learning Resources Center - Medical Library (Susquehanna Health System, Williamsport), http://www.shscares.org/services/lrc/index.asp
•
Pennsylvania: Medical Library (UPMC Health System, Pittsburgh), http://www.upmc.edu/passavant/library.htm
•
Quebec, Canada: Medical Library (Montreal General Hospital), http://www.mghlib.mcgill.ca/
138
Erythema
•
South Dakota: Rapid City Regional Hospital Medical Library (Rapid City Regional Hospital), http://www.rcrh.org/Services/Library/Default.asp
•
Texas: Houston HealthWays (Houston Academy of Medicine-Texas Medical Center Library), http://hhw.library.tmc.edu/
•
Washington: Community Health Library (Kittitas Valley Community Hospital), http://www.kvch.com/
•
Washington: Southwest Washington Medical Center Library (Southwest Washington Medical Center, Vancouver), http://www.swmedicalcenter.com/body.cfm?id=72
139
ONLINE GLOSSARIES The Internet provides access to a number of free-to-use medical dictionaries. The National Library of Medicine has compiled the following list of online dictionaries: •
ADAM Medical Encyclopedia (A.D.A.M., Inc.), comprehensive medical reference: http://www.nlm.nih.gov/medlineplus/encyclopedia.html
•
MedicineNet.com Medical Dictionary (MedicineNet, Inc.): http://www.medterms.com/Script/Main/hp.asp
•
Merriam-Webster Medical Dictionary (Inteli-Health, Inc.): http://www.intelihealth.com/IH/
•
Multilingual Glossary of Technical and Popular Medical Terms in Eight European Languages (European Commission) - Danish, Dutch, English, French, German, Italian, Portuguese, and Spanish: http://allserv.rug.ac.be/~rvdstich/eugloss/welcome.html
•
On-line Medical Dictionary (CancerWEB): http://cancerweb.ncl.ac.uk/omd/
•
Rare Diseases Terms (Office of Rare Diseases): http://ord.aspensys.com/asp/diseases/diseases.asp
•
Technology Glossary (National Library of Medicine) - Health Care Technology: http://www.nlm.nih.gov/nichsr/ta101/ta10108.htm
Beyond these, MEDLINEplus contains a very patient-friendly encyclopedia covering every aspect of medicine (licensed from A.D.A.M., Inc.). The ADAM Medical Encyclopedia can be accessed at http://www.nlm.nih.gov/medlineplus/encyclopedia.html. ADAM is also available on commercial Web sites such as drkoop.com (http://www.drkoop.com/) and Web MD (http://my.webmd.com/adam/asset/adam_disease_articles/a_to_z/a). The NIH suggests the following Web sites in the ADAM Medical Encyclopedia when searching for information on erythema: •
Basic Guidelines for Erythema Erythema multiforme Web site: http://www.nlm.nih.gov/medlineplus/ency/article/000851.htm Erythema nodosum Web site: http://www.nlm.nih.gov/medlineplus/ency/article/000881.htm Erythema toxicum Web site: http://www.nlm.nih.gov/medlineplus/ency/article/001458.htm
•
Signs & Symptoms for Erythema Blisters Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003939.htm Erythema Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003220.htm
140
Erythema
Eye burning, itching and discharge Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003034.htm Eye pain Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003032.htm Eyes, bloodshot Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003031.htm Fever Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003090.htm General ill feeling Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003089.htm Itching Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003217.htm Joint aches Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003261.htm Leukemia Web site: http://www.nlm.nih.gov/medlineplus/ency/article/001299.htm Malaise Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003089.htm Mouth lesions Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003059.htm Mouth sores Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003059.htm Nikolsky's sign Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003285.htm Pallor Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003244.htm Skin lesion Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003220.htm Skin lesions Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003220.htm Skin redness Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003220.htm Swelling Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003103.htm
Online Glossaries 141
Tearing, decreased Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003087.htm Vesicles Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003939.htm Vision abnormalities Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003029.htm •
Diagnostics and Tests for Erythema Biopsy Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003416.htm Skin lesion biopsy Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003840.htm
•
Nutrition for Erythema Bullae Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003239.htm
•
Background Topics for Erythema Acute Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002215.htm Allergic reaction Web site: http://www.nlm.nih.gov/medlineplus/ency/article/000005.htm Analgesics Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002123.htm Anterior Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002232.htm Antibody Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002223.htm Benign Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002236.htm Central Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002311.htm Iris Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002386.htm Macule Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003229.htm
142
Erythema
Necrosis Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002266.htm Newborn infant Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002271.htm Secondary infections Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002300.htm Shock Web site: http://www.nlm.nih.gov/medlineplus/ency/article/000039.htm Systemic Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002294.htm
Online Dictionary Directories The following are additional online directories compiled by the National Library of Medicine, including a number of specialized medical dictionaries: •
Medical Dictionaries: Medical & Biological (World Health Organization): http://www.who.int/hlt/virtuallibrary/English/diction.htm#Medical
•
MEL-Michigan Electronic Library List of Online Health and Medical Dictionaries (Michigan Electronic Library): http://mel.lib.mi.us/health/health-dictionaries.html
•
Patient Education: Glossaries (DMOZ Open Directory Project): http://dmoz.org/Health/Education/Patient_Education/Glossaries/
•
Web of Online Dictionaries (Bucknell University): http://www.yourdictionary.com/diction5.html#medicine
143
ERYTHEMA DICTIONARY The definitions below are derived from official public sources, including the National Institutes of Health [NIH] and the European Union [EU]. 3-dimensional: 3-D. A graphic display of depth, width, and height. Three-dimensional radiation therapy uses computers to create a 3-dimensional picture of the tumor. This allows doctors to give the highest possible dose of radiation to the tumor, while sparing the normal tissue as much as possible. [NIH] Abdomen: That portion of the body that lies between the thorax and the pelvis. [NIH] Abdominal: Having to do with the abdomen, which is the part of the body between the chest and the hips that contains the pancreas, stomach, intestines, liver, gallbladder, and other organs. [NIH] Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region. [NIH] Ablation: The removal of an organ by surgery. [NIH] Abortion: 1. The premature expulsion from the uterus of the products of conception - of the embryo, or of a nonviable fetus. The four classic symptoms, usually present in each type of abortion, are uterine contractions, uterine haemorrhage, softening and dilatation of the cervix, and presentation or expulsion of all or part of the products of conception. 2. Premature stoppage of a natural or a pathological process. [EU] Abrasion: 1. The wearing away of a substance or structure (such as the skin or the teeth) through some unusual or abnormal mechanical process. 2. An area of body surface denuded of skin or mucous membrane by some unusual or abnormal mechanical process. [EU] Acantholysis: Separation of the prickle cells of the stratum spinosum of the epidermis, resulting in atrophy of the prickle cell layer. It is seen in diseases such as pemphigus vulgaris (see pemphigus) and keratosis follicularis. [NIH] Acceptor: A substance which, while normally not oxidized by oxygen or reduced by hydrogen, can be oxidized or reduced in presence of a substance which is itself undergoing oxidation or reduction. [NIH] Acetylcysteine: The N-acetyl derivative of cysteine. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates. [NIH] Acidity: The quality of being acid or sour; containing acid (hydrogen ions). [EU] Acne: A disorder of the skin marked by inflammation of oil glands and hair glands. [NIH] Acoustic: Having to do with sound or hearing. [NIH] Acrodermatitis: Inflammation involving the skin of the extremities, especially the hands and feet. Several forms are known, some idiopathic and some hereditary. The infantile form is called Gianotti-Crosti syndrome. [NIH] Acrylonitrile: A highly poisonous compound used widely in the manufacture of plastics, adhesives and synthetic rubber. [NIH] Actinic keratosis: A precancerous condition of thick, scaly patches of skin. Also called solar or senile keratosis. [NIH] Acute leukemia: A rapidly progressing cancer of the blood-forming tissue (bone marrow). [NIH]
144
Erythema
Acute myeloid leukemia: AML. A quickly progressing disease in which too many immature blood-forming cells are found in the blood and bone marrow. Also called acute myelogenous leukemia or acute nonlymphocytic leukemia. [NIH] Acute renal: A condition in which the kidneys suddenly stop working. In most cases, kidneys can recover from almost complete loss of function. [NIH] Acyclovir: Functional analog of the nucleoside guanosine. It acts as an antimetabolite, especially in viruses. It is used as an antiviral agent, especially in herpes infections. [NIH] Adipocytes: Fat-storing cells found mostly in the abdominal cavity and subcutaneous tissue. Fat is usually stored in the form of tryglycerides. [NIH] Adipose Tissue: Connective tissue composed of fat cells lodged in the meshes of areolar tissue. [NIH] Adrenal Cortex: The outer layer of the adrenal gland. It secretes mineralocorticoids, androgens, and glucocorticoids. [NIH] Adrenal Glands: Paired glands situated in the retroperitoneal tissues at the superior pole of each kidney. [NIH] Adrenergic: Activated by, characteristic of, or secreting epinephrine or substances with similar activity; the term is applied to those nerve fibres that liberate norepinephrine at a synapse when a nerve impulse passes, i.e., the sympathetic fibres. [EU] Adverse Effect: An unwanted side effect of treatment. [NIH] Afferent: Concerned with the transmission of neural impulse toward the central part of the nervous system. [NIH] Affinity: 1. Inherent likeness or relationship. 2. A special attraction for a specific element, organ, or structure. 3. Chemical affinity; the force that binds atoms in molecules; the tendency of substances to combine by chemical reaction. 4. The strength of noncovalent chemical binding between two substances as measured by the dissociation constant of the complex. 5. In immunology, a thermodynamic expression of the strength of interaction between a single antigen-binding site and a single antigenic determinant (and thus of the stereochemical compatibility between them), most accurately applied to interactions among simple, uniform antigenic determinants such as haptens. Expressed as the association constant (K litres mole -1), which, owing to the heterogeneity of affinities in a population of antibody molecules of a given specificity, actually represents an average value (mean intrinsic association constant). 6. The reciprocal of the dissociation constant. [EU] Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis. [NIH]
Agonist: In anatomy, a prime mover. In pharmacology, a drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances. [EU] Airway: A device for securing unobstructed passage of air into and out of the lungs during general anesthesia. [NIH] Algorithms: A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. [NIH] Alkaline: Having the reactions of an alkali. [EU] Alleles: Mutually exclusive forms of the same gene, occupying the same locus on homologous chromosomes, and governing the same biochemical and developmental
Dictionary 145
process. [NIH] Allergen: An antigenic substance capable of producing immediate-type hypersensitivity (allergy). [EU] Allylamine: Possesses an unusual and selective cytotoxicity for vascular smooth muscle cells in dogs and rats. Useful for experiments dealing with arterial injury, myocardial fibrosis or cardiac decompensation. [NIH] Alpha Cell: A type of cell in the pancreas (in areas called the islets of Langerhans). Alpha cells make and release a hormone called glucagon, which raises the level of glucose (sugar) in the blood. [NIH] Alpha Particles: Positively charged particles composed of two protons and two neutrons, i.e., helium nuclei, emitted during disintegration of very heavy isotopes; a beam of alpha particles or an alpha ray has very strong ionizing power, but weak penetrability. [NIH] Alternative medicine: Practices not generally recognized by the medical community as standard or conventional medical approaches and used instead of standard treatments. Alternative medicine includes the taking of dietary supplements, megadose vitamins, and herbal preparations; the drinking of special teas; and practices such as massage therapy, magnet therapy, spiritual healing, and meditation. [NIH] Amber: A yellowish fossil resin, the gum of several species of coniferous trees, found in the alluvial deposits of northeastern Germany. It is used in molecular biology in the analysis of organic matter fossilized in amber. [NIH] Ameliorating: A changeable condition which prevents the consequence of a failure or accident from becoming as bad as it otherwise would. [NIH] Amenorrhea: Absence of menstruation. [NIH] Amine: An organic compound containing nitrogen; any member of a group of chemical compounds formed from ammonia by replacement of one or more of the hydrogen atoms by organic (hydrocarbon) radicals. The amines are distinguished as primary, secondary, and tertiary, according to whether one, two, or three hydrogen atoms are replaced. The amines include allylamine, amylamine, ethylamine, methylamine, phenylamine, propylamine, and many other compounds. [EU] Amino acid: Any organic compound containing an amino (-NH2 and a carboxyl (- COOH) group. The 20 a-amino acids listed in the accompanying table are the amino acids from which proteins are synthesized by formation of peptide bonds during ribosomal translation of messenger RNA; all except glycine, which is not optically active, have the L configuration. Other amino acids occurring in proteins, such as hydroxyproline in collagen, are formed by posttranslational enzymatic modification of amino acids residues in polypeptide chains. There are also several important amino acids, such as the neurotransmitter y-aminobutyric acid, that have no relation to proteins. Abbreviated AA. [EU] Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining protein conformation. [NIH] Ammonia: A colorless alkaline gas. It is formed in the body during decomposition of organic materials during a large number of metabolically important reactions. [NIH] Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broadspectrum antibiotic. [NIH] Amplification: The production of additional copies of a chromosomal DNA sequence, found as either intrachromosomal or extrachromosomal DNA. [NIH] Amputation: Surgery to remove part or all of a limb or appendage. [NIH]
146
Erythema
Amyloidosis: A group of diseases in which protein is deposited in specific organs (localized amyloidosis) or throughout the body (systemic amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary amyloidosis often affects the spleen, kidneys, liver, and adrenal glands. [NIH] Anaerobic: 1. Lacking molecular oxygen. 2. Growing, living, or occurring in the absence of molecular oxygen; pertaining to an anaerobe. [EU] Anaesthesia: Loss of feeling or sensation. Although the term is used for loss of tactile sensibility, or of any of the other senses, it is applied especially to loss of the sensation of pain, as it is induced to permit performance of surgery or other painful procedures. [EU] Analgesic: An agent that alleviates pain without causing loss of consciousness. [EU] Analog: In chemistry, a substance that is similar, but not identical, to another. [NIH] Analogous: Resembling or similar in some respects, as in function or appearance, but not in origin or development;. [EU] Anatomical: Pertaining to anatomy, or to the structure of the organism. [EU] Androgens: A class of sex hormones associated with the development and maintenance of the secondary male sex characteristics, sperm induction, and sexual differentiation. In addition to increasing virility and libido, they also increase nitrogen and water retention and stimulate skeletal growth. [NIH] Anemia: A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin. [NIH] Anemic: Hypoxia due to reduction of the oxygen-carrying capacity of the blood as a result of a decrease in the total hemoglobin or an alteration of the hemoglobin constituents. [NIH] Anesthesia: A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures. [NIH] Anesthetics: Agents that are capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general anesthesia, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. [NIH] Angioedema: A vascular reaction involving the deep dermis or subcutaneous or submucal tissues, representing localized edema caused by dilatation and increased permeability of the capillaries, and characterized by development of giant wheals. [EU] Angiogenesis: Blood vessel formation. Tumor angiogenesis is the growth of blood vessels from surrounding tissue to a solid tumor. This is caused by the release of chemicals by the tumor. [NIH] Angiogenesis inhibitor: A substance that may prevent the formation of blood vessels. In anticancer therapy, an angiogenesis inhibitor prevents the growth of blood vessels from surrounding tissue to a solid tumor. [NIH] Angiography: Radiography of blood vessels after injection of a contrast medium. [NIH] Animal model: An animal with a disease either the same as or like a disease in humans. Animal models are used to study the development and progression of diseases and to test new treatments before they are given to humans. Animals with transplanted human cancers or other tissues are called xenograft models. [NIH] Anions: Negatively charged atoms, radicals or groups of atoms which travel to the anode or
Dictionary 147
positive pole during electrolysis. [NIH] Annealing: The spontaneous alignment of two single DNA strands to form a double helix. [NIH]
Anorexia: Lack or loss of appetite for food. Appetite is psychologic, dependent on memory and associations. Anorexia can be brought about by unattractive food, surroundings, or company. [NIH] Anorexia Nervosa: The chief symptoms are inability to eat, weight loss, and amenorrhea. [NIH]
Anthropogenic: Of human origin or influence. [NIH] Antiallergic: Counteracting allergy or allergic conditions. [EU] Antibacterial: A substance that destroys bacteria or suppresses their growth or reproduction. [EU] Antibiotic: A drug used to treat infections caused by bacteria and other microorganisms. [NIH]
Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the antigen that induced their synthesis in cells of the lymphoid series (especially plasma cells), or with an antigen closely related to it. [NIH] Antibodies, Anticardiolipin: Antiphospholipid antibodies found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase immunoassay employing the purified phospholipid antigen cardiolipin. [NIH] Antibody: A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen. [NIH] Anticarcinogenic: Pertaining to something that prevents or delays the development of cancer. [NIH] Anticoagulant: A drug that helps prevent blood clots from forming. Also called a blood thinner. [NIH] Anticonvulsant: An agent that prevents or relieves convulsions. [EU] Antifungal: Destructive to fungi, or suppressing their reproduction or growth; effective against fungal infections. [EU] Antigen: Any substance which is capable, under appropriate conditions, of inducing a specific immune response and of reacting with the products of that response, that is, with specific antibody or specifically sensitized T-lymphocytes, or both. Antigens may be soluble substances, such as toxins and foreign proteins, or particulate, such as bacteria and tissue cells; however, only the portion of the protein or polysaccharide molecule known as the antigenic determinant (q.v.) combines with antibody or a specific receptor on a lymphocyte. Abbreviated Ag. [EU] Antigen-presenting cell: APC. A cell that shows antigen on its surface to other cells of the immune system. This is an important part of an immune response. [NIH] Antihypertensive: An agent that reduces high blood pressure. [EU] Anti-infective: An agent that so acts. [EU] Anti-Infective Agents: Substances that prevent infectious agents or organisms from
148
Erythema
spreading or kill infectious agents in order to prevent the spread of infection. [NIH] Anti-inflammatory: Having to do with reducing inflammation. [NIH] Anti-Inflammatory Agents: Substances that reduce or suppress inflammation. [NIH] Antimetabolite: A chemical that is very similar to one required in a normal biochemical reaction in cells. Antimetabolites can stop or slow down the reaction. [NIH] Antimicrobial: Killing microorganisms, or suppressing their multiplication or growth. [EU] Antineoplastic: Inhibiting or preventing the development of neoplasms, checking the maturation and proliferation of malignant cells. [EU] Antioxidant: A substance that prevents damage caused by free radicals. Free radicals are highly reactive chemicals that often contain oxygen. They are produced when molecules are split to give products that have unpaired electrons. This process is called oxidation. [NIH] Antiphospholipid Syndrome: The presence of antibodies directed against phospholipids (antibodies, antiphospholipid). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (antibodies, anticardiolipin). Present also are high levels of lupus anticoagulant (lupus coagulation inhibitor). [NIH] Antipyretic: An agent that relieves or reduces fever. Called also antifebrile, antithermic and febrifuge. [EU] Antiviral: Destroying viruses or suppressing their replication. [EU] Anus: The opening of the rectum to the outside of the body. [NIH] Aorta: The main trunk of the systemic arteries. [NIH] Aortic Aneurysm: Aneurysm of the aorta. [NIH] Aphthous Stomatitis: Inflammation of the mucous membrane of the mouth. [NIH] Apolipoproteins: The protein components of lipoproteins which remain after the lipids to which the proteins are bound have been removed. They play an important role in lipid transport and metabolism. [NIH] Apoptosis: One of the two mechanisms by which cell death occurs (the other being the pathological process of necrosis). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA (DNA fragmentation) at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. [NIH] Aqueous: Having to do with water. [NIH] Arachidonic Acid: An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides. It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. [NIH] Arterial: Pertaining to an artery or to the arteries. [EU] Arteries: The vessels carrying blood away from the heart. [NIH] Arterioles: The smallest divisions of the arteries located between the muscular arteries and the capillaries. [NIH]
Dictionary 149
Arteriovenous: Both arterial and venous; pertaining to or affecting an artery and a vein. [EU] Arteritis: Inflammation of an artery. [NIH] Artery: Vessel-carrying blood from the heart to various parts of the body. [NIH] Ascites: Accumulation or retention of free fluid within the peritoneal cavity. [NIH] Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant. [NIH] Assay: Determination of the amount of a particular constituent of a mixture, or of the biological or pharmacological potency of a drug. [EU] Astringents: Agents, usually topical, that cause the contraction of tissues for the control of bleeding or secretions. [NIH] Asymptomatic: Having no signs or symptoms of disease. [NIH] Atmospheric Pressure: The pressure at any point in an atmosphere due solely to the weight of the atmospheric gases above the point concerned. [NIH] Atopic: Pertaining to an atopen or to atopy; allergic. [EU] Atrium: A chamber; used in anatomical nomenclature to designate a chamber affording entrance to another structure or organ. Usually used alone to designate an atrium of the heart. [EU] Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes. [NIH] Attenuated: Strain with weakened or reduced virulence. [NIH] Attenuation: Reduction of transmitted sound energy or its electrical equivalent. [NIH] Atypical: Irregular; not conformable to the type; in microbiology, applied specifically to strains of unusual type. [EU] Auditory: Pertaining to the sense of hearing. [EU] Aural: Pertaining to or perceived by the ear, as an aural stimulus. [EU] Autoantibodies: Antibodies that react with self-antigens (autoantigens) of the organism that produced them. [NIH] Autoantigens: Endogenous tissue constituents that have the ability to interact with autoantibodies and cause an immune response. [NIH] Autoimmune disease: A condition in which the body recognizes its own tissues as foreign and directs an immune response against them. [NIH] Autologous: Taken from an individual's own tissues, cells, or DNA. [NIH] Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion. [NIH] Bacteria: Unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. [NIH] Bacterial Infections: Infections by bacteria, general or unspecified. [NIH]
150
Erythema
Bacteriophage: A virus whose host is a bacterial cell; A virus that exclusively infects bacteria. It generally has a protein coat surrounding the genome (DNA or RNA). One of the coliphages most extensively studied is the lambda phage, which is also one of the most important. [NIH] Bacterium: Microscopic organism which may have a spherical, rod-like, or spiral unicellular or non-cellular body. Bacteria usually reproduce through asexual processes. [NIH] Barbiturate: A drug with sedative and hypnotic effects. Barbiturates have been used as sedatives and anesthetics, and they have been used to treat the convulsions associated with epilepsy. [NIH] Barium: An element of the alkaline earth group of metals. It has an atomic symbol Ba, atomic number 56, and atomic weight 138. All of its acid-soluble salts are poisonous. [NIH] Basal cell carcinoma: A type of skin cancer that arises from the basal cells, small round cells found in the lower part (or base) of the epidermis, the outer layer of the skin. [NIH] Basal Cell Nevus Syndrome: Hereditary disorder consisting of multiple basal cell carcinomas, odontogenic keratocysts, and multiple skeletal defects, e.g., frontal and temporoparietal bossing, bifurcated and splayed ribs, kyphoscoliosis, fusion of vertebrae, and cervicothoracic spina bifida. Genetic transmission is autosomal dominant. [NIH] Basal cells: Small, round cells found in the lower part (or base) of the epidermis, the outer layer of the skin. [NIH] Basal Ganglia: Large subcortical nuclear masses derived from the telencephalon and located in the basal regions of the cerebral hemispheres. [NIH] Basement Membrane: Ubiquitous supportive tissue adjacent to epithelium and around smooth and striated muscle cells. This tissue contains intrinsic macromolecular components such as collagen, laminin, and sulfated proteoglycans. As seen by light microscopy one of its subdivisions is the basal (basement) lamina. [NIH] Basophil: A type of white blood cell. Basophils are granulocytes. [NIH] Baths: The immersion or washing of the body or any of its parts in water or other medium for cleansing or medical treatment. It includes bathing for personal hygiene as well as for medical purposes with the addition of therapeutic agents, such as alkalines, antiseptics, oil, etc. [NIH] Benign: Not cancerous; does not invade nearby tissue or spread to other parts of the body. [NIH]
Bilateral: Affecting both the right and left side of body. [NIH] Bile: An emulsifying agent produced in the liver and secreted into the duodenum. Its composition includes bile acids and salts, cholesterol, and electrolytes. It aids digestion of fats in the duodenum. [NIH] Bile Acids: Acids made by the liver that work with bile to break down fats. [NIH] Bile Acids and Salts: Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones. [NIH] Bile duct: A tube through which bile passes in and out of the liver. [NIH] Bioassay: Determination of the relative effective strength of a substance (as a vitamin, hormone, or drug) by comparing its effect on a test organism with that of a standard preparation. [NIH]
Dictionary 151
Biochemical: Relating to biochemistry; characterized by, produced by, or involving chemical reactions in living organisms. [EU] Biological Assay: A method of measuring the effects of a biologically active substance using an intermediate in vivo or in vitro tissue or cell model under controlled conditions. It includes virulence studies in animal fetuses in utero, mouse convulsion bioassay of insulin, quantitation of tumor-initiator systems in mouse skin, calculation of potentiating effects of a hormonal factor in an isolated strip of contracting stomach muscle, etc. [NIH] Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc. [NIH] Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body. [NIH] Biopsy specimen: Tissue removed from the body and examined under a microscope to determine whether disease is present. [NIH] Biosynthesis: The building up of a chemical compound in the physiologic processes of a living organism. [EU] Biotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., genetic engineering) is a central focus; laboratory methods used include transfection and cloning technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction. [NIH] Bladder: The organ that stores urine. [NIH] Blastomycosis: A fungal infection that may appear in two forms: 1) a primary lesion characterized by the formation of a small cutaneous nodule and small nodules along the lymphatics that may heal within several months; and 2) chronic granulomatous lesions characterized by thick crusts, warty growths, and unusual vascularity and infection in the middle or upper lobes of the lung. [NIH] Bleomycin: A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. [NIH] Blister: Visible accumulations of fluid within or beneath the epidermis. [NIH] Blood Coagulation: The process of the interaction of blood coagulation factors that results in an insoluble fibrin clot. [NIH] Blood Coagulation Factors: Endogenous substances, usually proteins, that are involved in the blood coagulation process. [NIH] Blood Glucose: Glucose in blood. [NIH] Blood Platelets: Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. [NIH] Blood pressure: The pressure of blood against the walls of a blood vessel or heart chamber. Unless there is reference to another location, such as the pulmonary artery or one of the heart chambers, it refers to the pressure in the systemic arteries, as measured, for example, in the forearm. [NIH]
152
Erythema
Blood vessel: A tube in the body through which blood circulates. Blood vessels include a network of arteries, arterioles, capillaries, venules, and veins. [NIH] Blood Volume: Volume of circulating blood. It is the sum of the plasma volume and erythrocyte volume. [NIH] Blot: To transfer DNA, RNA, or proteins to an immobilizing matrix such as nitrocellulose. [NIH]
Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blotting and transferred to strips of nitrocellulose paper. The blots are then detected by radiolabeled antibody probes. [NIH] Body Fluids: Liquid components of living organisms. [NIH] Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. [NIH] Bone Marrow Cells: Cells contained in the bone marrow including fat cells, stromal cells, megakaryocytes, and the immediate precursors of most blood cells. [NIH] Borrelia: A genus of gram-negative, anaerobic, helical bacteria; various species of which produce relapsing fever in man and other animals. [NIH] Bowel: The long tube-shaped organ in the abdomen that completes the process of digestion. There is both a small and a large bowel. Also called the intestine. [NIH] Brachytherapy: A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues. [NIH] Broad-spectrum: Effective against a wide range of microorganisms; said of an antibiotic. [EU] Bronchi: The larger air passages of the lungs arising from the terminal bifurcation of the trachea. [NIH] Bronchial: Pertaining to one or more bronchi. [EU] Bronchitis: Inflammation (swelling and reddening) of the bronchi. [NIH] Bronchus: A large air passage that leads from the trachea (windpipe) to the lung. [NIH] Buccal: Pertaining to or directed toward the cheek. In dental anatomy, used to refer to the buccal surface of a tooth. [EU] Buccal mucosa: The inner lining of the cheeks and lips. [NIH] Bullous: Pertaining to or characterized by bullae. [EU] Bupivacaine: A widely used local anesthetic agent. [NIH] Bupropion: A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment. [NIH] Burns: Injuries to tissues caused by contact with heat, steam, chemicals (burns, chemical), electricity (burns, electric), or the like. [NIH] Burns, Electric: Burns produced by contact with electric current or from a sudden discharge of electricity. [NIH] Bypass: A surgical procedure in which the doctor creates a new pathway for the flow of body fluids. [NIH]
Dictionary 153
Calcification: Deposits of calcium in the tissues of the breast. Calcification in the breast can be seen on a mammogram, but cannot be detected by touch. There are two types of breast calcification, macrocalcification and microcalcification. Macrocalcifications are large deposits and are usually not related to cancer. Microcalcifications are specks of calcium that may be found in an area of rapidly dividing cells. Many microcalcifications clustered together may be a sign of cancer. [NIH] Calcitonin: A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults. [NIH] Calcium: A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. [NIH] Callus: A callosity or hard, thick skin; the bone-like reparative substance that is formed round the edges and fragments of broken bone. [NIH] Candidiasis: Infection with a fungus of the genus Candida. It is usually a superficial infection of the moist cutaneous areas of the body, and is generally caused by C. albicans; it most commonly involves the skin (dermatocandidiasis), oral mucous membranes (thrush, def. 1), respiratory tract (bronchocandidiasis), and vagina (vaginitis). Rarely there is a systemic infection or endocarditis. Called also moniliasis, candidosis, oidiomycosis, and formerly blastodendriosis. [EU] Candidosis: An infection caused by an opportunistic yeasts that tends to proliferate and become pathologic when the environment is favorable and the host resistance is weakened. [NIH]
Cannula: A tube for insertion into a duct or cavity; during insertion its lumen is usually occupied by a trocar. [EU] Capillary: Any one of the minute vessels that connect the arterioles and venules, forming a network in nearly all parts of the body. Their walls act as semipermeable membranes for the interchange of various substances, including fluids, between the blood and tissue fluid; called also vas capillare. [EU] Capsaicin: Cytotoxic alkaloid from various species of Capsicum (pepper, paprika), of the Solanaceae. [NIH] Capsicum: A genus of Solanaceous shrubs that yield capsaicin. Several varieties have sweet or pungent edible fruits that are used as vegetables when fresh and spices when the pods are dried. [NIH] Carbamazepine: An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. [NIH] Carbohydrate: An aldehyde or ketone derivative of a polyhydric alcohol, particularly of the pentahydric and hexahydric alcohols. They are so named because the hydrogen and oxygen are usually in the proportion to form water, (CH2O)n. The most important carbohydrates are the starches, sugars, celluloses, and gums. They are classified into mono-, di-, tri-, polyand heterosaccharides. [EU] Carcinogen: Any substance that causes cancer. [NIH]
154
Erythema
Carcinogenesis: The process by which normal cells are transformed into cancer cells. [NIH] Carcinogenic: Producing carcinoma. [EU] Carcinoma: Cancer that begins in the skin or in tissues that line or cover internal organs. [NIH]
Cardiac: Having to do with the heart. [NIH] Cardiac Output: The volume of blood passing through the heart per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with stroke volume (volume per beat). [NIH] Cardiolipins: Acidic phospholipids composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol. They occur primarily in mitochondrial inner membranes and in bacterial plasma membranes. They are the main antigenic components of the Wassermann-type antigen that is used in nontreponemal syphilis serodiagnosis. [NIH] Cardiovascular: Having to do with the heart and blood vessels. [NIH] Carotene: The general name for a group of pigments found in green, yellow, and leafy vegetables, and yellow fruits. The pigments are fat-soluble, unsaturated aliphatic hydrocarbons functioning as provitamins and are converted to vitamin A through enzymatic processes in the intestinal wall. [NIH] Carotenoids: Substance found in yellow and orange fruits and vegetables and in dark green, leafy vegetables. May reduce the risk of developing cancer. [NIH] Case report: A detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin). [NIH] Cataracts: In medicine, an opacity of the crystalline lens of the eye obstructing partially or totally its transmission of light. [NIH] Cathode: An electrode, usually an incandescent filament of tungsten, which emits electrons in an X-ray tube. [NIH] Caudal: Denoting a position more toward the cauda, or tail, than some specified point of reference; same as inferior, in human anatomy. [EU] Cecum: The beginning of the large intestine. The cecum is connected to the lower part of the small intestine, called the ileum. [NIH] Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of cephalexin. [NIH] Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. [NIH] Cell: The individual unit that makes up all of the tissues of the body. All living things are made up of one or more cells. [NIH] Cell Adhesion: Adherence of cells to surfaces or to other cells. [NIH] Cell Count: A count of the number of cells of a specific kind, usually measured per unit volume of sample. [NIH] Cell Cycle: The complex series of phenomena, occurring between the end of one cell division and the end of the next, by which cellular material is divided between daughter cells. [NIH] Cell Death: The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability. [NIH] Cell Division: The fission of a cell. [NIH]
Dictionary 155
Cell membrane: Cell membrane = plasma membrane. The structure enveloping a cell, enclosing the cytoplasm, and forming a selective permeability barrier; it consists of lipids, proteins, and some carbohydrates, the lipids thought to form a bilayer in which integral proteins are embedded to varying degrees. [EU] Cell proliferation: An increase in the number of cells as a result of cell growth and cell division. [NIH] Cellobiose: A disaccharide consisting of two glucose units in beta (1-4) glycosidic linkage. Obtained from the partial hydrolysis of cellulose. [NIH] Cellulose: A polysaccharide with glucose units linked as in cellobiose. It is the chief constituent of plant fibers, cotton being the purest natural form of the substance. As a raw material, it forms the basis for many derivatives used in chromatography, ion exchange materials, explosives manufacturing, and pharmaceutical preparations. [NIH] Central Nervous System: The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges. [NIH] Central Nervous System Infections: Pathogenic infections of the brain, spinal cord, and meninges. DNA virus infections; RNA virus infections; bacterial infections; mycoplasma infections; Spirochaetales infections; fungal infections; protozoan infections; helminthiasis; and prion diseases may involve the central nervous system as a primary or secondary process. [NIH] Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of cephaloridine or cephalothin, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. [NIH] Ceramide: A type of fat produced in the body. It may cause some types of cells to die, and is being studied in cancer treatment. [NIH] Cerebral: Of or pertaining of the cerebrum or the brain. [EU] Cerebrospinal: Pertaining to the brain and spinal cord. [EU] Cerebrospinal fluid: CSF. The fluid flowing around the brain and spinal cord. Cerebrospinal fluid is produced in the ventricles in the brain. [NIH] Cerium: An element of the rare earth family of metals. It has the atomic symbol Ce, atomic number 58, and atomic weight 140.12. Cerium is a malleable metal used in industrial applications. [NIH] Cervical: Relating to the neck, or to the neck of any organ or structure. Cervical lymph nodes are located in the neck; cervical cancer refers to cancer of the uterine cervix, which is the lower, narrow end (the "neck") of the uterus. [NIH] Character: In current usage, approximately equivalent to personality. The sum of the relatively fixed personality traits and habitual modes of response of an individual. [NIH] Cheilitis: Inflammation of the lips. It is of various etiologies and degrees of pathology. [NIH] Chemopreventive: Natural or synthetic compound used to intervene in the early precancerous stages of carcinogenesis. [NIH] Chemotherapy: Treatment with anticancer drugs. [NIH] Chest Pain: Pressure, burning, or numbness in the chest. [NIH] Chickenpox: A mild, highly contagious virus characterized by itchy blisters all over the body. [NIH] Chlorophyll: Porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms. [NIH]
156
Erythema
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. [NIH] Cholangiography: Radiographic examination of the bile ducts. [NIH] Cholangitis: Inflammation of a bile duct. [NIH] Cholesterol: The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. [NIH] Cholesterol Esters: Fatty acid esters of cholesterol which constitute about two-thirds of the cholesterol in the plasma. The accumulation of cholesterol esters in the arterial intima is a characteristic feature of atherosclerosis. [NIH] Chorioallantoic membrane: The membrane in hen's eggs that helps chicken embryos get enough oxygen and calcium for development. The calcium comes from the egg shell. [NIH] Chromatin: The material of chromosomes. It is a complex of DNA, histones, and nonhistone proteins (chromosomal proteins, non-histone) found within the nucleus of a cell. [NIH] Chromosomal: Pertaining to chromosomes. [EU] Chromosome: Part of a cell that contains genetic information. Except for sperm and eggs, all human cells contain 46 chromosomes. [NIH] Chronic: A disease or condition that persists or progresses over a long period of time. [NIH] Chylomicrons: A class of lipoproteins that carry dietary cholesterol and triglycerides from the small intestines to the tissues. [NIH] Claudication: Limping or lameness. [EU] Cleft Lip: Congenital defect in the upper lip where the maxillary prominence fails to merge with the merged medial nasal prominences. It is thought to be caused by faulty migration of the mesoderm in the head region. [NIH] Clinical study: A research study in which patients receive treatment in a clinic or other medical facility. Reports of clinical studies can contain results for single patients (case reports) or many patients (case series or clinical trials). [NIH] Clinical trial: A research study that tests how well new medical treatments or other interventions work in people. Each study is designed to test new methods of screening, prevention, diagnosis, or treatment of a disease. [NIH] Clone: The term "clone" has acquired a new meaning. It is applied specifically to the bits of inserted foreign DNA in the hybrid molecules of the population. Each inserted segment originally resided in the DNA of a complex genome amid millions of other DNA segment. [NIH]
Cloning: The production of a number of genetically identical individuals; in genetic engineering, a process for the efficient replication of a great number of identical DNA molecules. [NIH] Coccidioidomycosis: An infectious disease caused by a fungus, Coccidioides immitis, that is prevalent in the western United States and is acquired by inhalation of dust containing the spores. [NIH] Coenzyme: An organic nonprotein molecule, frequently a phosphorylated derivative of a water-soluble vitamin, that binds with the protein molecule (apoenzyme) to form the active enzyme (holoenzyme). [EU] Cofactor: A substance, microorganism or environmental factor that activates or enhances the action of another entity such as a disease-causing agent. [NIH]
Dictionary 157
Colitis: Inflammation of the colon. [NIH] Collagen: A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of skin, connective tissue, and the organic substance of bones and teeth. Different forms of collagen are produced in the body but all consist of three alpha-polypeptide chains arranged in a triple helix. Collagen is differentiated from other fibrous proteins, such as elastin, by the content of proline, hydroxyproline, and hydroxylysine; by the absence of tryptophan; and particularly by the high content of polar groups which are responsible for its swelling properties. [NIH] Collagen disease: A term previously used to describe chronic diseases of the connective tissue (e.g., rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis), but now is thought to be more appropriate for diseases associated with defects in collagen, which is a component of the connective tissue. [NIH] Colloidal: Of the nature of a colloid. [EU] Colon: The long, coiled, tubelike organ that removes water from digested food. The remaining material, solid waste called stool, moves through the colon to the rectum and leaves the body through the anus. [NIH] Combination chemotherapy: Treatment using more than one anticancer drug. [NIH] Complement: A term originally used to refer to the heat-labile factor in serum that causes immune cytolysis, the lysis of antibody-coated cells, and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed 'components of complement' and are designated by the symbols C1 through C9. C1 is a calcium-dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower-case letter suffixes, e.g., C3a. Inactivated fragments may be designated with the suffix 'i', e.g. C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol e.g. C1 or C4b,2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3; C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides, and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3; activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins, or chemotactic factors. [EU] Complementary and alternative medicine: CAM. Forms of treatment that are used in addition to (complementary) or instead of (alternative) standard treatments. These practices are not considered standard medical approaches. CAM includes dietary supplements, megadose vitamins, herbal preparations, special teas, massage therapy, magnet therapy, spiritual healing, and meditation. [NIH] Complementary medicine: Practices not generally recognized by the medical community as standard or conventional medical approaches and used to enhance or complement the standard treatments. Complementary medicine includes the taking of dietary supplements, megadose vitamins, and herbal preparations; the drinking of special teas; and practices such as massage therapy, magnet therapy, spiritual healing, and meditation. [NIH]
158
Erythema
Computational Biology: A field of biology concerned with the development of techniques for the collection and manipulation of biological data, and the use of such data to make biological discoveries or predictions. This field encompasses all computational methods and theories applicable to molecular biology and areas of computer-based techniques for solving biological problems including manipulation of models and datasets. [NIH] Concomitant: Accompanying; accessory; joined with another. [EU] Conduction: The transfer of sound waves, heat, nervous impulses, or electricity. [EU] Condyloma: C. acuminatum; a papilloma with a central core of connective tissue in a treelike structure covered with epithelium, usually occurring on the mucous membrane or skin of the external genitals or in the perianal region. [EU] Confusion: A mental state characterized by bewilderment, emotional disturbance, lack of clear thinking, and perceptual disorientation. [NIH] Congestion: Excessive or abnormal accumulation of blood in a part. [EU] Conjunctiva: The mucous membrane that lines the inner surface of the eyelids and the anterior part of the sclera. [NIH] Conjunctivitis: Inflammation of the conjunctiva, generally consisting of conjunctival hyperaemia associated with a discharge. [EU] Connective Tissue: Tissue that supports and binds other tissues. It consists of connective tissue cells embedded in a large amount of extracellular matrix. [NIH] Connective Tissue: Tissue that supports and binds other tissues. It consists of connective tissue cells embedded in a large amount of extracellular matrix. [NIH] Connective Tissue Cells: A group of cells that includes fibroblasts, cartilage cells, adipocytes, smooth muscle cells, and bone cells. [NIH] Connective Tissue Diseases: A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides. [NIH] Consciousness: Sense of awareness of self and of the environment. [NIH] Constipation: Infrequent or difficult evacuation of feces. [NIH] Constriction: The act of constricting. [NIH] Contact dermatitis: Inflammation of the skin with varying degrees of erythema, edema and vesinculation resulting from cutaneous contact with a foreign substance or other exposure. [NIH]
Contraindications: Any factor or sign that it is unwise to pursue a certain kind of action or treatment, e. g. giving a general anesthetic to a person with pneumonia. [NIH] Contrast medium: A substance that is introduced into or around a structure and, because of the difference in absorption of x-rays by the contrast medium and the surrounding tissues, allows radiographic visualization of the structure. [EU] Control group: In a clinical trial, the group that does not receive the new treatment being studied. This group is compared to the group that receives the new treatment, to see if the new treatment works. [NIH] Controlled clinical trial: A clinical study that includes a comparison (control) group. The comparison group receives a placebo, another treatment, or no treatment at all. [NIH] Contusions: Injuries resulting in hemorrhage, usually manifested in the skin. [NIH] Convulsion: A violent involuntary contraction or series of contractions of the voluntary muscles. [EU]
Dictionary 159
Cornea: The transparent part of the eye that covers the iris and the pupil and allows light to enter the inside. [NIH] Corneum: The superficial layer of the epidermis containing keratinized cells. [NIH] Coronary: Encircling in the manner of a crown; a term applied to vessels; nerves, ligaments, etc. The term usually denotes the arteries that supply the heart muscle and, by extension, a pathologic involvement of them. [EU] Coronary heart disease: A type of heart disease caused by narrowing of the coronary arteries that feed the heart, which needs a constant supply of oxygen and nutrients carried by the blood in the coronary arteries. When the coronary arteries become narrowed or clogged by fat and cholesterol deposits and cannot supply enough blood to the heart, CHD results. [NIH] Coronary Thrombosis: Presence of a thrombus in a coronary artery, often causing a myocardial infarction. [NIH] Corpus: The body of the uterus. [NIH] Corpus Luteum: The yellow glandular mass formed in the ovary by an ovarian follicle that has ruptured and discharged its ovum. [NIH] Corticosteroid: Any of the steroids elaborated by the adrenal cortex (excluding the sex hormones of adrenal origin) in response to the release of corticotrophin (adrenocorticotropic hormone) by the pituitary gland, to any of the synthetic equivalents of these steroids, or to angiotensin II. They are divided, according to their predominant biological activity, into three major groups: glucocorticoids, chiefly influencing carbohydrate, fat, and protein metabolism; mineralocorticoids, affecting the regulation of electrolyte and water balance; and C19 androgens. Some corticosteroids exhibit both types of activity in varying degrees, and others exert only one type of effect. The corticosteroids are used clinically for hormonal replacement therapy, for suppression of ACTH secretion by the anterior pituitary, as antineoplastic, antiallergic, and anti-inflammatory agents, and to suppress the immune response. Called also adrenocortical hormone and corticoid. [EU] Cranial: Pertaining to the cranium, or to the anterior (in animals) or superior (in humans) end of the body. [EU] Craniocerebral Trauma: Traumatic injuries involving the cranium and intracranial structures (i.e., brain; cranial nerves; meninges; and other structures). Injuries may be classified by whether or not the skull is penetrated (i.e., penetrating vs. nonpenetrating) or whether there is an associated hemorrhage. [NIH] Culture Media: Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as agar or gelatin. [NIH] Curative: Tending to overcome disease and promote recovery. [EU] Cutaneous: Having to do with the skin. [NIH] Cyclic: Pertaining to or occurring in a cycle or cycles; the term is applied to chemical compounds that contain a ring of atoms in the nucleus. [EU] Cysteine: A thiol-containing non-essential amino acid that is oxidized to form cystine. [NIH] Cytokine: Small but highly potent protein that modulates the activity of many cell types, including T and B cells. [NIH] Cytomegalovirus: A genus of the family Herpesviridae, subfamily Betaherpesvirinae,
160
Erythema
infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. [NIH] Cytoplasm: The protoplasm of a cell exclusive of that of the nucleus; it consists of a continuous aqueous solution (cytosol) and the organelles and inclusions suspended in it (phaneroplasm), and is the site of most of the chemical activities of the cell. [EU] Cytotoxic: Cell-killing. [NIH] Cytotoxicity: Quality of being capable of producing a specific toxic action upon cells of special organs. [NIH] Decarboxylation: The removal of a carboxyl group, usually in the form of carbon dioxide, from a chemical compound. [NIH] Decubitus: An act of lying down; also the position assumed in lying down. [EU] Decubitus Ulcer: An ulceration caused by prolonged pressure in patients permitted to lie too still for a long period of time. The bony prominences of the body are the most frequently affected sites. The ulcer is caused by ischemia of the underlying structures of the skin, fat, and muscles as a result of the sustained and constant pressure. [NIH] Degenerative: Undergoing degeneration : tending to degenerate; having the character of or involving degeneration; causing or tending to cause degeneration. [EU] Deletion: A genetic rearrangement through loss of segments of DNA (chromosomes), bringing sequences, which are normally separated, into close proximity. [NIH] Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. [NIH] Denaturation: Rupture of the hydrogen bonds by heating a DNA solution and then cooling it rapidly causes the two complementary strands to separate. [NIH] Dendrites: Extensions of the nerve cell body. They are short and branched and receive stimuli from other neurons. [NIH] Dendritic: 1. Branched like a tree. 2. Pertaining to or possessing dendrites. [EU] Dendritic cell: A special type of antigen-presenting cell (APC) that activates T lymphocytes. [NIH]
Density: The logarithm to the base 10 of the opacity of an exposed and processed film. [NIH] Depigmentation: Removal or loss of pigment, especially melanin. [EU] Dermal: Pertaining to or coming from the skin. [NIH] Dermatitis: Any inflammation of the skin. [NIH] Dermatitis Herpetiformis: Rare, chronic, papulo-vesicular disease characterized by an intensely pruritic eruption consisting of various combinations of symmetrical, erythematous, papular, vesicular, or bullous lesions. The disease is strongly associated with the presence of HLA-B8 and HLA-DR3 antigens. A variety of different autoantibodies has been detected in small numbers in patients with dermatitis herpetiformis. [NIH] Dermatology: A medical specialty concerned with the skin, its structure, functions, diseases, and treatment. [NIH] Dermatosis: Any skin disease, especially one not characterized by inflammation. [EU] Dermis: A layer of vascular connective tissue underneath the epidermis. The surface of the
Dictionary 161
dermis contains sensitive papillae. Embedded in or beneath the dermis are sweat glands, hair follicles, and sebaceous glands. [NIH] Detergents: Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. [NIH] Diabetes Mellitus: A heterogeneous group of disorders that share glucose intolerance in common. [NIH] Diagnosis, Differential: Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. [NIH] Diagnostic procedure: A method used to identify a disease. [NIH] Diarrhea: Passage of excessively liquid or excessively frequent stools. [NIH] Diffusion: The tendency of a gas or solute to pass from a point of higher pressure or concentration to a point of lower pressure or concentration and to distribute itself throughout the available space; a major mechanism of biological transport. [NIH] Digestion: The process of breakdown of food for metabolism and use by the body. [NIH] Dilator: A device used to stretch or enlarge an opening. [NIH] Diploid: Having two sets of chromosomes. [NIH] Direct: 1. Straight; in a straight line. 2. Performed immediately and without the intervention of subsidiary means. [EU] Discoid: Shaped like a disk. [EU] Discrete: Made up of separate parts or characterized by lesions which do not become blended; not running together; separate. [NIH] Dissociation: 1. The act of separating or state of being separated. 2. The separation of a molecule into two or more fragments (atoms, molecules, ions, or free radicals) produced by the absorption of light or thermal energy or by solvation. 3. In psychology, a defense mechanism in which a group of mental processes are segregated from the rest of a person's mental activity in order to avoid emotional distress, as in the dissociative disorders (q.v.), or in which an idea or object is segregated from its emotional significance; in the first sense it is roughly equivalent to splitting, in the second, to isolation. 4. A defect of mental integration in which one or more groups of mental processes become separated off from normal consciousness and, thus separated, function as a unitary whole. [EU] Docetaxel: An anticancer drug that belongs to the family of drugs called mitotic inhibitors. [NIH]
Dopamine: An endogenous catecholamine and prominent neurotransmitter in several systems of the brain. In the synthesis of catecholamines from tyrosine, it is the immediate precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of dopaminergic receptor subtypes mediate its action. Dopamine is used pharmacologically for its direct (beta adrenergic agonist) and indirect (adrenergic releasing) sympathomimetic effects including its actions as an inotropic agent and as a renal vasodilator. [NIH] Dorsal: 1. Pertaining to the back or to any dorsum. 2. Denoting a position more toward the back surface than some other object of reference; same as posterior in human anatomy; superior in the anatomy of quadrupeds. [EU] Dorsum: A plate of bone which forms the posterior boundary of the sella turcica. [NIH] Dosimeter: In nuclear science and radiotherapy, a device used for the detection and
162
Erythema
measurement of radiation absorbed dose or any dose-related ionizing radiation received by the individual; a radiation meter intended to measure absorbed dose. [NIH] Doxycycline: A synthetic tetracycline derivative with a range of antimicrobial activity and mode of action similar to that of tetracycline, but more effective against many species. Animal studies suggest that it may cause less tooth staining than other tetracyclines. [NIH] Drug Interactions: The action of a drug that may affect the activity, metabolism, or toxicity of another drug. [NIH] Duct: A tube through which body fluids pass. [NIH] Duodenum: The first part of the small intestine. [NIH] Edema: Excessive amount of watery fluid accumulated in the intercellular spaces, most commonly present in subcutaneous tissue. [NIH] Efferent: Nerve fibers which conduct impulses from the central nervous system to muscles and glands. [NIH] Efficacy: The extent to which a specific intervention, procedure, regimen, or service produces a beneficial result under ideal conditions. Ideally, the determination of efficacy is based on the results of a randomized control trial. [NIH] Egg Yolk: Cytoplasm stored in an egg that contains nutritional reserves for the developing embryo. It is rich in polysaccharides, lipids, and proteins. [NIH] Elastin: The protein that gives flexibility to tissues. [NIH] Elective: Subject to the choice or decision of the patient or physician; applied to procedures that are advantageous to the patient but not urgent. [EU] Electrolyte: A substance that dissociates into ions when fused or in solution, and thus becomes capable of conducting electricity; an ionic solute. [EU] Electrons: Stable elementary particles having the smallest known negative charge, present in all elements; also called negatrons. Positively charged electrons are called positrons. The numbers, energies and arrangement of electrons around atomic nuclei determine the chemical identities of elements. Beams of electrons are called cathode rays or beta rays, the latter being a high-energy biproduct of nuclear decay. [NIH] Ellagic Acid: A fused four ring compound occurring free or combined in galls. Isolated from the kino of Eucalyptus maculata Hook and E. Hemipholia F. Muell. Activates Factor XII of the blood clotting system which also causes kinin release; used in research and as a dye. [NIH]
Emboli: Bit of foreign matter which enters the blood stream at one point and is carried until it is lodged or impacted in an artery and obstructs it. It may be a blood clot, an air bubble, fat or other tissue, or clumps of bacteria. [NIH] Embryo: The prenatal stage of mammalian development characterized by rapid morphological changes and the differentiation of basic structures. [NIH] Emulsions: Colloids of two immiscible liquids where either phase may be either fatty or aqueous; lipid-in-water emulsions are usually liquid, like milk or lotion and water-in-lipid emulsions tend to be creams. [NIH] Endemic: Present or usually prevalent in a population or geographical area at all times; said of a disease or agent. Called also endemial. [EU] Endocarditis: Exudative and proliferative inflammatory alterations of the endocardium, characterized by the presence of vegetations on the surface of the endocardium or in the endocardium itself, and most commonly involving a heart valve, but sometimes affecting the inner lining of the cardiac chambers or the endocardium elsewhere. It may occur as a
Dictionary 163
primary disorder or as a complication of or in association with another disease. [EU] Endocardium: The innermost layer of the heart, comprised of endothelial cells. [NIH] Endothelial cell: The main type of cell found in the inside lining of blood vessels, lymph vessels, and the heart. [NIH] Endotoxins: Toxins closely associated with the living cytoplasm or cell wall of certain microorganisms, which do not readily diffuse into the culture medium, but are released upon lysis of the cells. [NIH] Enhancer: Transcriptional element in the virus genome. [NIH] Environmental Exposure: The exposure to potentially harmful chemical, physical, or biological agents in the environment or to environmental factors that may include ionizing radiation, pathogenic organisms, or toxic chemicals. [NIH] Environmental Health: The science of controlling or modifying those conditions, influences, or forces surrounding man which relate to promoting, establishing, and maintaining health. [NIH]
Enzymatic: Phase where enzyme cuts the precursor protein. [NIH] Enzyme: A protein that speeds up chemical reactions in the body. [NIH] Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. [NIH] Eosinophilic: A condition found primarily in grinding workers caused by a reaction of the pulmonary tissue, in particular the eosinophilic cells, to dust that has entered the lung. [NIH] Eosinophils: Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin. [NIH] Epidemic: Occurring suddenly in numbers clearly in excess of normal expectancy; said especially of infectious diseases but applied also to any disease, injury, or other healthrelated event occurring in such outbreaks. [EU] Epidemiologic Factors: Events, characteristics, or other definable entities that have the potential to bring about a change in a health condition or other defined outcome. [NIH] Epidemiologic Studies: Studies designed to examine associations, commonly, hypothesized causal relations. They are usually concerned with identifying or measuring the effects of risk factors or exposures. The common types of analytic study are case-control studies, cohort studies, and cross-sectional studies. [NIH] Epidemiological: Relating to, or involving epidemiology. [EU] Epidermal: Pertaining to or resembling epidermis. Called also epidermic or epidermoid. [EU] Epidermal Growth Factor: A 6 kD polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and epithelial cells. [NIH] Epidermis: Nonvascular layer of the skin. It is made up, from within outward, of five layers: 1) basal layer (stratum basale epidermidis); 2) spinous layer (stratum spinosum
164
Erythema
epidermidis); 3) granular layer (stratum granulosum epidermidis); 4) clear layer (stratum lucidum epidermidis); and 5) horny layer (stratum corneum epidermidis). [NIH] Epidural: The space between the wall of the spinal canal and the covering of the spinal cord. An epidural injection is given into this space. [NIH] Episcleritis: Inflammation of the episclera and/or the outer layers of the sclera itself. [NIH] Epithelial: Refers to the cells that line the internal and external surfaces of the body. [NIH] Epithelial Cells: Cells that line the inner and outer surfaces of the body. [NIH] Epithelium: One or more layers of epithelial cells, supported by the basal lamina, which covers the inner or outer surfaces of the body. [NIH] Erysipeloid: An infection caused by Erysipelothrix rhusiopathiae that is almost wholly restricted to persons who in their occupation handle infected fish, shellfish, poultry, or meat. Three forms of this condition exist: a mild localized form manifested by local swelling and redness of the skin; a diffuse form that might present with fever; and a rare systemic form associated with endocarditis. [NIH] Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of causes. [NIH] Erythema Chronicum Migrans: A deep type of gyrate erythema that follows a bite by an ixodid tick; it is a stage-1 manifestation of Lyme disease. The site of the bite is characterized by a red papule that expands peripherally as a nonscaling, palpable band that clears centrally. This condition is often associated with systemic symptoms such as chills, fever, headache, malaise, nausea, vomiting, fatigue, backache, and stiff neck. [NIH] Erythema Induratum: A type of panniculitis characterized histologically by the presence of granulomas, vasculitis, and necrosis. It is traditionally considered to be the tuberculous counterpart of nodular vasculitis, but is now known to occur without tuberculous precedent. It is seen most commonly in adolescent and menopausal women, is initiated or exacerbated by cold weather, and typically presents as one or more recurrent erythrocyanotic nodules or plaques on the calves. The nodules may progress to form indurations, ulcerations, and scars. [NIH]
Erythema Infectiosum: Contagious infection with human B19 Parvovirus most commonly seen in school age children and characterized by fever, headache, and rashes of the face, trunk, and extremities. It is often confused with rubella. [NIH] Erythema Multiforme: A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic "bull's-eye" lesions usually occurring on the dorsal aspect of the hands and forearms. [NIH] Erythema Nodosum: An erythematous eruption commonly associated with drug reactions or infection and characterized by inflammatory nodules that are usually tender, multiple, and bilateral. These nodules are located predominantly on the shins with less common occurrence on the thighs and forearms. They undergo characteristic color changes ending in temporary bruise-like areas. This condition usually subsides in 3-6 weeks without scarring or atrophy. [NIH] Erythrocytes: Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing hemoglobin whose function is to transport oxygen. [NIH] Esophageal: Having to do with the esophagus, the muscular tube through which food passes from the throat to the stomach. [NIH] Esophageal Stricture: A narrowing of the esophagus often caused by acid flowing back from the stomach. This condition may require surgery. [NIH] Esophagus: The muscular tube through which food passes from the throat to the stomach.
Dictionary 165
[NIH]
Ethnic Groups: A group of people with a common cultural heritage that sets them apart from others in a variety of social relationships. [NIH] Europium: An element of the rare earth family of metals. It has the atomic symbol Eu, atomic number 63, and atomic weight 152. Europium is used in the form of its salts as coatings for cathode ray tubes and in the form of its organic derivatives as shift reagents in NMR spectroscopy. [NIH] Exanthema: Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (erythema infectiosum), and sixth (exanthema subitum) numeric designations survive as occasional synonyms in current terminology. [NIH] Exfoliation: A falling off in scales or layers. [EU] Exon: The part of the DNA that encodes the information for the actual amino acid sequence of the protein. In many eucaryotic genes, the coding sequences consist of a series of exons alternating with intron sequences. [NIH] Exotoxin: Toxic substance excreted by living bacterial cells. [NIH] Extensor: A muscle whose contraction tends to straighten a limb; the antagonist of a flexor. [NIH]
External-beam radiation: Radiation therapy that uses a machine to aim high-energy rays at the cancer. Also called external radiation. [NIH] Extracellular: Outside a cell or cells. [EU] Extracellular Matrix: A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere. [NIH] Extracellular Matrix Proteins: Macromolecular organic compounds that contain carbon, hydrogen, oxygen, nitrogen, and usually, sulfur. These macromolecules (proteins) form an intricate meshwork in which cells are embedded to construct tissues. Variations in the relative types of macromolecules and their organization determine the type of extracellular matrix, each adapted to the functional requirements of the tissue. The two main classes of macromolecules that form the extracellular matrix are: glycosaminoglycans, usually linked to proteins (proteoglycans), and fibrous proteins (e.g., collagen, elastin, fibronectins and laminin). [NIH] Extracellular Space: Interstitial space between cells, occupied by fluid as well as amorphous and fibrous substances. [NIH] Facial: Of or pertaining to the face. [EU] Facial Expression: Observable changes of expression in the face in response to emotional stimuli. [NIH] Facial Nerve: The 7th cranial nerve. The facial nerve has two parts, the larger motor root which may be called the facial nerve proper, and the smaller intermediate or sensory root. Together they provide efferent innervation to the muscles of facial expression and to the lacrimal and salivary glands, and convey afferent information for taste from the anterior two-thirds of the tongue and for touch from the external ear. [NIH] Family Planning: Programs or services designed to assist the family in controlling reproduction by either improving or diminishing fertility. [NIH] Fat: Total lipids including phospholipids. [NIH]
166
Erythema
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli. [NIH]
Febrile: Pertaining to or characterized by fever. [EU] Fetal Death: Death of the young developing in utero. [NIH] Fibroblasts: Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. [NIH] Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury. [NIH] Filtration: The passage of a liquid through a filter, accomplished by gravity, pressure, or vacuum (suction). [EU] Fistula: Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body. [NIH] Fixation: 1. The act or operation of holding, suturing, or fastening in a fixed position. 2. The condition of being held in a fixed position. 3. In psychiatry, a term with two related but distinct meanings : (1) arrest of development at a particular stage, which like regression (return to an earlier stage), if temporary is a normal reaction to setbacks and difficulties but if protracted or frequent is a cause of developmental failures and emotional problems, and (2) a close and suffocating attachment to another person, especially a childhood figure, such as one's mother or father. Both meanings are derived from psychoanalytic theory and refer to 'fixation' of libidinal energy either in a specific erogenous zone, hence fixation at the oral, anal, or phallic stage, or in a specific object, hence mother or father fixation. 4. The use of a fixative (q.v.) to preserve histological or cytological specimens. 5. In chemistry, the process whereby a substance is removed from the gaseous or solution phase and localized, as in carbon dioxide fixation or nitrogen fixation. 6. In ophthalmology, direction of the gaze so that the visual image of the object falls on the fovea centralis. 7. In film processing, the chemical removal of all undeveloped salts of the film emulsion, leaving only the developed silver to form a permanent image. [EU] Flagellum: A whiplike appendage of a cell. It can function either as an organ of locomotion or as a device for moving the fluid surrounding the cell. [NIH] Flexor: Muscles which flex a joint. [NIH] Flush: Transient, episodic redness of the face and neck caused by certain diseases, ingestion of certain drugs or other substances, heat, emotional factors, or physical exertion. [EU] Flushing: A transient reddening of the face that may be due to fever, certain drugs, exertion, stress, or a disease process. [NIH] Fold: A plication or doubling of various parts of the body. [NIH] Forearm: The part between the elbow and the wrist. [NIH] Formulary: A book containing a list of pharmaceutical products with their formulas and means of preparation. [NIH] Free Radicals: Highly reactive molecules with an unsatisfied electron valence pair. Free radicals are produced in both normal and pathological processes. They are proven or suspected agents of tissue damage in a wide variety of circumstances including radiation, damage from environment chemicals, and aging. Natural and pharmacological prevention of free radical damage is being actively investigated. [NIH] Fungi: A kingdom of eukaryotic, heterotrophic organisms that live as saprobes or parasites, including mushrooms, yeasts, smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi refer to
Dictionary 167
those that grow as multicelluar colonies (mushrooms and molds). [NIH] Fungus: A general term used to denote a group of eukaryotic protists, including mushrooms, yeasts, rusts, moulds, smuts, etc., which are characterized by the absence of chlorophyll and by the presence of a rigid cell wall composed of chitin, mannans, and sometimes cellulose. They are usually of simple morphological form or show some reversible cellular specialization, such as the formation of pseudoparenchymatous tissue in the fruiting body of a mushroom. The dimorphic fungi grow, according to environmental conditions, as moulds or yeasts. [EU] Gallate: Antioxidant present in tea. [NIH] Gallbladder: The pear-shaped organ that sits below the liver. Bile is concentrated and stored in the gallbladder. [NIH] Gamma Rays: Very powerful and penetrating, high-energy electromagnetic radiation of shorter wavelength than that of x-rays. They are emitted by a decaying nucleus, usually between 0.01 and 10 MeV. They are also called nuclear x-rays. [NIH] Ganglia: Clusters of multipolar neurons surrounded by a capsule of loosely organized connective tissue located outside the central nervous system. [NIH] Ganglion: 1. A knot, or knotlike mass. 2. A general term for a group of nerve cell bodies located outside the central nervous system; occasionally applied to certain nuclear groups within the brain or spinal cord, e.g. basal ganglia. 3. A benign cystic tumour occurring on a aponeurosis or tendon, as in the wrist or dorsum of the foot; it consists of a thin fibrous capsule enclosing a clear mucinous fluid. [EU] Gas: Air that comes from normal breakdown of food. The gases are passed out of the body through the rectum (flatus) or the mouth (burp). [NIH] Gastric: Having to do with the stomach. [NIH] Gastrointestinal: Refers to the stomach and intestines. [NIH] Gastrointestinal tract: The stomach and intestines. [NIH] Gene: The functional and physical unit of heredity passed from parent to offspring. Genes are pieces of DNA, and most genes contain the information for making a specific protein. [NIH]
Gene Expression: The phenotypic manifestation of a gene or genes by the processes of gene action. [NIH] General practitioner: A medical practitioner who does not specialize in a particular branch of medicine or limit his practice to a specific class of diseases. [NIH] Genetic testing: Analyzing DNA to look for a genetic alteration that may indicate an increased risk for developing a specific disease or disorder. [NIH] Genital: Pertaining to the genitalia. [EU] Genotype: The genetic constitution of the individual; the characterization of the genes. [NIH] Giant Cells: Multinucleated masses produced by the fusion of many cells; often associated with viral infections. In AIDS, they are induced when the envelope glycoprotein of the HIV virus binds to the CD4 antigen of uninfected neighboring T4 cells. The resulting syncytium leads to cell death and thus may account for the cytopathic effect of the virus. [NIH] Gingival Hyperplasia: A pathological increase in the depth of the gingival crevice surrounding a tooth at the gum margin. [NIH] Gingivitis: Inflammation of the gingivae. Gingivitis associated with bony changes is referred to as periodontitis. Called also oulitis and ulitis. [EU]
168
Erythema
Gland: An organ that produces and releases one or more substances for use in the body. Some glands produce fluids that affect tissues or organs. Others produce hormones or participate in blood production. [NIH] Glossitis: Inflammation of the tongue. [NIH] Glucagonoma: Glucagon-secreting tumor of the pancreatic alpha cells characterized by a distinctive rash, weight loss, stomatitis, glossitis, diabetes, hypoaminoacidemia, and normochromic normocytic anemia. [NIH] Glucocorticoids: A group of corticosteroids that affect carbohydrate metabolism (gluconeogenesis, liver glycogen deposition, elevation of blood sugar), inhibit corticotropin secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. [NIH] Glucose: D-Glucose. A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. [NIH] Glucuronic Acid: Derivatives of uronic acid found throughout the plant and animal kingdoms. They detoxify drugs and toxins by conjugating with them to form glucuronides in the liver which are more water-soluble metabolites that can be easily eliminated from the body. [NIH] Glycerol: A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, and sweetening agent. [NIH]
Glycerophospholipids: Derivatives of phosphatidic acid in which the hydrophobic regions are composed of two fatty acids and a polar alcohol is joined to the C-3 position of glycerol through a phosphodiester bond. They are named according to their polar head groups, such as phosphatidylcholine and phosphatidylethanolamine. [NIH] Glycine: A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [NIH] Glycoprotein: A protein that has sugar molecules attached to it. [NIH] Glycosaminoglycans: Heteropolysaccharides which contain an N-acetylated hexosamine in a characteristic repeating disaccharide unit. The repeating structure of each disaccharide involves alternate 1,4- and 1,3-linkages consisting of either N-acetylglucosamine or Nacetylgalactosamine. [NIH] Gonadal: Pertaining to a gonad. [EU] Gonorrhea: Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, Neisseria gonorrhoeae, was isolated by Neisser in 1879. [NIH] Governing Board: The group in which legal authority is vested for the control of healthrelated institutions and organizations. [NIH] Graft: Healthy skin, bone, or other tissue taken from one part of the body and used to replace diseased or injured tissue removed from another part of the body. [NIH] Graft-versus-host disease: GVHD. A reaction of donated bone marrow or peripheral stem cells against a person's tissue. [NIH] Gram-negative: Losing the stain or decolorized by alcohol in Gram's method of staining, a primary characteristic of bacteria having a cell wall composed of a thin layer of peptidoglycan covered by an outer membrane of lipoprotein and lipopolysaccharide. [EU]
Dictionary 169
Gram-Negative Bacteria: Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. [NIH] Gram-positive: Retaining the stain or resisting decolorization by alcohol in Gram's method of staining, a primary characteristic of bacteria whose cell wall is composed of a thick layer of peptidologlycan with attached teichoic acids. [EU] Granular Cell Tumor: Unusual tumor affecting any site of the body, but most often encountered in the head and neck. Considerable debate has surrounded the histogenesis of this neoplasm; however, it is considered to be a myoblastoma of, usually, a benign nature. It affects women more often than men. When it develops beneath the epidermis or mucous membrane, it can lead to proliferation of the squamous cells and mimic squamous cell carcinoma. [NIH] Granulocytes: Leukocytes with abundant granules in the cytoplasm. They are divided into three groups: neutrophils, eosinophils, and basophils. [NIH] Granuloma: A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents. [NIH] Granuloma Annulare: Benign granulomatous disease of unknown etiology characterized by a ring of localized or disseminated papules or nodules on the skin and palisading histiocytes surrounding necrobiotic tissue resulting from altered collagen structures. [NIH] Haemophilus: A genus of Pasteurellaceae that consists of several species occurring in animals and humans. Its organisms are described as gram-negative, facultatively anaerobic, coccobacillus or rod-shaped, and nonmotile. [NIH] Hair follicles: Shafts or openings on the surface of the skin through which hair grows. [NIH] Halitosis: An offensive, foul breath odor resulting from a variety of causes such as poor oral hygiene, dental or oral infections, or the ingestion of certain foods. [NIH] Haploid: An organism with one basic chromosome set, symbolized by n; the normal condition of gametes in diploids. [NIH] Haptens: Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response. [NIH] Headache: Pain in the cranial region that may occur as an isolated and benign symptom or as a manifestation of a wide variety of conditions including subarachnoid hemorrhage; craniocerebral trauma; central nervous system infections; intracranial hypertension; and other disorders. In general, recurrent headaches that are not associated with a primary disease process are referred to as headache disorders (e.g., migraine). [NIH] Headache Disorders: Common conditions characterized by persistent or recurrent headaches. Headache syndrome classification systems may be based on etiology (e.g., vascular headache, post-traumatic headaches, etc.), temporal pattern (e.g., cluster headache, paroxysmal hemicrania, etc.), and precipitating factors (e.g., cough headache). [NIH] Health Status: The level of health of the individual, group, or population as subjectively assessed by the individual or by more objective measures. [NIH] Heart failure: Loss of pumping ability by the heart, often accompanied by fatigue, breathlessness, and excess fluid accumulation in body tissues. [NIH] Hemoglobin: One of the fractions of glycosylated hemoglobin A1c. Glycosylated hemoglobin is formed when linkages of glucose and related monosaccharides bind to hemoglobin A and its concentration represents the average blood glucose level over the previous several weeks. HbA1c levels are used as a measure of long-term control of plasma glucose (normal, 4 to 6 percent). In controlled diabetes mellitus, the concentration of
170
Erythema
glycosylated hemoglobin A is within the normal range, but in uncontrolled cases the level may be 3 to 4 times the normal conentration. Generally, complications are substantially lower among patients with Hb levels of 7 percent or less than in patients with HbA1c levels of 9 percent or more. [NIH] Hemoglobin A: Normal adult human hemoglobin. The globin moiety consists of two alpha and two beta chains. [NIH] Hemoglobin C: A commonly occurring abnormal hemoglobin in which lysine replaces a glutamic acid residue at the sixth position of the beta chains. It results in reduced plasticity of erythrocytes. [NIH] Hemolytic: A disease that affects the blood and blood vessels. It destroys red blood cells, cells that cause the blood to clot, and the lining of blood vessels. HUS is often caused by the Escherichia coli bacterium in contaminated food. People with HUS may develop acute renal failure. [NIH] Hemorrhage: Bleeding or escape of blood from a vessel. [NIH] Hemostasis: The process which spontaneously arrests the flow of blood from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements, and the process of blood or plasma coagulation. [NIH]
Heparin: Heparinic acid. A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. [NIH] Hepatitis: Inflammation of the liver and liver disease involving degenerative or necrotic alterations of hepatocytes. [NIH] Hepatocytes: The main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules. [NIH] Hepatomegaly: Enlargement of the liver. [NIH] Hereditary: Of, relating to, or denoting factors that can be transmitted genetically from one generation to another. [NIH] Heredity: 1. The genetic transmission of a particular quality or trait from parent to offspring. 2. The genetic constitution of an individual. [EU] Herpes: Any inflammatory skin disease caused by a herpesvirus and characterized by the formation of clusters of small vesicles. When used alone, the term may refer to herpes simplex or to herpes zoster. [EU] Herpes Zoster: Acute vesicular inflammation. [NIH] Herpetiformis: Duhring's disease a recurring, inflammatory disease of the skin of unknown etiology characterized by erythematous, papular, pustular, or vesicular lesions which tend to group and are accompanied by itching and burning. [NIH] Heterogeneity: The property of one or more samples or populations which implies that they are not identical in respect of some or all of their parameters, e. g. heterogeneity of variance. [NIH]
Heterotrophic: Pertaining to organisms that are consumers and dependent on other organisms for their source of energy (food). [NIH] Heterozygote: An individual having different alleles at one or more loci in homologous chromosome segments. [NIH]
Dictionary 171
Histamine: 1H-Imidazole-4-ethanamine. A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. [NIH] Histamine Release: The secretion of histamine from mast cell and basophil granules by exocytosis. This can be initiated by a number of factors, all of which involve binding of IgE, cross-linked by antigen, to the mast cell or basophil's Fc receptors. Once released, histamine binds to a number of different target cell receptors and exerts a wide variety of effects. [NIH] Histidine: An essential amino acid important in a number of metabolic processes. It is required for the production of histamine. [NIH] Histology: The study of tissues and cells under a microscope. [NIH] Hoarseness: An unnaturally deep or rough quality of voice. [NIH] Homologous: Corresponding in structure, position, origin, etc., as (a) the feathers of a bird and the scales of a fish, (b) antigen and its specific antibody, (c) allelic chromosomes. [EU] Hormonal: Pertaining to or of the nature of a hormone. [EU] Hormone: A substance in the body that regulates certain organs. Hormones such as gastrin help in breaking down food. Some hormones come from cells in the stomach and small intestine. [NIH] Horseradish Peroxidase: An enzyme isolated from horseradish which is able to act as an antigen. It is frequently used as a histochemical tracer for light and electron microscopy. Its antigenicity has permitted its use as a combined antigen and marker in experimental immunology. [NIH] Humoral: Of, relating to, proceeding from, or involving a bodily humour - now often used of endocrine factors as opposed to neural or somatic. [EU] Humour: 1. A normal functioning fluid or semifluid of the body (as the blood, lymph or bile) especially of vertebrates. 2. A secretion that is itself an excitant of activity (as certain hormones). [EU] Hybrid: Cross fertilization between two varieties or, more usually, two species of vines, see also crossing. [NIH] Hydrogen: The first chemical element in the periodic table. It has the atomic symbol H, atomic number 1, and atomic weight 1. It exists, under normal conditions, as a colorless, odorless, tasteless, diatomic gas. Hydrogen ions are protons. Besides the common H1 isotope, hydrogen exists as the stable isotope deuterium and the unstable, radioactive isotope tritium. [NIH] Hydrogen Peroxide: A strong oxidizing agent used in aqueous solution as a ripening agent, bleach, and topical anti-infective. It is relatively unstable and solutions deteriorate over time unless stabilized by the addition of acetanilide or similar organic materials. [NIH] Hydrophobic: Not readily absorbing water, or being adversely affected by water, as a hydrophobic colloid. [EU] Hydroxylysine: A hydroxylated derivative of the amino acid lysine that is present in certain collagens. [NIH] Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ascorbic acid can result in impaired hydroxyproline formation. [NIH] Hygienic: Pertaining to hygiene, or conducive to health. [EU] Hyperaemia: An excess of blood in a part; engorgement. [EU] Hyperbaric: Characterized by greater than normal pressure or weight; applied to gases under greater than atmospheric pressure, as hyperbaric oxygen, or to a solution of greater
172
Erythema
specific gravity than another taken as a standard of reference. [EU] Hyperbaric oxygen: Oxygen that is at an atmospheric pressure higher than the pressure at sea level. Breathing hyperbaric oxygen to enhance the effectiveness of radiation therapy is being studied. [NIH] Hyperpigmentation: Excessive pigmentation of the skin, usually as a result of increased melanization of the epidermis rather than as a result of an increased number of melanocytes. Etiology is varied and the condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance. [NIH] Hyperplasia: An increase in the number of cells in a tissue or organ, not due to tumor formation. It differs from hypertrophy, which is an increase in bulk without an increase in the number of cells. [NIH] Hypersensitivity: Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. [NIH] Hypertension: Persistently high arterial blood pressure. Currently accepted threshold levels are 140 mm Hg systolic and 90 mm Hg diastolic pressure. [NIH] Hypertrophy: General increase in bulk of a part or organ, not due to tumor formation, nor to an increase in the number of cells. [NIH] Hypnotic: A drug that acts to induce sleep. [EU] Hypoglycaemia: An abnormally diminished concentration of glucose in the blood, which may lead to tremulousness, cold sweat, piloerection, hypothermia, and headache, accompanied by irritability, confusion, hallucinations, bizarre behaviour, and ultimately, convulsions and coma. [EU] Hypothermia: Lower than normal body temperature, especially in warm-blooded animals; in man usually accidental or unintentional. [NIH] Ibuprofen: A nonsteroidal anti-inflammatory agent with analgesic properties used in the therapy of rheumatism and arthritis. [NIH] Ichthyosis: Any of several generalized skin disorders characterized by dryness, roughness, and scaliness, due to hypertrophy of the stratum corneum epidermis. Most are genetic, but some are acquired, developing in association with other systemic disease or genetic syndrome. [NIH] Idiopathic: Describes a disease of unknown cause. [NIH] Immersion: The placing of a body or a part thereof into a liquid. [NIH] Immune function: Production and action of cells that fight disease or infection. [NIH] Immune response: The activity of the immune system against foreign substances (antigens). [NIH]
Immune Sera: Serum that contains antibodies. It is obtained from an animal that has been immunized either by antigen injection or infection with microorganisms containing the antigen. [NIH] Immune system: The organs, cells, and molecules responsible for the recognition and disposal of foreign ("non-self") material which enters the body. [NIH] Immunization: Deliberate stimulation of the host's immune response. Active immunization involves administration of antigens or immunologic adjuvants. Passive immunization involves administration of immune sera or lymphocytes or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). [NIH] Immunoassay: Immunochemical assay or detection of a substance by serologic or
Dictionary 173
immunologic methods. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. [NIH] Immunoblotting: Immunologic methods for isolating and quantitatively measuring immunoreactive substances. When used with immune reagents such as monoclonal antibodies, the process is known generically as western blot analysis (blotting, western). [NIH]
Immunocompromised: Having a weakened immune system caused by certain diseases or treatments. [NIH] Immunocompromised Host: A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation. [NIH] Immunodeficiency: The decreased ability of the body to fight infection and disease. [NIH] Immunodiffusion: Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction. [NIH]
Immunoelectrophoresis: A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera. [NIH] Immunoglobulin: A protein that acts as an antibody. [NIH] Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents. [NIH] Immunologic: The ability of the antibody-forming system to recall a previous experience with an antigen and to respond to a second exposure with the prompt production of large amounts of antibody. [NIH] Immunology: The study of the body's immune system. [NIH] Immunosuppressant: An agent capable of suppressing immune responses. [EU] Immunosuppression: Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. [NIH] Immunosuppressive: Describes the ability to lower immune system responses. [NIH] Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of suppressor T-cell populations or by inhibiting the activation of helper cells. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of interleukins and other cytokines are emerging. [NIH] Impairment: In the context of health experience, an impairment is any loss or abnormality of psychological, physiological, or anatomical structure or function. [NIH] Impetigo: A common superficial bacterial infection caused by staphylococcus aureus or group A beta-hemolytic streptococci. Characteristics include pustular lesions that rupture and discharge a thin, amber-colored fluid that dries and forms a crust. This condition is commonly located on the face, especially about the mouth and nose. [NIH] Implant radiation: A procedure in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near the tumor. Also called [NIH]
174
Erythema
In situ: In the natural or normal place; confined to the site of origin without invasion of neighbouring tissues. [EU] In vitro: In the laboratory (outside the body). The opposite of in vivo (in the body). [NIH] In vivo: In the body. The opposite of in vitro (outside the body or in the laboratory). [NIH] Incision: A cut made in the body during surgery. [NIH] Indocyanine Green: A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output. [NIH] Induction: The act or process of inducing or causing to occur, especially the production of a specific morphogenetic effect in the developing embryo through the influence of evocators or organizers, or the production of anaesthesia or unconsciousness by use of appropriate agents. [EU] Induration: 1. The quality of being hard; the process of hardening. 2. An abnormally hard spot or place. [EU] Infantile: Pertaining to an infant or to infancy. [EU] Infarction: A pathological process consisting of a sudden insufficient blood supply to an area, which results in necrosis of that area. It is usually caused by a thrombus, an embolus, or a vascular torsion. [NIH] Infection: 1. Invasion and multiplication of microorganisms in body tissues, which may be clinically unapparent or result in local cellular injury due to competitive metabolism, toxins, intracellular replication, or antigen-antibody response. The infection may remain localized, subclinical, and temporary if the body's defensive mechanisms are effective. A local infection may persist and spread by extension to become an acute, subacute, or chronic clinical infection or disease state. A local infection may also become systemic when the microorganisms gain access to the lymphatic or vascular system. 2. An infectious disease. [EU]
Infectious Mononucleosis: A common, acute infection usually caused by the Epstein-Barr virus (Human herpesvirus 4). There is an increase in mononuclear white blood cells and other atypical lymphocytes, generalized lymphadenopathy, splenomegaly, and occasionally hepatomegaly with hepatitis. [NIH] Infiltration: The diffusion or accumulation in a tissue or cells of substances not normal to it or in amounts of the normal. Also, the material so accumulated. [EU] Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. [NIH] Inflammatory bowel disease: A general term that refers to the inflammation of the colon and rectum. Inflammatory bowel disease includes ulcerative colitis and Crohn's disease. [NIH]
Infusion: A method of putting fluids, including drugs, into the bloodstream. Also called intravenous infusion. [NIH] Ingestion: Taking into the body by mouth [NIH] Inhalation: The drawing of air or other substances into the lungs. [EU] Initiation: Mutation induced by a chemical reactive substance causing cell changes; being a step in a carcinogenic process. [NIH] Initiator: A chemically reactive substance which may cause cell changes if ingested, inhaled or absorbed into the body; the substance may thus initiate a carcinogenic process. [NIH] Innervation: 1. The distribution or supply of nerves to a part. 2. The supply of nervous
Dictionary 175
energy or of nerve stimulus sent to a part. [EU] Inoculum: The spores or tissues of a pathogen that serve to initiate disease in a plant. [NIH] Inorganic: Pertaining to substances not of organic origin. [EU] Insecticides: Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. [NIH] Insight: The capacity to understand one's own motives, to be aware of one's own psychodynamics, to appreciate the meaning of symbolic behavior. [NIH] Insulin: A protein hormone secreted by beta cells of the pancreas. Insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose. It is also an important regulator of protein and lipid metabolism. Insulin is used as a drug to control insulin-dependent diabetes mellitus. [NIH] Interferon: A biological response modifier (a substance that can improve the body's natural response to disease). Interferons interfere with the division of cancer cells and can slow tumor growth. There are several types of interferons, including interferon-alpha, -beta, and gamma. These substances are normally produced by the body. They are also made in the laboratory for use in treating cancer and other diseases. [NIH] Interferon-alpha: One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products. It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, it causes activation of NK cells. [NIH] Interleukin-1: A soluble factor produced by monocytes, macrophages, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. IL-1 consists of two distinct forms, IL-1 alpha and IL-1 beta which perform the same functions but are distinct proteins. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. The factor is distinct from interleukin-2. [NIH] Interleukin-2: Chemical mediator produced by activated T lymphocytes and which regulates the proliferation of T cells, as well as playing a role in the regulation of NK cell activity. [NIH] Internal radiation: A procedure in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near the tumor. Also called brachytherapy, implant radiation, or interstitial radiation therapy. [NIH] Interstitial: Pertaining to or situated between parts or in the interspaces of a tissue. [EU] Intestinal: Having to do with the intestines. [NIH] Intestinal Obstruction: Any impairment, arrest, or reversal of the normal flow of intestinal contents toward the anus. [NIH] Intestine: A long, tube-shaped organ in the abdomen that completes the process of digestion. There is both a large intestine and a small intestine. Also called the bowel. [NIH] Intoxication: Poisoning, the state of being poisoned. [EU] Intracellular: Inside a cell. [NIH] Intracellular Membranes: Membranes of subcellular structures. [NIH] Intraperitoneal: IP. Within the peritoneal cavity (the area that contains the abdominal organs). [NIH] Intravascular: Within a vessel or vessels. [EU] Intravenous: IV. Into a vein. [NIH]
176
Erythema
Intrinsic: Situated entirely within or pertaining exclusively to a part. [EU] Invasive: 1. Having the quality of invasiveness. 2. Involving puncture or incision of the skin or insertion of an instrument or foreign material into the body; said of diagnostic techniques. [EU]
Ionizing: Radiation comprising charged particles, e. g. electrons, protons, alpha-particles, etc., having sufficient kinetic energy to produce ionization by collision. [NIH] Iris: The most anterior portion of the uveal layer, separating the anterior chamber from the posterior. It consists of two layers - the stroma and the pigmented epithelium. Color of the iris depends on the amount of melanin in the stroma on reflection from the pigmented epithelium. [NIH] Irradiance: At a point of a surface, the quotient of the radiant flux incident on an element of the surface containing the point, by the area of that element. [NIH] Irradiation: The use of high-energy radiation from x-rays, neutrons, and other sources to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy) or from materials called radioisotopes. Radioisotopes produce radiation and can be placed in or near the tumor or in the area near cancer cells. This type of radiation treatment is called internal radiation therapy, implant radiation, interstitial radiation, or brachytherapy. Systemic radiation therapy uses a radioactive substance, such as a radiolabeled monoclonal antibody, that circulates throughout the body. Irradiation is also called radiation therapy, radiotherapy, and x-ray therapy. [NIH] Irritants: Drugs that act locally on cutaneous or mucosal surfaces to produce inflammation; those that cause redness due to hyperemia are rubefacients; those that raise blisters are vesicants and those that penetrate sebaceous glands and cause abscesses are pustulants; tear gases and mustard gases are also irritants. [NIH] Ischemia: Deficiency of blood in a part, due to functional constriction or actual obstruction of a blood vessel. [EU] Ischial: A pointed projection on the posterior margin of the ischium. [NIH] Ixodid: A tick of the genus Ixodes. [NIH] Kb: A measure of the length of DNA fragments, 1 Kb = 1000 base pairs. The largest DNA fragments are up to 50 kilobases long. [NIH] Keratin: A class of fibrous proteins or scleroproteins important both as structural proteins and as keys to the study of protein conformation. The family represents the principal constituent of epidermis, hair, nails, horny tissues, and the organic matrix of tooth enamel. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms an alpha-helix, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. [NIH] Keratinocytes: Epidermal cells which synthesize keratin and undergo characteristic changes as they move upward from the basal layers of the epidermis to the cornified (horny) layer of the skin. Successive stages of differentiation of the keratinocytes forming the epidermal layers are basal cell, spinous or prickle cell, and the granular cell. [NIH] Keratoconjunctivitis: Simultaneous inflammation of the cornea and conjunctiva. [NIH] Keratoconjunctivitis Sicca: Drying and inflammation of the conjunctiva as a result of insufficient lacrimal secretion. When found in association with xerostomia and polyarthritis, it is called Sjogren's syndrome. [NIH] Keratosis: Any horny growth such as a wart or callus. [NIH] Keto: It consists of 8 carbon atoms and within the endotoxins, it connects poysaccharide and lipid A. [NIH]
Dictionary 177
Ketoconazole: Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. [NIH] Lacerations: Torn, ragged, mangled wounds. [NIH] Lacrimal: Pertaining to the tears. [EU] Lamella: A layer of the iris containing the fibrils of the dilator pupillae muscle, exclusive of their cell bodies, located between the anterior pigment layer of Fuchs and the stroma. [NIH] Large Intestine: The part of the intestine that goes from the cecum to the rectum. The large intestine absorbs water from stool and changes it from a liquid to a solid form. The large intestine is 5 feet long and includes the appendix, cecum, colon, and rectum. Also called colon. [NIH] Laryngeal: Having to do with the larynx. [NIH] Laryngitis: Inflammation of the larynx. This condition presents itself with dryness and soreness of the throat, difficulty in swallowing, cough, and hoarseness. [NIH] Larynx: An irregularly shaped, musculocartilaginous tubular structure, lined with mucous membrane, located at the top of the trachea and below the root of the tongue and the hyoid bone. It is the essential sphincter guarding the entrance into the trachea and functioning secondarily as the organ of voice. [NIH] Latency: The period of apparent inactivity between the time when a stimulus is presented and the moment a response occurs. [NIH] Laxative: An agent that acts to promote evacuation of the bowel; a cathartic or purgative. [EU]
Lectin: A complex molecule that has both protein and sugars. Lectins are able to bind to the outside of a cell and cause biochemical changes in it. Lectins are made by both animals and plants. [NIH] Lens: The transparent, double convex (outward curve on both sides) structure suspended between the aqueous and vitreous; helps to focus light on the retina. [NIH] Leprosy: A chronic granulomatous infection caused by Mycobacterium leprae. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid. [NIH] Lesion: An area of abnormal tissue change. [NIH] Lethal: Deadly, fatal. [EU] Leukemia: Cancer of blood-forming tissue. [NIH] Leukocytes: White blood cells. These include granular leukocytes (basophils, eosinophils, and neutrophils) as well as non-granular leukocytes (lymphocytes and monocytes). [NIH] Leukoplakia: A white patch that may develop on mucous membranes such as the cheek, gums, or tongue and may become cancerous. [NIH] Lichen Planus: An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flattopped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a "saw-tooth" pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown. [NIH] Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [NIH]
178
Erythema
Life cycle: The successive stages through which an organism passes from fertilized ovum or spore to the fertilized ovum or spore of the next generation. [NIH] Ligament: A band of fibrous tissue that connects bones or cartilages, serving to support and strengthen joints. [EU] Ligation: Application of a ligature to tie a vessel or strangulate a part. [NIH] Linkages: The tendency of two or more genes in the same chromosome to remain together from one generation to the next more frequently than expected according to the law of independent assortment. [NIH] Lip: Either of the two fleshy, full-blooded margins of the mouth. [NIH] Lipid: Fat. [NIH] Lipid Peroxidation: Peroxidase catalyzed oxidation of lipids using hydrogen peroxide as an electron acceptor. [NIH] Lipopolysaccharide: Substance consisting of polysaccaride and lipid. [NIH] Lipoprotein: Any of the lipid-protein complexes in which lipids are transported in the blood; lipoprotein particles consist of a spherical hydrophobic core of triglycerides or cholesterol esters surrounded by an amphipathic monolayer of phospholipids, cholesterol, and apolipoproteins; the four principal classes are high-density, low-density, and very-lowdensity lipoproteins and chylomicrons. [EU] Liver: A large, glandular organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile. [NIH] Localization: The process of determining or marking the location or site of a lesion or disease. May also refer to the process of keeping a lesion or disease in a specific location or site. [NIH] Localized: Cancer which has not metastasized yet. [NIH] Locomotion: Movement or the ability to move from one place or another. It can refer to humans, vertebrate or invertebrate animals, and microorganisms. [NIH] Low-density lipoprotein: Lipoprotein that contains most of the cholesterol in the blood. LDL carries cholesterol to the tissues of the body, including the arteries. A high level of LDL increases the risk of heart disease. LDL typically contains 60 to 70 percent of the total serum cholesterol and both are directly correlated with CHD risk. [NIH] Lupus: A form of cutaneous tuberculosis. It is seen predominantly in women and typically involves the nasal, buccal, and conjunctival mucosa. [NIH] Lycopene: A red pigment found in tomatoes and some fruits. [NIH] Lyme Disease: An infectious disease caused by a spirochete, Borrelia burgdorferi, which is transmitted chiefly by Ixodes dammini and pacificus ticks in the United States and Ixodes ricinis in Europe. It is a disease with early and late cutaneous manifestations plus involvement of the nervous system, heart, eye, and joints in variable combinations. The disease was formerly known as Lyme arthritis and first discovered at Old Lyme, Connecticut. [NIH] Lymph: The almost colorless fluid that travels through the lymphatic system and carries cells that help fight infection and disease. [NIH] Lymph node: A rounded mass of lymphatic tissue that is surrounded by a capsule of connective tissue. Also known as a lymph gland. Lymph nodes are spread out along lymphatic vessels and contain many lymphocytes, which filter the lymphatic fluid (lymph). [NIH]
Lymphadenopathy: Disease or swelling of the lymph nodes. [NIH]
Dictionary 179
Lymphatic: The tissues and organs, including the bone marrow, spleen, thymus, and lymph nodes, that produce and store cells that fight infection and disease. [NIH] Lymphatic system: The tissues and organs that produce, store, and carry white blood cells that fight infection and other diseases. This system includes the bone marrow, spleen, thymus, lymph nodes and a network of thin tubes that carry lymph and white blood cells. These tubes branch, like blood vessels, into all the tissues of the body. [NIH] Lymphocyte: A white blood cell. Lymphocytes have a number of roles in the immune system, including the production of antibodies and other substances that fight infection and diseases. [NIH] Lymphocytic: Referring to lymphocytes, a type of white blood cell. [NIH] Lymphoid: Referring to lymphocytes, a type of white blood cell. Also refers to tissue in which lymphocytes develop. [NIH] Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue. [NIH] Lysosome: A sac-like compartment inside a cell that has enzymes that can break down cellular components that need to be destroyed. [NIH] Lytic: 1. Pertaining to lysis or to a lysin. 2. Producing lysis. [EU] Macrophage: A type of white blood cell that surrounds and kills microorganisms, removes dead cells, and stimulates the action of other immune system cells. [NIH] Maculopapular: Both macular and papular, as an eruption consisting of both macules and papules; sometimes erroneously used to designate a papule that is only slightly elevated. [EU]
Malaise: A vague feeling of bodily discomfort. [EU] Malignancy: A cancerous tumor that can invade and destroy nearby tissue and spread to other parts of the body. [NIH] Malignant: Cancerous; a growth with a tendency to invade and destroy nearby tissue and spread to other parts of the body. [NIH] Malignant tumor: A tumor capable of metastasizing. [NIH] Malnutrition: A condition caused by not eating enough food or not eating a balanced diet. [NIH]
Mammary: Pertaining to the mamma, or breast. [EU] Mammogram: An x-ray of the breast. [NIH] Mannans: Polysaccharides consisting of mannose units. [NIH] Mastitis: Inflammatory disease of the breast, or mammary gland. [NIH] Matrix metalloproteinase: A member of a group of enzymes that can break down proteins, such as collagen, that are normally found in the spaces between cells in tissues (i.e., extracellular matrix proteins). Because these enzymes need zinc or calcium atoms to work properly, they are called metalloproteinases. Matrix metalloproteinases are involved in wound healing, angiogenesis, and tumor cell metastasis. [NIH] Maxillary: Pertaining to the maxilla : the irregularly shaped bone that with its fellow forms the upper jaw. [EU] Meat: The edible portions of any animal used for food including domestic mammals (the major ones being cattle, swine, and sheep) along with poultry, fish, shellfish, and game. [NIH]
Medial: Lying near the midsaggital plane of the body; opposed to lateral. [NIH] Mediator: An object or substance by which something is mediated, such as (1) a structure of
180
Erythema
the nervous system that transmits impulses eliciting a specific response; (2) a chemical substance (transmitter substance) that induces activity in an excitable tissue, such as nerve or muscle; or (3) a substance released from cells as the result of the interaction of antigen with antibody or by the action of antigen with a sensitized lymphocyte. [EU] MEDLINE: An online database of MEDLARS, the computerized bibliographic Medical Literature Analysis and Retrieval System of the National Library of Medicine. [NIH] Megacolon: Pathological enlargement of the colon. [NIH] Melanin: The substance that gives the skin its color. [NIH] Melanocytes: Epidermal dendritic pigment cells which control long-term morphological color changes by alteration in their number or in the amount of pigment they produce and store in the pigment containing organelles called melanosomes. Melanophores are larger cells which do not exist in mammals. [NIH] Melanoma: A form of skin cancer that arises in melanocytes, the cells that produce pigment. Melanoma usually begins in a mole. [NIH] Melanosomes: Melanin-containing organelles found in melanocytes and melanophores. [NIH]
Membrane: A very thin layer of tissue that covers a surface. [NIH] Membrane Lipids: Lipids, predominantly phospholipids, cholesterol and small amounts of glycolipids found in membranes including cellular and intracellular membranes. These lipids may be arranged in bilayers in the membranes with integral proteins between the layers and peripheral proteins attached to the outside. Membrane lipids are required for active transport, several enzymatic activities and membrane formation. [NIH] Membrane Proteins: Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. [NIH] Memory: Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory. [NIH] Meninges: The three membranes that cover and protect the brain and spinal cord. [NIH] Mental: Pertaining to the mind; psychic. 2. (L. mentum chin) pertaining to the chin. [EU] Mental Health: The state wherein the person is well adjusted. [NIH] Mercury: A silver metallic element that exists as a liquid at room temperature. It has the atomic symbol Hg (from hydrargyrum, liquid silver), atomic number 80, and atomic weight 200.59. Mercury is used in many industrial applications and its salts have been employed therapeutically as purgatives, antisyphilitics, disinfectants, and astringents. It can be absorbed through the skin and mucous membranes which leads to mercury poisoning. Because of its toxicity, the clinical use of mercury and mercurials is diminishing. [NIH] Mesenchymal: Refers to cells that develop into connective tissue, blood vessels, and lymphatic tissue. [NIH] Mesoderm: The middle germ layer of the embryo. [NIH] Metastasis: The spread of cancer from one part of the body to another. Tumors formed from cells that have spread are called "secondary tumors" and contain cells that are like those in the original (primary) tumor. The plural is metastases. [NIH] Metastatic: Having to do with metastasis, which is the spread of cancer from one part of the body to another. [NIH]
Dictionary 181
Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of dihydrofolate reductase and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. [NIH] Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. [NIH] Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Before its alphaadrenergic actions became clear, methyldopa was thought to act by inhibiting decarboxylation of DOPA leading to depletion of norepinephrine or by conversion to and release as the false transmitter alpha-methylnorepinephrine. [NIH] MI: Myocardial infarction. Gross necrosis of the myocardium as a result of interruption of the blood supply to the area; it is almost always caused by atherosclerosis of the coronary arteries, upon which coronary thrombosis is usually superimposed. [NIH] Mice Minute Virus: The type species of parvovirus prevalent in mouse colonies and found as a contaminant of many transplanted tumors or leukemias. [NIH] Microbiology: The study of microorganisms such as fungi, bacteria, algae, archaea, and viruses. [NIH] Microcalcifications: Tiny deposits of calcium in the breast that cannot be felt but can be detected on a mammogram. A cluster of these very small specks of calcium may indicate that cancer is present. [NIH] Microcirculation: The vascular network lying between the arterioles and venules; includes capillaries, metarterioles and arteriovenous anastomoses. Also, the flow of blood through this network. [NIH] Microorganism: An organism that can be seen only through a microscope. Microorganisms include bacteria, protozoa, algae, and fungi. Although viruses are not considered living organisms, they are sometimes classified as microorganisms. [NIH] Migrans: Infestation of the dermis by various larvae, characterized by bizarre red irregular lines which are broad at one end and fade at the other, produced by burrowing larvae. [NIH] Migration: The systematic movement of genes between populations of the same species, geographic race, or variety. [NIH] Millimeter: A measure of length. A millimeter is approximately 26-times smaller than an inch. [NIH] Mineralocorticoids: A group of corticosteroids primarily associated with the regulation of water and electrolyte balance. This is accomplished through the effect on ion transport in renal tubules, resulting in retention of sodium and loss of potassium. Mineralocorticoid secretion is itself regulated by plasma volume, serum potassium, and angiotensin II. [NIH] Mitochondrial Swelling: Increase in volume of mitochondria due to an influx of fluid; it occurs in hypotonic solutions due to osmotic pressure and in isotonic solutions as a result of altered permeability of the membranes of respiring mitochondria. [NIH] Mitosis: A method of indirect cell division by means of which the two daughter nuclei normally receive identical complements of the number of chromosomes of the somatic cells of the species. [NIH] Mitotic: Cell resulting from mitosis. [NIH] Mitotic inhibitors: Drugs that kill cancer cells by interfering with cell division (mitostis). [NIH]
182
Erythema
Modification: A change in an organism, or in a process in an organism, that is acquired from its own activity or environment. [NIH] Molecular: Of, pertaining to, or composed of molecules : a very small mass of matter. [EU] Molecule: A chemical made up of two or more atoms. The atoms in a molecule can be the same (an oxygen molecule has two oxygen atoms) or different (a water molecule has two hydrogen atoms and one oxygen atom). Biological molecules, such as proteins and DNA, can be made up of many thousands of atoms. [NIH] Monitor: An apparatus which automatically records such physiological signs as respiration, pulse, and blood pressure in an anesthetized patient or one undergoing surgical or other procedures. [NIH] Monoclonal: An antibody produced by culturing a single type of cell. It therefore consists of a single species of immunoglobulin molecules. [NIH] Monoclonal antibodies: Laboratory-produced substances that can locate and bind to cancer cells wherever they are in the body. Many monoclonal antibodies are used in cancer detection or therapy; each one recognizes a different protein on certain cancer cells. Monoclonal antibodies can be used alone, or they can be used to deliver drugs, toxins, or radioactive material directly to a tumor. [NIH] Monocytes: Large, phagocytic mononuclear leukocytes produced in the vertebrate bone marrow and released into the blood; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. [NIH] Mononuclear: A cell with one nucleus. [NIH] Mononucleosis: The presence of an abnormally large number of mononuclear leucocytes (monocytes) in the blood. The term is often used alone to refer to infectious mononucleosis. [EU]
Morphological: Relating to the configuration or the structure of live organs. [NIH] Motility: The ability to move spontaneously. [EU] Mucociliary: Pertaining to or affecting the mucus membrane and hairs (including eyelashes, nose hair, .): mucociliary clearing: the clearance of mucus by ciliary movement ( particularly in the respiratory system). [EU] Mucocutaneous: Pertaining to or affecting the mucous membrane and the skin. [EU] Mucolytic: Destroying or dissolving mucin; an agent that so acts : a mucopolysaccharide or glycoprotein, the chief constituent of mucus. [EU] Mucosa: A mucous membrane, or tunica mucosa. [EU] Mucus: The viscous secretion of mucous membranes. It contains mucin, white blood cells, water, inorganic salts, and exfoliated cells. [NIH] Mustard Gas: Severe irritant and vesicant of skin, eyes, and lungs. It may cause blindness and lethal lung edema and was formerly used as a war gas. The substance has been proposed as a cytostatic and for treatment of psoriasis. It has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP-85-002, 1985) (Merck, 11th ed). [NIH] Mutagenesis: Process of generating genetic mutations. It may occur spontaneously or be induced by mutagens. [NIH] Mutagens: Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. [NIH] Myalgia: Pain in a muscle or muscles. [EU]
Dictionary 183
Mycophenolate mofetil: A drug that is being studied for its effectiveness in preventing graft-versus-host disease and autoimmune disorders. [NIH] Mycosis: Any disease caused by a fungus. [EU] Mycotic: Pertaining to a mycosis; caused by fungi. [EU] Myelodysplasia: Abnormal bone marrow cells that may lead to myelogenous leukemia. [NIH]
Myelodysplastic syndrome: Disease in which the bone marrow does not function normally. Also called preleukemia or smoldering leukemia. [NIH] Myelogenous: Produced by, or originating in, the bone marrow. [NIH] Myocardium: The muscle tissue of the heart composed of striated, involuntary muscle known as cardiac muscle. [NIH] Naevus: A circumscribed area of pigmentation or vascularization, usually in the form of a congenital benign neoplasm occurring in the skin or in various ocular tissues. [NIH] Nasal Cavity: The proximal portion of the respiratory passages on either side of the nasal septum, lined with ciliated mucosa, extending from the nares to the pharynx. [NIH] Nasal Septum: The partition separating the two nasal cavities in the midplane, composed of cartilaginous, membranous and bony parts. [NIH] Nasopharynx: The nasal part of the pharynx, lying above the level of the soft palate. [NIH] Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses. [NIH] Necrolysis: Separation or exfoliation of tissue due to necrosis. [EU] Necrosis: A pathological process caused by the progressive degradative action of enzymes that is generally associated with severe cellular trauma. It is characterized by mitochondrial swelling, nuclear flocculation, uncontrolled cell lysis, and ultimately cell death. [NIH] Neoplasm: A new growth of benign or malignant tissue. [NIH] Neoplastic: Pertaining to or like a neoplasm (= any new and abnormal growth); pertaining to neoplasia (= the formation of a neoplasm). [EU] Nerve: A cordlike structure of nervous tissue that connects parts of the nervous system with other tissues of the body and conveys nervous impulses to, or away from, these tissues. [NIH] Nerve Endings: Specialized terminations of peripheral neurons. Nerve endings include neuroeffector junction(s) by which neurons activate target organs and sensory receptors which transduce information from the various sensory modalities and send it centrally in the nervous system. Presynaptic nerve endings are presynaptic terminals. [NIH] Nervous System: The entire nerve apparatus composed of the brain, spinal cord, nerves and ganglia. [NIH] Neural: 1. Pertaining to a nerve or to the nerves. 2. Situated in the region of the spinal axis, as the neutral arch. [EU] Neuroeffector Junction: The synapse between a neuron (presynaptic) and an effector cell other than another neuron (postsynaptic). Neuroeffector junctions include synapses onto muscles and onto secretory cells. [NIH] Neurologic: Having to do with nerves or the nervous system. [NIH] Neurons: The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the nervous system. [NIH]
184
Erythema
Neuropeptide: A member of a class of protein-like molecules made in the brain. Neuropeptides consist of short chains of amino acids, with some functioning as neurotransmitters and some functioning as hormones. [NIH] Neurotransmitter: Any of a group of substances that are released on excitation from the axon terminal of a presynaptic neuron of the central or peripheral nervous system and travel across the synaptic cleft to either excite or inhibit the target cell. Among the many substances that have the properties of a neurotransmitter are acetylcholine, norepinephrine, epinephrine, dopamine, glycine, y-aminobutyrate, glutamic acid, substance P, enkephalins, endorphins, and serotonin. [EU] Neutrons: Electrically neutral elementary particles found in all atomic nuclei except light hydrogen; the mass is equal to that of the proton and electron combined and they are unstable when isolated from the nucleus, undergoing beta decay. Slow, thermal, epithermal, and fast neutrons refer to the energy levels with which the neutrons are ejected from heavier nuclei during their decay. [NIH] Neutrophil: A type of white blood cell. [NIH] Niacin: Water-soluble vitamin of the B complex occurring in various animal and plant tissues. Required by the body for the formation of coenzymes NAD and NADP. Has pellagra-curative, vasodilating, and antilipemic properties. [NIH] Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme urease. [NIH] Nitrogen: An element with the atomic symbol N, atomic number 7, and atomic weight 14. Nitrogen exists as a diatomic gas and makes up about 78% of the earth's atmosphere by volume. It is a constituent of proteins and nucleic acids and found in all living cells. [NIH] Norepinephrine: Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic. [NIH] Nuclear: A test of the structure, blood flow, and function of the kidneys. The doctor injects a mildly radioactive solution into an arm vein and uses x-rays to monitor its progress through the kidneys. [NIH] Nuclei: A body of specialized protoplasm found in nearly all cells and containing the chromosomes. [NIH] Nucleic acid: Either of two types of macromolecule (DNA or RNA) formed by polymerization of nucleotides. Nucleic acids are found in all living cells and contain the information (genetic code) for the transfer of genetic information from one generation to the next. [NIH] Nucleus: A body of specialized protoplasm found in nearly all cells and containing the chromosomes. [NIH] Ocular: 1. Of, pertaining to, or affecting the eye. 2. Eyepiece. [EU] Oedema: The presence of abnormally large amounts of fluid in the intercellular tissue spaces of the body; usually applied to demonstrable accumulation of excessive fluid in the subcutaneous tissues. Edema may be localized, due to venous or lymphatic obstruction or to increased vascular permeability, or it may be systemic due to heart failure or renal disease. Collections of edema fluid are designated according to the site, e.g. ascites (peritoneal cavity), hydrothorax (pleural cavity), and hydropericardium (pericardial sac). Massive generalized edema is called anasarca. [EU]
Dictionary 185
Ointments: Semisolid preparations used topically for protective emollient effects or as a vehicle for local administration of medications. Ointment bases are various mixtures of fats, waxes, animal and plant oils and solid and liquid hydrocarbons. [NIH] Opacity: Degree of density (area most dense taken for reading). [NIH] Oral Hygiene: The practice of personal hygiene of the mouth. It includes the maintenance of oral cleanliness, tissue tone, and general preservation of oral health. [NIH] Oral Manifestations: Disorders of the mouth attendant upon non-oral disease or injury. [NIH]
Organelles: Specific particles of membrane-bound organized living substances present in eukaryotic cells, such as the mitochondria; the golgi apparatus; endoplasmic reticulum; lysomomes; plastids; and vacuoles. [NIH] Orofacial: Of or relating to the mouth and face. [EU] Osmotic: Pertaining to or of the nature of osmosis (= the passage of pure solvent from a solution of lesser to one of greater solute concentration when the two solutions are separated by a membrane which selectively prevents the passage of solute molecules, but is permeable to the solvent). [EU] Osteoclasts: A large multinuclear cell associated with the absorption and removal of bone. An odontoclast, also called cementoclast, is cytomorphologically the same as an osteoclast and is involved in cementum resorption. [NIH] Otitis: Inflammation of the ear, which may be marked by pain, fever, abnormalities of hearing, hearing loss, tinnitus, and vertigo. [EU] Outpatient: A patient who is not an inmate of a hospital but receives diagnosis or treatment in a clinic or dispensary connected with the hospital. [NIH] Ovum: A female germ cell extruded from the ovary at ovulation. [NIH] Oxidation: The act of oxidizing or state of being oxidized. Chemically it consists in the increase of positive charges on an atom or the loss of negative charges. Most biological oxidations are accomplished by the removal of a pair of hydrogen atoms (dehydrogenation) from a molecule. Such oxidations must be accompanied by reduction of an acceptor molecule. Univalent o. indicates loss of one electron; divalent o., the loss of two electrons. [EU]
Oxides: Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides. [NIH] Paediatric: Of or relating to the care and medical treatment of children; belonging to or concerned with paediatrics. [EU] Palate: The structure that forms the roof of the mouth. It consists of the anterior hard palate and the posterior soft palate. [NIH] Palliative: 1. Affording relief, but not cure. 2. An alleviating medicine. [EU] Pancreas: A mixed exocrine and endocrine gland situated transversely across the posterior abdominal wall in the epigastric and hypochondriac regions. The endocrine portion is comprised of the Islets of Langerhans, while the exocrine portion is a compound acinar gland that secretes digestive enzymes. [NIH] Pancreatic: Having to do with the pancreas. [NIH] Panniculitis: General term for inflammation of adipose tissue, usually of the skin, characterized by reddened subcutaneous nodules. [NIH] Panuveitis: Inflammation in which both the anterior and posterior segments of the uvea are involved and a specific focus is not apparent. It is often severe and extensive and a serious
186
Erythema
threat to vision. Causes include systemic diseases such as tuberculosis, sarcoidosis, and syphilis, as well as malignancies. The intermediate segment of the eye is not involved. [NIH] Papilla: A small nipple-shaped elevation. [NIH] Papillary: Pertaining to or resembling papilla, or nipple. [EU] Papilloma: A benign epithelial neoplasm which may arise from the skin, mucous membranes or glandular ducts. [NIH] Papule: A small circumscribed, superficial, solid elevation of the skin. [EU] Paralysis: Loss of ability to move all or part of the body. [NIH] Parasite: An animal or a plant that lives on or in an organism of another species and gets at least some of its nutrition from that other organism. [NIH] Parasitic: Having to do with or being a parasite. A parasite is an animal or a plant that lives on or in an organism of another species and gets at least some of its nutrients from it. [NIH] Parasitic Diseases: Infections or infestations with parasitic organisms. They are often contracted through contact with an intermediate vector, but may occur as the result of direct exposure. [NIH] Parotid: The space that contains the parotid gland, the facial nerve, the external carotid artery, and the retromandibular vein. [NIH] Particle: A tiny mass of material. [EU] Parvovirus: A genus of the family Parvoviridae, subfamily Parvovirinae, infecting a variety of vertebrates including humans. Parvoviruses are responsible for a number of important diseases but also can be non-pathogenic in certain hosts. The type species is mice minute virus. [NIH] Patch: A piece of material used to cover or protect a wound, an injured part, etc.: a patch over the eye. [NIH] Pathogen: Any disease-producing microorganism. [EU] Pathogenesis: The cellular events and reactions that occur in the development of disease. [NIH]
Pathologic: 1. Indicative of or caused by a morbid condition. 2. Pertaining to pathology (= branch of medicine that treats the essential nature of the disease, especially the structural and functional changes in tissues and organs of the body caused by the disease). [EU] Pathologic Processes: The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs. [NIH] Pathophysiology: Altered functions in an individual or an organ due to disease. [NIH] Patient Education: The teaching or training of patients concerning their own health needs. [NIH]
Pelvic: Pertaining to the pelvis. [EU] Pelvis: The lower part of the abdomen, located between the hip bones. [NIH] Pemphigus: Group of chronic blistering diseases characterized histologically by acantholysis and blister formation within the epidermis. [NIH] Penicillin: An antibiotic drug used to treat infection. [NIH] Peptide: Any compound consisting of two or more amino acids, the building blocks of proteins. Peptides are combined to make proteins. [NIH] Percutaneous: Performed through the skin, as injection of radiopacque material in radiological examination, or the removal of tissue for biopsy accomplished by a needle. [EU]
Dictionary 187
Perennial: Lasting through the year of for several years. [EU] Perianal: Located around the anus. [EU] Pericarditis: Inflammation of the pericardium. [EU] Periodontal disease: Disease involving the supporting structures of the teeth (as the gums and periodontal membranes). [NIH] Periodontal disease: Disease involving the supporting structures of the teeth (as the gums and periodontal membranes). [NIH] Periodontitis: Inflammation of the periodontal membrane; also called periodontitis simplex. [NIH]
Perioral: Situated or occurring around the mouth. [EU] Peripheral blood: Blood circulating throughout the body. [NIH] Peripheral Nerves: The nerves outside of the brain and spinal cord, including the autonomic, cranial, and spinal nerves. Peripheral nerves contain non-neuronal cells and connective tissue as well as axons. The connective tissue layers include, from the outside to the inside, the epineurium, the perineurium, and the endoneurium. [NIH] Peripheral Nervous System: The nervous system outside of the brain and spinal cord. The peripheral nervous system has autonomic and somatic divisions. The autonomic nervous system includes the enteric, parasympathetic, and sympathetic subdivisions. The somatic nervous system includes the cranial and spinal nerves and their ganglia and the peripheral sensory receptors. [NIH] Peripheral stem cells: Immature cells found circulating in the bloodstream. New blood cells develop from peripheral stem cells. [NIH] Peritoneal: Having to do with the peritoneum (the tissue that lines the abdominal wall and covers most of the organs in the abdomen). [NIH] Peritoneal Cavity: The space enclosed by the peritoneum. It is divided into two portions, the greater sac and the lesser sac or omental bursa, which lies behind the stomach. The two sacs are connected by the foramen of Winslow, or epiploic foramen. [NIH] Peritoneum: Endothelial lining of the abdominal cavity, the parietal peritoneum covering the inside of the abdominal wall and the visceral peritoneum covering the bowel, the mesentery, and certain of the organs. The portion that covers the bowel becomes the serosal layer of the bowel wall. [NIH] Peritonitis: Inflammation of the peritoneum; a condition marked by exudations in the peritoneum of serum, fibrin, cells, and pus. It is attended by abdominal pain and tenderness, constipation, vomiting, and moderate fever. [EU] PH: The symbol relating the hydrogen ion (H+) concentration or activity of a solution to that of a given standard solution. Numerically the pH is approximately equal to the negative logarithm of H+ concentration expressed in molarity. pH 7 is neutral; above it alkalinity increases and below it acidity increases. [EU] Pharmaceutical Preparations: Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. [NIH] Pharmacologic: Pertaining to pharmacology or to the properties and reactions of drugs. [EU] Pharyngitis: Inflammation of the throat. [NIH] Pharynx: The hollow tube about 5 inches long that starts behind the nose and ends at the top of the trachea (windpipe) and esophagus (the tube that goes to the stomach). [NIH]
188
Erythema
Phenotype: The outward appearance of the individual. It is the product of interactions between genes and between the genotype and the environment. This includes the killer phenotype, characteristic of yeasts. [NIH] Phenytoin: An anticonvulsant that is used in a wide variety of seizures. It is also an antiarrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. [NIH] Phospholipids: Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides; glycerophospholipids) or sphingosine (sphingolipids). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. [NIH] Phosphorus: A non-metallic element that is found in the blood, muscles, nevers, bones, and teeth, and is a component of adenosine triphosphate (ATP; the primary energy source for the body's cells.) [NIH] Phosphorylation: The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. [NIH] Photoallergy: Sensitization of the skin to light usually due to the action of certain substances or drugs, may occur shortly after exposure to a substance or after a latent period of from days to months. [NIH] Photodynamic therapy: Treatment with drugs that become active when exposed to light. These drugs kill cancer cells. [NIH] Photosensitivity: An abnormal cutaneous response involving the interaction between photosensitizing substances and sunlight or filtered or artificial light at wavelengths of 280400 mm. There are two main types : photoallergy and photoxicity. [EU] Photosensitizer: A drug used in photodynamic therapy. When absorbed by cancer cells and exposed to light, the drug becomes active and kills the cancer cells. [NIH] Physiologic: Having to do with the functions of the body. When used in the phrase "physiologic age," it refers to an age assigned by general health, as opposed to calendar age. [NIH]
Physiology: The science that deals with the life processes and functions of organismus, their cells, tissues, and organs. [NIH] Pigment: A substance that gives color to tissue. Pigments are responsible for the color of skin, eyes, and hair. [NIH] Pigmentation: Coloration or discoloration of a part by a pigment. [NIH] Piloerection: Involuntary erection or bristling of hairs. [NIH] Pilot study: The initial study examining a new method or treatment. [NIH] Pituitary Gland: A small, unpaired gland situated in the sella turcica tissue. It is connected to the hypothalamus by a short stalk. [NIH] Placenta: A highly vascular fetal organ through which the fetus absorbs oxygen and other nutrients and excretes carbon dioxide and other wastes. It begins to form about the eighth day of gestation when the blastocyst adheres to the decidua. [NIH] Plague: An acute infectious disease caused by Yersinia pestis that affects humans, wild
Dictionary 189
rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form. [NIH] Plants: Multicellular, eukaryotic life forms of the kingdom Plantae. They are characterized by a mainly photosynthetic mode of nutrition; essentially unlimited growth at localized regions of cell divisions (meristems); cellulose within cells providing rigidity; the absence of organs of locomotion; absense of nervous and sensory systems; and an alteration of haploid and diploid generations. [NIH] Plaque: A clear zone in a bacterial culture grown on an agar plate caused by localized destruction of bacterial cells by a bacteriophage. The concentration of infective virus in a fluid can be estimated by applying the fluid to a culture and counting the number of. [NIH] Plasma: The clear, yellowish, fluid part of the blood that carries the blood cells. The proteins that form blood clots are in plasma. [NIH] Plasma cells: A type of white blood cell that produces antibodies. [NIH] Plasma protein: One of the hundreds of different proteins present in blood plasma, including carrier proteins ( such albumin, transferrin, and haptoglobin), fibrinogen and other coagulation factors, complement components, immunoglobulins, enzyme inhibitors, precursors of substances such as angiotension and bradykinin, and many other types of proteins. [EU] Plasmid: An autonomously replicating, extra-chromosomal DNA molecule found in many bacteria. Plasmids are widely used as carriers of cloned genes. [NIH] Platelets: A type of blood cell that helps prevent bleeding by causing blood clots to form. Also called thrombocytes. [NIH] Pleural: A circumscribed area of hyaline whorled fibrous tissue which appears on the surface of the parietal pleura, on the fibrous part of the diaphragm or on the pleura in the interlobar fissures. [NIH] Pleural cavity: A space enclosed by the pleura (thin tissue covering the lungs and lining the interior wall of the chest cavity). It is bound by thin membranes. [NIH] Pneumonia: Inflammation of the lungs. [NIH] Pneumonitis: A disease caused by inhaling a wide variety of substances such as dusts and molds. Also called "farmer's disease". [NIH] Poisoning: A condition or physical state produced by the ingestion, injection or inhalation of, or exposure to a deleterious agent. [NIH] Polyarteritis Nodosa: A form of necrotizing vasculitis involving small- and medium-sized arteries. The signs and symptoms result from infarction and scarring of the affected organ system. [NIH] Polyarthritis: An inflammation of several joints together. [EU] Polyethylene: A vinyl polymer made from ethylene. It can be branched or linear. Branched or low-density polyethylene is tough and pliable but not to the same degree as linear polyethylene. Linear or high-density polyethylene has a greater hardness and tensile strength. Polyethylene is used in a variety of products, including implants and prostheses. [NIH]
Polymerase: An enzyme which catalyses the synthesis of DNA using a single DNA strand as a template. The polymerase copies the template in the 5'-3'direction provided that sufficient quantities of free nucleotides, dATP and dTTP are present. [NIH] Polymerase Chain Reaction: In vitro method for producing large amounts of specific DNA
190
Erythema
or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. [NIH] Polymorphic: Occurring in several or many forms; appearing in different forms at different stages of development. [EU] Polymorphism: The occurrence together of two or more distinct forms in the same population. [NIH] Polypeptide: A peptide which on hydrolysis yields more than two amino acids; called tripeptides, tetrapeptides, etc. according to the number of amino acids contained. [EU] Polysaccharide: A type of carbohydrate. It contains sugar molecules that are linked together chemically. [NIH] Port: An implanted device through which blood may be withdrawn and drugs may be infused without repeated needle sticks. Also called a port-a-cath. [NIH] Port-a-cath: An implanted device through which blood may be withdrawn and drugs may be infused without repeated needle sticks. Also called a port. [NIH] Posterior: Situated in back of, or in the back part of, or affecting the back or dorsal surface of the body. In lower animals, it refers to the caudal end of the body. [EU] Postoperative: After surgery. [NIH] Potentiates: A degree of synergism which causes the exposure of the organism to a harmful substance to worsen a disease already contracted. [NIH] Potentiating: A degree of synergism which causes the exposure of the organism to a harmful substance to worsen a disease already contracted. [NIH] Practice Guidelines: Directions or principles presenting current or future rules of policy for the health care practitioner to assist him in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery. [NIH] Precancerous: A term used to describe a condition that may (or is likely to) become cancer. Also called premalignant. [NIH] Precursor: Something that precedes. In biological processes, a substance from which another, usually more active or mature substance is formed. In clinical medicine, a sign or symptom that heralds another. [EU] Predictive factor: A situation or condition that may increase a person's risk of developing a certain disease or disorder. [NIH] Preleukemia: Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria. [NIH] Presynaptic: Situated proximal to a synapse, or occurring before the synapse is crossed. [EU] Presynaptic Terminals: The distal terminations of axons which are specialized for the release of neurotransmitters. Also included are varicosities along the course of axons which
Dictionary 191
have similar specializations and also release transmitters. Presynaptic terminals in both the central and peripheral nervous systems are included. [NIH] Prickle: Several layers of the epidermis where the individual cells are connected by cell bridges. [NIH] Probe: An instrument used in exploring cavities, or in the detection and dilatation of strictures, or in demonstrating the potency of channels; an elongated instrument for exploring or sounding body cavities. [NIH] Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). [NIH] Progesterone: Pregn-4-ene-3,20-dione. The principal progestational hormone of the body, secreted by the corpus luteum, adrenal cortex, and placenta. Its chief function is to prepare the uterus for the reception and development of the fertilized ovum. It acts as an antiovulatory agent when administered on days 5-25 of the menstrual cycle. [NIH] Progression: Increase in the size of a tumor or spread of cancer in the body. [NIH] Progressive: Advancing; going forward; going from bad to worse; increasing in scope or severity. [EU] Projection: A defense mechanism, operating unconsciously, whereby that which is emotionally unacceptable in the self is rejected and attributed (projected) to others. [NIH] Proliferating Cell Nuclear Antigen: Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types. [NIH] Proline: A non-essential amino acid that is synthesized from glutamic acid. It is an essential component of collagen and is important for proper functioning of joints and tendons. [NIH] Promyelocytic leukemia: A type of acute myeloid leukemia, a quickly progressing disease in which too many immature blood-forming cells are found in the blood and bone marrow. [NIH]
Prophylaxis: An attempt to prevent disease. [NIH] Prospective study: An epidemiologic study in which a group of individuals (a cohort), all free of a particular disease and varying in their exposure to a possible risk factor, is followed over a specific amount of time to determine the incidence rates of the disease in the exposed and unexposed groups. [NIH] Prostaglandins: A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. [NIH] Prostate: A gland in males that surrounds the neck of the bladder and the urethra. It secretes a substance that liquifies coagulated semen. It is situated in the pelvic cavity behind the lower part of the pubic symphysis, above the deep layer of the triangular ligament, and rests upon the rectum. [NIH] Protein C: A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation. [NIH] Protein Conformation: The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. Quaternary protein structure describes the conformation assumed by
192
Erythema
multimeric proteins (aggregates of more than one polypeptide chain). [NIH] Protein S: The vitamin K-dependent cofactor of activated protein C. Together with protein C, it inhibits the action of factors VIIIa and Va. A deficiency in protein S can lead to recurrent venous and arterial thrombosis. [NIH] Proteins: Polymers of amino acids linked by peptide bonds. The specific sequence of amino acids determines the shape and function of the protein. [NIH] Proteoglycan: A molecule that contains both protein and glycosaminoglycans, which are a type of polysaccharide. Proteoglycans are found in cartilage and other connective tissues. [NIH]
Protocol: The detailed plan for a clinical trial that states the trial's rationale, purpose, drug or vaccine dosages, length of study, routes of administration, who may participate, and other aspects of trial design. [NIH] Protons: Stable elementary particles having the smallest known positive charge, found in the nuclei of all elements. The proton mass is less than that of a neutron. A proton is the nucleus of the light hydrogen atom, i.e., the hydrogen ion. [NIH] Protozoa: A subkingdom consisting of unicellular organisms that are the simplest in the animal kingdom. Most are free living. They range in size from submicroscopic to macroscopic. Protozoa are divided into seven phyla: Sarcomastigophora, Labyrinthomorpha, Apicomplexa, Microspora, Ascetospora, Myxozoa, and Ciliophora. [NIH] Protozoal: Having to do with the simplest organisms in the animal kingdom. Protozoa are single-cell organisms, such as ameba, and are different from bacteria, which are not members of the animal kingdom. Some protozoa can be seen without a microscope. [NIH] Pruritic: Pertaining to or characterized by pruritus. [EU] Pruritus: An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief. [NIH] Psoralen: A substance that binds to the DNA in cells and stops them from multiplying. It is being studied in the treatment of graft-versus-host disease and is used in the treatment of psoriasis and vitiligo. [NIH] Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. [NIH] Psychiatric: Pertaining to or within the purview of psychiatry. [EU] Psychoactive: Those drugs which alter sensation, mood, consciousness or other psychological or behavioral functions. [NIH] Psychogenic: Produced or caused by psychic or mental factors rather than organic factors. [EU]
Psychomotor: Pertaining to motor effects of cerebral or psychic activity. [EU] PTC: Percutaneous transhepatic cholangiography (per-kyoo-TAN-ee-us trans-heh-PAT-ik ko-LAN-jee-AH-gra-fee). A procedure to x-ray the bile ducts. In this procedure, a dye is injected through a thin needle inserted through the skin into the liver or the gallbladder, and an x-ray picture is taken. [NIH] Public Health: Branch of medicine concerned with the prevention and control of disease and disability, and the promotion of physical and mental health of the population on the international, national, state, or municipal level. [NIH]
Dictionary 193
Public Policy: A course or method of action selected, usually by a government, from among alternatives to guide and determine present and future decisions. [NIH] Publishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing. [NIH]
Pulmonary: Relating to the lungs. [NIH] Purulent: Consisting of or containing pus; associated with the formation of or caused by pus. [EU] Pustular: Pertaining to or of the nature of a pustule; consisting of pustules (= a visible collection of pus within or beneath the epidermis). [EU] Pyoderma: Any purulent skin disease (Dorland, 27th ed). [NIH] Pyoderma Gangrenosum: An idiopathic, rapidly evolving, and severely debilitating disease occurring most commonly in association with chronic ulcerative colitis. It is characterized by the presence of boggy, purplish ulcers with undermined borders, appearing mostly on the legs. The majority of cases are in people between 40 and 60 years old. Its etiology is unknown. [NIH] Pyrethrins: The active insecticidal constituent of pyrethrum flowers. Pyrethrin I is the pyretholone ester of chrysanthemummonocarboxylic acid and pyrethrin II is the pyretholone ester of chrysanthemumdicarboxylic acid monomethyl ester. [NIH] Pyrethrum: Species cinerafolium vis. and coccineum willd. of the genus Chrysanthemum (Compositae). The flowers contain pyrethrins, cinerolones, and chrysanthemines which are powerful contact insecticides. [NIH] Pyrimidine Dimers: Dimers found in DNA chains damaged by ultraviolet irradiation. They consist of two adjacent pyrimidine nucleotides, usually thymine nucleotides, in which the pyrimidine residues are covalently joined by a cyclobutane ring. These dimers stop DNA replication. [NIH] Quiescent: Marked by a state of inactivity or repose. [EU] Race: A population within a species which exhibits general similarities within itself, but is both discontinuous and distinct from other populations of that species, though not sufficiently so as to achieve the status of a taxon. [NIH] Racemic: Optically inactive but resolvable in the way of all racemic compounds. [NIH] Radiation: Emission or propagation of electromagnetic energy (waves/rays), or the waves/rays themselves; a stream of electromagnetic particles (electrons, neutrons, protons, alpha particles) or a mixture of these. The most common source is the sun. [NIH] Radiation therapy: The use of high-energy radiation from x-rays, gamma rays, neutrons, and other sources to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy), or it may come from radioactive material placed in the body in the area near cancer cells (internal radiation therapy, implant radiation, or brachytherapy). Systemic radiation therapy uses a radioactive substance, such as a radiolabeled monoclonal antibody, that circulates throughout the body. Also called radiotherapy. [NIH] Radioactive: Giving off radiation. [NIH] Radioimmunotherapy: Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (immunotoxins) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire.
194
Erythema
Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (radiotherapy). [NIH] Radiolabeled: Any compound that has been joined with a radioactive substance. [NIH] Radiological: Pertaining to radiodiagnostic and radiotherapeutic procedures, and interventional radiology or other planning and guiding medical radiology. [NIH] Radiotherapy: The use of ionizing radiation to treat malignant neoplasms and other benign conditions. The most common forms of ionizing radiation used as therapy are x-rays, gamma rays, and electrons. A special form of radiotherapy, targeted radiotherapy, links a cytotoxic radionuclide to a molecule that targets the tumor. When this molecule is an antibody or other immunologic molecule, the technique is called radioimmunotherapy. [NIH] Randomized: Describes an experiment or clinical trial in which animal or human subjects are assigned by chance to separate groups that compare different treatments. [NIH] Receptor: A molecule inside or on the surface of a cell that binds to a specific substance and causes a specific physiologic effect in the cell. [NIH] Receptors, Serotonin: Cell-surface proteins that bind serotonin and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. [NIH] Recombinant: A cell or an individual with a new combination of genes not found together in either parent; usually applied to linked genes. [EU] Rectal: By or having to do with the rectum. The rectum is the last 8 to 10 inches of the large intestine and ends at the anus. [NIH] Rectum: The last 8 to 10 inches of the large intestine. [NIH] Recurrence: The return of a sign, symptom, or disease after a remission. [NIH] Red blood cells: RBCs. Cells that carry oxygen to all parts of the body. Also called erythrocytes. [NIH] Reductase: Enzyme converting testosterone to dihydrotestosterone. [NIH] Refer: To send or direct for treatment, aid, information, de decision. [NIH] Refraction: A test to determine the best eyeglasses or contact lenses to correct a refractive error (myopia, hyperopia, or astigmatism). [NIH] Refractory: Not readily yielding to treatment. [EU] Regimen: A treatment plan that specifies the dosage, the schedule, and the duration of treatment. [NIH] Reinfection: A second infection by the same pathogenic agent, or a second infection of an organ such as the kidney by a different pathogenic agent. [EU] Remission: A decrease in or disappearance of signs and symptoms of cancer. In partial remission, some, but not all, signs and symptoms of cancer have disappeared. In complete remission, all signs and symptoms of cancer have disappeared, although there still may be cancer in the body. [NIH] Resected: Surgical removal of part of an organ. [NIH] Reticular: Coarse-fibered, netlike dermis layer. [NIH] Reticulate: An area of the cell wall involved in the coalescence of two vessel elements having multiple perforations that are netlike. [NIH] Retina: The ten-layered nervous tissue membrane of the eye. It is continuous with the optic nerve and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the choroid and the inner surface with the vitreous body. The
Dictionary 195
outer-most layer is pigmented, whereas the inner nine layers are transparent. [NIH] Retinoid: Vitamin A or a vitamin A-like compound. [NIH] Retrospective: Looking back at events that have already taken place. [NIH] Rheumatism: A group of disorders marked by inflammation or pain in the connective tissue structures of the body. These structures include bone, cartilage, and fat. [NIH] Rheumatoid: Resembling rheumatism. [EU] Rheumatoid arthritis: A form of arthritis, the cause of which is unknown, although infection, hypersensitivity, hormone imbalance and psychologic stress have been suggested as possible causes. [NIH] Rhusiopathiae: Causal agent of the anthropozoonosis called erysipeloid. [NIH] Ribavirin: 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide. A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [NIH] Rickettsiae: One of a group of obligate intracellular parasitic microorganisms, once regarded as intermediate in their properties between bacteria and viruses but now classified as bacteria in the order Rickettsiales, which includes 17 genera and 3 families: Rickettsiace. [NIH]
Risk factor: A habit, trait, condition, or genetic alteration that increases a person's chance of developing a disease. [NIH] Rubber: A high-molecular-weight polymeric elastomer derived from the milk juice (latex) of Hevea brasiliensis and other trees. It is a substance that can be stretched at room temperature to atleast twice its original length and after releasing the stress, retractrapidly, and recover its original dimensions fully. Synthetic rubber is made from many different chemicals, including styrene, acrylonitrile, ethylene, propylene, and isoprene. [NIH] Rubella: An acute, usually benign, infectious disease caused by a togavirus and most often affecting children and nonimmune young adults, in which the virus enters the respiratory tract via droplet nuclei and spreads to the lymphatic system. It is characterized by a slight cold, sore throat, and fever, followed by enlargement of the postauricular, suboccipital, and cervical lymph nodes, and the appearances of a fine pink rash that begins on the head and spreads to become generalized. Called also German measles, roetln, röteln, and three-day measles, and rubeola in French and Spanish. [EU] Saliva: The clear, viscous fluid secreted by the salivary glands and mucous glands of the mouth. It contains mucins, water, organic salts, and ptylin. [NIH] Salivary: The duct that convey saliva to the mouth. [NIH] Salivary glands: Glands in the mouth that produce saliva. [NIH] Saponins: Sapogenin glycosides. A type of glycoside widely distributed in plants. Each consists of a sapogenin as the aglycon moiety, and a sugar. The sapogenin may be a steroid or a triterpene and the sugar may be glucose, galactose, a pentose, or a methylpentose. Sapogenins are poisonous towards the lower forms of life and are powerful hemolytics when injected into the blood stream able to dissolve red blood cells at even extreme dilutions. [NIH] Sarcoid: A cutaneus lesion occurring as a manifestation of sarcoidosis. [NIH] Sarcoidosis: An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands. [NIH]
196
Erythema
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. [NIH] Scalpel: A small pointed knife with a convex edge. [NIH] Scarlet Fever: Infection with group A streptococci that is characterized by tonsillitis and pharyngitis. An erythematous rash is commonly present. [NIH] Scatter: The extent to which relative success and failure are divergently manifested in qualitatively different tests. [NIH] Schizoid: Having qualities resembling those found in greater degree in schizophrenics; a person of schizoid personality. [NIH] Schizophrenia: A mental disorder characterized by a special type of disintegration of the personality. [NIH] Schizotypal Personality Disorder: A personality disorder in which there are oddities of thought (magical thinking, paranoid ideation, suspiciousness), perception (illusions, depersonalization), speech (digressive, vague, overelaborate), and behavior (inappropriate affect in social interactions, frequently social isolation) that are not severe enough to characterize schizophrenia. [NIH] Sclera: The tough white outer coat of the eyeball, covering approximately the posterior fivesixths of its surface, and continuous anteriorly with the cornea and posteriorly with the external sheath of the optic nerve. [EU] Scleritis: Refers to any inflammation of the sclera including episcleritis, a benign condition affecting only the episclera, which is generally short-lived and easily treated. Classic scleritis, on the other hand, affects deeper tissue and is characterized by higher rates of visual acuity loss and even mortality, particularly in necrotizing form. Its characteristic symptom is severe and general head pain. Scleritis has also been associated with systemic collagen disease. Etiology is unknown but is thought to involve a local immune response. Treatment is difficult and includes administration of anti-inflammatory and immunosuppressive agents such as corticosteroids. Inflammation of the sclera may also be secondary to inflammation of adjacent tissues, such as the conjunctiva. [NIH] Scleroderma: A chronic disorder marked by hardening and thickening of the skin. Scleroderma can be localized or it can affect the entire body (systemic). [NIH] Sclerosis: A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve. [NIH] Screening: Checking for disease when there are no symptoms. [NIH] Sebaceous: Gland that secretes sebum. [NIH] Sebaceous gland: Gland that secretes sebum. [NIH] Sebum: The oily substance secreted by sebaceous glands. It is composed of keratin, fat, and cellular debris. [NIH] Secretion: 1. The process of elaborating a specific product as a result of the activity of a gland; this activity may range from separating a specific substance of the blood to the elaboration of a new chemical substance. 2. Any substance produced by secretion. [EU] Secretory: Secreting; relating to or influencing secretion or the secretions. [NIH] Sedatives, Barbiturate: Those derivatives of barbituric or thiobarbituric acid that are used as hypnotics or sedatives. The structural class of all such derivatives, regardless of use, is barbiturates. [NIH] Sediment: A precipitate, especially one that is formed spontaneously. [EU] Sedimentation: The act of causing the deposit of sediment, especially by the use of a
Dictionary 197
centrifugal machine. [EU] Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as epilepsy or "seizure disorder." [NIH] Selenomethionine: Diagnostic aid in pancreas function determination. [NIH] Semen: The thick, yellowish-white, viscid fluid secretion of male reproductive organs discharged upon ejaculation. In addition to reproductive organ secretions, it contains spermatozoa and their nutrient plasma. [NIH] Senile: Relating or belonging to old age; characteristic of old age; resulting from infirmity of old age. [NIH] Sensitization: 1. Administration of antigen to induce a primary immune response; priming; immunization. 2. Exposure to allergen that results in the development of hypersensitivity. 3. The coating of erythrocytes with antibody so that they are subject to lysis by complement in the presence of homologous antigen, the first stage of a complement fixation test. [EU] Sensor: A device designed to respond to physical stimuli such as temperature, light, magnetism or movement and transmit resulting impulses for interpretation, recording, movement, or operating control. [NIH] Sepsis: The presence of bacteria in the bloodstream. [NIH] Septal: An abscess occurring at the root of the tooth on the proximal surface. [NIH] Septum: A dividing wall or partition; a general term for such a structure. The term is often used alone to refer to the septal area or to the septum pellucidum. [EU] Septum Pellucidum: A triangular double membrane separating the anterior horns of the lateral ventricles of the brain. It is situated in the median plane and bounded by the corpus callosum and the body and columns of the fornix. [NIH] Sequencing: The determination of the order of nucleotides in a DNA or RNA chain. [NIH] Serologic: Analysis of a person's serum, especially specific immune or lytic serums. [NIH] Serotonin: A biochemical messenger and regulator, synthesized from the essential amino acid L-tryptophan. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (receptors, serotonin) explain the broad physiological actions and distribution of this biochemical mediator. [NIH] Serum: The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed. [NIH] Serum Albumin: A major plasma protein that serves in maintaining the plasma colloidal osmotic pressure and transporting large organic anions. [NIH] Shedding: Release of infectious particles (e. g., bacteria, viruses) into the environment, for example by sneezing, by fecal excretion, or from an open lesion. [NIH] Shock: The general bodily disturbance following a severe injury; an emotional or moral upset occasioned by some disturbing or unexpected experience; disruption of the circulation, which can upset all body functions: sometimes referred to as circulatory shock. [NIH]
Shunt: A surgically created diversion of fluid (e.g., blood or cerebrospinal fluid) from one area of the body to another area of the body. [NIH] Sialorrhea: Increased salivary flow. [NIH]
198
Erythema
Sicca: Failure of lacrimal secretion, keratoconjunctivitis sicca, failure of secretion of the salivary glands and mucous glands of the upper respiratory tract and polyarthritis. [NIH] Side effect: A consequence other than the one(s) for which an agent or measure is used, as the adverse effects produced by a drug, especially on a tissue or organ system other than the one sought to be benefited by its administration. [EU] Signs and Symptoms: Clinical manifestations that can be either objective when observed by a physician, or subjective when perceived by the patient. [NIH] Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of silicon dioxide. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight 28.09. [NIH] Silicon Dioxide: Silica. Transparent, tasteless crystals found in nature as agate, amethyst, chalcedony, cristobalite, flint, sand, quartz, and tridymite. The compound is insoluble in water or acids except hydrofluoric acid. [NIH] Sinusitis: An inflammatory process of the mucous membranes of the paranasal sinuses that occurs in three stages: acute, subacute, and chronic. Sinusitis results from any condition causing ostial obstruction or from pathophysiologic changes in the mucociliary transport mechanism. [NIH] Skeletal: Having to do with the skeleton (boney part of the body). [NIH] Skeleton: The framework that supports the soft tissues of vertebrate animals and protects many of their internal organs. The skeletons of vertebrates are made of bone and/or cartilage. [NIH] Skin Care: Maintenance of the hygienic state of the skin under optimal conditions of cleanliness and comfort. Effective in skin care are proper washing, bathing, cleansing, and the use of soaps, detergents, oils, etc. In various disease states, therapeutic and protective solutions and ointments are useful. The care of the skin is particularly important in various occupations, in exposure to sunlight, in neonates, and in decubitus ulcer. [NIH] Skin graft: Skin that is moved from one part of the body to another. [NIH] Skin Manifestations: Dermatologic disorders attendant upon non-dermatologic disease or injury. [NIH] Skin Pigmentation: Coloration of the skin. [NIH] Skull: The skeleton of the head including the bones of the face and the bones enclosing the brain. [NIH] Smoking Cessation: Discontinuation of the habit of smoking, the inhaling and exhaling of tobacco smoke. [NIH] Smoldering leukemia: Disease in which the bone marrow does not function normally. Also called preleukemia or myelodysplastic syndrome. [NIH] Smooth muscle: Muscle that performs automatic tasks, such as constricting blood vessels. [NIH]
Sneezing: Sudden, forceful, involuntary expulsion of air from the nose and mouth caused by irritation to the mucous membranes of the upper respiratory tract. [NIH] Soaps: Sodium or potassium salts of long chain fatty acids. These detergent substances are obtained by boiling natural oils or fats with caustic alkali. Sodium soaps are harder and are used as topical anti-infectives and vehicles in pills and liniments; potassium soaps are soft, used as vehicles for ointments and also as topical antimicrobials. [NIH] Sodium: An element that is a member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23. With a valence of 1, it has a strong affinity for
Dictionary 199
oxygen and other nonmetallic elements. Sodium provides the chief cation of the extracellular body fluids. Its salts are the most widely used in medicine. (From Dorland, 27th ed) Physiologically the sodium ion plays a major role in blood pressure regulation, maintenance of fluid volume, and electrolyte balance. [NIH] Soft tissue: Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body. [NIH] Solar radiation: Sunbathing as a therapeutic measure. [NIH] Solid tumor: Cancer of body tissues other than blood, bone marrow, or the lymphatic system. [NIH] Somatic: 1. Pertaining to or characteristic of the soma or body. 2. Pertaining to the body wall in contrast to the viscera. [EU] Sound wave: An alteration of properties of an elastic medium, such as pressure, particle displacement, or density, that propagates through the medium, or a superposition of such alterations. [NIH] Specialist: In medicine, one who concentrates on 1 special branch of medical science. [NIH] Species: A taxonomic category subordinate to a genus (or subgenus) and superior to a subspecies or variety, composed of individuals possessing common characters distinguishing them from other categories of individuals of the same taxonomic level. In taxonomic nomenclature, species are designated by the genus name followed by a Latin or Latinized adjective or noun. [EU] Specificity: Degree of selectivity shown by an antibody with respect to the number and types of antigens with which the antibody combines, as well as with respect to the rates and the extents of these reactions. [NIH] Spectrum: A charted band of wavelengths of electromagnetic vibrations obtained by refraction and diffraction. By extension, a measurable range of activity, such as the range of bacteria affected by an antibiotic (antibacterial s.) or the complete range of manifestations of a disease. [EU] Spina bifida: A defect in development of the vertebral column in which there is a central deficiency of the vertebral lamina. [NIH] Spinal cord: The main trunk or bundle of nerves running down the spine through holes in the spinal bone (the vertebrae) from the brain to the level of the lower back. [NIH] Spinous: Like a spine or thorn in shape; having spines. [NIH] Spirochete: Lyme disease. [NIH] Spirometry: Measurement of volume of air inhaled or exhaled by the lung. [NIH] Spleen: An organ that is part of the lymphatic system. The spleen produces lymphocytes, filters the blood, stores blood cells, and destroys old blood cells. It is located on the left side of the abdomen near the stomach. [NIH] Splenomegaly: Enlargement of the spleen. [NIH] Sporadic: Neither endemic nor epidemic; occurring occasionally in a random or isolated manner. [EU] Spores: The reproductive elements of lower organisms, such as protozoa, fungi, and cryptogamic plants. [NIH] Squamous: Scaly, or platelike. [EU] Squamous cell carcinoma: Cancer that begins in squamous cells, which are thin, flat cells resembling fish scales. Squamous cells are found in the tissue that forms the surface of the
200
Erythema
skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts. Also called epidermoid carcinoma. [NIH] Squamous cell carcinoma: Cancer that begins in squamous cells, which are thin, flat cells resembling fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts. Also called epidermoid carcinoma. [NIH] Squamous cells: Flat cells that look like fish scales under a microscope. These cells cover internal and external surfaces of the body. [NIH] Staging: Performing exams and tests to learn the extent of the cancer within the body, especially whether the disease has spread from the original site to other parts of the body. [NIH]
Staphylococcal Scalded Skin Syndrome: A disease of infants due to group 2 phage type 17 staphylococci that produce an epidermolytic exotoxin. Superficial fine vesicles and bullae form and rupture easily, resulting in loss of large sheets of epidermis. [NIH] Staphylococcus: A genus of gram-positive, facultatively anaerobic, coccoid bacteria. Its organisms occur singly, in pairs, and in tetrads and characteristically divide in more than one plane to form irregular clusters. Natural populations of Staphylococcus are membranes of warm-blooded animals. Some species are opportunistic pathogens of humans and animals. [NIH] Staphylococcus aureus: Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications. [NIH] Stenosis: Narrowing or stricture of a duct or canal. [EU] Sterile: Unable to produce children. [NIH] Steroid: A group name for lipids that contain a hydrogenated cyclopentanoperhydrophenanthrene ring system. Some of the substances included in this group are progesterone, adrenocortical hormones, the gonadal hormones, cardiac aglycones, bile acids, sterols (such as cholesterol), toad poisons, saponins, and some of the carcinogenic hydrocarbons. [EU] Stimulant: 1. Producing stimulation; especially producing stimulation by causing tension on muscle fibre through the nervous tissue. 2. An agent or remedy that produces stimulation. [EU]
Stimulus: That which can elicit or evoke action (response) in a muscle, nerve, gland or other excitable issue, or cause an augmenting action upon any function or metabolic process. [NIH] Stomach: An organ of digestion situated in the left upper quadrant of the abdomen between the termination of the esophagus and the beginning of the duodenum. [NIH] Stomatitis: Inflammation of the oral mucosa, due to local or systemic factors which may involve the buccal and labial mucosa, palate, tongue, floor of the mouth, and the gingivae. [EU]
Stool: The waste matter discharged in a bowel movement; feces. [NIH] Strand: DNA normally exists in the bacterial nucleus in a helix, in which two strands are coiled together. [NIH] Streptococci: A genus of spherical Gram-positive bacteria occurring in chains or pairs. They are widely distributed in nature, being important pathogens but often found as normal commensals in the mouth, skin, and intestine of humans and other animals. [NIH] Stress: Forcibly exerted influence; pressure. Any condition or situation that causes strain or tension. Stress may be either physical or psychologic, or both. [NIH]
Dictionary 201
Stricture: The abnormal narrowing of a body opening. Also called stenosis. [NIH] Stroke: Sudden loss of function of part of the brain because of loss of blood flow. Stroke may be caused by a clot (thrombosis) or rupture (hemorrhage) of a blood vessel to the brain. [NIH] Stroma: The middle, thickest layer of tissue in the cornea. [NIH] Strontium: An element of the alkaline earth family of metals. It has the atomic symbol Sr, atomic number 38, and atomic weight 87.62. [NIH] Styrene: A colorless, toxic liquid with a strong aromatic odor. It is used to make rubbers, polymers and copolymers, and polystyrene plastics. [NIH] Subacute: Somewhat acute; between acute and chronic. [EU] Subarachnoid: Situated or occurring between the arachnoid and the pia mater. [EU] Subcapsular: Situated below a capsule. [EU] Subclinical: Without clinical manifestations; said of the early stage(s) of an infection or other disease or abnormality before symptoms and signs become apparent or detectable by clinical examination or laboratory tests, or of a very mild form of an infection or other disease or abnormality. [EU] Subcutaneous: Beneath the skin. [NIH] Sublingual: Located beneath the tongue. [EU] Submaxillary: Four to six lymph glands, located between the lower jaw and the submandibular salivary gland. [NIH] Submucous: Occurring beneath the mucosa or a mucous membrane. [NIH] Subspecies: A category intermediate in rank between species and variety, based on a smaller number of correlated characters than are used to differentiate species and generally conditioned by geographical and/or ecological occurrence. [NIH] Substance P: An eleven-amino acid neurotransmitter that appears in both the central and peripheral nervous systems. It is involved in transmission of pain, causes rapid contractions of the gastrointestinal smooth muscle, and modulates inflammatory and immune responses. [NIH]
Substrate: A substance upon which an enzyme acts. [EU] Subungual: Beneath a nail. [NIH] Suction: The removal of secretions, gas or fluid from hollow or tubular organs or cavities by means of a tube and a device that acts on negative pressure. [NIH] Sun protection factor: SPF. A scale for rating the level of sunburn protection in sunscreen products. The higher the SPF, the more sunburn protection it provides. Sunscreens with an SPF value of 2 through 11 provide minimal protection against sunburns. Sunscreens with an SPF of 12 through 29 provide moderate protection, which is adequate for most people. Those with an SPF of 30 or higher provide high protection against sunburn and are sometimes recommended for people who are highly sensitive to the sun. [NIH] Superinfection: A frequent complication of drug therapy for microbial infection. It may result from opportunistic colonization following immunosuppression by the primary pathogen and can be influenced by the time interval between infections, microbial physiology, or host resistance. Experimental challenge and in vitro models are sometimes used in virulence and infectivity studies. [NIH] Supplementation: Adding nutrients to the diet. [NIH] Suppression: A conscious exclusion of disapproved desire contrary with repression, in which the process of exclusion is not conscious. [NIH]
202
Erythema
Sweat: The fluid excreted by the sweat glands. It consists of water containing sodium chloride, phosphate, urea, ammonia, and other waste products. [NIH] Sweat Glands: Sweat-producing structures that are embedded in the dermis. Each gland consists of a single tube, a coiled body, and a superficial duct. [NIH] Symphysis: A secondary cartilaginous joint. [NIH] Symptomatic: Having to do with symptoms, which are signs of a condition or disease. [NIH] Synergistic: Acting together; enhancing the effect of another force or agent. [EU] Synovial: Of pertaining to, or secreting synovia. [EU] Syphilis: A contagious venereal disease caused by the spirochete Treponema pallidum. [NIH]
Systemic: Affecting the entire body. [NIH] Systemic disease: Disease that affects the whole body. [NIH] Systemic lupus erythematosus: SLE. A chronic inflammatory connective tissue disease marked by skin rashes, joint pain and swelling, inflammation of the kidneys, inflammation of the fibrous tissue surrounding the heart (i.e., the pericardium), as well as other problems. Not all affected individuals display all of these problems. May be referred to as lupus. [NIH] Systemic therapy: Treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body. [NIH] Tachycardia: Excessive rapidity in the action of the heart, usually with a heart rate above 100 beats per minute. [NIH] Tachypnea: Rapid breathing. [NIH] Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro. [NIH] Tea Tree Oil: Essential oil extracted from Melaleuca alternifolia (tea tree). It is used as a topical antimicrobial due to the presence of terpineol. [NIH] Tear Gases: Gases that irritate the eyes, throat, or skin. Severe lacrimation develops upon irritation of the eyes. [NIH] Telangiectasia: The permanent enlargement of blood vessels, causing redness in the skin or mucous membranes. [NIH] Telencephalon: Paired anteriolateral evaginations of the prosencephalon plus the lamina terminalis. The cerebral hemispheres are derived from it. Many authors consider cerebrum a synonymous term to telencephalon, though a minority include diencephalon as part of the cerebrum (Anthoney, 1994). [NIH] Tetracycline: An antibiotic originally produced by Streptomyces viridifaciens, but used mostly in synthetic form. It is an inhibitor of aminoacyl-tRNA binding during protein synthesis. [NIH] Thalidomide: A pharmaceutical agent originally introduced as a non-barbiturate hypnotic, but withdrawn from the market because of its known tetratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor alpha from monocytes, and modulates other cytokine action. [NIH] Therapeutics: The branch of medicine which is concerned with the treatment of diseases, palliative or curative. [NIH] Thermal: Pertaining to or characterized by heat. [EU]
Dictionary 203
Thigh: A leg; in anatomy, any elongated process or part of a structure more or less comparable to a leg. [NIH] Thoracic: Having to do with the chest. [NIH] Thorax: A part of the trunk between the neck and the abdomen; the chest. [NIH] Threshold: For a specified sensory modality (e. g. light, sound, vibration), the lowest level (absolute threshold) or smallest difference (difference threshold, difference limen) or intensity of the stimulus discernible in prescribed conditions of stimulation. [NIH] Thrombocytes: Blood cells that help prevent bleeding by causing blood clots to form. Also called platelets. [NIH] Thrombocytopenia: A decrease in the number of blood platelets. [NIH] Thrombopenia: Reduction in the number of platelets in the blood. [NIH] Thromboses: The formation or presence of a blood clot within a blood vessel during life. [NIH]
Thrombosis: The formation or presence of a blood clot inside a blood vessel. [NIH] Thromboxanes: Physiologically active compounds found in many organs of the body. They are formed in vivo from the prostaglandin endoperoxides and cause platelet aggregation, contraction of arteries, and other biological effects. Thromboxanes are important mediators of the actions of polyunsaturated fatty acids transformed by cyclooxygenase. [NIH] Thrush: A disease due to infection with species of fungi of the genus Candida. [NIH] Thymoma: A tumor of the thymus, an organ that is part of the lymphatic system and is located in the chest, behind the breastbone. [NIH] Thymus: An organ that is part of the lymphatic system, in which T lymphocytes grow and multiply. The thymus is in the chest behind the breastbone. [NIH] Thyroid: A gland located near the windpipe (trachea) that produces thyroid hormone, which helps regulate growth and metabolism. [NIH] Ticks: Blood-sucking arachnids of the order Acarina. [NIH] Tinnitus: Sounds that are perceived in the absence of any external noise source which may take the form of buzzing, ringing, clicking, pulsations, and other noises. Objective tinnitus refers to noises generated from within the ear or adjacent structures that can be heard by other individuals. The term subjective tinnitus is used when the sound is audible only to the affected individual. Tinnitus may occur as a manifestation of cochlear diseases; vestibulocochlear nerve diseases; intracranial hypertension; craniocerebral trauma; and other conditions. [NIH] Tissue: A group or layer of cells that are alike in type and work together to perform a specific function. [NIH] Tome: A zone produced by a number of irregular spaces contained in the outermost layer of denture of the root of a tooth. [NIH] Tomography: Imaging methods that result in sharp images of objects located on a chosen plane and blurred images located above or below the plane. [NIH] Tonsillitis: Inflammation of the tonsils, especially the palatine tonsils. It is often caused by a bacterium. Tonsillitis may be acute, chronic, or recurrent. [NIH] Topical: On the surface of the body. [NIH] Toxemia: A generalized intoxication produced by toxins and other substances elaborated by an infectious agent. [NIH] Toxic: Having to do with poison or something harmful to the body. Toxic substances
204
Erythema
usually cause unwanted side effects. [NIH] Toxicity: The quality of being poisonous, especially the degree of virulence of a toxic microbe or of a poison. [EU] Toxicology: The science concerned with the detection, chemical composition, and pharmacologic action of toxic substances or poisons and the treatment and prevention of toxic manifestations. [NIH] Toxins: Specific, characterizable, poisonous chemicals, often proteins, with specific biological properties, including immunogenicity, produced by microbes, higher plants, or animals. [NIH] Trace element: Substance or element essential to plant or animal life, but present in extremely small amounts. [NIH] Trachea: The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi. [NIH] Transduction: The transfer of genes from one cell to another by means of a viral (in the case of bacteria, a bacteriophage) vector or a vector which is similar to a virus particle (pseudovirion). [NIH] Transfection: The uptake of naked or purified DNA into cells, usually eukaryotic. It is analogous to bacterial transformation. [NIH] Transfer Factor: Factor derived from leukocyte lysates of immune donors which can transfer both local and systemic cellular immunity to nonimmune recipients. [NIH] Translation: The process whereby the genetic information present in the linear sequence of ribonucleotides in mRNA is converted into a corresponding sequence of amino acids in a protein. It occurs on the ribosome and is unidirectional. [NIH] Translational: The cleavage of signal sequence that directs the passage of the protein through a cell or organelle membrane. [NIH] Transmitter: A chemical substance which effects the passage of nerve impulses from one cell to the other at the synapse. [NIH] Transplantation: Transference of a tissue or organ, alive or dead, within an individual, between individuals of the same species, or between individuals of different species. [NIH] Trauma: Any injury, wound, or shock, must frequently physical or structural shock, producing a disturbance. [NIH] Trees: Woody, usually tall, perennial higher plants (Angiosperms, Gymnosperms, and some Pterophyta) having usually a main stem and numerous branches. [NIH] Tropism: Directed movements and orientations found in plants, such as the turning of the sunflower to face the sun. [NIH] Tryptophan: An essential amino acid that is necessary for normal growth in infants and for nitrogen balance in adults. It is a precursor serotonin and niacin. [NIH] Tuberculosis: Any of the infectious diseases of man and other animals caused by species of Mycobacterium. [NIH] Tumor Necrosis Factor: Serum glycoprotein produced by activated macrophages and other mammalian mononuclear leukocytes which has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. It mimics the action of endotoxin but differs from it. It has a molecular weight of less than 70,000 kDa. [NIH] Tunica: A rather vague term to denote the lining coat of hollow organs, tubes, or cavities. [NIH]
Dictionary 205
Typhoid fever: The most important member of the enteric group of fevers which also includes the paratyphoids. [NIH] Typhoid fever: The most important member of the enteric group of fevers which also includes the paratyphoids. [NIH] Ulcer: A localized necrotic lesion of the skin or a mucous surface. [NIH] Ulceration: 1. The formation or development of an ulcer. 2. An ulcer. [EU] Ulcerative colitis: Chronic inflammation of the colon that produces ulcers in its lining. This condition is marked by abdominal pain, cramps, and loose discharges of pus, blood, and mucus from the bowel. [NIH] Ultraviolet radiation: Invisible rays that are part of the energy that comes from the sun. UV radiation can damage the skin and cause melanoma and other types of skin cancer. UV radiation that reaches the earth's surface is made up of two types of rays, called UVA and UVB rays. UVB rays are more likely than UVA rays to cause sunburn, but UVA rays pass deeper into the skin. Scientists have long thought that UVB radiation can cause melanoma and other types of skin cancer. They now think that UVA radiation also may add to skin damage that can lead to skin cancer and cause premature aging. For this reason, skin specialists recommend that people use sunscreens that reflect, absorb, or scatter both kinds of UV radiation. [NIH] Unconscious: Experience which was once conscious, but was subsequently rejected, as the "personal unconscious". [NIH] Urease: An enzyme that catalyzes the conversion of urea and water to carbon dioxide and ammonia. EC 3.5.1.5. [NIH] Urethra: The tube through which urine leaves the body. It empties urine from the bladder. [NIH]
Urinary: Having to do with urine or the organs of the body that produce and get rid of urine. [NIH] Urinary Retention: Inability to urinate. The etiology of this disorder includes obstructive, neurogenic, pharmacologic, and psychogenic causes. [NIH] Urinate: To release urine from the bladder to the outside. [NIH] Urine: Fluid containing water and waste products. Urine is made by the kidneys, stored in the bladder, and leaves the body through the urethra. [NIH] Urticaria: A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress. [NIH] Uterus: The small, hollow, pear-shaped organ in a woman's pelvis. This is the organ in which a fetus develops. Also called the womb. [NIH] Uvea: The middle coat of the eyeball, consisting of the choroid in the back of the eye and the ciliary body and iris in the front of the eye. [NIH] Uveitis: An inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (the sclera and cornea, and the retina). [EU] Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. [NIH] Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa, or rickettsiae), antigenic proteins derived from them, or synthetic constructs, administered for the prevention, amelioration, or treatment of infectious and other diseases. [NIH]
206
Erythema
Vagina: The muscular canal extending from the uterus to the exterior of the body. Also called the birth canal. [NIH] Vaginal: Of or having to do with the vagina, the birth canal. [NIH] Vaginitis: Inflammation of the vagina characterized by pain and a purulent discharge. [NIH] Varicella: Chicken pox. [EU] Vascular: Pertaining to blood vessels or indicative of a copious blood supply. [EU] Vascular endothelial growth factor: VEGF. A substance made by cells that stimulates new blood vessel formation. [NIH] Vasculitis: Inflammation of a blood vessel. [NIH] Vasodilator: An agent that widens blood vessels. [NIH] Vector: Plasmid or other self-replicating DNA molecule that transfers DNA between cells in nature or in recombinant DNA technology. [NIH] Vein: Vessel-carrying blood from various parts of the body to the heart. [NIH] Venereal: Pertaining or related to or transmitted by sexual contact. [EU] Venous: Of or pertaining to the veins. [EU] Ventricles: Fluid-filled cavities in the heart or brain. [NIH] Venules: The minute vessels that collect blood from the capillary plexuses and join together to form veins. [NIH] Verruca: A circumscribed, cutaneous excrescence having a papilliferous surface; a small, circumscribed, epidermal tumor. [NIH] Vertebrae: A bony unit of the segmented spinal column. [NIH] Vertigo: An illusion of movement; a sensation as if the external world were revolving around the patient (objective vertigo) or as if he himself were revolving in space (subjective vertigo). The term is sometimes erroneously used to mean any form of dizziness. [EU] Vesicular: 1. Composed of or relating to small, saclike bodies. 2. Pertaining to or made up of vesicles on the skin. [EU] Vestibular: Pertaining to or toward a vestibule. In dental anatomy, used to refer to the tooth surface directed toward the vestibule of the mouth. [EU] Vestibule: A small, oval, bony chamber of the labyrinth. The vestibule contains the utricle and saccule, organs which are part of the balancing apparatus of the ear. [NIH] Veterinary Medicine: The medical science concerned with the prevention, diagnosis, and treatment of diseases in animals. [NIH] Vinblastine: An anticancer drug that belongs to the family of plant drugs called vinca alkaloids. It is a mitotic inhibitor. [NIH] Vinca Alkaloids: A class of alkaloids from the genus of apocyanaceous woody herbs including periwinkles. They are some of the most useful antineoplastic agents. [NIH] Viral: Pertaining to, caused by, or of the nature of virus. [EU] Viral Load: The quantity of measurable virus in the blood. Change in viral load, measured in plasma, is used as a surrogate marker in HIV disease progression. [NIH] Viremia: The presence of viruses in the blood. [NIH] Virulence: The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. [NIH]
Dictionary 207
Virus: Submicroscopic organism that causes infectious disease. In cancer therapy, some viruses may be made into vaccines that help the body build an immune response to, and kill, tumor cells. [NIH] Viscosity: A physical property of fluids that determines the internal resistance to shear forces. [EU] Visual Acuity: Acuteness or clearness of vision, especially of form vision, which is dependent mainly on the sharpness of the retinal focus. [NIH] Vitiligo: A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached. [NIH] Vitro: Descriptive of an event or enzyme reaction under experimental investigation occurring outside a living organism. Parts of an organism or microorganism are used together with artificial substrates and/or conditions. [NIH] Vivo: Outside of or removed from the body of a living organism. [NIH] Voriconazole: A drug that treats infections caused by fungi. [NIH] Vulgaris: An affection of the skin, especially of the face, the back and the chest, due to chronic inflammation of the sebaceous glands and the hair follicles. [NIH] Vulva: The external female genital organs, including the clitoris, vaginal lips, and the opening to the vagina. [NIH] Wart: A raised growth on the surface of the skin or other organ. [NIH] White blood cell: A type of cell in the immune system that helps the body fight infection and disease. White blood cells include lymphocytes, granulocytes, macrophages, and others. [NIH]
Windpipe: A rigid tube, 10 cm long, extending from the cricoid cartilage to the upper border of the fifth thoracic vertebra. [NIH] Withdrawal: 1. A pathological retreat from interpersonal contact and social involvement, as may occur in schizophrenia, depression, or schizoid avoidant and schizotypal personality disorders. 2. (DSM III-R) A substance-specific organic brain syndrome that follows the cessation of use or reduction in intake of a psychoactive substance that had been regularly used to induce a state of intoxication. [EU] Wound Healing: Restoration of integrity to traumatized tissue. [NIH] Wounds and Injuries: Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity. [NIH] Xenograft: The cells of one species transplanted to another species. [NIH] Xerostomia: Decreased salivary flow. [NIH] X-ray: High-energy radiation used in low doses to diagnose diseases and in high doses to treat cancer. [NIH] X-ray therapy: The use of high-energy radiation from x-rays to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy) or from materials called radioisotopes. Radioisotopes produce radiation and can be placed in or near the tumor or in the area near cancer cells. This type of radiation treatment is called internal radiation therapy, implant radiation, interstitial radiation, or brachytherapy. Systemic radiation therapy uses a radioactive substance, such as a radiolabeled monoclonal antibody, that circulates throughout the body. X-ray therapy is also called radiation therapy, radiotherapy, and irradiation. [NIH]
208
Erythema
Yeasts: A general term for single-celled rounded fungi that reproduce by budding. Brewers' and bakers' yeasts are Saccharomyces cerevisiae; therapeutic dried yeast is dried yeast. [NIH] Zoster: A virus infection of the Gasserian ganglion and its nerve branches, characterized by discrete areas of vesiculation of the epithelium of the forehead, the nose, the eyelids, and the cornea together with subepithelial infiltration. [NIH]
209
INDEX 3 3-dimensional, 17, 143, 191 A Abdomen, 11, 143, 152, 175, 178, 186, 187, 199, 200, 203 Abdominal, 128, 143, 144, 175, 185, 187, 205 Abdominal Pain, 128, 143, 187, 205 Ablation, 87, 143 Abortion, 143, 148 Abrasion, 87, 143 Acantholysis, 143, 186 Acceptor, 143, 178, 185 Acetylcysteine, 6, 82, 94, 143 Acidity, 143, 187 Acne, 101, 143 Acoustic, 96, 143 Acrodermatitis, 21, 22, 32, 143 Acrylonitrile, 143, 195 Actinic keratosis, 107, 143 Acute leukemia, 30, 143, 190 Acute myeloid leukemia, 144, 191 Acute renal, 38, 144, 170 Acyclovir, 63, 144 Adipocytes, 144, 158 Adipose Tissue, 144, 185 Adrenal Cortex, 144, 159, 191 Adrenal Glands, 144, 146 Adrenergic, 144, 161, 181 Adverse Effect, 87, 144, 188, 198 Afferent, 144, 165 Affinity, 7, 144, 198 Agar, 18, 144, 159, 173, 189 Agonist, 144, 161, 181 Airway, 5, 144 Algorithms, 13, 60, 144, 151 Alkaline, 144, 145, 150, 153, 185, 201 Alleles, 11, 144, 170 Allergen, 61, 145, 197 Allylamine, 145 Alpha Cell, 145, 168 Alpha Particles, 145, 193 Alternative medicine, 112, 145 Amber, 145, 173 Ameliorating, 82, 94, 145 Amenorrhea, 145, 147 Amine, 102, 145, 171
Amino acid, 18, 145, 147, 159, 165, 168, 171, 184, 186, 190, 191, 192, 197, 201, 204 Amino Acid Sequence, 18, 145, 147, 165 Ammonia, 145, 202, 205 Ampicillin, 106, 145 Amplification, 14, 21, 145 Amputation, 13, 145 Amyloidosis, 11, 108, 146 Anaerobic, 146, 152, 169, 200 Anaesthesia, 146, 174 Analgesic, 88, 146, 172 Analog, 144, 146 Analogous, 146, 204 Anatomical, 146, 149, 173, 196 Androgens, 144, 146, 159 Anemia, 17, 146, 168 Anemic, 17, 146 Anesthesia, 33, 36, 144, 146, 191 Anesthetics, 33, 146, 150 Angioedema, 23, 77, 107, 146 Angiogenesis, 18, 98, 146, 179 Angiogenesis inhibitor, 18, 146 Angiography, 39, 146 Animal model, 11, 13, 15, 16, 146 Anions, 146, 197 Annealing, 147, 190 Anorexia, 48, 147 Anorexia Nervosa, 48, 147 Anthropogenic, 87, 147 Antiallergic, 147, 159 Antibacterial, 105, 147, 199 Antibiotic, 7, 10, 16, 21, 145, 147, 152, 154, 155, 186, 199, 202 Antibodies, 5, 18, 21, 147, 148, 149, 169, 172, 173, 179, 182, 189, 193 Antibodies, Anticardiolipin, 147, 148 Anticarcinogenic, 19, 147 Anticoagulant, 147, 148, 191 Anticonvulsant, 44, 147, 153, 188 Antifungal, 52, 105, 147, 177 Antigen, 9, 10, 16, 20, 22, 144, 147, 154, 157, 160, 163, 167, 171, 172, 173, 174, 180, 191, 197 Antigen-presenting cell, 147, 160 Antihypertensive, 147, 181 Anti-infective, 105, 147, 171, 198 Anti-Infective Agents, 105, 147
210
Erythema
Anti-inflammatory, 16, 17, 66, 67, 70, 88, 102, 148, 159, 168, 172, 196 Anti-Inflammatory Agents, 67, 148, 159 Antimetabolite, 144, 148, 181, 195 Antimicrobial, 37, 148, 155, 161, 162, 202 Antineoplastic, 148, 151, 159, 181, 206 Antioxidant, 16, 97, 148, 149, 167 Antiphospholipid Syndrome, 49, 147, 148 Antipyretic, 88, 148 Antiviral, 143, 144, 148, 175, 195 Anus, 148, 157, 175, 187, 194 Aorta, 148 Aortic Aneurysm, 5, 148 Aphthous Stomatitis, 129, 148 Apolipoproteins, 148, 178 Apoptosis, 8, 11, 12, 16, 17, 19, 148 Aqueous, 102, 103, 148, 160, 162, 171, 177 Arachidonic Acid, 13, 148, 191 Arterial, 145, 148, 149, 156, 168, 172, 192 Arteries, 148, 151, 152, 159, 178, 181, 189, 203 Arterioles, 148, 152, 153, 181 Arteriovenous, 149, 181 Arteritis, 39, 107, 149 Artery, 5, 148, 149, 151, 159, 162, 186 Ascites, 149, 184 Ascorbic Acid, 63, 149, 171 Assay, 5, 6, 12, 17, 23, 149, 172 Astringents, 149, 180 Asymptomatic, 16, 149 Atmospheric Pressure, 149, 171, 172 Atopic, 101, 149 Atrium, 56, 149 Atrophy, 143, 149, 164 Attenuated, 149, 205 Attenuation, 89, 149 Atypical, 25, 106, 149, 174 Auditory, 129, 149 Aural, 35, 149 Autoantibodies, 29, 149, 160 Autoantigens, 149 Autoimmune disease, 16, 46, 107, 149 Autologous, 9, 149 B Bacteremia, 52, 149 Bacterial Infections, 91, 149, 155 Bacteriophage, 150, 189, 204 Bacterium, 150, 170, 203 Barbiturate, 150, 202 Barium, 86, 150 Basal cell carcinoma, 19, 26, 150 Basal Cell Nevus Syndrome, 19, 150
Basal cells, 150 Basal Ganglia, 56, 150, 167 Basement Membrane, 150, 165 Basophil, 150, 171 Baths, 70, 150 Benign, 3, 4, 107, 141, 150, 167, 169, 183, 186, 194, 195, 196 Bilateral, 150, 164 Bile, 45, 150, 156, 167, 171, 178, 192, 200 Bile Acids, 150, 200 Bile Acids and Salts, 150 Bile duct, 150, 156, 192 Bioassay, 150, 151 Biochemical, 144, 148, 151, 177, 197 Biological Assay, 18, 151 Biological Markers, 19, 151 Biopsy, 7, 43, 45, 47, 50, 141, 151, 186 Biopsy specimen, 45, 151 Biosynthesis, 103, 148, 151 Biotechnology, 20, 23, 109, 112, 123, 151 Bladder, 151, 191, 205 Blastomycosis, 108, 151 Bleomycin, 26, 38, 151 Blister, 56, 151, 186 Blood Coagulation, 102, 151, 153 Blood Coagulation Factors, 151 Blood Glucose, 151, 169 Blood Platelets, 151, 197, 203 Blood pressure, 147, 151, 168, 172, 182, 199 Blood Volume, 152, 174 Blot, 7, 10, 152, 173 Blotting, Western, 152, 173 Body Fluids, 152, 162, 199 Bone Marrow, 17, 106, 143, 144, 152, 168, 172, 179, 182, 183, 190, 191, 198, 199 Bone Marrow Cells, 152, 183 Borrelia, 4, 7, 9, 10, 20, 21, 22, 26, 29, 30, 32, 35, 37, 41, 46, 57, 152, 178 Bowel, 43, 77, 110, 152, 174, 175, 177, 187, 200, 205 Brachytherapy, 152, 175, 176, 193, 207 Broad-spectrum, 145, 152, 154 Bronchi, 152, 204 Bronchial, 152, 171 Bronchitis, 5, 152 Bronchus, 28, 152 Buccal, 4, 106, 152, 178, 200 Buccal mucosa, 106, 152 Bullous, 3, 27, 28, 38, 42, 51, 62, 89, 107, 152, 160 Bupivacaine, 152, 177 Bupropion, 28, 45, 111, 152
211
Burns, 45, 77, 152 Burns, Electric, 152 Bypass, 45, 152 C Calcification, 56, 153 Calcitonin, 90, 153 Calcium, 6, 153, 156, 157, 179, 181 Callus, 153, 176 Candidiasis, 3, 8, 106, 108, 153 Candidosis, 129, 153 Cannula, 13, 153 Capillary, 98, 153, 206 Capsaicin, 153 Capsicum, 72, 153 Carbamazepine, 39, 153 Carbohydrate, 5, 153, 159, 168, 190 Carcinogen, 17, 153, 182 Carcinogenesis, 6, 17, 19, 154, 155 Carcinogenic, 154, 174, 200 Carcinoma, 28, 37, 41, 87, 107, 113, 154, 200 Cardiac, 145, 154, 162, 174, 177, 183, 200 Cardiac Output, 154, 174 Cardiolipins, 148, 154 Cardiovascular, 154, 197 Carotene, 75, 154 Carotenoids, 70, 75, 154 Case report, 24, 44, 47, 53, 54, 154, 156 Cataracts, 56, 154 Cathode, 154, 162, 165 Caudal, 154, 190 Cecum, 154, 177 Cefaclor, 59, 154 Cefuroxime, 21, 30, 154 Cell Adhesion, 16, 154 Cell Count, 16, 154 Cell Cycle, 154, 191 Cell Death, 148, 154, 167, 183 Cell Division, 149, 154, 155, 181, 189 Cell membrane, 13, 84, 155, 188 Cell proliferation, 17, 155 Cellobiose, 155 Cellulose, 102, 155, 167, 189 Central Nervous System, 5, 16, 29, 155, 162, 167, 168, 169, 197 Central Nervous System Infections, 155, 169 Cephalexin, 154, 155 Ceramide, 84, 155 Cerebral, 150, 155, 192, 202 Cerebrospinal, 5, 29, 155, 197 Cerebrospinal fluid, 5, 29, 155, 197
Cerium, 86, 155 Cervical, 155, 195 Character, 155, 160 Cheilitis, 106, 107, 108, 155 Chemopreventive, 19, 155 Chemotherapy, 28, 29, 66, 73, 74, 129, 155 Chest Pain, 23, 155 Chickenpox, 108, 155 Chlorophyll, 155, 167 Chloroquine, 61, 116, 156 Cholangiography, 156, 192 Cholangitis, 129, 156 Cholesterol, 84, 150, 156, 159, 178, 180, 200 Cholesterol Esters, 156, 178 Chorioallantoic membrane, 15, 156 Chromatin, 148, 156, 163 Chromosomal, 145, 156, 189 Chromosome, 156, 169, 170, 178 Chylomicrons, 156, 178 Claudication, 5, 156 Cleft Lip, 107, 156 Clinical study, 156, 158 Clinical trial, 4, 15, 123, 156, 158, 192, 194 Clone, 14, 156 Cloning, 151, 156 Coccidioidomycosis, 108, 156 Coenzyme, 149, 156 Cofactor, 17, 156, 184, 192 Colitis, 78, 128, 129, 157 Collagen, 87, 98, 103, 145, 150, 157, 158, 165, 166, 169, 179, 191, 196 Collagen disease, 157, 196 Colloidal, 157, 197 Colon, 157, 174, 177, 180, 205 Combination chemotherapy, 74, 157 Complement, 157, 189, 197 Complementary and alternative medicine, 69, 79, 157 Complementary medicine, 69, 157 Computational Biology, 123, 158 Concomitant, 27, 158 Conduction, 102, 158 Condyloma, 106, 158 Confusion, 158, 172 Congestion, 158, 164 Conjunctiva, 158, 176, 196 Conjunctivitis, 110, 158 Connective Tissue Cells, 102, 158 Connective Tissue Diseases, 148, 158 Consciousness, 146, 158, 160, 161, 192 Constipation, 158, 187 Constriction, 158, 176
212
Erythema
Contact dermatitis, 9, 33, 48, 54, 61, 66, 70, 71, 72, 73, 74, 89, 90, 158 Contraindications, ii, 158 Contrast medium, 146, 158 Control group, 14, 158 Controlled clinical trial, 69, 158 Contusions, 98, 158 Convulsion, 151, 158 Cornea, 26, 67, 159, 176, 196, 201, 205, 208 Corneum, 84, 159, 164, 172 Coronary, 5, 159, 181 Coronary heart disease, 5, 159 Coronary Thrombosis, 159, 181 Corpus, 159, 191, 197 Corpus Luteum, 159, 191 Corticosteroid, 56, 159 Cranial, 159, 165, 169, 187 Craniocerebral Trauma, 159, 169, 203 Culture Media, 144, 159 Curative, 159, 184, 202 Cyclic, 92, 159 Cysteine, 143, 159 Cytokine, 8, 11, 15, 16, 21, 32, 44, 59, 159, 202 Cytomegalovirus, 106, 159 Cytoplasm, 148, 155, 160, 162, 163, 169, 182 Cytotoxic, 153, 160, 173, 193, 194 Cytotoxicity, 15, 145, 160 D Decarboxylation, 160, 171, 181 Decubitus, 160, 198 Decubitus Ulcer, 160, 198 Degenerative, 90, 100, 160, 170 Deletion, 7, 148, 160 Dementia, 101, 160 Denaturation, 160, 190 Dendrites, 160, 183 Dendritic, 9, 11, 160, 180 Dendritic cell, 9, 11, 160 Density, 19, 87, 160, 178, 185, 189, 199 Depigmentation, 82, 160, 207 Dermal, 18, 37, 45, 51, 62, 89, 92, 96, 100, 101, 103, 160, 177 Dermatitis, 9, 27, 28, 40, 48, 52, 54, 56, 61, 70, 71, 72, 73, 89, 90, 101, 107, 160 Dermatitis Herpetiformis, 89, 90, 160 Dermatosis, 34, 48, 53, 66, 107, 160 Dermis, 84, 146, 160, 181, 194, 202 Detergents, 161, 198 Diabetes Mellitus, 161, 169, 175 Diagnosis, Differential, 4, 110, 161
Diagnostic procedure, 81, 112, 161 Diarrhea, 128, 161 Diffusion, 161, 173, 174 Digestion, 150, 152, 161, 175, 178, 200 Dilator, 161, 177 Diploid, 161, 189 Direct, iii, 8, 9, 19, 83, 94, 96, 115, 161, 186, 194, 207 Discoid, 16, 34, 161 Discrete, 90, 161, 177, 208 Dissociation, 144, 161 Docetaxel, 73, 161 Dopamine, 152, 161, 184 Dorsal, 15, 53, 161, 164, 190 Dorsum, 161, 167 Dosimeter, 86, 161 Doxycycline, 21, 162 Drug Interactions, 116, 162 Duct, 153, 162, 195, 200, 202 Duodenum, 150, 162, 200 E Edema, 19, 24, 60, 87, 89, 101, 146, 158, 162, 182, 184 Efferent, 162, 165 Efficacy, 10, 15, 17, 58, 69, 70, 162 Egg Yolk, 101, 162 Elastin, 98, 157, 158, 162, 165 Elective, 59, 162 Electrolyte, 159, 162, 181, 199 Electrons, 148, 154, 162, 176, 185, 193, 194 Ellagic Acid, 6, 162 Emboli, 18, 162 Embryo, 143, 162, 174, 180 Emulsions, 144, 162 Endemic, 43, 162, 199 Endocarditis, 108, 153, 162, 164 Endocardium, 162, 163 Endothelial cell, 45, 90, 163 Endotoxins, 157, 163, 176 Enhancer, 98, 163 Environmental Exposure, 151, 163 Environmental Health, 122, 124, 163 Enzymatic, 145, 153, 154, 157, 163, 171, 180, 190 Enzyme, 10, 22, 35, 151, 156, 163, 171, 184, 189, 194, 201, 205, 207 Enzyme-Linked Immunosorbent Assay, 10, 22, 163 Eosinophilic, 61, 108, 163 Eosinophils, 11, 163, 169, 177 Epidemic, 163, 199 Epidemiologic Factors, 108, 163
213
Epidemiologic Studies, 151, 163 Epidemiological, 19, 31, 42, 163 Epidermal, 9, 12, 19, 24, 41, 42, 62, 71, 73, 84, 100, 105, 106, 163, 176, 177, 180, 206 Epidermal Growth Factor, 19, 62, 163 Epidermis, 9, 43, 84, 143, 150, 151, 159, 160, 163, 169, 172, 176, 177, 186, 191, 193, 200 Epidural, 36, 164 Episcleritis, 164, 196 Epithelial, 5, 18, 92, 106, 163, 164, 170, 186 Epithelial Cells, 5, 163, 164, 170 Epithelium, 150, 158, 164, 176, 208 Erysipeloid, 11, 164, 195 Erythema Chronicum Migrans, 22, 28, 43, 164 Erythema Induratum, 24, 54, 164 Erythema Infectiosum, 17, 164, 165 Erythema Nodosum, 5, 14, 16, 21, 22, 23, 24, 25, 27, 31, 32, 33, 36, 37, 39, 40, 41, 42, 43, 44, 45, 47, 49, 50, 52, 54, 58, 59, 62, 63, 73, 74, 106, 111, 112, 129, 164 Erythrocytes, 146, 152, 164, 170, 194, 197 Esophageal, 33, 164 Esophageal Stricture, 33, 164 Esophagus, 164, 187, 200 Ethnic Groups, 11, 165 Europium, 86, 165 Exanthema, 33, 165 Exfoliation, 165, 183 Exon, 11, 165 Exotoxin, 10, 22, 165, 200 Extensor, 90, 165, 192, 207 External-beam radiation, 165, 176, 193, 207 Extracellular, 87, 158, 165, 166, 179, 199 Extracellular Matrix, 87, 158, 165, 166, 179 Extracellular Matrix Proteins, 165, 179 Extracellular Space, 165 F Facial, 25, 36, 44, 45, 46, 52, 56, 66, 106, 108, 165, 186 Facial Expression, 165 Facial Nerve, 106, 165, 186 Family Planning, 123, 165 Fat, 37, 92, 144, 148, 150, 152, 154, 155, 159, 160, 162, 165, 168, 178, 195, 196, 199 Fatigue, 164, 166, 169 Febrile, 24, 38, 107, 166 Fetal Death, 17, 166 Fibroblasts, 11, 100, 158, 166 Fibrosis, 103, 107, 145, 166, 195, 196
Filtration, 100, 166 Fistula, 107, 166 Fixation, 166, 197 Flagellum, 22, 166 Flexor, 165, 166, 177 Flush, 13, 89, 166 Flushing, 36, 166 Fold, 5, 76, 166 Forearm, 51, 151, 166 Formulary, 108, 166 Free Radicals, 148, 161, 166 Fungi, 14, 147, 166, 167, 181, 183, 199, 203, 205, 207, 208 Fungus, 129, 153, 156, 167, 183 G Gallate, 6, 167 Gallbladder, 143, 167, 192 Gamma Rays, 167, 193, 194 Ganglia, 167, 183, 187 Ganglion, 167, 208 Gas, 145, 161, 167, 171, 182, 184, 201 Gastric, 102, 163, 167, 171 Gastrointestinal, 35, 167, 197, 201 Gastrointestinal tract, 167, 197 Gene, 10, 12, 14, 18, 19, 20, 47, 50, 75, 90, 109, 144, 151, 167 Gene Expression, 12, 20, 75, 167 General practitioner, 43, 167 Genetic testing, 167, 190 Genital, 25, 77, 110, 167, 207 Genotype, 167, 188 Giant Cells, 167, 195 Gingival Hyperplasia, 107, 167 Gingivitis, 4, 14, 96, 106, 107, 108, 129, 167 Gland, 107, 108, 144, 168, 178, 179, 185, 186, 188, 191, 196, 200, 201, 202, 203 Glossitis, 108, 168 Glucagonoma, 51, 53, 74, 168 Glucocorticoids, 144, 159, 168 Glucose, 145, 149, 151, 155, 161, 168, 169, 172, 175, 195 Glucuronic Acid, 168, 170 Glycerol, 154, 168, 188 Glycerophospholipids, 168, 188 Glycine, 145, 150, 168, 184 Glycoprotein, 167, 168, 182, 204 Glycosaminoglycans, 7, 165, 168, 192 Gonadal, 168, 200 Gonorrhea, 154, 168 Governing Board, 168, 190 Graft, 36, 45, 107, 168, 183, 192
214
Erythema
Graft-versus-host disease, 36, 45, 107, 168, 183, 192 Gram-negative, 108, 152, 154, 155, 168, 169 Gram-Negative Bacteria, 108, 169 Gram-positive, 154, 155, 169, 200 Granular Cell Tumor, 108, 169 Granulocytes, 150, 169, 207 Granuloma, 16, 33, 169 Granuloma Annulare, 33, 169 H Haemophilus, 154, 169 Hair follicles, 161, 169, 200, 207 Halitosis, 107, 169 Haploid, 169, 189 Haptens, 144, 169 Headache, 74, 164, 169, 172 Headache Disorders, 169 Health Status, 97, 169 Heart failure, 169, 184 Hemoglobin, 31, 146, 164, 169, 170 Hemoglobin A, 31, 170 Hemoglobin C, 146, 170 Hemolytic, 17, 170, 173 Hemorrhage, 3, 107, 158, 159, 169, 170, 201 Hemostasis, 170, 197 Heparin, 7, 170 Hepatitis, 35, 45, 58, 170, 174 Hepatocytes, 170 Hepatomegaly, 170, 174 Hereditary, 23, 143, 150, 158, 170 Heredity, 167, 170 Herpes, 12, 25, 27, 31, 41, 42, 52, 77, 106, 107, 110, 144, 170 Herpes Zoster, 27, 106, 170 Herpetiformis, 90, 160, 170 Heterogeneity, 144, 170 Heterotrophic, 166, 170 Heterozygote, 11, 170 Histamine, 85, 95, 102, 171 Histamine Release, 102, 171 Histidine, 102, 171 Histology, 15, 171 Hoarseness, 171, 177 Homologous, 144, 170, 171, 197 Hormonal, 149, 151, 159, 171 Hormone, 145, 150, 151, 153, 159, 171, 175, 180, 191, 195, 203 Horseradish Peroxidase, 163, 171 Humoral, 8, 10, 171 Humour, 171 Hybrid, 156, 171
Hydrogen, 143, 145, 153, 160, 165, 171, 178, 182, 184, 185, 187, 192 Hydrogen Peroxide, 171, 178 Hydrophobic, 161, 168, 171, 178 Hydroxylysine, 157, 171 Hydroxyproline, 145, 157, 171 Hygienic, 171, 198 Hyperaemia, 158, 171 Hyperbaric, 75, 171, 172 Hyperbaric oxygen, 171, 172 Hyperpigmentation, 106, 172 Hyperplasia, 6, 106, 172, 177 Hypersensitivity, 12, 62, 89, 90, 145, 172, 195, 197 Hypertension, 169, 172, 203 Hypertrophy, 172 Hypnotic, 71, 150, 172, 202 Hypoglycaemia, 40, 172 Hypothermia, 172 I Ibuprofen, 88, 172 Ichthyosis, 101, 172 Idiopathic, 61, 143, 172, 193, 195 Immersion, 74, 150, 172 Immune function, 8, 172, 173 Immune response, 8, 10, 16, 20, 147, 149, 159, 169, 172, 173, 196, 197, 201, 205, 207 Immune Sera, 172 Immune system, 147, 172, 173, 179, 207 Immunization, 35, 172, 197 Immunoassay, 35, 147, 163, 172 Immunoblotting, 22, 173 Immunocompromised, 35, 173 Immunocompromised Host, 35, 173 Immunodeficiency, 17, 173 Immunodiffusion, 144, 173 Immunoelectrophoresis, 144, 173 Immunoglobulin, 22, 63, 147, 173, 182 Immunohistochemistry, 18, 173 Immunologic, 9, 14, 44, 172, 173, 194 Immunology, 30, 100, 144, 171, 173 Immunosuppressant, 173, 181 Immunosuppression, 173, 201 Immunosuppressive, 173, 196, 202 Immunosuppressive Agents, 173, 196 Impairment, 173, 175 Impetigo, 106, 173 Implant radiation, 173, 175, 176, 193, 207 In situ, 10, 174 In vitro, 6, 9, 10, 12, 17, 18, 38, 44, 50, 88, 92, 151, 174, 189, 201, 202
215
In vivo, 5, 6, 16, 17, 18, 19, 38, 44, 88, 92, 151, 170, 174, 202, 203 Incision, 174, 176 Indocyanine Green, 39, 174 Induction, 12, 19, 22, 100, 104, 146, 174 Induration, 46, 64, 89, 174 Infantile, 143, 174 Infarction, 159, 174, 181, 189 Infectious Mononucleosis, 108, 174, 182 Infiltration, 13, 97, 174, 191, 208 Inflammatory bowel disease, 12, 63, 128, 174 Infusion, 45, 174 Ingestion, 166, 169, 174, 189 Inhalation, 156, 174, 189 Initiation, 6, 17, 174 Initiator, 151, 174 Innervation, 165, 174 Inoculum, 18, 175 Inorganic, 101, 175, 182 Insecticides, 175, 193 Insight, 8, 14, 175 Insulin, 151, 175 Interferon, 16, 41, 44, 45, 52, 58, 175 Interferon-alpha, 45, 175 Interleukin-1, 85, 95, 175 Interleukin-2, 175 Internal radiation, 175, 176, 193, 207 Interstitial, 73, 152, 165, 175, 176, 207 Intestinal, 45, 100, 128, 154, 175 Intestinal Obstruction, 129, 175 Intestine, 150, 152, 154, 162, 171, 175, 177, 200 Intoxication, 175, 203, 207 Intracellular, 174, 175, 180, 194, 195 Intracellular Membranes, 175, 180 Intraperitoneal, 38, 175 Intravascular, 23, 72, 175 Intravenous, 45, 73, 174, 175 Intrinsic, 10, 144, 150, 176 Invasive, 87, 176 Ionizing, 145, 162, 163, 176, 194 Iris, 141, 159, 176, 177, 205 Irradiance, 37, 176 Irradiation, 15, 28, 67, 75, 88, 91, 99, 176, 181, 193, 207 Irritants, 9, 101, 176 Ischemia, 94, 97, 98, 149, 160, 176 Ischial, 94, 176 Ixodid, 164, 176 K Kb, 122, 176
Keratin, 176, 196 Keratinocytes, 9, 12, 75, 176 Keratoconjunctivitis, 38, 176, 198 Keratoconjunctivitis Sicca, 38, 176, 198 Keratosis, 108, 143, 176 Keto, 97, 176 Ketoconazole, 82, 94, 177 L Lacerations, 98, 100, 177 Lacrimal, 165, 176, 177, 198 Lamella, 84, 177 Large Intestine, 128, 154, 175, 177, 194 Laryngeal, 57, 177 Laryngitis, 57, 177 Larynx, 177, 204 Latency, 17, 177 Laxative, 144, 177 Lectin, 177, 180 Lens, 154, 177 Leprosy, 14, 22, 31, 33, 39, 59, 108, 177 Lesion, 10, 15, 22, 28, 93, 106, 140, 141, 151, 169, 177, 178, 195, 197, 205 Lethal, 18, 177, 182 Leukemia, 30, 62, 73, 140, 144, 177, 183, 190 Leukocytes, 152, 163, 169, 175, 177, 182, 204 Leukoplakia, 106, 107, 108, 177 Lichen Planus, 3, 107, 129, 177 Lidocaine, 45, 177 Life cycle, 166, 178 Ligament, 178, 191 Ligation, 14, 178 Linkages, 168, 169, 178 Lip, 107, 156, 178 Lipid, 16, 71, 84, 100, 102, 148, 162, 168, 175, 176, 178 Lipid Peroxidation, 71, 178 Lipopolysaccharide, 168, 178 Lipoprotein, 7, 10, 168, 178 Liver, 129, 143, 146, 148, 150, 156, 160, 167, 168, 170, 174, 178, 192, 195 Localization, 10, 173, 178 Localized, 4, 11, 19, 48, 73, 82, 93, 103, 110, 146, 164, 166, 169, 174, 177, 178, 184, 189, 196, 205 Locomotion, 166, 178, 189 Low-density lipoprotein, 178 Lupus, 16, 34, 38, 49, 77, 78, 107, 147, 148, 178, 202 Lycopene, 6, 178
216
Erythema
Lyme Disease, 9, 21, 22, 30, 47, 59, 108, 109, 128, 178 Lymph, 16, 31, 155, 163, 171, 174, 178, 179, 195, 201 Lymph node, 16, 155, 178, 179, 195 Lymphadenopathy, 31, 174, 178 Lymphatic, 174, 178, 179, 180, 184, 195, 199, 203 Lymphatic system, 178, 179, 195, 199, 203 Lymphocyte, 9, 16, 38, 147, 173, 179, 180 Lymphocytic, 10, 179 Lymphoid, 147, 179 Lymphoma, 23, 30, 62, 66, 72, 73, 106, 179 Lysosome, 5, 179 Lytic, 179, 197 M Macrophage, 50, 175, 179 Maculopapular, 33, 179 Malaise, 140, 164, 179 Malignancy, 19, 179 Malignant, 17, 26, 107, 148, 179, 183, 191, 194, 196 Malignant tumor, 107, 179 Malnutrition, 129, 149, 179 Mammary, 18, 179 Mammogram, 153, 179, 181 Mannans, 167, 179 Mastitis, 40, 179 Matrix metalloproteinase, 59, 94, 103, 179 Maxillary, 156, 179 Meat, 164, 179 Medial, 156, 179 Mediator, 90, 102, 175, 179, 197 MEDLINE, 123, 180 Megacolon, 129, 180 Melanin, 29, 31, 160, 176, 180 Melanocytes, 82, 172, 180 Melanoma, 19, 180, 205 Melanosomes, 180 Membrane Lipids, 180, 188 Membrane Proteins, 10, 180 Memory, 147, 160, 180 Meninges, 155, 159, 180 Mental, iv, 4, 122, 124, 158, 160, 161, 166, 180, 192, 196 Mental Health, iv, 4, 122, 124, 180, 192 Mercury, 85, 86, 180 Mesenchymal, 18, 163, 180 Mesoderm, 156, 180 Metastasis, 179, 180 Metastatic, 37, 180 Methotrexate, 25, 27, 42, 51, 71, 181
Methoxsalen, 61, 181 Methyldopa, 3, 181 MI, 82, 94, 103, 142, 181 Mice Minute Virus, 181, 186 Microbiology, 29, 31, 43, 57, 149, 181 Microcalcifications, 153, 181 Microcirculation, 89, 181 Microorganism, 156, 181, 186, 207 Migration, 50, 156, 181 Millimeter, 22, 57, 181 Mineralocorticoids, 144, 159, 181 Mitochondrial Swelling, 181, 183 Mitosis, 148, 181 Mitotic, 161, 181, 206 Mitotic inhibitors, 161, 181 Modification, 145, 182 Molecular, 6, 7, 12, 17, 20, 32, 87, 123, 125, 145, 146, 151, 158, 170, 182, 194, 195, 204 Molecule, 10, 11, 16, 147, 154, 156, 157, 161, 177, 182, 185, 189, 192, 194, 206 Monitor, 182, 184 Monoclonal, 117, 173, 176, 182, 193, 207 Monoclonal antibodies, 173, 182 Monocytes, 11, 175, 177, 182, 202 Mononuclear, 45, 169, 174, 182, 204 Mononucleosis, 106, 182 Morphological, 162, 167, 180, 182 Motility, 182, 197 Mucociliary, 182, 198 Mucocutaneous, 42, 182 Mucolytic, 143, 182 Mucosa, 4, 44, 91, 97, 106, 108, 110, 113, 129, 178, 182, 183, 200, 201 Mucus, 182, 205 Mustard Gas, 176, 182 Mutagenesis, 18, 182 Mutagens, 182 Myalgia, 11, 182 Mycophenolate mofetil, 58, 63, 183 Mycosis, 52, 183 Mycotic, 91, 183 Myelodysplasia, 30, 183 Myelodysplastic syndrome, 62, 183, 198 Myelogenous, 144, 183 Myocardium, 181, 183 N Naevus, 41, 183 Nasal Cavity, 113, 183 Nasal Septum, 183 Nasopharynx, 113, 183 Nausea, 164, 183 Necrolysis, 24, 42, 73, 106, 183
217
Necrosis, 13, 15, 31, 37, 100, 142, 148, 164, 174, 181, 183, 195 Neoplasm, 169, 183, 186, 196 Neoplastic, 179, 183 Nerve Endings, 100, 183 Nervous System, 7, 20, 47, 82, 144, 155, 178, 180, 183, 187 Neural, 144, 171, 183 Neuroeffector Junction, 183 Neurologic, 4, 183 Neurons, 160, 167, 183 Neuropeptide, 90, 184 Neurotransmitter, 145, 161, 168, 171, 184, 201 Neutrons, 145, 176, 184, 193 Neutrophil, 8, 184 Niacin, 13, 184, 204 Nickel, 61, 184 Nitrogen, 145, 146, 165, 166, 184, 204 Norepinephrine, 144, 161, 181, 184 Nuclear, 39, 75, 150, 161, 162, 167, 183, 184, 191 Nuclei, 84, 100, 145, 162, 181, 184, 192, 195 Nucleic acid, 182, 184, 195 Nucleus, 84, 148, 156, 159, 160, 163, 167, 182, 184, 192, 200 O Ocular, 100, 110, 183, 184 Oedema, 48, 98, 184 Ointments, 185, 198 Opacity, 154, 160, 185 Oral Hygiene, 169, 185 Oral Manifestations, 105, 106, 185 Organelles, 160, 180, 182, 185 Orofacial, 107, 185 Osmotic, 181, 185, 197 Osteoclasts, 153, 185 Otitis, 129, 185 Outpatient, 108, 185 Ovum, 159, 178, 185, 191 Oxidation, 143, 148, 178, 185 Oxides, 84, 185 P Paediatric, 36, 185 Palate, 107, 183, 185, 200 Palliative, 185, 202 Pancreas, 143, 145, 175, 185, 197 Pancreatic, 37, 77, 168, 185 Panniculitis, 34, 164, 185 Panuveitis, 53, 185 Papilla, 186 Papillary, 90, 186
Papilloma, 158, 186 Papule, 164, 179, 186 Paralysis, 106, 186 Parasite, 186 Parasitic, 107, 186, 195 Parasitic Diseases, 107, 186 Parotid, 107, 186, 195 Particle, 83, 186, 199, 204 Parvovirus, 17, 164, 181, 186 Patch, 56, 61, 177, 186 Pathogen, 5, 11, 175, 186, 201 Pathogenesis, 5, 7, 9, 12, 14, 45, 186 Pathologic, 18, 24, 90, 148, 151, 153, 159, 172, 186, 192 Pathologic Processes, 148, 186 Pathophysiology, 105, 186 Patient Education, 128, 129, 134, 136, 142, 186 Pelvic, 186, 191 Pelvis, 143, 186, 205 Pemphigus, 55, 129, 143, 186 Penicillin, 30, 90, 145, 186 Peptide, 7, 10, 90, 145, 153, 176, 186, 190, 191, 192 Percutaneous, 87, 186, 192 Perennial, 187, 204 Perianal, 158, 187 Pericarditis, 11, 74, 187 Periodontal disease, 8, 14, 96, 106, 187 Periodontitis, 14, 96, 106, 167, 187 Perioral, 106, 187 Peripheral blood, 9, 10, 30, 32, 45, 175, 187, 190 Peripheral Nerves, 177, 187 Peripheral Nervous System, 181, 184, 187, 191, 201 Peripheral stem cells, 168, 187 Peritoneal, 11, 149, 175, 184, 187 Peritoneal Cavity, 149, 175, 184, 187 Peritoneum, 187 Peritonitis, 11, 187 PH, 87, 102, 187 Pharmaceutical Preparations, 155, 187 Pharmacologic, 146, 187, 204, 205 Pharyngitis, 187, 196 Pharynx, 113, 183, 187 Phenotype, 9, 75, 151, 188 Phenytoin, 153, 188 Phospholipids, 84, 148, 154, 165, 178, 180, 188 Phosphorus, 153, 188 Phosphorylation, 19, 188
218
Erythema
Photoallergy, 188 Photodynamic therapy, 100, 188 Photosensitivity, 38, 50, 77, 106, 188 Photosensitizer, 15, 188 Physiologic, 144, 151, 188, 194 Physiology, 70, 151, 188, 201 Pigment, 45, 82, 104, 160, 177, 178, 180, 188 Pigmentation, 27, 36, 56, 57, 71, 82, 89, 106, 107, 172, 183, 188 Piloerection, 172, 188 Pilot study, 17, 188 Pituitary Gland, 159, 188 Placenta, 188, 191 Plague, 101, 188 Plants, 72, 168, 177, 181, 184, 189, 195, 199, 204 Plaque, 14, 189 Plasma, 16, 107, 147, 152, 153, 154, 155, 156, 169, 170, 181, 189, 197, 206 Plasma cells, 147, 189 Plasma protein, 189, 197 Plasmid, 10, 189, 206 Platelets, 100, 189, 203 Pleural, 184, 189 Pleural cavity, 184, 189 Pneumonia, 5, 106, 158, 189 Pneumonitis, 17, 189 Poisoning, 77, 175, 180, 183, 189 Polyarteritis Nodosa, 107, 189 Polyarthritis, 41, 176, 189, 198 Polyethylene, 5, 189 Polymerase, 12, 21, 31, 189 Polymerase Chain Reaction, 21, 31, 189 Polymorphic, 62, 190 Polymorphism, 36, 50, 190 Polypeptide, 145, 157, 163, 190, 192 Polysaccharide, 147, 155, 190, 192 Port, 15, 29, 190 Port-a-cath, 190 Posterior, 39, 44, 56, 57, 161, 176, 185, 190, 196 Postoperative, 108, 190 Potentiates, 175, 190 Potentiating, 151, 190 Practice Guidelines, 124, 190 Precancerous, 143, 155, 190 Precursor, 148, 161, 163, 184, 190, 204 Predictive factor, 36, 190 Preleukemia, 183, 190, 198 Presynaptic, 183, 184, 190 Presynaptic Terminals, 183, 190
Prickle, 143, 176, 191 Probe, 89, 91, 96, 191 Procaine, 177, 191 Progesterone, 28, 191, 200 Progression, 6, 17, 18, 146, 191, 206 Progressive, 15, 17, 160, 183, 191 Projection, 176, 184, 191 Proliferating Cell Nuclear Antigen, 19, 191 Proline, 157, 171, 191 Promyelocytic leukemia, 25, 191 Prophylaxis, 63, 191, 205 Prospective study, 37, 43, 191 Prostaglandins, 13, 148, 191 Prostate, 55, 191 Protein C, 145, 148, 150, 176, 178, 191 Protein Conformation, 145, 176, 191 Protein S, 12, 109, 151, 191, 192, 202 Proteoglycan, 7, 192 Protocol, 15, 108, 192 Protons, 145, 171, 176, 192, 193 Protozoa, 181, 192, 199, 205 Protozoal, 107, 192 Pruritic, 4, 90, 160, 177, 192 Pruritus, 75, 85, 95, 101, 102, 192 Psoralen, 19, 56, 192 Psoriasis, 3, 4, 30, 101, 107, 182, 192 Psychiatric, 151, 192 Psychoactive, 192, 207 Psychogenic, 192, 205 Psychomotor, 153, 192 PTC, 19, 192 Public Health, 5, 14, 124, 192 Public Policy, 123, 193 Publishing, 20, 193 Pulmonary, 16, 151, 163, 193 Purulent, 193, 206 Pustular, 39, 170, 173, 193 Pyoderma, 43, 129, 193 Pyoderma Gangrenosum, 43, 129, 193 Pyrethrins, 193 Pyrethrum, 69, 193 Pyrimidine Dimers, 17, 22, 193 Q Quiescent, 193, 207 R Race, 88, 101, 181, 193 Racemic, 88, 193 Radiation therapy, 75, 113, 143, 165, 172, 175, 176, 193, 207 Radioactive, 171, 173, 175, 176, 182, 184, 193, 194, 207
219
Radioimmunotherapy, 193, 194 Radiolabeled, 152, 176, 193, 194, 207 Radiological, 186, 194 Radiotherapy, 57, 58, 113, 152, 161, 176, 193, 194, 207 Randomized, 162, 194 Receptor, 5, 9, 12, 16, 18, 53, 147, 161, 194, 197 Receptors, Serotonin, 194, 197 Recombinant, 10, 18, 21, 43, 117, 194, 206 Rectal, 128, 194 Rectum, 148, 157, 167, 174, 177, 191, 194 Recurrence, 101, 194 Red blood cells, 13, 164, 170, 194, 195 Reductase, 181, 194 Refer, 1, 92, 152, 157, 166, 170, 178, 182, 184, 194, 197, 206 Refraction, 194, 199 Refractory, 58, 194 Regimen, 66, 73, 162, 194 Reinfection, 5, 194 Remission, 194 Resected, 18, 194 Reticular, 33, 59, 194 Reticulate, 51, 194 Retina, 39, 177, 194, 205 Retinoid, 52, 82, 94, 195 Retrospective, 7, 195 Rheumatism, 36, 172, 195 Rheumatoid, 7, 156, 157, 195 Rheumatoid arthritis, 7, 156, 157, 195 Rhusiopathiae, 164, 195 Ribavirin, 52, 195 Rickettsiae, 195, 205 Risk factor, 8, 46, 59, 107, 108, 113, 129, 163, 191, 195 Rubber, 48, 143, 195 Rubella, 108, 164, 195 S Saliva, 195 Salivary, 106, 108, 160, 165, 195, 197, 198, 201, 207 Salivary glands, 106, 160, 165, 195, 198 Saponins, 195, 200 Sarcoid, 16, 59, 195 Sarcoidosis, 5, 16, 36, 37, 50, 186, 195 Sarcoma, 106, 196 Scalpel, 87, 196 Scarlet Fever, 108, 196 Scatter, 196, 205 Schizoid, 196, 207 Schizophrenia, 13, 196, 207
Schizotypal Personality Disorder, 196, 207 Sclera, 158, 164, 196, 205 Scleritis, 53, 196 Scleroderma, 107, 196 Sclerosis, 30, 157, 196 Screening, 156, 196 Sebaceous, 161, 176, 196, 207 Sebaceous gland, 161, 176, 196, 207 Sebum, 92, 196 Secretion, 11, 159, 163, 168, 171, 176, 181, 182, 196, 197, 198 Secretory, 15, 183, 196 Sedatives, Barbiturate, 196 Sediment, 196 Sedimentation, 16, 196 Seizures, 153, 188, 197 Selenomethionine, 67, 197 Semen, 191, 197 Senile, 143, 197 Sensitization, 54, 188, 197 Sensor, 13, 89, 197 Sepsis, 108, 197 Septal, 197 Septum, 56, 197 Septum Pellucidum, 197 Sequencing, 190, 197 Serologic, 7, 21, 172, 197 Serotonin, 100, 184, 194, 197, 204 Serum, 10, 11, 16, 18, 31, 59, 157, 172, 178, 181, 187, 197, 204 Serum Albumin, 31, 197 Shedding, 8, 197 Shock, 108, 142, 197, 204 Shunt, 47, 197 Sialorrhea, 107, 197 Sicca, 50, 198 Side effect, 16, 28, 84, 91, 107, 113, 115, 117, 144, 198, 204 Signs and Symptoms, 189, 194, 198 Silicon, 86, 198 Silicon Dioxide, 198 Sinusitis, 5, 198 Skeletal, 146, 150, 198 Skeleton, 198 Skin Care, 84, 198 Skin graft, 13, 198 Skin Manifestations, 11, 198 Skin Pigmentation, 75, 198 Skull, 94, 113, 159, 198 Smoking Cessation, 152, 198 Smoldering leukemia, 183, 198 Smooth muscle, 145, 158, 171, 198, 201
220
Erythema
Sneezing, 197, 198 Soaps, 198 Sodium, 61, 181, 198, 202 Soft tissue, 4, 89, 97, 107, 152, 198, 199 Solar radiation, 70, 83, 103, 199 Solid tumor, 146, 151, 199 Somatic, 171, 181, 187, 199 Sound wave, 158, 199 Specialist, 91, 130, 199 Specificity, 12, 22, 144, 190, 199 Spectrum, 75, 86, 91, 100, 101, 177, 199 Spina bifida, 150, 199 Spinal cord, 155, 156, 164, 167, 180, 183, 187, 199 Spinous, 163, 176, 199 Spirochete, 7, 8, 10, 178, 199, 202 Spirometry, 16, 199 Spleen, 146, 160, 179, 195, 199 Splenomegaly, 174, 199 Sporadic, 19, 199 Spores, 156, 175, 199 Squamous, 169, 199, 200 Squamous cell carcinoma, 169, 199, 200 Squamous cells, 169, 199, 200 Staging, 113, 200 Staphylococcal Scalded Skin Syndrome, 108, 200 Staphylococcus, 173, 200 Staphylococcus aureus, 173, 200 Stenosis, 5, 200, 201 Sterile, 47, 200 Steroid, 16, 36, 150, 195, 200 Stimulant, 171, 200 Stimulus, 149, 175, 177, 200, 203 Stomach, 143, 151, 164, 167, 171, 183, 187, 199, 200 Stomatitis, 3, 4, 106, 107, 110, 168, 200 Stool, 157, 177, 200 Strand, 189, 200 Streptococci, 173, 196, 200 Stress, 106, 166, 183, 195, 200, 205 Stricture, 200, 201 Stroke, 5, 122, 154, 201 Stroma, 176, 177, 201 Strontium, 86, 201 Styrene, 195, 201 Subacute, 38, 174, 198, 201 Subarachnoid, 169, 201 Subcapsular, 56, 201 Subclinical, 174, 197, 201 Subcutaneous, 10, 87, 144, 146, 162, 184, 185, 201
Sublingual, 108, 201 Submaxillary, 163, 201 Submucous, 107, 201 Subspecies, 199, 201 Substance P, 196, 201 Substrate, 163, 201 Subungual, 61, 201 Suction, 56, 166, 201 Sun protection factor, 60, 92, 201 Superinfection, 18, 201 Supplementation, 66, 70, 71, 73, 75, 201 Suppression, 61, 62, 66, 159, 201 Sweat, 161, 172, 202 Sweat Glands, 161, 202 Symphysis, 191, 202 Symptomatic, 4, 202 Synergistic, 6, 202 Synovial, 11, 202 Syphilis, 11, 106, 108, 154, 186, 202 Systemic disease, 62, 106, 172, 186, 202 Systemic lupus erythematosus, 44, 48, 147, 148, 156, 157, 202 Systemic therapy, 156, 202 T Tachycardia, 149, 202 Tachypnea, 149, 202 Tacrolimus, 61, 202 Tea Tree Oil, 66, 70, 202 Tear Gases, 176, 202 Telangiectasia, 47, 202 Telencephalon, 150, 202 Tetracycline, 106, 162, 202 Thalidomide, 16, 50, 111, 112, 116, 117, 202 Therapeutics, 12, 117, 202 Thermal, 33, 87, 98, 101, 161, 184, 190, 202 Thigh, 28, 203 Thoracic, 16, 203, 207 Thorax, 143, 203 Threshold, 15, 93, 98, 103, 172, 203 Thrombocytes, 189, 203 Thrombocytopenia, 106, 203 Thrombopenia, 148, 203 Thromboses, 148, 203 Thrombosis, 192, 201, 203 Thromboxanes, 148, 203 Thrush, 108, 153, 203 Thymoma, 26, 203 Thymus, 172, 179, 203 Thyroid, 26, 108, 153, 203 Ticks, 109, 178, 203 Tinnitus, 185, 203 Tome, 79, 203
221
Tomography, 15, 203 Tonsillitis, 196, 203 Toxemia, 90, 203 Toxic, iv, 24, 39, 42, 82, 105, 106, 107, 108, 129, 160, 163, 165, 201, 203, 204 Toxicity, 162, 180, 204 Toxicology, 124, 204 Toxins, 147, 163, 168, 174, 182, 193, 203, 204 Trace element, 184, 198, 204 Trachea, 152, 177, 187, 203, 204 Transduction, 16, 17, 204 Transfection, 18, 151, 204 Transfer Factor, 172, 204 Translation, 145, 204 Translational, 18, 204 Transmitter, 161, 180, 181, 184, 204 Transplantation, 100, 172, 204 Trauma, 3, 97, 107, 108, 183, 204 Trees, 74, 145, 195, 204 Tropism, 20, 204 Tryptophan, 157, 197, 204 Tuberculosis, 16, 106, 178, 186, 204 Tumor Necrosis Factor, 41, 202, 204 Tunica, 182, 204 Typhoid fever, 108, 205 U Ulcer, 16, 89, 101, 108, 160, 205 Ulceration, 106, 160, 205 Ulcerative colitis, 128, 174, 193, 205 Ultraviolet radiation, 19, 62, 87, 88, 91, 205 Unconscious, 146, 205 Urease, 184, 205 Urethra, 191, 205 Urinary, 110, 205 Urinary Retention, 110, 205 Urinate, 205 Urine, 21, 32, 151, 163, 205 Urticaria, 12, 75, 107, 205 Uterus, 143, 155, 159, 191, 205, 206 Uvea, 185, 205 Uveitis, 39, 63, 110, 205 V Vaccination, 10, 36, 205 Vaccines, 20, 36, 205, 207 Vagina, 153, 206, 207 Vaginal, 206, 207 Vaginitis, 153, 206 Varicella, 27, 63, 106, 108, 206 Vascular, 3, 15, 62, 89, 100, 103, 145, 146, 160, 169, 174, 181, 184, 188, 205, 206
Vascular endothelial growth factor, 89, 206 Vasculitis, 11, 26, 37, 42, 48, 164, 189, 206 Vasodilator, 161, 171, 206 Vector, 186, 204, 206 Vein, 13, 101, 149, 175, 184, 186, 206 Venereal, 202, 206 Venous, 107, 148, 149, 184, 192, 206 Ventricles, 155, 197, 206 Venules, 152, 153, 181, 206 Verruca, 106, 206 Vertebrae, 150, 199, 206 Vertigo, 185, 206 Vesicular, 63, 107, 160, 170, 206 Vestibular, 44, 206 Vestibule, 206 Veterinary Medicine, 123, 206 Vinblastine, 73, 206 Vinca Alkaloids, 206 Viral, 8, 12, 14, 98, 107, 143, 167, 204, 206 Viral Load, 14, 206 Viremia, 18, 206 Virulence, 5, 7, 22, 149, 151, 201, 204, 206 Virus, 12, 17, 27, 31, 41, 50, 63, 64, 150, 155, 163, 167, 174, 175, 189, 195, 204, 206, 207, 208 Viscosity, 143, 207 Visual Acuity, 196, 207 Vitiligo, 82, 192, 207 Vitro, 6, 9, 10, 170, 207 Vivo, 6, 18, 20, 207 Voriconazole, 52, 207 Vulgaris, 30, 106, 143, 207 Vulva, 64, 207 W Wart, 176, 207 White blood cell, 97, 147, 150, 174, 177, 179, 182, 184, 189, 207 Windpipe, 152, 187, 203, 207 Withdrawal, 87, 207 Wound Healing, 14, 179, 207 Wounds and Injuries, 98, 207 X Xenograft, 146, 207 Xerostomia, 107, 113, 129, 176, 207 X-ray, 16, 154, 158, 167, 176, 179, 184, 192, 193, 194, 207 X-ray therapy, 176, 207 Y Yeasts, 153, 166, 167, 188, 208 Z Zoster, 27, 42, 63, 208
222
223
224
Erythema
